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Abstract 
 
The first part of the dissertation involves the use of ring closing metathesis (RCM) and 
ruthenium mediated isomerisation-RCM tandem reactions to form a wide range of nitrogen-
containing benzo-fused heterocycles. Those synthesized include the 6-membered 
isoquinolines, the 7-membered benzazepines and the 8-membered benzazocines. In order to 
put these compounds into perspective, a review of selected naturally occurring nitrogen-
containing benzo-fused heterocycles is included along with some of their synthetic 
approaches. Of major significance is our utilization of the Wits methodology allowing one to 
access the 6-, 7- and 8-membered ring systems from a common synthetic intermediate. The 
1,2,3,6-tetrahydro-2-benzazocines were all obtained after RCM in excellent yields (82-99%). 
We were also able to show that some ofthe protecting groups used were easily removed and 
that the ring could be hydrogenated after RCM to yield the 1,2,3,4,5,6-hexahydro-2-
benzazocines. The isoquinolines were synthesized in 78% and 27% yield for the Ac- and Ts-
protected compounds respectively, with no product isolated for the Boc- or SO2Bn-protected 
compounds. These poor results, caused a change to our strategy and we then used a 
“combinatorial-type” approach for the synthesis of the 2,5-dihydro-1H-2-benzazepines and 
the 2,3-dihydro-1H-2-benzazepines with yield of 9, 47, 58 and 82% and 8, 26, 39 and 82% 
obtained respectively for the RCM reaction Futhermore, we attempted the synthesis of the 
substituted 4-phenyl isoquinolines and 5-phenyl benzazepines, but we found that the systems 
would not undergo RCM even at high temperatures and with large amounts of Grubbs II 
metathesis catalyst. 
 
A short review is given in the second part of the dissertation concerning the naturally 
occurring and pharmaceutically useful indenols, indenones and indanones. It further 
highlights how our methodology was extended to include the synthesis of 4-isopropoxy-5-
methoxy-1H-inden-1-ol (X), 4-isopropoxy-5-methoxy-1H-inden-1-one (X) and 4-isopropoxy-
5-methoxy-1H-indanone (X) through the use of ruthenium-mediated isomerisation and RCM 
from a similar common intermediate. We have shown the synthesis of 3-substituted indenols, 
indenones and indanones using the same synthetic procedure, but by changing the reaction 
temperature during RCM. This dissertation also answers many of the questions posed during 
the post-doctoral work of Coyanis. Namely, we were able to support our proposed mechanism 
that the conversion of the unsubstituted indenol to the indenone was occurring via a 
       Abstract 
 
III
dehydrogenative-oxidation, through the use of 1H NMR studies that were coupled with an 
ICP-MS analysis. To the best of our knowledge, this is the first reported use of the Grubbs II 
catalyst (or its degradation products) in a tandem RCM-oxidation procedure by our group 
recently. 
 
Acknowledgements 
 
IV
Acknowledgements 
 
I would like to extend my gratitude to my supervisor Dr Willem van Otterlo and to my co-
supervisor Prof Charles de Koning for their support and guidance throughout this project. I 
was fortunate to have these two minds as my supervisors, they not only encouraged me to be 
better than I thought but also calmed me in my moments of despair. None of this would have 
been possible without their inspiration and the dedication they showed.  
 
I would also like to thank Prof Jo Michael for his valuable input and support, as well as Dr 
Andy Dinsmore for his delightful conversations. The organic group as whole has become a 
support base for me and I was fortunate enough to have gained many friends as well. Thanks 
to all the members of the organic group, both past and present, you know who you are… 
 
I would like to gratefully acknowledge the help of the NMR department, both Prof Lawrence 
Carlton and Mr Richard Mampa. Organic chemists are blind without the data you provide, 
thank you for all the work you have done and the many hours of guidance you have given me.  
 
Sincere thanks to Mr Tommy van der Merwe of the MS department, I am indebted to you for 
all the work you have put in on my behalf, and Mr Manuel Fernandes, for data collection and 
crystal structure solutions you provided me with, you are an absolute gem. I would also like to 
thank the Environmental Analytical group, Prof Ewa Cukrowska and Mr Ruphat Morena for 
the ICP-MS data they provided.  
 
The generous financial assistance of the National Research Foundation and the University of 
the Witwatersrand is gratefully acknowledged.  
 
I would like to thank my parents and brother for their encouragement in good times and bad, 
your support was invaluable. Lastly, thank you Darren Riley for all the guidance, wisdom and 
endless assistance you provided me with. I could never have finished this without you, and 
without you I would never have even began. 
 V
 
 
 
 
 
 
 
 
 
Of All The Things I Have Lost, 
I Miss My Mind The Most… 
 
~ Ozzy Osbourne ~ 
 
Table of Contents 
 
VI
Table of Contents 
 
Declaration  ..…………………………………………………………………………….…….I 
Abstract  …………………………………………………………………………….………...II 
Acknowledgements  ……….………………………………………………....………...……IV 
Quote  ………………………………………………………………………………….……...V 
Table of Contents  ……………………………………………………………………….…..VI 
List of Abbreviations  …………………………………………………………….……...…XV 
 
Chapter 1: General Introduction and Literature Review  ……………………………….…..1 
 
1. General Explanation and Project Overview  ………………………………………………………….2 
2. Ring Closing Metathesis using Transition Metal Catalysts  ………………………………...……….3 
3. Ruthenium Mediated Isomerisations  …………………………………………………………….…...6 
3.1 Proposed Isomerization Mechanisms  ………………………………………………………….7 
3.2 Ruthenium Catalyzed De-allylations  ……………………………………………...………….10 
3.3 Ruthenium Catalyzed Redox Isomerisations  ……………………………………...………….10 
4. Ruthenium Mediated Oxidations  ………………………………………………………...………….11 
 
Chapter 2: Introduction to N-containing benzo-fused heterocycles  ……………….……...13 
 
1. Benzazocines (8-membered rings)  …………………………………………………………...………14 
1.1 Cyclazocine and its Derivatives  ……………………………………………………...………15 
1.2 Aziridine Alkaloids  …………………………………………………………………...………15 
  1.2.1 Homo-Brook Fragmentation to Benzazocines  ………..……………………..……...17 
1.2.2 Aryl Nitro Cyclisation to Benzazocines  ……………………………………………..17 
1.2.3 Aldol Cycloaddition  to Benzazocines  ………….……………………………...……18 
1.2.4 Ring Closing Metathesis to Benzazocines  …………..………………………...…….19 
1.2.5 Epoxide Ring Opening to Benzazocines  ………………..…………………………...19 
1.2.6 Pd-catalyzed Carbonylative Lactamization to Benzazocines  ……………...……….20 
1.2.7  Reductive Amination – Highlighting the use of Benzazocines in Natural  
Products  ……………...………………..……………………………………………21 
2. Benzazepines (7-membered rings)  …………………………………………………………………...21 
 2.1 1,4-Benzaodiazepine compounds  ………………………………………………...…………..21 
 2.2 1,2-Dihydro(c)-benzazepine-3-one compounds  ….…………………………...……………...25 
 2.3 2-Benzazepine derivatives  ……………………….……………………………...……………26 
3. Isoquinolines and Related Compounds (6-membered rings)  …………….………………………...28 
3.1 The Simple Isoquinolines  ………………………………………………………………………..…..…28 
Table of Contents 
 
VII
3.1.1 The Anhalonium Bases  ……………………………………………….…….……….29 
3.1.2 Salsoline and Corypalline  ………………………………………………….……….30 
3.1.3 Crispine A-E  ………………………………………………………….……………..30 
3.2 The Naphylisoquinoline Alkaloids  ……………………………………………………………31 
3.3 The 1- and 4- Substituted Tetrahydroisoquinolines  ………………………..………………...32 
  3.3.1  The 1-Substituted Tetrahydroisoquinolines  ………………………….…….……….32 
3.3.2 The 4-Substituted Tetrahydroisoquinolines  ………………………….…….……….33 
3.4 The Benzophenanthridines  …………………………………………………………………...34 
3.5 Generally Reported Syntheses of the Isoquinolines, Dihydroisoquinolines and 
Tetrahydroisoquinolines  ….…………………………………………………………………..35 
3.5.1 Pictet-Spengler Cyclisation  …………………………………………………………35 
3.5.2 Bischler-Napieralski Cyclization  …………………………………….…….……….36 
3.5.3 Pomeranz-Fritsch Cyclization  …………………………………………………...…37 
3.5.4 Photocylization of N-Chloroacetylbenzylamines  …………………….…….……….37 
3.5.5 Ammination of Benzopyrylium Salts  ……………………………………….……….38 
3.5.6 Isoquinoline Synthesis via Ortho-Substituted Benzylamines  ……………………….38 
3.5.7 Cyclization of Aralkenyl-Substituted Quarternary Ammonium Salts  ……………….39 
3.5.8 Palladium-Catalyzed Arylation  ……………………………………………………..39 
3.5.9 Mitsunobu-Coupling Reaction  ……………………………………….…….……….40 
3.5.10 Chromium-Mediated Cyclization  …………………………………….…….……….40 
3.5.11 Pd(II) – Catalyzed Cyclisation  …...………………………….……………………...41 
3.5.12 Aza-Wittig Reaction  ………………………………………………………………...41 
3.5.13 Heteroatom-Directed Lateral Lithiation  ……………………………………………42 
4. The Wits RCM approach towards the synthesis of 6-, 7- and 8-membered benzo-fused 
heterocycles  ……………………………………………………………………………………………42 
5. Aims of  Section  ………………………………………………………….……………….…………...44 
 
Chapter 3: Introduction to the Indenols, Indenones and Indanones  ……………………..46 
 
1. General explanation of Indenols, Indenones and Indanones  …………….………………………...47 
2. Indenols  ……………………………………………………………………………………….……….48 
2.1 Illudin S and M  ……………………………………………………………………………….48 
2.2 Illudalane sesquiterpenoids  …………………………………………………………………..49 
2.3 Synthesis of Indenols by Ring Closing Metathesis  …………………………………………...50 
3. Indenones  ……………………………………………………………………………………………...50 
3.1 Indenone Based Lignans  …………………………………………………………….………..50 
3.2 3CP Inhibitors  ……………………………………………………………………….……….51 
3.3 FGFr and TK Inhibitors  ……………………………………………………………………...51 
3.4  COX-2 Inhibitors  …………………………………………………………………….……….53 
3.5 Ethacrynic Acid Analogues  ………………………………………………………….……….54 
Table of Contents 
 
VIII
3.6 Topoisomerase I Inhibitors  ………………………………………………………….………..55 
4. Indanones  …………………………………………………………………………………….………..56 
4.1 Ptaquiloside and the Pterosins  ……………………………………………….………………56 
4.2 20S and 26S Proteasome Inhibitors  ………………………………………….………………57 
4.3 Aromatase Inhibitors  …………………………………………………………………………58 
4.4 Alcyopterosin N  ………………………………………………………………………………58 
4.5 Cyclooxogenase Inhibitors  …………………………………………………………..……….59 
5. The Wits RCM approach towards the synthesis of indenols, indenones and 
indanones  ……………………………………………………………………………………………...60 
6. Aims of Section  ……………………………………………………………………………….……….61 
 
Chapter 4: Results and Discussion for the Synthesis of N-containing benzo-fused 
heterocycles  …………………………………………………………………………………63 
 
1. Introduction  ………………………………………………………………………………….……..…64 
2. The 1-Propenyl System  ……………….………...…………………………………………………….64 
2.1 Synthesis of Starting Materials  ……………………………………………………………….64 
2.1.1 O-Allylation of Isovanillin  …………………………………………………………..64 
2.1.2 Claisen Rearrangement and Protection Reactions  …………………………………65 
2.1.3 Imine Formation  …………………………………………………………………….67 
2.1.4 Reductive Amination Reactions  ……………………………………………………..68 
2.1.5 Protection of the Amine  ……………………………………………………………..69 
2.2 Synthesis of Benzazocines (8-membered rings)  ………………………………………………72 
2.2.1 Ring Closing Metathesis to Form Benzazocines  ……………………………………73 
2.2.2 Hydrogenation Reaction on Compound 216  ………………………….…………….75 
2.2.3 Deprotection Reaction of Compound 215  …..………………………………………77 
2.3 Synthesis of Isoquinolines (6-membered rings)……………...………………...………………78 
2.4 Synthesis of Benzazepines (7-membered rings)  ………………………………………………83 
2.4.1  Preparation of 2,5-dihydro-1H-2-benzazepines  ……………………………………84 
2.4.2 Preparation of 2,3-dihydro-1H-2-benzazepines  ……………………………………89 
2.5 De-allylated Compounds  …………………………………………………………….……….96 
3. The 1-Phenyl-1-Propenyl Substituted System  ……………………………………………………..100 
3.1 Synthesis of Phenyl-Substituted Starting Materials  ………………………………………...100 
3.1.1 O-Cinnamyl Addition to Isovanillin  …………………...…………………………..100 
3.1.2  Claisen Rearrangement and Protection  …………………………………………...101 
3.1.3 Reductive Amination Reactions  ……………………………………………………102 
3.1.4 Protection of the Amine  ……………………………………………………………104 
3.2 Phenyl-Substituted Benzazepines (7-membered rings)  ……………………………………..106 
3.3 Phenyl Substituted Isoquinolines (6-membered rings)  ……………………………………...108 
 
Table of Contents 
 
IX
3.3.1  Isomerisation Reactions  …………………………………………………………...108 
3.3.2 Ring Closing Metathesis  …………………………………………………………..110 
3.3.3 De-allylated Compound  …...……………………………………….……………...111 
3.4 The Cope Products  ………………………………………………………………………….112 
3.4.1 Claisen-Cope Rearrangement and Protection Reaction  …………………………..112 
3.4.2 Reductive Amination Reactions  ……………………………………………………114 
3.4.3  Protection Reactions  ……………………………………………………………...115 
3.4.4 Ring Closing Metathesis to form Compounds 273 and 274………………………...116 
 
Chapter 5: Results and Discussion for the Synthesis of Indenols, Indenones and Indanones  
……………………..………………………………………………………………………...119 
 
1. Introduction  ………………………………………………………………………………………….120 
2. The 1-Propenyl System  ………………………………...…………………….……………………...121 
 2.1 Synthesis of the Starting Material  …………………………………………………………..121 
2.2 Synthesis of the Indenol 203  ………………………………………………...……….……...122 
2.3 Synthesis of the Indenone 204  .……………………………………………………………...122 
2.4 Synthesis of the Indanone 205  ……………………………………………….……………...123 
3. The 1-Phenyl-1-Propenyl Substituted System  ……………………………………………………..124 
3.1 Synthesis of the Starting Material ….………………………………………………………..124 
3.2 Synthesis of the Indenol 276  ………………….……………………………………………..125 
3.3 Synthesis of the Indenone 277  ………………………………….…………………………...126 
3.4 Attempted Synthesis of the Indanone 278  ……………………………………….…………..127 
4. The 1-Methyl-2-Propenyl Substituted System  …………………………………….……….……...128 
4.1 Synthesis of Starting Materials  ……………………………………………………………...129 
4.1.1 O-Crotylation of Isovanillin  ……………………………………………………….129 
4.1.2 Claisen Rearrangement and Protection Reaction  …………………………………129 
4.1.3 Isomerisation Reactions for Compound 280  ………………………………………130 
4.1.4 Grignard Addition to Compound 280  ……………………………………………..131 
4.1.5 Isomerisation Reaction to  form Compound 283  ………………………………….132 
4.2 Synthesis of Indenol 285  …………………………………...………………………………..133 
4.3 Synthesis of Indenone 286  ………………………………………………...………………...133 
4.4 Synthesis of Indanone 287  …………………...……………………………………………...134 
5. NMR Experiments to Determine the Mechanism of Indenone/Indanone Formation  …………..135 
5.1 Ruthenium Removal  …………………………………………………………………………136 
5.2 1H NMR Spectroscopic Studies  of the Conversion of the Indenol to Indenone/Indanone  
………………………………………………………………………………………………..139 
5.3 ICP-MS Study to Determine Ruthenium Removal  …………………………………………..144 
 
Table of Contents 
 
X
Chapter 6: Conclusion and Future Work  ………………………………………………...147 
 
1. Summary and Conclusion  …………………………………………………………………………..148 
1.1 Synthesis of N-containing benzo-fused heterocycles  ………………………………………..148 
1.2 Synthesis of Indenols, Indenones and Indanones  ……………………….…………………..153 
2. Future work  …………………………………………………………………………………..……...155 
 
Chapter 7: Experimental Procedures  ……………………………………………………..158 
 
1. General Details  ……………………………………………………………………………….……...159 
1.1 Purification of Solvents and Reagents  ……………………………………….……………...159 
1.2 Experimental Techniques  …………………………………………………….……………..160 
1.3 General Procedures  ………………………………………………………….……………...160 
1.4 Chromatographic Separations  ……………………………………………….……………..160 
1.5 Spectroscopic and Physical Data  …………………………………………….……………..161 
1.6 Nomenclature and Numbering of Compounds  ……………………………….……………..162 
2. Experimental Procedures: N-containing benzo-fused heterocycles ……….……………………...163 
2.1 Preparation of 3-allyloxy-4-methoxybenzaldehyde 207  ………………………………..…...163 
2.2 Preparation of 2-allyl-3-hydroxy-4-methoxybenzaldehyde 208  ………………………….....163 
2.3 Preparation of 2-allyl-3-isopropoxy-4-methoxybenzaldehyde 138  ………………...……….164 
2.4 Preparation of N-[(E)-(2-allyl-3-isopropoxy-4-methoxyphenyl)methylidene]-2-propen-1- 
amine 209  …………………………………………………………………………………...165 
2.5 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-propen-1-amine 210  ………..166 
2.6 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)acetamide 211 ……….....168 
2.7 Preparation of tert-butyl allyl(2-allyl-3-isopropoxy-4-methoxybenzyl) carbamate 212 
…………………………………………………………………………………………….….169 
2.8 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)phenylmethanesulfon- 
amide 213  ………………………………………………………………………………...…170 
2.9 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzene-
sulfonamide 139  …………………………………………………………………………..…171 
2.10 Preparation of 1-[7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocin-2(1H)-yl]-1-  
ethanone 214  …………………………………………………………………………..……172 
2.11 Preparation of tert-butyl 7-isopropoxy-8-methoxy3,6-dihydro-2-benzazocine-2(1H)-
carboxylate 215………………………………………………………………………………173 
2.12 Preparation of 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 
216  ………………………………………………………………………………………..…174 
2.13 Preparation of 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,4,5,6-hexahydro-2-
benzazocine 217  ……………………………………………………………………………..175 
2.14 Preparation of 7-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetra- 
 
Table of Contents 
 
XI
hydro-2-benzazocine 140  …………………………………………………………………....176 
2.15 Preparation of 7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 218  …………...176 
2.16 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-N-(1-pro-penyl)acetamide 
221  ……………………………………………………………………………………..……177 
2.17 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl](phenyl)-N-(1-propenyl)-
methansulfonamide 222  ………………………………………………………………..……178 
2.18 Preparation of 2-acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 223  ………..….179 
2.19 Preparation of 2-acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 220  …………...180 
2.20 Preparation of 5-isopropoxy-6-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2-dihydroisoquinoline 
142  …………………………………………………………….…………………………….181 
2.21 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl](phenyl)methanesulfon-
amide 243  …………………………………………………………………………………...182 
2.22 Preparation of N-{3-isopropoxy-4-methoxy-2-[(1E)-1-propenyl]benzyl}-4-methylbenzene-
sulfonamide 200  ……………………………………………………………………………..183 
2.23 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzenesulfonamide  
245  …………………………………………………………………………………………..184 
2.24 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-N-(1-propenyl)acetamide  
227  …………………………………………………………………………………………..185 
2.25 Preparation of tert-butyl 2-allyl-3-isopropoxy-4-methoxybenzyl(1-propenyl)carbamate  
228  …………………………………………………………………………………………..186 
2.26 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)(phenyl)-N-(1-propenyl)methane-
sulfonamide 229  ……………………………………………………………………………..187 
2.27 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methyl-N-(1-propenyl)benzene-
sulfonamide 230  ………………………………………………….………………………….188 
2.28 Preparation of 2-acetyl-6-isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzazepine  
231 …………………………………………………………………………………………...189 
2.29 Preparation of tert-butyl 6-isopropoxy-7-methoxy-1,5-dihydro-2H-2-benzazepine-2-
carboxylate 232  ……………………………………………………………………………..189 
2.30 Preparation of 2-(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzazepine  
233  …………………………………………………………………………………………..190 
2.31 Preparation of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-2-
benzazepine 234  ……………………………………………………………………………..191 
2.32 Preparation of 3-isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 201  ………………...192 
2.33 Preparation of N-{[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]methyidene}-2-propen- 
1-amine 236  ………………………………………………………………………………....193 
2.34 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-2-propen-1-amine  
235  …………………………………………………………………………………………..194 
2.35 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]acetamide  
237  …………………………………………………………………………………………..195 
 
Table of Contents 
 
XII
2.36 Preparation of tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]carbamate  
238  …………………………………………………………………………………………..196 
2.37 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]phenylmethane-
sulfonamide 239  …………………………………………………….……………………….197 
2.38 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-4-methyl-
benzenesulfonamide 144  …………………………………………………………….………198 
2.39 Preparation of 2-acetyl-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine  
240  …………………………………………………………………………………………..199  
2.40 Preparation of tert-butyl 6-isopropoxy-7-methoxy-1,3-dihydro-2H-2-benzazepine-2-
carboxylate 241  ……………………………………………………………………………..200 
2.41 Preparation of 2-(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine  
242  …………………………………………………………………………………………..200 
2.42 Preparation of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-2-
benzazepine 145  ……………………………………………………………………………..201 
2.43 Preparation of 4-methoxy-3-{[(2E)-3-phenyl-2-propenyl]oxy}benzaldehyde 246  ………....202 
2.44 Preparation of 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzaldehyde 247 ………203 
2.45 Preparation of N-{(E)-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)phenyl]methyl-
idene}2-propen-1-amine 248  ……………………………………………………………..…204 
2.46 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-2-propen-1- 
amine 249  …………………………………………………………………………………...205 
2.47 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]- 
acetamide 250  …………………………………………………………………………….....206 
2.48 Preparation of tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-
carbamate 251  ……………………………………………………………………………....207 
2.49 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-
phenylmethanesulfonamide 252  …………………………………………………………….208 
2.50 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-
methylbenzenesulfonamide 253  ……………………………………………………………..209 
2.51 Attempted synthesis of 2-acetyl-6-isopropoxy-7-methoxy-5-phenyl-2,3-dihydro-1H-2-
benzazepine 254  ……………………………………………………………………………..210 
2.52 Attempted synthesis of tert-butyl 6-isopropoxy-7-methoxy-5-phenyl-1,3-dihydro-2H-2-
bezazepine-2-carboxylate 255  …………………………………………………….………...211 
2.53 Attempted synthesis of 6-isopropoxy-7-methoxy-5-phenyl-2-[(phenylsulfonyl)methyl]-2,3-
dihydro-1H-2-benzazepine 256  ……………………………………………………………..211 
2.54 Attempted synthesis of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-5-phenyl-2,3-
dihydro-1H-2-benzazepine 257  ……………………………………………………………..212 
2.55 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-N-(1-propenyl)-
acetamide 258  ……………………………………………………………………………….212 
2.56 Preparation of tert-butyl 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl(1-propenyl)-
carbamate 259  ……………………………………………………………………………....213 
Table of Contents 
 
XIII
2.57 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl](phenyl)-N-(1-
propenyl)methanesulfonamide 260  …………………………………………………………214 
2.58 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-methyl-N-(1-
propenyl)benzenesulfonamide 261  ………………………………………………………….215 
2.59 Attempted synthesis of 2-acetyl-5-isopropoxy-6-methoxy-4-phenyl-1,2-dihydro-isoquinoline 
262  …………………………………………………………………….…………………….216 
2.60 Attempted synthesis of tert-butyl 5-isopropoxy-6-methoxy-4-phenyl-2(1H)-isoquinoline-
carboxylate 263  ……………………………………………………………………………..216 
2.61 Attempted synthesis of 2-(benzylsulfonyl)-5-isopropoxy-6-methoxy-4-phenyl-1,2-
dihydroisoquinoline 264  …………………………………………………………….………217 
2.62 Attempted synthesis of 5-isopropoxy-6-methoxy-2-[(4-methylphenyl)sulfonyl]-4-phenyl-1,2-
dihydroisoquinoline 265  …………………………………………………………………….217 
2.63 Preparation of 5-hydroxy-4-methoxy-2-[(1E)-3-phenyl-2-propenyl]benzaldehyde  
267  …………………………………………………………………………………………..219 
2.64 Preparation of 5-isopropoxy-4-methoxy-2-[(1E)-3-phenyl-2-propenyl-benzaldehyde  
268  …………………………………………………………………………………………..219 
2.65 Preparation of N-((E)-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]phenyl}methyli-
dene)-2-propen-1-amine 269  ………………………………………………………………..220 
2.66 Preparation of N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]benzyl}-2-propen-1-
amine 270  …………………………………………………………………………………...221 
2.67 Preparation of tert-butyl allyl{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]benzyl}-
carbamate 271  ………………………………………………………………………………222 
2.68 Preparation of N-allyl-N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]-benzyl}-4-
methylbenzenesulfonamide 272  ……………………………………………………………..223 
2.69 Preparation of tert-butyl 9-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocine-2(1H)-
carboxylate 273  ……………………………………………………………………………..224 
2.70 Preparation of 9-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetrahydro-2-
benzazocine 274  ……………………………………………………………………………..225 
3. Experimental Procedures: Indenols, Indenones and Indanones  ……………….………….……...226 
3.1 Preparation of 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol  
202  …………………………………………………………………………………………..226 
3.2 Preparation of 4-isopropoxy-5-methoxy-1H-inden-1-ol 203  ……………………….………226 
3.3 Preparation of 4-isopropoxy-5-methoxy-1H-inden-1-one 204  ……………………………..227 
3.4 Preparation of 4-isopropoxy-5-methoxy-1-indanone 205  …………………………………..228 
3.5 Ruthenium Removal, NMR experiments and ICP-MS testing  ……………………….……...228 
3.5.1 Ruthenium Removal  ……………………………………………………………….228 
3.5.2 1H NMR Spectroscopy Experiments  ……………………………………………….229 
3.5.3 ICP-MS Testing  ……………………………………………………………………230 
3.6 Preparation of 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-phenyl-1-propenyl]phenyl}-2-propen-1-
ol 275  ………………………………………………………………………………………..231 
Table of Contents 
 
XIV
3.7 Preparation of 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-ol 276  ……………………..232 
3.8 Preparation of 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-one 277  …………………...232 
3.9 Preparation of 3-[(2E)-2-butenyloxy]-4-methoxybenzaldehyde 279 ……………….……….233 
3.10 Preparation of 3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)benzaldehyde  
280 …………………………………………………………………………………………...234 
3.11 Preparation of 3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-propenyl]benzaldehyde  
281 …………………………………………………………………………………………...234 
3.12 Preparation of 1-[3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)phenyl]-2-propen-1-ol  
283 …………………………………………………………………………………………...236 
3.13 Preparation of 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-propenyl]-phenyl}-2-propen-1-
ol 284  ………………………………………………………………………………………..237 
3.14 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1H-inden-1-ol 285  ……………………..237 
3.15 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1H-inden-1-one 286  …………………...238 
3.16 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1-indanone 287  ………………………..239 
 
Chapter 8: References  ……………………………………………………………….…….241 
 
Appendix A:  Selected NMR Spectra 
 
Appendix B:  Single-Crystal X-Ray Diffraction Data 
 
Appendix C:  ICP-MS Data 
 
Appendix D: Published Papers 
 
 
 
 
 
 
 
 
Please Note: 
All 1H and 13C NMR spectroscopic data is provided on the attached CD-ROM, along with 
the cif files for each single-crystal X-ray structure. 
 
List of Abbreviations 
 
XV
List of Abbreviations 
 
AD    Alzheimer’s disease 
ADMET   acyclic diene metathesis polymerisation 
Boc2O    di-tert-butyl-dicarbonate 
CM    cross metathesis 
CNS    central nervous system 
Cox    cyclooxogenase enzyme 
3CP    3C protease 
DEAD    Diethyl azocarboxylate 
DMAP    4-(dimethylamino)pyridine 
DMF    N,N-dimethylformamide 
DMSO    dimethylsulfoxide 
DNA    deoxyribonucleic acid 
DNPH    2.4-dinitrophenylhydrazine 
ECA    ethacrynic acid 
FGFr    fibroblast growth factor receptor 
FTIR    Fourier Transform Infrared 
Grubbs II catalyst  Grubbs catalyst 2nd generation 
HIV    human immunodeficiency virus 
HMPA    hexamethyl phosphoric triamide 
HRMS    high-resolution mass spectrometry 
HRV    human rhinoviruses 
ICP-MS   inductively coupled plasma mass spectrometry 
IR    infrared 
KHMDS   potassium hexamethyldisilazide 
LHMDS   lithium hexamethyldisilazide 
Leu    leucine 
NHC    N-heterocyclic carbene 
NMDA   N-methyl D-aspartate 
NMR    nuclear magnetic resonance 
NSAIDs   non-steroidal anti-inflammatory drugs 
Pd2(dba)3   tris(dibenzylideneacetone)dipalladium(0) 
List of Abbreviations 
 
XVI
PDGFr    platelet derived growth factor receptor kinase 
Pd(PPh3)2   bis(triphenylphosphine)palladium(II) 
p-TsOH   p-toluenesulfonic acid 
RCM    ring closing metathesis 
ROM    ring opening metathesis 
ROMP    ring-opening metathesis polymerisation 
rt    room temperature 
Ru-isomerisation catalyst carbonylchlorohydridotris(triphenylphosphine)-ruthenium (II) 
TBS ether   tributylsilyl ether 
TFA    trifluoroacetic acid 
THF    tetrahydrofuran 
TK    tyrosine kinase 
TLC    thin layer chromatography 
top I    topoisomerase I 
tosyl chloride   toluene-4-sulfonyl-chloride 
Wits    University of the Witwatersrand 
 
  
 
 
 
 
 
 
 
 
 
Chapter 1:  
 
General Introduction and Literature Review 
 
Chapter 1 General Introduction and Literature Review 2
Chapter 1: General Introduction and Literature Review 
 
1. General Explanation and Project Overview 
 
Polyaromatic and heteroaromatic compounds, for instance, naphthalenes, isoquinolines, 4H- 
and 2H-chromenes, benzo[1,4]dioxins, benzo[b]furans and indenols are important structural 
motifs common to both natural products and a wide range of pharmaceuticals. They display a 
variety of biological activities, ranging from anti-microbials (such as anti-malarials) to anti-
virals (such as anti-HIV drugs). These properties make them exciting targets for synthetic 
chemists, with consequently a wide range of syntheses reported, many of which are based on 
classical organic chemistry. However, these often have a number of drawbacks, including 
cost, scalability, low yields and problematic purifications. Thus, as part of our research 
program, a methodology study was undertaken by our research group to develop new reliable 
methods for the synthesis of these biological motifs, based on the use of ring closing 
metathesis (RCM) as the key step.1-5 
 
Recent publications from our laboratories have shown that a ruthenium-mediated allyl 
isomerisation to the corresponding styrene and/or enol ether, complemented by ruthenium-
mediated RCM can lead to a variety of ring systems, starting from the same precursor.2,3,5 A 
large amount of the methodology developed in our laboratories that is related to this field has 
been in the formation of oxygen-containing benzo-fused heterocycles, with very little work 
done on the synthesis of the nitrogen-containing benzo-fused systems. The first part of this 
dissertation deals with an extension of our previously developed methodology to include the 
synthesis of a wide range of 6-, 7- and 8-membered nitrogen-containing benzo-fused 
heterocycles, employing both ruthenium-mediated allyl isomerisations and RCM.  
 
Various methods for the synthesis of indenols and indenones are also reported in the 
literature. The second part of this dissertation deals with the synthesis of a number of 
indenols, indenones and indanones utilizing similar isomerisation-RCM methodology to form 
these 5-membered ring systems. This section of the dissertation exploits the “non-metathetic 
behaviour”6,7 of Grubbs second generation catalyst to synthesize indenones and indanones 
from indenols, via the tandem RCM-dehydrogenative oxidation reaction.8 
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2. Ring Closing Metathesis using Transition Metal Catalysts 
 
Transition metals are becoming increasingly important in modern organic synthesis, often 
playing pivotal roles in the total synthesis of many natural products.9 Of key importance in 
these syntheses is the efficient formation of the C=C bond and one of the most widespread 
and efficient ways of achieving this is through the use of olefin metathesis. It has become so 
important that Grubbs, Schrock and Chauvin received the Nobel Prize in Chemistry (2005) 
based on their contributions to this ever-expanding field. 
 
Olefin metathesis is defined as a unique carbon skeleton redistribution in which unsaturated 
carbon-carbon bonds are rearranged in the presence of metal carbene complexes.10,11 With the 
advent of efficient catalysts, olefin metathesis is quickly emerging as one of the most 
powerful strategies for carbon-carbon bond formation. The number of applications of this 
reaction has dramatically increased in the past few years. Of particular significance, this type 
of metathesis utilizes no additional reagents beyond a catalytic amount of metal carbene and 
the only other product from the reaction is, in most cases, a volatile olefin such as ethylene. 
RCM reactions are often simple, high yielding and friendly to the environment.12 
 
Olefin metathesis can be utilized in several closely related reaction types as outlined in 
Scheme 1: (i) ring-opening metathesis polymerization (ROMP), (ii) ring-closing metathesis 
(RCM), (iii) cross metathesis (CM), (iv) ring-opening metathesis (ROM) and (v) acyclic diene 
metathesis polymerisation (ADMET).13-16 The major thrust of this dissertation deals with the 
application of ring closing metathesis to the synthesis of small benzo-fused molecules. 
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Scheme 1 Different forms of olefin metathesis13-16 
 
RCM has received a great deal of attention for the synthesis of medium or large sized rings 
from acyclic diene precursors. This intensive study is primarily due to the development of 
well-defined metathesis catalysts, which are tolerant to many functional groups, as well as 
reactive towards a diverse range of substrates.12 
 
The disclosure by Grubbs that ruthenium carbene complexes of the general type 1 (Scheme 2) 
are highly active single component catalysts for all types of alkene metathesis reactions 
denoted a real breakthrough and triggered an avalanche of interest in this transformation.17-19 
Their activity is usually lower than that of the other classical carbene, Schrock’s molybdenum 
alkylidene 2; however the “late” transition metal compounds of Grubbs show tolerance 
towards a wide array of functional groups and exhibit ease of handling as a result of 
reasonable stability against oxygen, water and minor impurities in solvents. This renders them 
as exceedingly practical tools for RCM type reactions.20 Scheme 2 displays a range of other 
catalysts and pre-catalysts that have also been shown to have metathetic capabilities. 
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Scheme 2 Some typical metathesis catalysts and precatalysts20 
 
The mechanism of RCM has been the subject of debate for several years and it was Chauvin, 
in 1971, who first proposed what is now the commonly accepted mechanism for this 
reaction.13 It involves a sequence of formal [2+2] cycloadditions/cycloreversions, a series of 
alkene metal carbenes and metallacyclobutane intermediates such as those depicted in 
Scheme 3.13,21  
 
However, it is important to note that this process is reversible. The forward reaction is 
entropically driven since it “cuts” one substrate into two products. However, the desired 
cycloalkene accumulates in the reaction mixture as one of the components is volatile (eg: 
ethene or propene), and hence, readily removed.22 
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Scheme 3 Basic catalytic cycle of ring closing metathesis13,21 
 
Grubbs introduced the first metathesis catalyst of the general formula [(PR3)2X2Ru=CHR], 
with the most prominent example of the first generation compounds being catalyst 10 (Figure 
1).  The replacement of one trialkylphosphane ligand by a N-heterocyclic carbene (NHC) has 
led to the new class of metathesis catalysts with the general formula [(PR3)(NHC)X2RuCHR], 
which are even more active than the original complexes. The most representative of these 
second generation compounds is catalyst 11. 
 
11
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Cl
Cl
Ru
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Ph
Cl
Cl
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Figure 1 Grubbs Metathesis Catalysts 
 
3. Ruthenium Mediated Isomerisations 
 
Several reports published over the last few years indicate that decomposition products of these 
ruthenium metathesis catalysts might be responsible for undesired side reactions, especially 
alkene isomerisation. Examples have been reported of an isomerisation subsequent to the 
metathesis step by Prunet and co-workers23 (Scheme 4a) and Taylor and co-workers24 
(Scheme 4b), and prior to RCM by Fürstner et al.25 (Scheme 4c).  
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Scheme 4 Examples of isomerisation reactions interfering with olefin metathesis23-25 
 
It was stated, by Fürstner, that ruthenium hydride complexes are formed as by-products in 
some cases during the preparation of the second-generation metathesis catalysts.26 If these are 
present as an impurity in the metathesis catalyst, they might be responsible for the observed 
isomerisation reactions. Alternatively, a ruthenium hydride species might be formed by 
decomposition of the ruthenium carbene species under the reaction conditions.6 
 
3.1 Proposed Isomerization Mechanisms 
 
Other proposals have however been put forward to explain the formation of products resulting 
from double bond isomerisation. Nolan and co-workers27 have investigated the competition of 
RCM and double bond isomerisation in some detail. Based on their experimental observations 
for an unsubstituted model system, the authors proposed a mechanism for the isomerisation 
process (Scheme 5) that involves coordination of the alkene to the 14-electron fragment E 
(from Grubbs second generation precatalyst). In the resulting π complex, F, an agostic 
interaction might facilitate deprotonation at the allylic position leading to a σ-alkyl/π-allyl 
complex G, which reacts to give the carbene complex H. Dissociation of the isomerised 
alkene regenerates the catalytically active species E.6,27 
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Scheme 5 Proposed mechanism for alkene isomerisations via π-allyl complexes6 
 
This mechanism is a modification of the π-allyl hydride mechanism (Scheme 6, cycle A), 
which is one of the two commonly proposed mechanisms for olefin isomerisation.28 In the π-
allyl hydride mechanism, an intermediate K is assumed to form that results from migration of 
the hydride from the allylic position of the alkene substrate to the metal centre. Reductive 
elimination gives the η2 complex L, from which the substrate dissociates to regenerate the 
catalytically active species I. The second mechanism (Scheme 6, cycle B) is believed to occur 
via a hydrometalation/β-hydride elimination sequence, which requires the presence of a 
coordinatively unsaturated ruthenium hydride species M. Coordination of the alkene gives the 
π complex N, which undergoes a migratory insertion (hydrometalation) to give the σ-alkyl 
complex O. β-hydride elimination leads to the π complex P, from which the catalytically 
active species M is regenerated by dissociation of the isomerised alkene.6  
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Scheme 6 Mechanistic proposals for double bond isomerisation in alkenes6 
Cycle A: π-allyl hydride mechanism 
Cycle B: hydrometalation/β-hydride elimination mechanism 
 
Ruthenium-mediated catalysis has recently gained popularity for the isomerisation of terminal 
alkenes to internal alkenes, using the ruthenium isomerisation catalyst 12 (Figure 2). 
Krompiec et al.29 has extensively investigated the use of this catalyst for propenyl ether 
synthesis by an isomerisation of the appropriately easy to synthesize allyl ethers. Their 
method shows an alternative to the use of bases, zeolites, supported metals and other 
transition metal complexes (rhodium, iridium, palladium, chromium, molybdenum, iron and 
platinum) for the isomerisation of these double bonds, that is both convenient and universal in 
use.  
 
[RuClH(CO)(PPh3)3]
12
 
 
Figure 2 
 
Krompiec et al.30 has further highlighted the use of catalyst 12, [RuCl2(PPh3)3] or 
[RhH(CO(PPh3)3)] for the selective isomerisation of N-allylamides and N-allylamines. These 
types of enamines occupy a predominant place as intermediates in organic synthesis and in 
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the biological world, and as such there are many methods of enamine synthesis. Examples 
include: condensation of a secondary amine with a carbonyl compound,31 hydroamination of 
alkynes,32 methylenation of amides33 and vinylamination.34 An alternative method for the 
synthesis of enamines is the isomerisation of allyl amines using strong bases such as tBuOK,34 
nBuLi35 or ruthenium,36 rhodium37 and iron38 complexes. However, a number of these 
procedures have specific drawbacks, and the use of the mild conditions required by catalyst 
12 are therefore favoured.  
 
3.2 Ruthenium Catalyzed De-allylations  
 
In 2001 Alcaide et al.7 reported a novel application of Grubbs first generation catalyst 10, 
namely the first examples accounting for the catalytic deprotection of tertiary allylic amines 
by using reagents different from palladium catalysts.39 The catalytic system directs the 
reaction towards the selective deprotection of allylamines, even in the presence of allylic 
ethers. This ruthenium promoted method is more convenient, chemoselective and 
operationally simple in comparison to the conventional palladium-catalyzed method. The 
current mechanistic hypothesis invokes a nitrogen-assisted ruthenium-catalyzed 
isomerisation, followed by hydrolysis of the enamine intermediate 13 (Scheme 7).7 
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Scheme 7 Grubbs carbene-catalysed deprotection of allylic amines7 
 
The isomerisation of the N-allyl to N-propenyl amines is also the key step in the deprotection 
of amino groups that are protected as their N-allyl derivatives.40 Krompiec30 highlighted the 
use of catalyst 12 for these de-allylation deprotections. 
 
3.3 Ruthenium Catalyzed Redox Isomerisations 
 
The isomerisation of allylic alcohols to ketones, often referred to as redox isomerisation, can 
be catalysed by ruthenium complexes, and examples of the use of Grubbs catalyst in this 
transformation have been published recently.6 It is believed that the mechanism for this 
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transformation involves replacement of a ruthenium-bound chloride ion in Q by the allylic 
alcohol, giving intermediate R. β-Hydride elimination gives enone S, which is coordinated to 
a Ru-H species and undergoes subsequent migratory insertion into the Ru-H bond, leading to 
η3 complex T. The complex T is cleaved from the metal by protonation to yield Q and the 
ketone (Scheme 8).41 
 
R
O
H3C R
OH
R
O
R
OH Ru
Ru
H
R
HORu
[Ru]-Cl
H+ + Cl- H+ + Cl-
Q
R
S
T
 
 
Scheme 8 Proposed mechanism for redox isomerisation of allylic alcohols to ketones6 
 
4. Ruthenium Mediated Oxidations 
 
As mentioned in the previous section a number of other non-metathetic catalytic properties of 
the RCM catalysts have been noted, including isomerisation of alkenes pre-25 or post-
metathesis42 Other examples includeatom transfer radical additions,43 enol ester synthesis,43 
hydrogenation and dehydrogenative oxidations of alcohols.44 A number of one-pot tandem 
RCM reactions have also been reported, including RCM-hydrogenation,2,45 metathesis-
dehydrogenation-hydro-genation,44 RCM-Diels-Alder46 and RCM-Pausen-Khand47 reactions. 
 
Recent work in our laboratories has noted a tandem ring closing metathesis-oxidation that 
results selectively in substituted indenols or indenones using only the Grubbs second 
generation catalyst 11, and by varying the reaction conditions.8 To the best of our knowledge 
formation of the latter indenone compounds construes the first observation of a one-pot 
tandem RCM-oxidation reaction mediated by a ruthenium-based metathesis catalyst.8 A small 
amount of indanone was also noted during the abovementioned syntheses and further 
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investigation is required to clarify if this was due to the tandem ring closing metathesis-redox 
isomerisation reaction.48  
 
The oxidizing ability of ruthenium is well documented and may be classified into two general 
categories, namely, dehydrogenative oxygenation, and oxidation with metal-oxo and metal-
hydroperoxo species. The latter is well known in synthetic chemistry and will not be 
discussed.49a Dehydrogenative oxidation of organic substances with or without hydrogen 
acceptors is important from both biological and industrial aspects. Low-valent ruthenium 
complexes are excellent catalysts for the dehydrogenation of alcohols because of their low 
redox potential and affinity towards oxygen atoms.49a The basic concept of the catalytic 
dehydrogenative oxidation of alcohols is outlined in Scheme 9 below. Oxidative addition of 
the low-valent ruthenium complex to the substrate and β-ruthenium hydride elimination 
produces the dehydrogenated compound and a ruthenium dihydride species, which react with 
a hydrogen acceptor U to afford hydrogenated product UH2 and a ruthenium complex catalyst 
to complete the cycle.49a 
 
UH2
U
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SH2
S
(Ru)
(RuH2)
 
 
Scheme 9 Catalytic Dehydrogenative Oxidation49a 
 
It is also important to realize that ruthenium-mediated dehydrogenation of alcohols without 
hydrogen acceptors has also been reported; these include the use of the catalysts: 
RuH2(PPh3)4, Ru(OCOCF3)2(CO)(PPh3) and Ru3(CO)12/PPh3.49a-d 
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Chapter 2: Introduction to N-containing benzo-fused heterocycles 
 
As mentioned in Chapter 1, this dissertation deals primarily with the use of ring closing 
metathesis (RCM) in the formation of small benzo-fused molecules. The first part of the 
dissertation deals with the synthesis of a range of nitrogen-containing benzo-fused 
heterocycles. Thus, as an introduction to this work, the general 8-, 7- and 6-membered groups 
are outlined below. The commonly reported syntheses for the formation of these natural 
products, based on their skeletons, are also briefly outlined below. 
 
1. Benzazocines (8-membered rings) 
 
The benzazocines have been isolated from a wide number of sources, and it is hoped that their 
syntheses may provide useful routes to new and interesting types of narcotic antagonists.50 
New derivatives of benzazocines that have been synthesized show analgesic activity, affinity 
to the opiate receptor and potential antagonistic properties.51 They are also found to be useful 
intermediates for the synthesis of a number of naturally occurring compounds, including the 
aziridine alkaloids, cyclazocine and its derivatives.  
 
Members of the plant family Berberidaceae are known to contain a novel class of the 
isoindolobenzazocine alkaloid, magallanesine, isolated from Berberis darwinii. The unique 
framework of isoindolobenzazocine 14 contains the medium sized nitrogen-containing 
heterocyclic ring, which has generally proved the most difficult to prepare by conventional 
synthetic methods.52 A number of other examples of the benzazocines and their derivatives 
will be described below. 
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Figure 352 
 
 
Chapter 2 Introduction to N-containing benzo-fused heterocycles 15
1.1 Cyclazocine and its Derivatives 
 
Cyclazocine (±)-15 is a member of the 2,6-methano-3-benzazocine class of opioid receptor-
interactive agents which contains a bridged 8-membered benzo-fused heterocyclic ring.53-60 
Numerous breakthroughs in understanding opioid receptor pharmacology (for example, the 
deduction of the multiple opioid receptor subtypes61) have been made in part through the 
study of cyclazocine and its enantiomers (-)-16 and (+)-17.53 In the 1960s and early 1970s, 
cyclazocine was evaluated in humans for analgesia and as a positive treatment in heroine 
addicts to prevent relapse.53,60 Potent analgesia was observed in humans dosed with 
cyclazocine, and even after abrupt cyclazocine withdrawal, patients did not display drug-
seeking behaviour.60  
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Figure 462 
 
The observations that cyclazocine produced opioid-induced analgesia in humans with a lower 
risk of dependency and displayed a milder withdrawal from morphine suggested that the agent 
might serve as a useful therapeutic for the treatment of heroine addiction.63-65 Currently, 
cyclazocine is undergoing NIDA-sponsored evaluation for potential clinical utility as a 
treatment for cocaine abuse.66 Results of this study so far do not support the use of 
cyclazocine for this indication; however, there was some suggestion that an analogue having a 
somewhat different opioid receptor profile might be useful.62 
 
1.2 Aziridine Alkaloids 
 
In 1987, a new class of aziridine natural products, structurally similar to the mitomycins, was 
isolated from a culture broth of Streptomyces sandaenis by the Fujisawa Pharmaceutical 
Company.67 The compounds were denoted FR-900482 18 and FR-66979 19 (Figure 5). 
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Compounds 18 and 19 exhibited potent antitumour activity against LX-1, MX-1, SC-6 and 
LC-6 carcinomas, as well as P-388 murine leukemia cells.68 The triacetate derivative FR-973 
20 was three times more potent as an anticancer agent than 18 or 19, in addition to being 
significantly less toxic. 
 
N
O
OR3
OR2
R1
NR4
OCONH2
18  FR-900482    R1=CHO, R2=R3=R4=H
19  FR-66979      R1=CH2OH, R2=R3=R4=H
20  FK-973          R1=CHO, R2=R3=R4=Ac
 
 
Figure 5 Aziridine Alkaloids68 
 
Due to the interconversion of 18 and 19 via simple chemical transformations,69 the total 
synthesis of one can be treated as the formal synthesis of the other. Fukuyama et al.70 
accomplished the first total synthesis of racemic FR-900482 18 in 1992, and since then 
another racemic synthesis was completed by Schkeryantz and Danishefsky71 Enantioselective 
syntheses have also been completed by Terashima,72 Williams,69 Fukuyama73 and Ciufolini;74 
with formal syntheses being reported by Rapaport75 and Martin.76  
 
There are three common approaches to the core of the natural product, two include nitroso- or 
nitrone-cycloadditions to access the 1,2-oxazine core and the oxidation of a pyrroloindole to 
form the aminoxyhemiketal group.77 The final method involves the synthesis of an 8-
membered benzazocine system followed by a late stage aminoxyhemiketal formation, and 
herein lies the interest in these synthetic targets to our group. 
 
The diversity of the benzazocine approaches to aminoxyhemiketal core synthesis stems from 
the formation of the 8-membered ring via a number of different synthetic pathways, which are 
highlighted in detail below. The initial studies performed by Fukuyama proved to be a crucial 
development that resulted in a host of similar syntheses based upon intermediates related to 
functionalized benzazocine 21.70  
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1.2.1 Homo-Brook Fragmentation to Benzazocines 
 
Photolysis of triazoline 22 generated aziridine 23 which underwent a novel base-induced 
homo-Brook fragmentation (Scheme 10). Deprotonation of the 8-C hydroxyl led to the 
formation of an oxysiletane ring, which fragmented to open the aziridine and form 
cyclooctenol 24. The remainder of the synthesis is an extension of work previously performed 
by Fukuyama70 Subsequent selective N-oxidation of 24 and O-acetylation proceeded in 87% 
yield, this was followed by epoxidation of olefin 21 from the less hindered face to obtain the 
oxirane 25 in 70% yield. Then epoxide 25 was opened using an azide, and a subsequent series 
of protections produced azidomesylate 26 in 8% yield. Overall the natural product (+)-19 was 
synthesized in twenty-eight steps and in 0.2% yield.74 
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Scheme 10 A segment of the Ciufolini Total Synthesis74 
 
1.2.2 Aryl Nitro Cyclisation to Benzazocines 
 
The total synthesis of (±)-18 demonstrated that a skeletally simple benzazocine could be 
converted into the natural product.70 The synthesis of (+)-18 by Fukuyama began with a 
Sonagashira coupling of acetylene 27 and aryl triflate 28 (Scheme 11).73 Hydration of the 
triple bond proceeded regioselectively to ketone 30. Six steps were required to form epoxide 
31 from 1,3-dioxolane 30. The TBS ether was selectively deprotonated, the resulting alcohol 
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oxidized with the Dess-Martin periodinane, and the aryl nitro compound was hydrogenated 
over Pt/C to produce the N-hydroxybenzazocine 32 in 89% yield. Eighteen additional steps 
were used to transform 32 into (+)-18 in 13% yield. Overall, (+)-18 was synthesized in thirty-
three steps in 1% yield.77 
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Scheme 11 A segment of the Fukuyama Total Synthesis73 
 
1.2.3 Aldol Cycloaddition to Benzazocines 
 
The first enantioselective total synthesis was completed by Terashima and co-workers in 
1996.72 The lengthy synthesis began with L-diethyl tartrate and hinged upon an intramolecular 
aldol reaction to form the 8-membered ring (Scheme 12).78 Dialdehyde 33 was prepared in 37 
steps from tartrate, was then treated with LiN(SiMe3)2 followed by sodium borohydride to 
afford diol 34 as the exclusive cyclized product in 48% overall yield. The corresponding 
acyclic diol was recovered in 33% yield. The remainder of the synthesis involved differential 
protections and oxidations of the primary and secondary alcohols as well as inversion of the 
7-C stereogenic center.77 
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Scheme 12 A segment of the Terashima Total Synthesis78 
 
 
1.2.4 Ring Closing Metathesis to Benzazocines 
 
It was initially shown by Grubbs79 that ring closing metathesis could be utilized for 
cyclization reactions yielding tetrahydrobenzazocine products and this was later implemented 
by Martin and co-workers.75 After functional group manipulations to produce alcohol 35, a 
tandem Swern oxidation-Grignard addition afforded diene 36 (Scheme 13). Subsequent RCM 
afforded benzazocine 37 in 78% yield.75 Protection strategies were then employed to intersect 
with an intermediate in the Fukuyama synthesis.70 
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Scheme 13 A segment of the Martin Formal Synthesis75 
 
1.2.5 Epoxide Ring Opening to Benzazocines 
 
This synthesis was outlined by Rapaport and co-workers in 200376 and they found that 
lithiation of the ester 38 with KHMDS deprotonated the benzylic methyl group and the 
resulting carbanion attacked the methyl ester to form ketone 39 in 72% yield (Scheme 14). A 
series of steps similar to those found in the syntheses of Fukuyama70 and Terashima72 resulted 
in a formal synthesis of 20.77 
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Scheme 14 A segment of the Rapaport Formal Synthesis76 
 
1.2.6 Pd-catalyzed Carbonylative Lactamization to Benzazocines 
 
The novel Pd-catalyzed carbonalative lactamization of 40 proceeded in 64% yield under one 
atmosphere of carbon monoxide and refluxing DMA to afford 41 (Scheme 15).81 Subsequent 
reduction of lactam 41 with borane-methyl sulfide provided benzazocine 42 in 55% yield, 
without competitive hydroxyamine cleavage or 1,4-reduction.77 While not a formal synthesis, 
it is anticipated that the strategy can be developed into an enantioselective synthesis of the 
natural product 20, given the structural similarity to the Fukuyama70 synthesis intermediates 
21.77 
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Scheme 15 The Trost Synthetic Approach81 
 
As can be seen by the syntheses outlined above, the current methods available for the 
synthesis of 18 provide intriguing avenues to the natural product. However, all the available 
syntheses are longer than twenty-five steps, highlighting the need for a more efficient 
synthesis of the benzazocine skeleton. Also, given the more pronounced and selective DNA 
cross-linking activity of FK-973 20, a synthesis allowing for generation of various analogues 
could provide more efficient anticancer agents.77 
 
 
Chapter 2 Introduction to N-containing benzo-fused heterocycles 21
1.2.7 Reductive Amination-Highlighting a Use of Benzazocines in Natural Products 
 
Jimenez80 established that pyrroloindoles could be oxidized by dimethydioxirane to yield the 
hemiketal core of the natural product. Recently Williams69 demonstrated that oxidation of p-
methoxybenzylamine 43 with dimethyldioxirane gave hydroxylamine that concomitantly 
extruded p-methoxybenzaldehyde (Scheme 16).77 The single synthetic step oxidized and 
deprotected the amine and ultimately afforded the desired hemiketal core 44, upon cyclization 
with the C8 carbonyl group.  
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Scheme 16 A segment of the Williams Total Synthesis69 
 
2. Benzazepines (7-membered rings) 
 
A number of categories of benzazepine compounds are known, each with unique biological 
activities. This section will highlight some of these groups and describe various syntheses. 
 
2.1 1,4 Benzodiazepine Compounds 
 
1,4-Benzodiazepine compounds have been extensively investigated owing to their important 
biological properties, and in recent times their structure has been widely used as a “molecular 
scaffold”.82 Several of these nitrogen-containing heterocycles have been identified as anti-
tumour, antibiotics (e.g. DC-81),83 anti-HIV84 and anti-thrombotic85 agents, in addition to 
their well-known anxiolytic,86 sedative,87 and anti-convulsant88 activities. A selected number 
of examples are highlighted in the chapter below to demonstrate the importance of N-
containing 7-membered benzofused ring systems. 
 
Because of both their structural motifs and physiochemical properties, this stucture has been 
considered among novel non-peptide peptidomimetics, as it can act as a mimic of peptide 
secondary structures (eg: γ- and β-turns).85,89 As such, many stereocontrolled synthetic 
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approaches to the 1,4-benzodiazepine compounds have been developed.82 Among the most 
impotant strategies are the reductive cyclisation of amino aldehydes,90 amino thioacetals,91 
cyclisation via isatoic anhydride by condensation with an amino acid derivative,92 coupling of 
N-carboxy α-amino acid anhydrides with anthranilic acid derivatives,93 condensation between 
2-aminobenzophenone and α-substituted glycine derivatives89a,94 and the use of a chiral 
auxillary attached to the 1,4-benzodiazepine structure.92b,95,96 However, relatively little work 
has been done on the asymmetric synthesis of 2-substituted-1,4-benzodiazepines (Scheme 
17).97 
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Scheme 17 Access to 2-substituted 1,4-benzodiazepine97 
 
Cabedo et al.82 have recently reported a novel route towards the asymmetric synthesis of 1,4–
benzodiazepine core derivatives by preparing the enantiopure 1,4-benzodiazepine-3-one 45 
from (R)-phenylglycinol (Scheme 18). This approach began with a reductive amination of 
aldehyde 46, allowing the introduction of a chiral inductor giving amine 47. The nitro group 
of 47 was then reduced in the presence of the chiral auxillary under standard hydrogenation 
conditions, without any cleavage of the auxillary yielding 48. The lack of reactivity of the 
secondary benzyl derivatives of amino alcohols allows this transformation that was previously 
observed by Micouin and co-workers.98  
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The selective protection of the alcohol with tBuPh2SiCl and the aromatic amine with Boc2O in 
the presence of sodium hydride afforded the secondary benzylamine 49. Treatment of the 
resulting amine 49 with chloroacetyl bromide99 gave the N-acylated derivative 50. Subsequent 
treatment with sodium hydride in DMF facilitated an intramolecular cyclisation, and silyl 
group deprotection in a one-pot procedure. The seven-membered ring lactam 45 was obtained 
in a 16% overall yield from 46.82 
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Scheme 18 Synthesis of 1,4-benzodiazepine-3-one from (R)-phenylglycinol82 
 
Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease characterized 
by a progressive cognitive and memory decline. The neurodegeneration is thought to be due 
to the deposition and accumulation of amyloid (Aβ) peptides into extracellular proteinaceous 
plaques.100 These Aβ peptides are produced by the sequential cleavage of membrane-bound 
amyloid-β precursor protein (βAPP) by two proteases known as β- and γ-secretases. The 
inhibition of either of these two proteases is a potential approach to treating AD as that would 
reduce the formation of Aβ peptides and consequently their aggregation into amyloid plaques. 
Investigations have been undertaken on a γ-secretase inhibitor discovery program to find an 
orally bioavailable, high potency compound.101 
 
Chapter 2 Introduction to N-containing benzo-fused heterocycles 24
N
N
O
N
H
Cl
Cl
O
Me
O NH2
51  
Figure 6102 
 
A novel γ-secretase inhibitor 51, shown in Figure 6 above, has been identified. The original 
synthesis involved 16-steps,102 which was not ideal for the preparation of analogues to 
investigate structure-activity relationships. A novel strategy describing the synthesis of 3-
amino-1,4-benzodiazepines starting from chloroimidate 52 (Scheme 19) has been 
published,103 which allows the convergent construction of structures such as compound 51 
and 56-57 from a central intermediate.  
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Scheme 19 Synthesis of 3-amino-1,4-benzodiazepines from chloroimidate 52103 
 
The ring-forming processes of conjugated 1,3-dipoles are an important hetero-cyclisation 
method for the construction of five-membered ring-systems.104 This methodology has 
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successfully been applied to the construction of seven-membered heterocycles, using 
conjugated nitriles, ylides, azomethine imines and nitrones.105 
 
Conjugated nitrones of type 58 can undergo three different cyclisation processes: Two 
intramolecular [4+2] cycloadditions resulting in the formation of the bicyclic derivatives 59 
and 60, and a 1,7-ring-closure affording the exo-methyleneoxazepine 61 (Scheme 20).106 It is 
hoped that this methodology for the formation of 61 may be extended to include the synthesis 
of the benzo-fused systems. 
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Scheme 20 Cyclization processes of conjugated nitrones106 
 
2.2 1,2-Dihydro[c]-benzazepine-3-one Compounds 
 
Despite the structural simplicity of the 1,2-dihydro[c]-benzazepine-3-one system 62 (Figure 
7), which occurs as a substrate in a number of naturally occurring compounds,107 there is no 
general synthetic approach for it’s synthesis. Thus far only a few syntheses have been 
described, most having been elaborated for the synthesis of further annulated compounds, 
which frequently possess biological activity.108 
 
N
O
R1
R3
R4
R2
62  
 
Figure 7 The 1,2-dihydro[c]-benzazepine-3-one system107 
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The kinetic stability, both thermal and chemical, of these heterocycles is usually high. No 
cleavage of the amide bonds has been reported under forced acidic or basic conditions.106 The 
C=C and C=O groups can be reduced chemoselectively, depending on the reducing agent. 
Catalytic hydrogenation affords the tetrahydrobenzazepinone 64, whereas treatment with 
lithium aluminium hydride yields the desired dihydroazepines 63 (Scheme 21). Thionation 
using phosphorus pentasulfide to afford thioketone 65 has also been reported.106 
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Scheme 21 Reactivity of dihydrobenzazepin-3-ones106 
 
2.3 2-Benzazepine Derivatives 
 
The synthesis of 2-benzazepine derivatives is also of importance as these compounds are 
shown to have potential biological activity, an example being an N-cyclopropylmethyl 
derivative of 2-benzazepine which displays a high CNS activity, with an eight fold increase of 
in vivo analgesic activity compared to morphine.109 One of the methods for the synthesis of 
these derivatives is outlined in Scheme 22 below. N-Methyl-N-allyl-2-(1-
acetoxallyl)benzylamine 66 reacts in the presence of tetrakis(triphenylphosphine)palladium to 
give a mixture of isoindole 67, 2-benzazepine 68 and allyl acetate 69 (Scheme 22). After 
almost all of 66 has reacted the isoindole 67 isomerizes to 68.110 
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Scheme 22 Reaction of 64 and Pd(PPh3)4110 
 
A potential mechanistic pathway has been identified (Scheme 23).110 The key intermediate, 
70, leads to benzazepine 68 via an intramolecular attack of the amino group in the position 
opposite to the Pd(PPh3)2 moiety with respect to the allyl fragment after a syn-anti 
isomerisation of the latter has taken place.111 
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Scheme 23 Reaction pathway for isomerization110 
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3. Isoquinolines and Related Compounds (6-membered rings) 
 
The isoquinoline systems are well known and numerous reviews are available. The following 
sections serve to highlight the different classes of isoquinoline alkaloids that are applicable to 
our project.  
 
3.1 The Simple Isoquinolines 
 
The chemistry, synthesis and biogenesis of peyote, Lophophora Williamsii, and other cactus 
alkaloids have been thoroughly reviewed.112-116 New natural sources of simple isoquinoline 
alkaloids are the Euphorbiaceae and the Rhamnaceae. Some recently isolated alkaloids of 
interest are shown in Scheme 24.117 
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Scheme 24 Recently Isolated Isoquinoline Alkaloids117 
 
The simplest isoquinoline alkaloids that are found in plants are derivatives of the 
tetrahydroisoquinoline alkaloids, which contain oxygen substituents at positions 6 and 7, and 
occasionally at position 8. The most commonly seen oxygen substituents are hydroxyl and 
methoxy groups. The bases, which may be secondary or tertiary, often bear a methyl group at 
position 1.124 They are thought to arise in nature from the condensation of β-
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phenylethylamines with formaldehyde, acetaldehyde or their equivalents with the amines 
themselves generally derived from amino acids. This process is shown in Scheme 25, starting 
from dihydroxyphenylalanine 71, which appears to be the fundamental building block from 
which all the bases of the isoquinoline series are derived.124 
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Scheme 25 Formation of a Simple Isoquinoline124 
 
3,4-Dihydroxytyramine 73 is one of the hypertensive agents of the common broom, Cytisus 
scoparius. Its structure is clear from its formation by decarboxylation of 3,4-
dihydroxyphenylalanine 71.124 
 
3.1.1 The Anhalonium Bases 
 
The cactus Anhalonium lewinii contains a series of alkaloids, which are derivatives of 
mescaline. Spath confirmed their structure by synthesizing the tetrahydroquinoline 74 
(Scheme 26), by Bischler-Napieralski cyclisation of N-acetylmescaline 75, to yield 
dihydroiosquinoline 76, which was then reduced to give 74. N-methylation of 74 yielded the 
quarternary methiodide which was identical to the corresponding alkaloid derivatives, O-
methyl-O-methylpellotine methiodide and O,N-dimethylanhalonidine methiodide.124 The 
Bischler-Napieralski cyclisation is described in detail in Section 3.5.2 below. 
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Scheme 26 A Bischler-Napieralski Cyclisation to form tetrahydroisoquinolines124 
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3.1.2 Salsoline and Corypalline 
 
Salsoline 77 is found in Salsola arbuscula a desert plant, has a composition of C11H15O2N, 
and contains a phenolic hydroxyl, a methoxy and an imino group.124 The stucture of salsoline 
77 has been determined by its synthesis from isovanillin. Salsoline 77 can be prepared using 
optically active immonium salts, by the Bischler-Napieralski route. 
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Figure 8 Salsoline124 
 
Corypalline 78 is isolated from Corydalis pallida, and is isomeric with salsoline 77, also 
containing a phenolic hydroxyl and a methoxy group. However, it contains an N-methyl 
group and the C-methyl group is not present. The structure for the base was proven by its 
synthesis from vanillin.124 
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Figure 9 Corypalline124 
 
3.1.3 Crispine A-E 
 
Carduus crispus L. has been used in Chinese folk medicine for the treatment of colds, 
stomachache and rheumatism. The screening test for the inhibitory effect on the growth of 
some human cancer lines in vitro showed the extracts of C. crispus had significant effects on 
the cytotoxic activity. Phytochemical studies on the plant have led to the isolation of crispine 
A-E (79-83 respectively).125 
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Scheme 27 Structures of Compounds 79-83125 
 
Crispine A 79 and B 80 are alkaloids with a pyrrolo-[2,1-a]-isoquinoline skeleton and crispine 
C-E 81-83 are isoquinoline alkaloids with a guanidinyl group. Evaluation of the cytotoxic 
activity by the SRB method of all of these alkloids showed that compound 80 had some 
activity against certain human cancer lines.125 
 
3.2 The Naphthylisoquinoline Alkaloids 
 
More complex compounds that contain the isoquinoline skeleton are the naphthylisoquinoline 
alkaloids such as michellamine A 84 and korupensamine A 85, which show strong anti-
malarial, anti-HIV1 and anti-HIV2 activities.126 The michellamines A, B and C were isolated 
from Ancistrocladius korupensis.127 It has been found that michellamine B inhibits the 
formation of syncytium, a primary route of cell to cell HIV transmission.128 It has also been 
reported that the biological activities of the michellamines are primarily due to the 
heterocyclic portion of the tetrahydroisoquinoline unit. 
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Figure 10 Naphthylisoquinoline Alkaloids 
 
3.3 The 1- and 4-Substituted Tetrahydroisoquinolines 
 
Over fifty anti-tumour and antibiotic natural products belonging to the tetrahydroisoquinoline 
family are known to date. Some of these are very potent cytotoxic agents and show a wide 
variety of other biological activities, such as anti-bacterial, anti-plasmoidal, and β-adrenergic 
receptor antagonism.129  
 
 3.3.1 The 1-Substituted Tetrahydroisoquinolines 
 
The N-methyl D-aspartate (NMDA) receptor is a subtype of the excitatory amino acid 
receptors and has been implicated in a number of different physiological and pathological 
events in the brain. At present this site is a major target for the development of new drugs for 
the treatment of neuronal diseases, such as Alzheimer’s disease and Parkinson’s disease. MK-
801 86 is a well-known high-affinity ligand for the aforementioned binding site with a unique 
structure.130 A select number of these potential drug compounds are described in this section. 
 
In 1989 Gray et al.131 reported new ligands for the binding site with the general structure 87, a 
1-substituted tetrahydroisoquinoline, however, it was found that these analogues had an 
affinity for the binding site that was three orders of magnitude less than MK-801. A few years 
later the research group at the Fujisawa Pharmaceutical Company presented the 
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tetrahydroisoquinoline 88 with a quarternary carbon atom at C-1 as a new and distinctly more 
potent ligand for the binding site as compared to 87.132 
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Figure 11 Ligands for the PCP binding site130 
 
3.3.2 The 4-Substituted Tetrahydroisoquinolines 
 
The 4-aryl-1,2,3,4-tetrahydroisoquinoline system 89 has attracted much attention over the past 
few years, owing to its physiological activities and its presence as the backbone in a number 
of natural products and pharmaceutical drugs.133 These include nomifensine 90134 which 
inhibits dopamine and noradrenaline (re)uptake mechanisms, and infrequent phenolic 
Amaryllidaceae alkaloids, such as cherylline 91,135 isolated from Crinum powelli, and latifine 
92,136 isolated from Crinum latifolium. This genus has been used in Vietnamese and Chinese 
traditional medicine as a rub and a tonic, for the treatment of allergic disorders and tumor 
diseases. 
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Figure 12 4-Aryl Tetrahydroisoquinolines133 
 
Due to the increasing medicinal interest in this family of compounds, several syntheses of this 
skeleton have been published; they may be grouped according to the key bond formed (the 
bonds are labeled in Figure 12 compound 89): 
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 Bond a – formed by a Bischler-Napieralski reaction of N-formyl derivatives of   
phenethylamines or by cyclization of β-phenethylisocyanates, 
 Bond b – formed by intramolecular Horner reaction, 
 Bond c – achieved by several methods, including, photoinduced cyclization of ortho-
halogenated N-acylbenzylamines, Friedel-Crafts type reactions, intramolecular 
coupling of quinoid intermediates, and palladium-catalyzed cylization of amide-
enolates, 
 Bond d – constructed by N-alkylation, 
 Bond e – formed by N-alkylation.133 
 
3.4 The Benzophenanthridines 
 
A number of more complex isoquinolines are also found in nature, for example, the Rutaceae 
are a common source of the benzophenanthridine alkaloids. Some relatively new 
benzophenanthridine alkaloids are outlined in Figure 13 below. 
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Figure 13 Benzophenanthridine Alkaloids137-140 
 
The most important benzophenanthridines, from a pharmacological standpoint, are nitidine141 
and fagaronine 98.142 Nitidine is active in the P388 lymphocytic test and is strongly cytotoxic. 
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Fagaronine 98 is as active as nitidine in the P388 system, but is devoid of cytotoxicity. Pre-
clinical studies have been limited to nitidine.143 The methoxy derivative of nitidine 99, 
allonitidine 100, and the tetramethoxy derivative 101, are all active in the P388 test and the 
more resistant L1210 mouse leukemia test.144 Compound 101 also shows curative activity 
against Lewis lung carcenoma (Figure 14). 
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Figure 14 Nitidine Derivatives141 
 
3.5 Generally Reported Syntheses of the Isoquinolines, Dihydroisoquinolines and 
Tetrahydroisoquinolines 
 
3.5.1 Pictet-Spengler Cyclisation 
 
The Pictet-Spengler cyclization has been used to prepare a variety of optically active 
tetrahydroisoquinolines, including salsoline 77 and salsolinol, as well as the alkaloids O-
methylpeyoxylic and O-methylpeyoruvic acids from mescaline hydrochloride (Scheme 28).129 
It relies on the N/C1/Ar disconnection of the tetrahydroisoquinoline system.  
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Scheme 28 General Disconnection using the Pictet-Spengler Cyclization129 
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A study of the cyclization of Schiff bases under neutral or weakly acidic conditions has been 
undertaken144 and it has shown that a phenolic group ortho or para to the cyclization site 
greatly facilitates the reaction (Scheme 29).117 
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Scheme 29117 
 
3.5.2 Bischler-Napieralski Cyclization 
 
Salsolidines can be prepared by the Bischler-Napieralski route, using optically active 
immonium salts.124 The general disconnection for the Bischler-Napieralski route is shown in 
Scheme 30. 
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Scheme 30 General Disconnection using the Bischler-Napieralski Route 
 
Another variation of the Bischler-Napieralski approach uses an amino alcohol 105, which is 
then N-formylated and cyclized. The product is a 3-benzylisoquinoline derivative 106 as 
shown in Scheme 31 below.117 
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Scheme 31117 
 
3.5.3 Pomeranz-Fritsch Cyclization 
 
The Bobbit variation of the Pomeranz-Fritsch cyclization is an exceptionally useful approach 
to obtain the 4-hydroxytetrahydroisoquinolines.117 Jackson and co-workers have worked out a 
superior method for the preparation of substituted isoquinolines, it involves the cyclization of 
acetal sulfonamides 108 under mildly acidic conditions (Scheme 32).145 
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Scheme 32117 
 
3.5.4 Photocylization of N-Chloroacetylbenzylamines 
 
A novel route to isoquinoline derivatives involves irradiation of an N-
chloroacetylbenzylamine 110 to afford an isoquinoline lactam 111 (Scheme 33).146 
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Scheme 33117 
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3.5.5 Amination of Benzopyrylium Salts 
 
Acylation of 3,4-dimethoxyphenylpyruvic methyl ester 112 with acetic anhydride provides 
113 followed by acid-catalyzed cyclization provides a benzopyrylium salt 114. Further 
treatment with ammonia affords the dihydroisoquinoline derivative 115 in good yield 
(Scheme 34).117 
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Scheme 34117 
 
3.5.6 Isoquinoline Synthesis via Ortho-Substituted Benzylamines 
 
A synthesis of isoquinolines was developed that takes advantage of the fact that the o-
tolunitrile carbanion 116 can be acetylated with an aromatic ester to afford 117.117 The overall 
yield from o-tolunitrile to isoquinoline 119 was 24% (Scheme 35).147 
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Scheme 35147 
 
3.5.7 Cyclization of Aralkenyl-Substituted Quarternary Ammonium Salts 
 
Quarternary ammonium salts 120 possessing both a β-alkenyl and a benzyl substituents 
cyclize in the presence of polyphosphoric acid to furnish tetrahydroisoquinoline salts 121 in 
respectable yields (Scheme 36).148 
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Scheme 36148 
 
3.5.8 Palladium-Catalyzed Arylation 
 
The palladium-catalyzed enolate arylation of ketones is a useful tool for the synthesis of α-
arylated carbonyl compounds. Gaertzen and Buchwald have reported the palladium-catalyzed 
intramolecular α-arylation of the related carbonyl compounds, the esters to synthesize a 
variety of fused bicyclic and tricyclic systems. When the ester 122 was treated with tBuOLi, 
Pd2(dba)3 and a phosphine ligand in dioxane, it gave the tetrahydroisoquinoline carboxylic 
acid ester 123 in good yield (Scheme 37).149 
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Scheme 37149 
 
3.5.9 Mitsunobu-Coupling Reaction 
 
Kaufman has used the Mitsunobu reaction for the synthesis of dihydroisoquinolines. Upon 
treatment of the secondary alcohol 124 with toluene p-sulfonamide, triphenylphosphine, 
DEAD and pyridine, the tosylaminoacetal 125 was obtained in 64% yield.150 This compound 
was then cyclized using 6N HCl to obtain the tetrahydroisoquinoline 126 in 80% yield 
(Scheme 38). 
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Scheme 38150 
 
3.5.10 Chromium-Mediated Cyclization 
 
Using the inherent ability of nucleophiles to add to arene Cr(CO)3 complexes, Yeh et al.151 
have reported the synthesis of tetrahydroisoquinolines. The addition of N-methyl-β-
alaninenitrile to benzylchloride chromiumtricarbonyl complexes 127, followed by the 
treatment of the arene-chromium tricarbonyl complex 128 with lithium-hexamethyldisilazide 
in hexamethylphosphoric triamide, gave the product of nucleophilic addition, 129 (Scheme 
39). 
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Scheme 39151 
 
3.5.11 Pd(II)-Catalyzed Cyclization 
 
The Heck reaction and other palladium-catalyzed cylizations are well known methods for the 
preparation of cyclic systems. Recently, Huang and Larock described the synthesis of a 
number of different 4-arylisoquinolines 130 by the Pd(II)-catalyzed cyclization of substituted 
imines 131 followed by alkenylation.152 An example of this is outlined in Scheme 40 below. 
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Scheme 40152 
 
3.5.12 Aza-Wittig Reaction 
 
Even an intramolecular aza-Wittig reaction was used by Rodrigues et al.153 to synthesize 
substituted 1-benzyl-3,4-dihydroisoquinolines 132 from phenethylimino-phosphoranes 133 
with arylketenes 134 in good yields (Scheme 41). 
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Scheme 41153 
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3.5.13 Heteroatom-Directed Lateral Lithiation 
 
A number of heterocycle forming annelations based on heteroatom-facilitated lateral lithiation 
reactions have recently been reported and these procedures offer useful alternatives to the 
classical syntheses of isoquinoline derivatives 137.154 A synthesis of tetrahydroisoquinolines 
that was based on the lateral lithiation of N-(tert-butoxycarbonyl)-2-methylbenzylamine 135 
is described in Scheme 42 below. It provides routes to a variety of substituted 
dihydroisoquinolines, tetrahydroisoquinolines and the simple isoquinolines.154 
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Scheme 42154 
 
4. The Wits RCM approach towards the synthesis of 6-, 7- and 8-membered  
benzo-fused heterocycles 
 
Having looked at a number of different synthetic approaches to the benzazocines, 
benzazepines and isoquinolines, this section will now outline the Wits approach to these 
systems in detail. The Wits methodology encompasses the fact that the selective isomerisation 
of one or both double bonds in a certain substrates can sometimes facilitate the synthesis of 
various ring sizes from the same set of starting materials.5  
 
The Wits approach began with the synthesis of the common intermediate 138, which was 
prepared according to the methodology published by Rousseau.1 The common intermediate 
138 then underwent a reductive amination and the amine formed was tosyl protected to give 
compound 139. The protected amine was then subjected to standard methathesis conditions, 
using 5 mol % Grubbs II catalyst 11, and the desired benzazocine 140 was obtained in 
quantitative yield.129  
 
The 6-membered ring 142 was prepared by the isomerisation of both the allyl chains in the 
protected amine 139, using Ru-isomerisation catalyst 12 giving intermediate 141, before 
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RCM was performed. The desired compound 142 was obtained in 76% yield from the one-pot 
reaction.129  
 
In order to access the benzazepine skeleton, a different approach was utilized. The common 
intermediate 138 was treated with tosyl amine yielding imine 143. This was then subjected to 
a sodium borohydride reduction and the intermediate formed was subsequently allylated to 
give compound 144. Amine 144 was then subjected to the RCM conditions, yielding the 
desired benzazepine 145 in quantitative yield.129 
 
A general overview to the approach developed by Pathak is shown schematically in Scheme 
43 below.129  
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Scheme 43 An outline of the Wits Approach to 6-, 7- and 8-membered benzo-fused 
heterocycles5 
 
5. Aims of this Section 
 
• To synthesize a range of benzazocines from the common synthetic precursor 138 
using the ring closing metathesis strategy developed by Pathak129 (Route A). 
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• To test the feasibility of deprotection reactions on the final 6-, 7- and 8-membered 
nitrogen-containing benzo-fused systems. 
• To utilize ring closing metathesis to access a range of benzazepine systems from a 
common synthetic precursor (Route B). 
• To investigate the possibility of selective isomerisations in our diene systems, using 
the ruthenium-based catalyst outlined by Krompiec29 (catalyst 12). 
• To examine other diene systems to determine if with double allyl isomerisations it is 
possible to obtain isoquinoline analogues via ring closing metathesis (Route C). 
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Scheme 44 
 
The results concerning our synthesis of the nitrogen-containing benzo-fused heterocycles are 
discussed in detail in Chapter 4. 
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Chapter 3: Introduction to the Indenols, Indenones and Indanones 
 
In the previous chapter the importance of 6, 7 and 8 membered benzofused heterocyclic rings 
was described. In this chapter we will now introduce important 5 membered benzofused 
heterocycles, namely the indenols, indenones and indanones. The indan skeleton 146 (Figure 
15) is ubiquitous in nature and examples are found in the indenol, indenone and indanone 
families. 
 
X  
 
Figure 15 
 
1. General explanation of Indenols, Indenones and Indanones 
 
The general indene skeleton is a fairly common motif in natural and artificial compounds e.g. 
indenol 147, isolated from the plant Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf)155 and 
indenone 148, a synthetic derivative from the rhizomes of Pteris wallichiana.156 Another 
example would be the neo-lignin 149 from the fruits of Virola Sebifera (Figure 16).157 As a 
result, various methods for the synthesis of indenols158 and indenones159 have been recently 
reported in the literature. 
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Figure 16155-157 
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2. Indenols 
 
Indenols can be used as intermediates in the synthesis of organic compounds such as the 
chrysanthemates, which possess potent insecticidal properties.160 Some indenols have also 
shown analgesic and myorelaxation activity.161 They can be prepared by the reaction of ortho-
manganated aryl ketones or benzaldehydes with alkynes.162 A number of representative 
indenol examples and compounds related in structure will be described in the following sub-
sections. 
 
2.1 Illudin S and M  
 
In a report in the journal Nature in 1963 describing the isolation of an anti-tumor substance 
from Lampteromyces japonicus (synonymous with O. illudens), a bioluminescent 
mushroom,163 it was stated that the mushroom was known in Japan for its toxicity, which had 
occasionally caused accidents due to its similarity in appearance to edible mushrooms.164 A 
survey of wood-destroying fungi with anti-bacterial activity was carried out at the New York 
Botanical Garden in 1943, and O. illudens was found to inhibit the growth of Staphlococcus 
aureus.165 Isolation of crystalline antibiotic substances illudin S 150 and illudin M 151 from 
culture liquids of the fungus was reported in 1950,165 and elucidation of the structures was 
reported in 1963.166 It was found to contain an indenol-like backbone. Although compounds 
150 and 151 are not strictly indenols it can be postulated that they can be converted into their 
corresponding biological “relatives”, the indenols (see section 4.1 for other examples as well 
as Scheme 45). 
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Figure 17164 
 
Illudin S 150 was also isolated from the mushroom L. japonicus by two groups in Japan and 
was found to be the toxic factor in the mushroom.167 Illudins and certain derivatives have 
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been evaluated for anti-tumor activity and illudin M 151 significantly increased the life span 
of rats with Dunning leukemia.164 Illudin S 150 and illudin M 151 are toxic to a wide range of 
tumor cells and normal cells after prolonged exposure, but show selective toxicity on short 
exposure for human myelocytic leukemia, and epidermoid, lung, ovarian, and breast 
carcinoma cells of various species of origin.168 
 
Thus, illudins have the potential to be useful antitumour agents, however, because of their 
extreme toxicity and consequent low therapeutic index, there is scope for modified structures 
that may reduce cytotoxicity without compromising anti-tumour activity.164 
 
2.2 Illudalane sesquiterpenoids 
 
Illudalane sesquiterpenoids are not widely distributed in nature, and to date most of the 
compounds of this class have been isolated from ferns169 and fungi.170 It has been found that 
the soft coral Alcyonium paessleri from the South Georgia Islands is a rich source of aromatic 
sesquiterpinoids of the rare illudalane class.171 Recently 15 novel illudulane sesquiterpinoids, 
alcyopterosins A-O were isolated, with eight of these containing nitrate ester groups.171 These 
are the first nitrate esters to be reported as natural products, as well as the first illudalane 
sesquiterpinoids from the marine environment. These compounds contain both a modified 
indanol and various indanone backbones171 (Scheme 45), with a full discussion of the 
indanone containing compounds following in Section 4.4. 
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Scheme 45 Illudalane sesquiterpenoids171 
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2.3 Synthesis of Indenols by Ring Closing Metathesis 
 
Recent methods towards the synthesis of indenols include transition metal-catalyzed 
carbocyclisations utilizing nickel,172 manganese,173 cobalt174 and palladium.150b-d,175 The first 
reported use of RCM for the synthesis of an indenol was outlined by Clive and Yu176 Their 
synthesis of (+)-puraquinonic acid included a ruthenium-mediated RCM to form substituted 
indenol 152 from diene 153 (Scheme 46).  
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Scheme 46 Synthesis of indenol using ring closing metathesis by Clive176 
 
3. Indenones 
 
Indenones have been used as fungicides, estrogen binding receptors, and fermentation 
activators.165 They are also useful intermediates in the synthesis of a wide variety of natural 
products (eg: steroids or gibberellins).165 They can be prepared by following traditional 
organic synthetic methods177 or by metal-mediated reactions using carbonyl complexes (in 
these examples the carbonyl group comes from metal coordinated carbon monoxide).160 
Indenones, have also been synthesized by ruthenium-,151c palladium-165 and rhodium-
mediated cyclizations151b amongst others. A select number of examples will be described in 
the section below. Where applicable, synthetic approaches of interest to the indenone 
skeletons will also be described. 
 
3.1 Indenone Based Lignans 
 
Compound 149 was isolated from the fruits of Virola sibifera.149 This indenone has attracted 
much interest as it is the only 3-arylindenone to have been isolated from natural sources and 
thus represents a new class of lignans. It was reported recently that the 3-arylindenones 
display anti-tumour178 and post coital contraceptive activity.179 
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Two syntheses of indenone 149 have been investigated, the first based on a classical 
intramolecular aldol condensation,149 and the second based on a new annulation procedure 
developed by Heck and Larock.165,180 The retrosynthesis for these approaches are outlined in 
Scheme 47 below. 
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Scheme 47 Retrosynthetic analysis for indenone 149149 
 
3.2 3CP Inhibitors 
 
The human rhinoviruses (HRV) are the primary cause of the common cold and belong to the 
Picornovirus family.181 Picornoviruses have a single positive-stranded RNA genome that is 
translated into a 2000+ amino acid polyprotein. The 2A and 3C protease (3CP) processes this 
polyprotein into functional HRV viral proteins,182 thus a synthesis of a series of inhibitors of 
3CP could lead to a cure for the common cold. So far, the bicyclic indenone 154 has been 
found to be the most potent of the ketone derivatives, affording potent reversible inhibition of 
3CP.182 
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Figure 18182 
 
3.3 FGFr and TK Inhibitors 
 
Fibroblast growth factor receptors (FGFr) belong to a family of transmembrane proteins that 
are involved in mitogenic signaling and the regulation of a number of cellular processes.183 
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The binding of the fibroblast growth factor to its receptor (FGFr) activates the cytosolic 
tyrosine kinase (TK) domain for substrate binding and phosphorylation.184 
 
It has been suggested that loss of regulatory control of FGFr is linked to a number of disease 
states, including rheumatoid arthritis, angiogenesis, restenosis (following coronary 
angioplasty), and various kinds of cancers.185,186 FGFr may stimulate production of 
plaminogen activator, mediating migration of tumor cells into normal tissues.185 A number of 
1-oxo-3-substituted-1H-indene-2-carboxamides 155-157 have been identified as potent 
inhibitors of TK activity. These compounds also exhibited selective inhibition of FGFr 
relative to platelet derived growth factor receptor kinase (PDGFr).186 
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Figure 19186 
 
The method used to prepare 155 is outlined in Scheme 48 below. Benzophenone 158 was 
converted to the corresponding malonitrile 159 and this was then cyclized in sulfuric acid. 
The desired product was obtained in only 9% yield.186 This method provides a direct route to 
3-substituted analogues of 155, but offers little flexibility of the carboxylic moiety. 
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Scheme 48186 
 
Another route involved an intermediate reported by Burger and co-workers.187 In this route 2-
benzoylbenzoic acid 160 was converted to a diethyl malonate adduct 161 using thionyl 
chloride and potassium diethyl malonate (Scheme 49).186 
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3.4  COX-2 Inhibitors 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen or inomethacin 
are widely used in the treatment of pain and inflammatory diseases.188 Selective 
cyclooxogenase enzyme (COX-2) inhibitors could provide anti-inflammatory, analgesic and 
antipyretic drugs devoid of the unwanted side effects such as ulcers and renal failure 
associated with the classical nonselective NSAIDs.189 Selective COX-2 inhibition could also 
be an important strategy to prevent or treat a number of cancers and to delay or slow the 
clinical expression of Alzheimer’s disease.190 Examples of this class of compounds include 
those with both the indenone and the indanone backbone.  
 
Indenone 165 was synthesized by Chavatte et al. as outlined in Scheme 50.188 Intramolecular 
cyclization of chalcone 166 was achieved by the treatment with polyphosphoric acid affording 
indanone 167 in 30% yield. The reaction of bromine in acetic acid-chloroform gave 
compound 168, which was followed by debromination with triethylamine in acetone to yield 
compound 169. Treatment of 169 with methanesulfonyl chloride in pyridine gave 165 in 76% 
yield.188 
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Scheme 50 Synthesis of indenone 165 by Chavatte and co-workers188 
 
3.5 Ethacrynic Acid Analogues 
 
Ethacrynic acid (ECA) 170 is a potent anti-gelling and anti-sickling agent, making ECA and 
its structural analogues useful therapeutic agents for the treatment of sickle cell anemia.191 
ECA however, may not be used due to its strong diuretic properties, and thus the analogues 
are important targets for synthesis. A number of structural analogues exist 171-174, having 
both the indenone and the indanone moiety present (Figure 20).191 
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3.6 Topoisomerase I inhibitors 
 
The indenoisoquinolines are a class of cytotoxic molecules that have been demonstrated to 
inhibit topoisomerase I (top I) by intercalating between DNA bases at the enzymes cleavage 
site.192 This mechanism of action is identical to the natural product camptothecin 175 and its 
clinically useful derivative topotecan 176.192 
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Figure 21193 
 
Recently, a new class of indenoisoquinolines and dihydroindenoisoquinolines was 
synthesized by Morrell et al.193 They possess a nitro substituent on the isoquinoline ring. The 
molecules have been tested for cytotoxicity in a 55 cell line screen and for top 1 inhibition. 
Results indicate that these substances are the most potent class of indenoisoquinolines 
synthesized to date.193 Examples of these indenoisoquinolines (177-179) are outlined in 
Figure 22 below. 
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4. Indanones 
 
In this section a few examples of important indanone containing compounds will be described 
as well as some relevant synthetic approaches to them. 
 
4.1 Ptaquiloside and the Pterosins 
 
A number of compounds related to the illudins have been isolated from O. illudens and other 
basidiomycetes.194 Similar compounds have also been found in certain ferns, including the 
bracken, Pteridium aquilinum, which is a commercially important and widely distributed 
fern.164 One bracken metabolite, ptaquiloside 180, an indanone related structure, was found to 
be carcinogenic and to be a toxic factor responsible for acute cattle bracken poisoning.195 
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Figure 23164 
 
The related indanones are called pterosins and were reported to be cytotoxic and to possess 
antibacterial activity. The two most cytotoxic compounds were pterosin Z 181 and 
dehydropterosin B acetate 182.164 The chloroindantriols 183 and 184 derived from treatment 
of illudin M with dilute hydrochloric acid, were found to be comparable to the anticancer 
alkylating agent BCNU (Figure 24).164 Thus, it appears that the indan-type structures are 
inherently somewhat cytotoxic. 
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Figure 24164 
 
The major pterosin found in bracken is pterosin B 185. This compound may be an artifact 
formed by the decomposition of an unstable precursor, namely ptaquiloside 180. Ptaquiloside 
readily loses a molecule of glucose giving an unstable dienone which reacts with water 
forming pterosin B 185 (Figure 25).164 
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Figure 25164 
 
4.2 20S and 26S Proteasome Inhibitors 
 
The 26S proteasome is recognized as one of the central enzymes of nonlysosomal protein 
degradation.196 This proteasomal protein degradation of key regulatory proteins, such as the 
cyclins and Iκ-B, has been identified as a mandatory step in controlling the respective 
signaling pathways for cell cycling and activation of NFκ-B.197 Inhibiting the degradation of 
these important signal proteins may prove useful in controlling diseases, such as cancer and 
inflammation, that are driven by these cascades.196 It has been reported that there exists a 
series of 5-methoxy-1-indanone-3-acetic acid based proteasome inhibitors that are highly 
selective for the chymotrypsin-like activity of the 20S proteasome. The structure of a 
representative example 186 of these novel proteasome inhibitors is shown in Figure 26.196 
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Figure 26196 
 
4.3 Aromatase Inhibitors 
 
The aromatase enzyme complex, responsible for the conversion of androgen to estrogen, is 
involved in reproduction, development, sexual differentiation, behavior, in some brain 
functions, as well as in the growth of hormone-dependent cancers (including some breast 
cancers).198 Many inhibitors have already been studied; the first and second generation 
aromatase inhibitors are presently the major clinically available inhibitors. However, a third 
generation of potent non-steroidal aromatase inhibitors has been developed recently, and these 
include letrozole, vorozole and anastrozole.199 These methoxy-3-trifluoroacetylaminoindan-1-
ones 187 are prepared by a one-pot synthesis starting from methoxybenzaldehydes 188 via 3-
amino-3-(methoxyphenyl)propionic acids 189 by means of refluxing trifluoroacetic acid and 
its anhydride (Scheme 51).200 
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Scheme 51200 
 
4.4 Alcyopterosin N 
 
Alcyopterosin N 190 has recently been isolated from sub-Antarctic soft coral, Alcyonium 
paessleri, for background information refer to Section 2.2 (Illudalane sesquiterpenoids). 
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Outlined in Scheme 52 below is the synthesis of alcyopterosin N 190 using stannylative 
cycloaddition of enynes catalyzed by a palladium-iminophosphine.201 
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Scheme 52 Synthesis of alcyopterosin N 171201 
 
4.5 Cyclooxogenase Inhibitors 
 
The cyclooxogenase enzyme exists in two forms,202 a constitutive form COX-1, and an 
inducible form COX-2.203 The COX-1 form is believed to be important in the maintenance of 
normal physiological functions, such as gastric cytoprotection and the COX-2 form can be 
induced by a wide variety of inflammatory mediators, and appears to play a major role in the 
production of prostglandins associated with inflammation responses.203 Selective inhibition of 
COX-2 has useful anti-inflammatory therapeutic effects without the ulcerogenic side effects 
associated with the currently available nonsteroidal anti-inflammatory drugs, all of which 
inhibit both COX-1 and COX-2.204 The aryl sulfonamide flosulide 199 is a potent and 
selective COX-2 inhibitor.205 It has also been reported that the thioether analogue of flosulide, 
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L-745,337 200, is a potent and more selective COX-2 inhibitor, with superior 
pharmacokinetic and in vivo profiles.203  
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Figure 27203 
 
5. The Wits RCM approach towards the synthesis of indenols, indenones and 
indanones8 
 
In this approach, the readily available substituted benzaldehyde 138 was prepared according 
to the procedure outlined by Rousseau.1 The benzaldehyde 138 was then treated with the Ru-
isomerisation catalyst 12 and the isomerised product 201 was obtained. This was then 
subjected to a Grignard addition reaction,206 affording the alcohol 202. Standard RCM 
procedures were then employed for the synthesis of the indenol 203, ustilising 5 mol % 
Grubbs II catalyst 11 in dichloromethane at 60oC. The desired product, compound 203, was 
isolated in 64% yield.  
 
During the synthesis of the indenols, a small highly-fluorescent yellow spot was observed by 
thin layer chromatography that increased over time.8 It was shown in the post-doctoral work 
of Coyanis,48 that by optimizing the conditions for the indenol synthesis it was possible to 
isolate the corresponding indenone.161 Coyanis found that longer reaction times and harsher 
conditions, i.e. toluene at 80oC, utilising 8 mol % Grubbs II catalyst 11, led to the synthesis of 
indenone 204 in 62% yield (Scheme 53).158 
 
Quite serendipitously, the corresponding indanone 205 (Scheme 53) was isolated when the 
reaction mixture ran dry overnight. It was fully characterized and when the reaction was 
repeated, the indanone was found to form under exceptionally harsh conditions, namely 
solvent-free conditions at high temperatures and catalyst concentrations. The desired indanone 
205 was isolated in 51% yield on the second attempt. 
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Scheme 53 The Wits Approach158 
 
6. Aims of this Section 
 
• To synthesize a range of substituted indenols, indenones and indanones from the 
common synthetic precursors (eg: compound 176) using the previously developed 
methodology of Coyanis.48 
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• To attempt to explain the role of ruthenium in indenol-indenone-indanone conversions 
via the implementation of a model 1H NMR study, which would include control 
samples where ruthenium has been depleted. 
 
Results pertaining to the synthetic study of the indenols, indenones and indanones are 
described in Chapter 5. 
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Chapter 4: Results and Discussion for the Synthesis of N-containing benzo-
fused heterocycles 
 
1. Introduction 
 
This chapter concerns our results on the preparation of the nitrogen-containing benzo-fused 
heterocycles. First, it will cover the synthesis of a number of common starting materials from 
a common intermediate. Then, the following sections will each deal with the individual 
synthesis of the 6-, 7- and 8-membered heterocyclic ring systems. Please refer to the 
experimental section (Chapter 7) for the detailed description of each synthetic step. 
 
2. The 1-Propenyl System 
 
2.1 Synthesis of Starting Materials 
 
A number of starting materials that were common to the synthesis of the 6-, 7- and 8-
membered ring systems will be outlined in this section.  
 
 2.1.1 O-Allylation of Isovanillin 
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Scheme 55 (i) 2.5eq, K2CO3, 2.5eq allyl bromide, DMF, 60oC, 20 h 
 
3-Allyloxy-4-methoxybenzaldehyde 207 was prepared according to the procedure outlined in 
Rousseau1 which was developed in our laboratories a few years ago. This method involves the 
O-allylation of isovanillin 206, with the phenol on isovanillin being deprotonated using 
potassium carbonate and then allyl bromide being added to facilitate the O-allylation. 
Rousseau obtained the desired product in 99% yield after 3-12 h. Our best yield to date is 
99% after stirring for 20 h, which was obtained when the reaction was performed on 
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132mmol scale. 3-Allyloxy-4-methoxybenzaldehyde 207 was obtained as a bright yellow oil 
and its spectroscopic data corresponded closely with literature values.1  
 
2.1.2 Claisen Rearrangement and Protection Reactions 
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Scheme 56 (i) commercial microwave, 100 sec or  
(i) microwave reactor, 30 min, 200oC 
 
The Claisen rearrangement is known to proceed by means of a concerted, pericyclic [3,3] 
sigmatropic shift where a six-membered cyclic transition state in a chair conformation is 
preferred. Many different methods for achieving this rearrangement have been applied 
successfully207 and include solvent-free high-temperature conditions as well as low-
temperature conditions involving a Lewis acid catalyst such as BF3.OEt2.208 Other examples 
have even used water as a catalyst.209 Recently, the use of microwave irradiation to facilitate 
Claisen rearrangements has gained popularity.210 Thus, we attempted the Claisen 
rearrangement of 207 by heating the compound under microwave irradiation, either in a 
commercial microwave or in the microwave reactor.  
 
The commercial microwave oven was set to high power and 207 was heated in the Teflon 
container in short bursts (15, 15, 20 and 30 sec respectively with 5 min intervals in between 
each heating), the compound changed colour to brown and 2-allyl-3-hydroxy-4-
methoxybenzaldehyde 208 was obtained in 100% yield. The compound was spectroscopically 
pure and no further purification was required.  
 
We also attempted the Claisen rearrangement using the Discovery microwave reactor, setting 
the temperature to 200oC and performing the reaction in a sealed tube. This required much 
longer reaction times, with the best yield of 100% being obtained after 30 min. The desired 
product 2-allyl-3-hydroxy-4-methoxybenzaldehyde 208 was obtained as a viscous yellow oil 
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with no further purification being required. Even though this reaction required a longer period 
of time it was favoured over the use of the commercial microwave as it allowed for more 
controlled conditions that would be easily repeatable and ultimately safer (eg: pressure and 
temperature regulation, thus preventing runaway reactions).  
 
The major advantage of using the microwave procedures for the Claisen rearrangement is that 
the product obtained was spectroscopically pure and limited the need for further purification. 
We observed that the reaction had occurred based on the spectroscopic data obtained as the 1H 
NMR spectrum showed the disappearance of the peak at 7.41ppm for 2-H and the presence of 
a broad singlet for the OH peak at 5.86ppm. 13C NMR spectroscopy showed the 
corresponding disappearance of the 2-C peak at 110.9ppm and a new peak in the 127-128ppm 
region that could correspond to the new quaternary carbon, as well as the presence of a new 
peak at 143.8ppm which corresponds to 3-C. The HRMS displayed a peak at 192.08046, 
which corresponds to the calculated value for C11H12O3: 192.07864. 
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Scheme 57 (i) 2.5eq K2CO3, 2.5eq isopropyl bromide, DMF, 60oC, 66 h or 
(ii) DMF, 150-160oC, 64 h, (iii) 2.5eq K2CO3, 2.5eq isopropyl bromide, 60oC, 18 h 
 
Two different approaches were used in the synthesis of 2-allyl-3-isopropoxy-4-
methoxybenzaldehyde 138 and they are outlined in Scheme 57 above. The first of which 
employed the protection of 2-allyl-3-hydroxy-4-methoxybenzaldehyde 208, with isopropyl 
bromide, and yielded the desired compound in 89% yield. The second of which required two 
steps from 3-allyloxy-4-methoxybenzaldehyde 207, the Claisen rearrangement followed by 
the protection of the phenol with isopropyl bromide, as a one-pot reaction and gave the 
desired product in 75% yield over the two-steps.  
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In both instances, the product, 2-allyl-3-isopropoxy-4-methoxy-benzaldehyde 138, was 
obtained as a bright yellow oil after chromatography. The spectroscopic data was in 
agreement with that reported in the literature.1  
 
2.1.3 Imine Formation 
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Scheme 58 (i) 1.4eq allyl amine, rt, 3 h 
 
2-Allyl-3-isopropoxy-4-methoxybenzaldehyde 138 was transferred directly to a round-
bottomed flask and to this was added allyl amine; after which the solution was allowed to stir 
at rt under a nitrogen atmosphere for 3 h. Dry conditions were required for this reaction in 
order to prevent the reverse reaction from occurring, whereby water adds across the C=N 
bond and starting materials are obtained. The excess allyl amine was removed in vacuo and 
the N-[(E)-(2-allyl-3-isopropoxy-4-methoxy-phenyl)methylidene]-2-propen-1-amine 209 was 
obtained was a yellow oil that was spectroscopically pure and unexpectedly found to be 
exceptionally stable to air and moisture.  
 
The product was identified by the characteristic loss of the aldehyde peak for 2-allyl-3-
isopropoxy-4-methoxybenzaldehyde 138 that was found as a singlet at 10.08ppm in the 1H 
NMR spectrum and a peak at 191.1ppm in the 13C NMR spectrum. The new imine proton and 
carbon signals were identified as the singlet at 8.44ppm in the 1H NMR spectrum and at 
160.4ppm in the 13C NMR spectrum, with the characteristic C=N- stretch found at 1682cm-1 
in the FTIR spectrum. 15N NMR spectroscopy was performed and it showed only one signal 
at –62.9ppm. In addition HRMS was performed on the compound and a peak was found at 
272.17086, which corresponds to M+ (M+ for C17H23NO2 is calculated as 273.17288, -1H 
272.16505). Even though HRMS was not conclusive, all the other spectroscopic data was in 
agreement and this was deemed sufficient to continue with the next experiment. 
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2.1.4 Reductive Amination Reactions 
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Scheme 59 (i) 3eq allyl amine, 0.1eq p-TsOH, benzene, Dean-Stark, reflux, 18 h,  
(ii) NaBH4, MeOH, 0oC, 1 h or (iii) 1.4eq allyl amine, rt, 24 h,  
(iv) 1.2eq NaBH4, MeOH, 0oC, 1.5 h 
 
Initially the reductive amination to form N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-
propen-1-amine 210 was performed according to the procedure outlined by Pathak and 
developed previously in our laboratories.129 In this procedure 2-allyl-3-isopropoxy-4-
methoxybenzaldehyde 138, allyl amine and the acid catalyst p-TsOH were dissolved in 
benzene and heated at reflux using a Dean-Stark head for 18 h, after which time the benzene 
was removed under reduced pressure, and the resulting mixture extracted with 
dichloromethane and saturated sodium bicarbonate solution. The residue was subsequently 
redissolved in methanol, cooled to 0oC, after which sodium borohydride was added and it was 
stirred at rt for 1 h. The desired compound 210 was then obtained in 90% yield over two steps 
after extraction.  
 
Although this method worked well, it was tedious to perform and we sought a simpler 
alternative. It was found that the imine 209 could be prepared under solvent-free conditions 
using only allyl amine at rt, as outlined in Section 2.1.3 and Scheme 58. The imine was 
exceptionally stable and could then be used in the reduction outlined in Scheme 59 (iv). The 
N-[(E)-(2-allyl-3-isopropoxy-4-methoxyphenyl)methylidene]-2-propen-1-amine 209 was then 
dissolved in methanol and cooled to 0oC before the addition of sodium borohydride. The 
solution was then stirred for 1.5 h, an extraction was performed and the solvent was removed 
in vacuo. The desired compound 210 was thereby obtained as a yellow oil in 81% yield. 
 
Owing to the success of the imine reduction 209 we then attempted a one-pot reductive 
amination using our new procedure on aldehyde 138. 2-Allyl-3-isopropoxy-4-
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methoxybenzaldehyde 138 was stirred with allyl amine under solvent-free conditions for 24 h. 
Then the excess allyl amine was removed under reduced pressure and the residue was 
dissolved up in methanol. To the methanolic solution was then added sodium borohydride and 
it was stirred for 1.6 h at rt. After the workup the solvent was removed in vacuo and the amine 
210 was obtained in 84% yield over the two steps.  
 
The imine 209 product was identified as outlined in Section 2.1.3 and the conversion of the 
imine to the desired amine 210 was followed to determine product formation. The 
characteristic changes that proved that the reduction had occurred were the disappearance of 
the N=CH peaks (singlet at 8.44ppm in the 1H NMR spectrum and 160.4ppm in the 13C NMR 
spectrum) and the appearance of new N-CH2 (singlet at 3.69ppm in the 1H NMR spectrum 
and 44.6ppm in the 13C NMR spectrum) and NH (broad singlet at 1.42) peaks in the 1H and 
13C NMR spectra respectively. All other spectroscopic data correlated to the reported values 
in the literature.5  
 
2.1.5 Protection of the Amine 
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Scheme 60 (i) 1.5eq acetic anhydride, 2.5eq pyridine, rt, 3 h, or 211 R = Ac 
(ii) 1.2eq Boc2O, 0.1eq DMAP, THF, rt, 3 h, or 212 R = Boc 
(iii) 2.5eq NEt3, 1.1eq α-toluenesulfonyl chloride, CH2Cl2, rt, 3 h, or 213 R = SO2Bn 
(iv) 1.4eq NEt3, 1.2eq tosyl chloride, CH2Cl2, 0oC, 3.5 h 139 R = Ts 
 
Originally four different protecting groups were chosen for use in this project. We hoped to 
compare how efficient they were as protecting groups, in particular to determine if they would 
remain in place during RCM, and whether or not they influenced the RCM reactions in any 
way. The reactivity with the different groups in place in order to determine if our procedures 
were applicable to a wide variety of substituents. Another reason for our choice of multiple 
protecting groups was to compare the ease with which the different protecting groups could 
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be removed in the final compounds in order to produce molecules that were similar in 
structure to a number of the natural products. 
 
Table 1 Yields for Protecting Group Additions 
 R Yield (%) 
211 
212 
213 
139 
Ac 
Boc 
SO2Bn 
Ts 
92 
97 
62 
94 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-propen-1-amine 210 was dissolved in 
pyridine and this was cooled to 0oC in an ice-water bath. Then a solution of acetic anhydride 
in pyridine was added dropwise to the amine, before the reaction mixture was allowed to 
warm to rt. The reaction mixture was subsequently stirred at rt for 3 h, before being subjected 
to workup. The resulting mixture was purified by column chromatography and N-allyl-N-(2-
allyl-3-isopropoxy-4-methoxybenzyl)acetamide 211 was obtained as a yellow oil.  
 
A solution of compound 210 in tetrahydrofuran was also prepared and to this solution was 
added Boc2O and DMAP. The reaction mixture was stirred at rt for 3 h, after which time the 
solvent was removed in vacuo and the residue was purified by chromatography. The Boc 
protected amine 212 was obtained as a pale yellow oil. 
 
To prepare the benzyl sulfonyl protected amine 213, compound 210 was dissolved in 
dichloromethane and to this solution was added triethylamine. The solution was then stirred 
for 15 min before the dropwise addition of a solution of α-toluenesulfonyl chloride in 
dichloromethane. The reaction mixture was stirred for 3 h at rt before the solvent was 
removed in vacuo. The residue was purified by chromatography to yield N-allyl-N-(2-allyl-3-
isopropoxy-4-methoxybenzyl)phenylmethanesulfonamide 213 as a yellow oil. 
 
Finally, to a stirred solution of compound 210 in dichloromethane at 0oC, was added 
triethylamine and tosyl chloride. The reaction mixture was stirred for 4 h and the resulting 
mixture was subjected to an extraction before the solvent was removed in vacuo. The residue 
was purified by column chromatography and N-allyl-N-(2-allyl-3-isopropoxy-4-
Chapter 4 Results and Discussion for the 
 Synthesis of N-containing benzo-fused heterocycles 
71
methoxybenzyl)-4-methylbenzenesulfonamide 139 was obtained in as a pale yellow oil that 
solidified on standing. The characterization of 139 by 1H and 13C NMR spectroscopy 
corresponded to the literature data,129 with both the 1H and 13NMR spectra providing evidence 
for the presence of the tosyl group. The signals due to the aromatic methyl group of the tosyl 
substituent were observed at 2.44ppm and two doublets due to the aromatic tosyl group were 
present at 7.32 and 7.73ppm, each with coupling constants of ~8.1Hz. 
 
Since the three amine derivatives 211-213 were new compounds, they were characterised 
thoroughly by 1H NMR, 13C NMR and IR spectroscopic techniques. The thorough 
characterisation involved the use of HRMS that suggested that the expected compounds were 
obtained. A brief outline of the characteristic signals in the new compounds 211-213 are 
outlined in Table 2 below. 
 
Table 2 Characteristic Spectroscopic Signals for the Protected Compounds 
 1H NMR 13C NMR 
211 
 
 
212 
 
 
 
213 
2.05 and 2.14ppm (CH3) 
 
 
1.46ppm [OC(CH3)3] 
 
 
 
4.25ppm (SO2CH2Ar) 
7.38ppm (SO2CH2Ar-H) 
21.4ppm (CH3) 
170.8 and 171.2ppm (C=O) 
 
30.3ppm [OC(CH3)3] 
80.0ppm [OC(CH3)3] 
155.6ppm (C=O) 
 
58.9ppm (SO2CH2Ar) 
127.1, 128.6, 130.7ppm (SO2CH2Ar-C) 
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       Table 2 contd. Characteristic Spectroscopic Signals for the Protected Compounds 
 IR HRMS 
211 
 
 
212 
 
 
213 
1637cm-1 (tertiary amide) 
 
 
1689cm-1 (C=O stretch) 
 
 
671 and 750cm-1 (5 adj Ar H) 
1152cm-1 (SO2) 
1273 and 1337cm-1 (SO2-N) 
C19H27NO3 Calculated: 317.19909 
Found: 317.19972 
 
C22H33NO4 Calculated: 375.24096 
Found: 375.24500 
 
C24H31NO4S Calculated: 429.19738 
Found: 429.19707 
 
2.2 Synthesis of Benzazocines (8-membered rings) 
 
At this point we decided it could be worthwhile to synthesize a range of protected 
benzazocines based on the RCM methodology outlined by Pathak129 in which the tosyl-
protected benzazocine 140 was prepared from the simple benzaldehyde 138. As this method 
had not been used for the synthesis of any other protected benzazocines, we hoped to extend 
the methodology to include a wider range of protected compounds, and also to show its 
versatility in the synthesis of deprotected 1,2,3,6-tetrahydro-2-benzazocines and the 
hydrogenated 1,2,3,4,5,6-hexahydro-2-benzazocines. The general retrosynthesis for 
compound 140 is outlined in Scheme 61 below.  
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Scheme 61 Retrosynthesis for the Benzazocines 
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 2.2.1 Ring Closing Metathesis to Form Benzazocines 
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Scheme 62 (i) 5 mol % catalyst 11, toluene, 60oC, 1 h 
 
The general procedure employed for the synthesis of the benzazocines was to dissolve the 
diene 139, 211-213 in distilled toluene and to heat the solution to 60oC. Then 5 mol % Grubbs 
II catalyst 11 was added and the reaction mixture was allowed to stir at 60oC for 1 h. After 
this time the solvent was removed in vacuo and the residue was purified by column 
chromatography to yield the corresponding benzazocine 140, 214-216. The yields for the 
RCM reactions are shown in Table 3 below along with a description of the product formed. 
 
Table 3 Yields and Products Formed by Ring Closing Metathesis 
 R Yield Product Formed 
214 
215 
216 
140 
Ac 
Boc 
SO2Bn 
Ts 
82% 
99% 
84% 
98% 
clear oil 
clear oil 
white crystals 
colourless crystals 
 
The formation of 1-[7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocin-2(1H)-yl]-1-ethan-
one 214 was proven based on the spectroscopic data. The terminal alkene peaks present in the 
1H NMR of the diene 211 disappeared, and these were replaced by a multiplet integrating for 
two protons at 5.86ppm. The three CH2 peaks (dd at 3.51ppm integrating for 2H; two d at 
3.85 and 4.17ppm, integrating for 1H each; and d at 4.64ppm, integrating for 2H) were 
present in the 1H NMR spectrum of 214, allowing us to conclude that no isomerisation had 
occurred prior to RCM. The three CH2 signals were also present in the 13C NMR spectrum at 
24.7 and 25.3ppm, 44.1 and 45.4ppm and 50.9 and 52.8ppm (doubling due to rotamers). Both 
the methyl group (22.0 and 22.4ppm) and the carbonyl group (170.4 and 170.9ppm) showed 
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signals in the 13C NMR spectrum, proving that the amine had not undergone a deprotection. 
All the signals are doubled up in both the 1H and 13C NMR spectra due to the presence of 
amide rotamers. The compound 214 was further analyzed by HRMS and a peak was found at 
298.16371, which is characteristic of the product (C17H23NO3 requires 289.16779). 
 
The preparation of tert-butyl 7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocine-2(1H)-
carboxylate 215 was also confirmed from the supporting spectroscopic data. The CH=CH2 
protons in the 1H NMR spectrum of the starting material 212 at 4.90-5.11ppm; were replaced 
by an alkene signal (multiplet) at 5.79ppm which integrated for 2H. The CH2 signals showed 
small shifts, viz. 3.45 to 3.53ppm, 3.67 to 3.82 and 4.00ppm, 4.38 to 4.49ppm for the 
ArCH2C, NCH2C and ArCH2N groups respectively. The nine methyl protons for the Boc 
protecting group were accounted for in the region of 1.38ppm. 13C NMR spectral analysis of 
the molecule found two new signal regions present in the molecule (at 128.1 and 128.4ppm 
for 5-C and at 130.3 and 130.6ppm for 4-C, with doubling due to rotamers). This was coupled 
to the disappearance of the allylic alkene peaks in the starting material 212, the CH=CH2 
peaks at 114.8 and 116.4ppm and the CH=CH2 peaks at 133.7 and 136.2ppm. HRMS analysis 
of compound 215 found a peak at 347.20551, with the calculated value for C20H29NO4 being 
347.20966. 
 
The RCM reaction to form 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-
benzazocine 216 was also deemed a success based on the spectroscopic data. The 1H NMR 
spectrum of the product 216 highlighted the formation of new peaks at 5.60 (1H, td, J=7.1 and 
10.5Hz) and 6.06ppm (1H, td, J=7.3 and 10.3Hz), which correspond to positions 4-H and 5-H 
respectively. The simultaneous disappearance of the allylic alkene protons in the starting 
material 213 was noted (4.80 and 4.93, ArCH2CH=CH2; 5.06, NCH2CH=CH2; 5.62, 
NCH2CH=CH2; 5.80ppm ArCH2CH=CH2). 13C NMR spectroscopic analysis showed the 
presence of the three CH2 peaks at 26.8, 44.8, and 59.4ppm, concluding that no isomerisation 
had occurred before RCM. Two new signals were found at 125.6 and 135.4ppm, 
corresponding to 4-C and 5-C respectively. The compound 216 was further analyzed by 
HRMS and a peak was found at 401.16655, which corresponds to the molecular peak for 
C22H27NO4S at 401.16608.  
 
The crystal structure was obtained for compound 216 and showed the formation of the 8-
membered ring. The structure was found to have a buckeled ring (similar to the chair 
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conformation found in the 6-membered rings) with the double bond clearly in place. This is 
shown by the ORTEP diagram displayed in Figure 28 below, with details outlined in 
Appendix B.  
 
Figure 28 ORTEP diagram of compound 216  
(showing the 50% probability thermal ellipsoids for all non-hydrogen atoms). 
 
We also synthesized 7-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetra-
hydro-2-benzazocine 140 according to the procedure previously developed in our laboratories 
and reported by Pathak et al.5 and found our NMR spectroscopic data agreed very well with 
that reported. IR and high-resolution mass spectroscopy were not performed as the compound 
had previously been synthesized in our laboratories.  
 
 2.2.2 Hydrogenation Reaction on Compound 216 
 
A hydrogenation reaction was performed on compound 216 in an attempted deprotection 
reaction. This procedure was employed as it was hoped that it would prove to be a simple 
method for the deprotection of the SO2Bn systems; other methods include the use of Raney 
nickel211 and photolysis.212 If the deprotection failed, we were hoping to be able to isolate and 
characterize the hydrogenated compound, thus proving that the systems could be 
hydrogenated if need be. 
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Scheme 63 (i) 10% Pd/C, 5 atm H2, EtOH, rt, 18 h  
 
The 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,4-tetrahydro-2-benzazocine 216 was 
dissolved in absolute ethanol through the use of sonnication. To the emulsion was added 10% 
Pd/C and the solution was subjected to hydrogenation in an autoclave at 5 atm H2 for 18 h. 
The reaction mixture was then filtered, rinsed with CH2Cl2, the solvent was removed in vacuo 
and the solid collected was recrystallised from EtOAc-Hexane to yield 2-(benzylsulfonyl)-7-
isopropoxy-8-methoxy-1,2,3,4,5,6-hexahydro-2-benzazocine 217 as colourless crystals in 
98% yield. None of the deprotected amine was observed.  
 
The product 217 was identified by the characteristic loss of the alkene protons and the 
appearance of two new CH2 groups in both the 1H and 13C spectra. 1H NMR spectroscopy 
showed the loss of the alkene peaks at 5.60 (1H, td, J=7.1 and 10.5Hz, 4-H) and 6.06ppm 
(1H, td, J=7.3 and 10.3Hz, 5-H) and the appearance of new CH2 peaks at 1.51 (2H, m, 4-H) 
and 1.66ppm (2H, m, 5-H). 13C NMR spectroscopy showed the loss of the alkene peaks at 
125.6 (4-C) and 135.4ppm (5-C) and the appearance of new CH2 peaks at 24.0 (5-C*) and 
29.3ppm (4-C1). The success of the reaction was further shown by the loss of the C=C 
isolated stretch at 1691cm-1 in the IR spectrum. HRMS analysis found a peak at 403.18176, 
which corresponds to the calculated peak for C22H29NO4S at 403.18173. 
 
The structure of the hydrogenated compound 217 was confirmed by a single-crystal X-ray 
structure. The structure was exceptionally interesting as it showed the presence of two 
distinctly different and completely unsymmetrical molecules in the unit cell. The ORTEP 
diagram is shown in Figure 29 below (further information may be found in Appendix B). 
 
                                                 
1 These two assignments may be interchanged as no C-H correlated spectrum was run that would identify them 
unambiguously. 
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Figure 29 ORTEP diagram of compound 217 
(showing the 50% probability thermal ellipsoids for all non-hydrogen atoms 
 
2.2.3 Deprotection Reaction of compound 215 
 
With the deprotection of the SO2Bn protected amine 216 having failed we wanted to attempt 
the deprotection reaction on another one of our amine protected benzazocine systems. 
Considering that Boc deprotections are relatively simple to perform and due to the complexity 
of the Boc protected NMR spectra (due to the presence of amide rotamers), we decided to 
attempt the deprotection reaction on benzazocine 215. 
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Scheme 64 (i) 1.5eq trifluoroacetic acid, CH2Cl2, rt, 1 h 
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A solution was prepared of the tert-butyl 7-isopropoxy-8-methoxy-3,6-dihydro-2-
benzazocine-2(1H)-carboxylate 215 in CH2Cl2 and to this solution was added trifluoroacetic 
acid. The reaction mixture was then left to stir at rt for 1 h, before being diluted with water 
and EtOAc. The mixture was then neutralized and extracted before the solvent was removed 
in vacuo. A dark orange semi-solid was obtained that was essentially pure by spectroscopy 
and no further purification was performed. 7-Isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-
benzazocine 218 was thus obtained in 99% yield. This result is indeed promising as it 
confirms that if we want to perform further N-alkylations on systems like 215 the Boc-
protection group is readily removed. 
As this was a new compound, characterisation involved NMR and IR spectroscopy as well as 
high-resolution mass spectroscopy. The 1H NMR spectrum highlighted the loss of the Boc 
protecting group by the lack of nine protons at 1.38ppm as well as by the presence of a new 
singlet at 8.84ppm for the NH. The 13C NMR spectrum also showed the loss of the Boc group 
by the lack of the peaks at 28.4 [OC(CH3)3] and 79.4 and 79.5 ppm [OC(CH3)3]. HRMS 
confirmed the formation of 7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 218 by 
a peak at 247.15654 which corresponds to the peak for C15H21NO2  (calculated to be present 
at 247.15723). 
 
2.3 Synthesis of Isoquinolines (6-membered rings) 
 
It had been previously shown in our laboratories that by treating diene 139 with 0.5 mol % 
catalyst 12 at 110oC for 2 h followed by RCM using Grubbs II catalyst 11, the 1,2-
dihydroisoquinoline ring system 142 was obtained, which alludes to the isomerisation of both 
double bonds. The general retrosynthesis illustrating our approach to the isoquinolines is 
shown below in Scheme 65 
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Scheme 65 Retrosynthesis for the Isoquinolines 
 
We decided to investigate this process, consisting of isomerisation followed by RCM, further 
by including the presence of other protecting groups. We initially tried the one-pot 
isomerisation-RCM procedure outlined by Pathak129 on our Ac-, Boc- and SO2Bn- protected 
compounds (211, 212 and 213 respectively). This procedure failed dismally with the products 
from the reactions being mixtures that were largely inseparable and generally unidentifiable.  
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Scheme 66 (i) 1 mol % catalyst 12, toluene, 110oC, 2 h,  
(ii) 5 mol % catalyst 11, toluene, 110oC, 2 h 
 
The only reaction that gave any identifiable product was with the use of the Boc protected 
compound 212, from which we were only able to isolate 10% of the desired product 2-acetyl-
5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 220. The procedure used for this reaction 
was to dissolve the amine 212 in distilled toluene, to heat the solution to 110oC and then to 
add 1 mol % Ru-isomerisation catalyst 12. The reaction mixture was then stirred for 2 h 
before the addition of 5 mol % of Grubbs II catalyst 11. The reaction mixture was then stirred 
for a further 2 h, the solvent was removed in vacuo and the residue was purified by 
chromatography.  
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The formation of product 220 was indicated by the loss of both the alkene protons in the 1H 
NMR spectrum of the starting material, as well as by the appearance of methyl groups in the 
spectrum of the isomerised intermediate. The presence of the double bond in the ring was 
shown by the multiplet at 5.83-5.91ppm, which was assigned as 4-H, and the multiplet at 
7.24-7.28ppm, which was assigned, as 3-H. The peak for the CH2 group was present in the 
multiplet between 4.47 and 4.77ppm. The spectral analysis of this compound was particularly 
problematic due to the presence of amide rotamers and the excessive broadening of the peaks 
due to the Boc protecting group. No variable temperature NMR was available to us that would 
have aided with this problem and insufficient material was recovered in order to perform the 
deprotection reaction that would simplify the spectra.  
 
We then decided to proceed by repeating the experiment outlined by Pathak129 (namely the 
tosyl protected compound 139) to confirm that there were no problems with our setup and 
experimental technique.  
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Scheme 67 (i) 5.5 mol % catalyst 12, toluene, 110oC, 4 h,  
(ii) 5 mol % catalyst 11, toluene , 110oC, 21 h 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzenesulfonamide 139 
was dissolved in distilled toluene and the solution was degassed. Then 0.5 mol % Ru-
isomerisation catalyst 12 was added and the reaction mixture was stirred for 2 h at 110-120oC. 
After this time 1H NMR spectroscopy showed no isomerisation had occurred so a further 5 
mol % isomerisation catalyst was added and the reaction mixture was stirred for a further 2 h. 
After this additional time 1H NMR spectroscopy showed total isomerisation of both of the 
double bonds. Grubbs II catalyst 11 (5 mol %) was then added and the reaction mixture was 
allowed to stir for 21 h at 110oC. After cooling the reaction mixture to rt and removing the 
solvent in vacuo, the resulting residue was purified by column chromatography to yield the 
desired product 5-isopropoxy-6-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2-dihydroisoquino-
Chapter 4 Results and Discussion for the 
 Synthesis of N-containing benzo-fused heterocycles 
81
line 142 in a poor 27% yield. This result was compared to that of Pathak129 and she obtained 
the product in 76% yield; the difference in yield was upsetting and led us to the decision that 
we should isolate the products directly after isomerisation in order to confirm the formation of 
the bis-isomerised compound and to hopefully improve the yield of the subsequent RCM. 
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Scheme 68 (i) 5 mol % catalyst 12, toluene, 100-110oC, 19 h 
 
This was then initially attempted for the N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-
acetamide 211 and for the N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-
phenylmethanesulfonamide 213. In both instances, the amine 211 or 213 was dissolved in 
distilled toluene and degassed. The solution was then heated to 100-110oC before the addition 
of 5 mol % of the Ru-isomerisation catalyst 12. The reaction mixture was then stirred for 19 
h, the solvent was removed in vacuo and the residue was purified by column chromatography. 
N-[3-Isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-N-(1-propenyl)acetamide 221 and N-[3-
isopropoxy-4-methoxy-2-(1-propenyl)benzyl](phenyl)-N-(1-propenyl)methanesulfonamide 
222 were obtained in yields of 94% and 87% respectively.  
 
Compound 221 was characterized by the loss of the “terminal methylene signals” and 
terminal alkene peaks of the starting material in the 1H and 13C NMR spectra, as well as the 
corresponding loss of the terminal RHC=CH2 stretches in the FTIR spectrum. The product 
221 showed significant splitting of the signals due to the presence of amide rotamers in both 
the 1H and 13C NMR spectra. The signals for the methyl groups were found at 1.59 and 
1.65ppm as well as at 1.91-1.95 and 2.04-2.07ppm in the 1H NMR spectrum. The 
corresponding signals were present at 15.3 and 15.5ppm for NCH=CHCH3 and at 19.0 and 
19.1ppm for ArCH=CHCH3 in the 13C NMR spectrum. The FTIR spectrum showed a signal 
at 1645cm-1 which was due to either the tertiary amide or the C=C conjugated with C=O. 
Finally, the compound was analysed by HRMS and the molecular ion was found at 317.19862 
(C19H27NO3 requires 317.19909). 
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In the same manner, product 222 was identified by the characteristic loss of the terminal 
alkene and CH2 peaks in both the 1H and 13C NMR spectra, coupled with the presence of two 
new methyl group peaks. These were found at 1.52 and 1.85ppm in the 1H NMR spectrum 
and at 15.2 and 19.0ppm in the 13C NMR spectrum. The structure of 225 was further 
confirmed by HRMS where a peak was found at 429.19830 that corresponded to the required 
molecular ion peak at 429.19738 for C24H31NO4S. 
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Scheme 69 (i) 5 mol % catalyst 11, toluene, 110oC, 3 h 
 
Knowing that there were no problems with the isomerisation step of the reaction, we were 
then able to move on to the metathesis reaction. Both compounds 221 and 222 were then 
dissolved in toluene and heated to 110oC before the addition of 5 mol % Grubbs II catalyst 11. 
The reaction mixture was then stirred for 3 h, before it was cooled to rt, the solvent was 
removed in vacuo and the resulting residue was purified by column chromatography. 2-
Acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquin-oline 223 was obtained as a clear oil in 
78% yield, but unfortunately, in the other reaction none of the desired 2-(benzylsulfonyl)-5-
isopropoxy-6-methoxy-1,2-dihydroisoquinoline 224 was obtained.  
 
2-Acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 223 was identified by the 
characteristic loss of the methyl signals and the shift of the alkene signals in both the 1H and 
the 13C NMR spectra. The FTIR spectrum for the product highlighted a peak at 669cm-1 for a 
cis alkene and a peak at 1625cm-1 which was due to the conjugated C=C and C=O. The 1H 
NMR spectrum displayed the signals for 4-H at 6.17 and 6.20ppm and the signals for 3-H at 
7.27 and 7.37ppm. The 13C NMR spectrum showed the peaks for 4-C at 105.3 and 105.6ppm 
and the peaks for 3-C at 125.4 and 125.8ppm. HRMS analysis of the compound showed a 
peak at 261.13696, which corresponds to that for C15H19NO3 at 261.13649. 
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The poor yields for the formation of 2-acetyl-5-isopropoxyx-6-methoxy-1,2-
dihydroisoquinoline 223 in 10% yield and for the formation of 5-isopropoxy-6-methoxy-2-
[(4-methylphenyl)sulfonyl]-1,2-dihydroisoquinoline 142 in 27% yield, as well as the lack of 
product formation for 2-(benzylsulfonyl)-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 
220, may be attributed to the steric hindrance caused by the bulky protections group. This 
may be preventing the ruthenium metal carbene from attaching to the site, thus preventing 
metathesis from occurring. The poor yields are also highlighted by the formation of a number 
of de-allylated by-products that were isolated and characterized. They are discussed fully in 
Section 2.5 below.  
 
2.4 Synthesis of Benzazepines (7-membered rings) 
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Scheme 70 (i) TsNH2, toluene, 110oC, 20%, (ii) 1 mol % catalyst 12, toluene, 90oC,  
2 h, 100%, (iii) NaBH4, MeOH, 0oC, 30 min, 98%, (iv) allyl bromide, NaH, THF, rt,  
6 h, 64%, (v) 5 mol % Grubbs II catalyst 11, toluene, 60oC, 2 h, 100% 
 
Previously the tosyl-protected 7-membered benzo-fused ring had been prepared in our group 
by a conversion of benzaldehyde 138 into the N-tosyl-protected imine 225 followed by the 
isomerisation of the terminal alkene, which led to the formation of the thermodynamically 
more stable styrene-type system 143. At this point the N-tosylimine 143 was reduced with 
sodium borohydride in methanol at 0oC to afford the amine 226 in 98% yield. The resultant 
amine 226 was then alkylated with allyl bromide in the presence of sodium hydride to give 
the N-allylated compound 144 in reasonable yield. Finally the precursor 144 was subjected to 
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metathesis conditions and gave the expected product, 2,3-dihydro-1H-2-benzazepine 145 in 
quantitative yield.  
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Scheme 71 Retrosyntheses to the Benzazepine Ring systems 
 
Alluding from this we decided to test whether we could selectively isomerise only one of the 
double bonds in our diene systems 139, 211-213 using the Ru-isomerisation catalyst 12, in 
order to access the benzazepine ring systems via a shorter route. In addition this could grant 
us access to the 7-membered systems where the double bond was in either of the two 
positions selectively, namely the 2,5-dihydro-2-benzazepines and the 2,3-dihydro-2-
benzazepines. Our approach is illustrated by the retrosyntheses in Scheme 71 above.  
 
2.4.1  Preparation of 2,5-dihydro-1H-2-benzazepines 
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Scheme 72 (i) Ru-isomerisation catalyst 12, toluene, 80oC, 20 h 
 
Initially, we attempted the isomerisations by employing a combinatorial approach. We set up 
the Carousel reactor with twelve reactions, thus each of the four protected amines had three 
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reaction vessels, with 0.5 mol %, 1 mol % and 2 mol % of the Ru-isomerisation catalyst 12 
respectively. The results of the reactions are outlined in Table 4 below. Each of the protected 
amines was dissolved in distilled toluene and the solution was degassed for 5 min using N2. 
Then Ru-isomerisation catalyst 12 was added and the solutions were heated to 80oC for 20 h 
(the temperature of 80oC was chosen to avoid double isomerisation that was shown to occur at 
110oC). After this time they were allowed to cool to rt, the solvent was removed in vacuo and 
the residues were then subjected to column chromatography. Initial determination of the 
products was by NMR spectroscopy, but this was subsequently supported by IR and HRMS 
spectroscopy. 
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Figure 27 Diagrammatic Representation of Products Formed 
 
Table 4 Results of Isomerisation Reactions 
R Catalyst 12 Product Formed Yield 
Ac 
Ac 
Ac 
Boc 
Boc 
Boc 
SO2Bn 
SO2Bn 
SO2Bn 
0.5 mol % 
1 mol % 
2 mol % 
0.5 mol % 
1 mol % 
2 mol % 
0.5 mol % 
1 mol % 
2 mol % 
227 
227 
227 
SM 
228 
228 
SM 
229 
222 + 229 
44% 
77% 
60% 
- 
80% 
70% 
- 
90% 
inseperable mixture
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Table 4 contd. Results of Isomerisation Reactions 
R Catalyst 12 Product Formed Yield 
Ts 
 
Ts 
 
Ts 
0.5 mol % 
 
1 mol % 
 
2 mol % 
SM 
 
SM + 230 
 
SM + 230 
- 
 
26% (58% SM 
recovered) 
57% (14% SM 
recovered) 
 
As can be seen from Table 4 above, the N-allyl chain shows the greater tendency for 
isomerisation and is thus favoured for all the protected amines. The best yields were obtained 
for 1 mol % isomerisation catalyst 12 for all of the compounds except the tosyl protected 
amine 139, where 2 mol % 12 was favoured.  
 
N-(2-Allyl-3-isopropoxy-4-methoxybenzyl)-N-(1-propenyl)acetamide 227 was fully 
characterized through the use of HRMS, NMR and IR spectroscopy. 1H NMR spectroscopy 
showed the presence of a multiplet at 1.63ppm for the methyl group and also showed signals 
for both of the alkene protons; a multiplet at 5.91 for NCH=CH and a doublet at 7.35ppm for 
NCH=CH. We were able to identify which of the double bonds isomerised based on the 13C 
NMR spectrum because of the large differences in the 13C NMR for the different CH2 groups. 
Our assignments were then supported by CH and COSY spectra. In the starting material 211, 
the NCH2C group had signals at 48.1 and 49.2ppm and the ArCH2C group showed peaks at 
30.0 and 30.5ppm. In the product 227, the signals at 48.1 and 49.2ppm had disappeared and 
the signal at 30.2 and 30.4ppm was present, allowing us to conclude that the N-allyl chain had 
isomerised. The ArCH2N signals remained unchanged and new methyl signals were found at 
15.3 and 15.5ppm for the CH=CHCH3 group. The product 227 was then analyzed by HRMS 
and a peak was found at 317.19916, which corresponds to the molecular peak for C19H27NO3 
at 317.19903.  
 
The same process of analysis was applied to the other new compounds 228-230. They were 
fully analyzed base on NMR and IR spectroscopy. HRMS confirmed the molecular ions for 
the products were present. The characteristic peaks in the new compounds are outlined briefly 
in Table 5 below. Two new methyl groups were found in both the 1H and the 13C NMR 
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spectra for 222, allowing us to conclude that both the double bonds had isomerised (see 
Section 2.3 above).  
 
Table 5 Characteristic Signals for Compounds 228-230 
Compound 1H NMR 13C NMR HRMS 
228 
 
 
 
229 
 
 
 
230 
 
 
1.49ppm CH3 
 
 
 
1.53ppm CH3 
 
 
 
2.44ppm CH3 
15.3ppm CH3 
104.2ppm CH=CHCH3 
124.7ppm CH=CHCH3 
 
15.2ppm CH3 
107.0ppm CH=CHCH3 
135.8ppm CH=CHCH3 
 
21.5ppm CH3 
137.1ppm CH=CHCH3 
C22H33NO4  
Calculated: 375.24096 
Found: 375.24162 
 
C24H31NO4S 
Calculated: 429.19738 
Found: 429.19812 
 
C24H31NO4S 
Calculated: 429.19738 
Found: 429.19760 
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Scheme 73 (i) Grubbs II catalyst 11, toluene, 60oC, 19-25 h 
 
Having successfully prepared the isomerised dienes 227-230 we were finally in a position to 
subject them to the metathesis conditions. RCM was performed on the compounds by 
preparing a solution of the diene 227-230 in distilled toluene and then heating the solution to 
60oC before the addition of Grubbs II catalyst 11. After 19-25 h the solutions were allowed to 
cool to rt, the solvent was removed in vacuo and the resulting residues were subjected to 
column chromatography. The yields of the benzazepines 231-234 are outlined in Table 6 
below.  
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Table 6 Yields for RCM Reactions to form 231-234 
Compound R Grubbs II 
catalyst 11 
Temp Time Yield 
231 
232 
233 
234 
Ac2 
Boc 
SO2Bn 
Ts 
10 mol % 
5 mol % 
5 mol % 
5 mol % 
80oC 
60oC 
60oC 
60oC 
25 h 
24 h 
19 h 
25 h 
9% 
82% 
58% 
47% 
 
We were able to confirm the formation of the 7-membered ring by the disappearance of the 
signals for the methyl group and terminal alkene group in the starting materials. This was 
further supported by the presence of two new alkene peaks (that had different shifts to the 
original alkene values). HRMS confirmed that the expected molecular ion was present in all 
the newly prepared compounds 231-234. This procedure of identification is explained below 
for the conversion of compound 228 to 232 (where R=Boc). 
 
The CH3 peak at 1.49ppm and the terminal alkene peaks at 4.93 and 5.03ppm which were 
present in the 1H NMR spectrum of the starting material 228 had disappeared after the 
reaction. The 1H NMR spectrum of the product 232 showed new alkene signals at 5.87-
5.93ppm (4-H) and 6.72-6.75ppm (3-H and Ar-H), which had a significantly shifted from 
those of the starting material 228: 5.89ppm (1H, dq, CH=CH2) and 6.63ppm (1H, d, NCH=C). 
This was supported by the corresponding disappearance of the CH3 peak at 15.3ppm and the 
terminal alkene peak at 115.2ppm in the 13C NMR spectrum of the starting material 228. The 
13C NMR spectrum for tert-butyl 6-isopropoxy-7-methoxy-1,5-dihydro-2H-2-benzazepine-2-
carboxylate 232 showed the alkene protons were present at 104.2ppm (4-C) and 124.7ppm (3-
C). These assignments were confirmed by COSY and CH correlated spectra. Product 
formation was further supported by the HRMS spectra, which found a peak at 333.19534 
(C19H27NO4 requires 333.19401). The identical method of identification was employed for the 
assignment of the other ring-closed compounds 231, 233 and 234. The characteristic peaks 
used in these assignments are outlined in Table 7 below. 
 
 
                                                 
2 Having attempted the reaction with 5 mol % Grubbs II catalyst 11 at 60oC and having isolated no product, we 
retried the experiment with 10 mol % Grubbs II catalyst 11 at 80oC. The desired product was obtained, but in 
poor yield. 
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Table 7 Characteristic Signals used for Identification of Benzazepines 231, 233, 234 
Compound R 1H NMR 13C NMR HRMS 
231 
 
 
 
233 
 
 
234 
Ac 
 
 
 
SO2Bn 
 
 
Ts 
6.36ppm 4-H 
7.57ppm 3-H 
 
 
5.79-6.01ppm 4-H 
6.32ppm 3-H 
 
5.90-6.02ppm 4-H 
6.21ppm 3-H 
113.7ppm 4-C 
135.7ppm 3-C 
 
 
115.3ppm 4-C 
137.1ppm 3-C 
 
124.9ppm 4-C 
132.6ppm 3-C 
C16H21NO3  
Calculated: 275.15214 
Found: 275.15020 
 
Insufficient Material 
 
 
Insufficient Material 
 
2.4.2 Preparation of 2,3-dihydro-1H-2-benzazepines 
 
Accepting that we had synthesized the one type of benzazepine, we were hopeful that by 
changing the order of our synthetic steps we would be able to afford the benzazepines with 
the double bond in the 4-position. The substituted benzaldehyde 138 (Scheme 74) was used 
as the starting material for this synthetic strategy, and the initial step was to isomerise the allyl 
bond. This isomerisation step had been previously attempted in our laboratories using various 
isomerisation methods, including the use of potassium tert-butoxide and palladium (II) 
chloride. However, Coyanis48 found the Ru-isomerisation catalyst 12 to be the most effective. 
Following this route, the reductive amination was performed and the subsequent free amine 
235 was protected with each of the four protecting groups earmarked for this methodological 
study. This then set the scene for us to perform the metathesis reaction in order to obtain the 
2,3-dihydro-2-benzazepine series. This method was a favoured alternative to that of Pathak 
(Section 2.3 Scheme 72) as it would ultimately allow a wide variety of different benzazepines 
to be synthesized from a common intermediate.1 
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Scheme 74 (i) 2 mol % catalyst 12, toluene, 80oC, 23 h 
 
The previously prepared benzaldehyde 138 was dissolved in toluene and the solution was 
heated to 80oC before the addition of the Ru-isomerisation catalyst 12. The reaction mixture 
was then stirred for 23 h; after this time 1H NMR spectroscopy showed partial isomerisation, 
so a further 2 mol % Ru-isomerisation catalyst 12 was added. After the reaction mixture was 
stirred for a further 23 h, the solvent was removed in vacuo and the remaining residue was 
purified by column chromatography. 3-Isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 
201 was obtained as a yellow-brown oil that solidified on standing in 92% yield.  
 
The formation of 3-isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 201 was proven by 
the loss of the allyl alkene protons and the presence of a new methyl group and new alkene 
protons in the 1H NMR spectrum. The signals for these were found at 1.98ppm (CH3), 5.80-
6.09ppm (ArCH=CHCH3) and 6.59-6.73ppm (ArCH=CHCH3) respectively, with mixtures of 
E/Z isomers being present in each of the alkene regions. The corresponding changes were 
observed in the 13C NMR spectrum, a new methyl peak was found at 19.0ppm and new alkene 
peaks were found at 125.2ppm (ArCH=CHCH3) and 136.1ppm (ArCH=CHCH3). All of the 
other signals in the proton and carbon spectra corresponded to those described by Coyanis.48 
 
236 235
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Scheme 75 (i) 1.4eq allyl amine, rt, 22 h, (ii) 1.2eq NaBH4, MeOH, 0oC, 2 h 
 
The N-{[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]methylidene}-2-propen-1-amine 236 
was prepared according to the procedure outlined in Section 2.1.3 above. The 3-isopropoxy-4-
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methoxy-2-(1-propenyl)benzaldehyde 201 was stirred with allyl amine for 22 h at rt. Then the 
excess allyl amine was removed in vacuo and the product was isolated as a yellow-orange oil 
in 100% without the need for further purification. The product was identified by the obvious 
loss of the aldehyde peak in both the 1H and 13C NMR spectra. The allyl chain was clearly 
observed in the 1H NMR spectrum by the presence of the CH2 group at 4.20ppm, the 
CH=CH2 at 5.12-5.23ppm and the CH=CH2 at 5.72ppm. The imine formation was proven by 
the presence of the ArCH=N peak at 8.41ppm in the 1H NMR spectrum. Similarly, the CH2 
peak was found at 63.5 and 63.7ppm and the CH=CH2 peak was found at 115.7ppm in the 13C 
NMR spectrum. Also, the CH=CH2 signal was present at 134.0ppm and the ArCH=N peak 
was present at 161.8ppm. The HRMS of the compound identified the molecular ion at 
273.17290 with the expected molecular ion having been calculated to be at 273.17288 (for 
C17H23NO2). In addition FTIR confirmed the presence of the imine through the imine H 
stretch at 3617cm-1. 
 
Step (ii) in Scheme 75 above, outlines the reduction of the imine to form N-[3-isopropoxy-4-
methoxy-2-(1-propenyl)benzyl]-2-propen-1-amine 235. The imine 236 was dissolved in 
methanol and the solution was cooled to 0oC in an ice-water bath. To the methanolic solution 
was then added sodium borohydride and the reaction mixture was stirred at 0oC for 2 h. After 
this time the excess sodium borohydride was destroyed and the residue was extracted. The 
desired product 235 was then obtained as a yellow oil in 82% yield, with no further 
purification required. The product 235 was identified by the characteristic loss of the N=CH 
peak in both the proton and the 13C spectra and by the presence of the new CH2 singlet in the 
proton spectrum at 3.73ppm. This was further supported by the presence of a CH2 peak in the 
carbon spectrum at 51.0ppm and by the broad singlet integrating for one proton at 1.68ppm 
that we identified as the NH peak in the 1H NMR spectrum. FTIR spectroscopy highlighted 
both the NCH2 stretch at 2838cm-1 as well as the NH band at 3666cm-1. HRMS analysis of the 
compound showed a peak at 275.19120, with C17H25NO2 having a calculated molecular ion of 
275.18853. 
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Scheme 76 (i) 1.5eq acetic anhydride, 2.5eq pyridine, rt, 3 h or 237 R = Ac 
(ii) 1.2eq Boc2O, 0.1eq DMAP, THF, rt, 3 h or 238 R = Boc 
(iii) 2.5eq NEt3, 1.1eq α-toluenesulfonyl chloride, CH2Cl2, rt, 18 h or 239 R = SO2Bn 
 (iv) 1.4eq NEt3, 1.2eq tosyl chloride, CH2Cl2, 0oC-rt, 3 h 144 R = Ts 
 
At this point the amine nitrogen needed to be protected. Again, for this section of the project, 
the same four protecting groups were chosen. The protection reactions followed the same 
general procedures as those outlined in the sections above. The yields obtained for the 
protection reactions are outlined in Table 8 below.  
 
Table 8 Yields for Protecting Group Additions 
Compound R Yield (%) 
237 
238 
239 
144 
Ac 
Boc 
SO2Bn 
Ts 
72 
86 
29 
77 
 
A solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-2-propen-1-
amine 235 and distilled pyridine, which was cooled to 0oC. To this was then added dropwise a 
solution of acetic anhydride in pyridine, which was then left to stir at rt for 3 h. After 
purification the desired compound was obtained as a clear oil, with the residue further purified 
by column chromatography. The NMR spectra obtained were exceptionally complex due to 
the presence of amide rotamers as well as the E/Z isomers.The product, N-allyl-N-[3-
isopropoxy-4-methoxy-2-(1-propenyl)benzyl]ac-etamide 237, was identified by the presence 
of two new singlets at 2.08 and 2.13ppm in the 1H NMR spectrum, which corresponded to 
those expected for the acetyl group. This was also confirmed in the 13C NMR spectrum by the 
presence of the new CH3 peaks at 21.4 and 21.5ppm, as well as the carbonyl peaks at 170.7 
and 171.0ppm. Further support for the protection was found in the FTIR spectrum, with the 
Chapter 4 Results and Discussion for the 
 Synthesis of N-containing benzo-fused heterocycles 
93
signal at 1630cm-1 that may have been due to a tertiary amide. The compound was also 
analyzed by HRMS, which confirmed the presence of the molecular ion peak at 317.19985 
(C19H27NO3 requires 317.19909).  
 
The second protection was performed as follows; starting material 235 was dissolved in 
tetrahydrofuran and to this was added Boc2O. After a few minutes of stirring, the DMAP was 
added and the reaction mixture was then stirred for a further 3 h. After this time the solvent 
was removed in vacuo and the residue was purified by column chromatography. The desired 
compound, tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]carbamate 238, 
was obtained as a pale yellow oil in 86% yield. Characterization of the product found a singlet 
at 1.53ppm in the proton NMR spectrum for OC(CH3)2. The 13C NMR spectrum showed new 
peaks at 28.4 and 79.5ppm for the OC(CH3)3 and OC(CH3)3 peaks respectively. The 
characteristic carbonyl peak was also present at 155.6ppm in the 13C NMR spectrum. HRMS 
revealed the molecular ion at 375.23970, which correlates to the peak for C22H33NO4 at 
375.24096. 
 
The amine 235 was dissolved in dichloromethane and to this solution was added 
triethylamine. After a few minutes of stirring, the α-toluenesulfonyl chloride-dichloromethane 
solution was added dropwise and a white gas was evolved that was probably hydrochloric 
acid gas. The reaction mixture was stirred overnight and the solvent was then removed in 
vacuo. The crude mixture was further purified by column chromatography to yield N-allyl-N-
(3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]phenylmethanesulfonamide 239 as a yellow 
oil. The protecting group was identified in the NMR spectra and this confirmed the reaction 
had occurred. In the 1H NMR spectrum, the CH2 peak was observed at 4.23 ppm and the five 
phenyl protons were found at 7.35-7.36ppm. The 13C NMR spectrum displayed the CH2 peak 
at 59.4ppm, the phenyl protons at 128.6, 129.2 and 130.8ppm and the quarternary phenyl 
carbon at 132.9ppm. FTIR spectroscopy was useful in identifying the SO2-N- stretches at 
1150 and 1334cm-1, while the HRMS showed the molecular ion to be at 429.19619 
(calculated as 429.19738 for C24H31NO4S). 
 
Lastly compound 235 was dissolved in dichloromethane and then cooled to 0oC, before the 
addition of triethylamine and tosyl chloride. The reaction mixture was then stirred for 3 h 
before extraction. The desired product, N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)-
benzyl]-4-methylbenzenesulfonamide 144, was obtained as a cream-white solid after 
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chromatography. All of the spectroscopic data correlated well to that of Pathak,129 however, 
our melting point was found to be 62-64oC (Pathak quoted 81-82oC). This value was 
significantly different, thus FTIR and HRMS spectroscopic analyses were performed on the 
compound as well. The FTIR spectrum showed the SO2-N- stretches as 1339 and 1522cm-1 
and HRMS found the molecular ion to be at 429.19780 (calculated for C24H31NO4S: 
429.19738). We concluded from this supporting information that we had in fact synthesized 
the desired compound 144. 
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Scheme 77 (i) catalyst 11, toluene, 60-80oC, 18-21 h 
 
Having our desired dienes in hand, we were then able to proceed to the RCM step. 
Considering our previous success, we were hopeful of our product formation and we thus 
employed similar conditions to those used in the synthesis of the 8-membered ring systems. 
The general procedure employed was to dissolve the protected amine 144, 237-239 in distilled 
toluene and to heat the solution to 60-80oC. Grubbs II metathesis catalyst 11 was then added 
and the reaction mixtures were stirred for 18-21 h. After this time the solvent was removed in 
vacuo and the residue was purified by column chromatography. The yields for the metathesis 
reactions to obtain benzazepines 145, 240-242 are shown in Table 9 below.  
 
Table 9 Yields for RCM reactions to form 145, 240-242 
Compound R Grubbs II 
catalyst (11) 
Temperature Time Yield 
240 
241 
242 
145 
Ac3 
Boc 
SO2Bn‡ 
Ts 
10 mol % 
5 mol % 
10 mol % 
5 mol % 
80oC 
60oC 
80oC 
60oC 
21 h 
18 h 
21 h 
19.5 h 
8% 
26% 
39% 
82% 
                                                 
3 These reactions were initially attempted with 5 mol % catalyst 11 at 60oC, but they gave poor yields, thus they 
were repeated using the conditions outlined in the table.  
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All of the spectra were consequently compared to those of the 2,5-dihydro-1H-2-benzazepines 
in order to determine if isomerisation of the double bond had occurred. It was found that none 
of the compounds were in fact identical, and we were thus able to confirm that no 
isomerisation had occurred post-metathesis. All of the compounds discussed below showed 
the three CH2 signals for the benzazepine ring in both the 1H and 13C spectra, proving that no 
isomerisation had occurred pre-metathesis. 
 
The formation of 2-acetyl-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine 240 was 
highlighted by the loss of the methyl group and terminal alkene signals in both the 1H and 13C 
NMR spectra. The 1H NMR spectrum also showed the presence of the alkene protons, a signal 
at 6.36ppm for 4-H, and a doublet at 7.57ppm for 5-H. In the 13C NMR spectrum, peaks were 
found for 4-C at 126.1ppm and for 5-C at 135.7ppm. 
 
The 2-(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine 242 was 
shown to have been formed by the lack of a CH3 signal and the lack of the terminal alkene 
peaks that were present in the starting material 194. The 1H NMR spectrum had peaks at 5.76 
and 6.92-6.99ppm for 4-H and 5-H respectively. The 13C NMR spectra showed signals at 
125.3ppm (4-C) and 128.9ppm (5-C), which were different from those for the alkene protons 
of the starting diene 239. HRMS was then performed and a peak was found at 387.14958, 
which corresponds to that expected for C21H25NO4S, namely 387.15043. 
 
The formation of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-2-
benzazepine 145 was highlighted by the presence of the peaks for 4-H (5.86ppm) and 5-H 
(6.68ppm) in the 1H NMR spectrum, and those for 4-C (130.0ppm) and 5-C (132.2ppm) in the 
13C NMR spectrum (the carbon assignments are interchangeable as no CH correlated 
spectrum was run as this is not a new compound for our laboratories). Our spectroscopic data 
correlated well to that outlined by Pathak.129 However, our melting point, which was found to 
be 147-149oC, could not be compared to Pathak as the compound that they isolated was an 
oil. This again prompted us to analyze the compound further by HRMS in order to confirm 
the product formation. HRMS for C21H25NO4S required that the molecular ion be at 
387.15043 and we found a peak at 387.14872, confirming the formation of 6-isopropoxy-7-
methoxy-2-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-2-benzazepine 145. 
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2.5 De-allylated Compounds 
 
While attempting the isomerisations on our diene systems to form the isoquinoline structures 
a few other compounds were isolated. These compounds showed that N-de-allylation was 
occurring when a large amount of the Ru-isomerisation catalyst was added and the reactions 
were performed at elevated temperatures. The catalytic deprotection of tertiary allylic amines 
is well known in the presence of palladium catalysts.39  
 
Knowing that these de-allylation reactions were occurring we decided to investigate the exact 
conditions that allowed these products to form. These types of de-allylation reactions were 
originally shown to occur in the presence of Grubbs first generation catalyst 10 by Alcaide 
and Almendros,7 but to the best of our knowledge this is the first reported de-allylation 
reaction using catalyst 12. Background information on the proposed mechanism of this 
reaction has already been outlined in Chapter 1.  
 
5
6
N
O
O
SO2Bn
(i) N
H
SO2Bn
O
O
213 243  
 
Scheme 78 (i) 5 mol % catalyst 12, 135-140oC, 19 h 
 
Our initial attempts at the isomerisation of N-allyl-N-(2-allyl-3-isopropoxy-4-
methoxybenzyl)phenylmethanesulfonamide 213 used mild conditions, but when these failed 
we opted for very harsh conditions to see if we could force the isomerisation to occur. What 
we found instead was that de-allylation had occurred to form N-[3-isopropoxy-4-methoxy-2-
(1-propenyl)benzyl](phenyl)methanesulfonamide 243 presumably via the isomerised alkene 
238. This discovery encouraged us to repeat the reaction to determine the optimal conditions 
for de-allylation reaction to occur on this system. We found that when 213 was mixed with 
the Ru-isomerisation catalyst 12 under solvent-free conditions, and the reaction mixture was 
heated to 135-140oC for 19 h, the product isolated after chromatography was 243. The yield 
for the de-allylation reaction was 56% and the product, 243, was found to be cream-coloured 
crystals with a melting point of 127-130oC. 
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The product 243 was identified by the characteristic loss of the allyl alkene protons. Two 
peaks were found at 1.49 and 1.88ppm in the 1H NMR spectrum that were assigned as the 
methyl group (mixture of E/Z isomers). The corresponding methyl peaks were shown in the 
13C NMR spectrum at 15.2 and 19.2ppm. A broad singlet was observed in the proton 
spectrum at 1.60ppm that was identified as the NH peak based on the disappearance of the 
signal after a D2O wash and an NH bend was observed in the FTIR spectrum at 1481cm-1. 
Subsequent HRMS analysis found a molecular ion peak at 389.16542, which correlates to that 
for C21H27NO4S at 389.16608. After recrystallisation, a single-crystal X-ray structure was 
obtained that proved the structure we proposed for compound 243. It is shown schematically 
by the ORTEP diagram illustrated in Figure 31 below.  
 
 
Figure 31 ORTEP diagram of compound 243  
(showing the 50% probability thermal ellipsoids for all non-hydrogen atoms). 
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Scheme 79 (i) 0.5+5 mol % catalyst 12, toluene, 110-115oC, 2+2 h,  
followed by 5 mol % catalyst 11, 110oC, 21 h 
 
As described in the section on 6-membered ring formations above, Section 2.3, when 
attempting the isomerisation reactions at high temperatures and with large amounts of the Ru-
isomerisation catalyst 12 present, de-allylated compounds were found. The desired 
isoquinoline 142 was obtained in 21% yield along with the de-allylated product, N-[3-
isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-4-methylbenzenesulfon-amide 244, in 27% 
yield.  
 
De-allylated compound 244 was obtained as a yellow solid with a melting point of 129-
135oC. It was identified by the characteristic loss of the alkene protons from the allyl chain 
and the presence of a new NH peak in the NMR spectra. The 1H NMR spectrum showed a 
new methyl group at 1.77ppm along with the two shifted alkene protons at 5.96 and 6.21ppm, 
which showed that isomerisation of the double bond had occurred. The NH proton was 
identified as the peak at 4.48ppm by the corresponding lack of signal in the CH correlated 
spectrum. The methyl group was observed at 19.1ppm in the 13C spectrum, along with the two 
alkene peaks at 124.2 and 132.6ppm. The loss of the allyl chain was supported by the HRMS 
spectrum that found a peak at 389.16367, the corresponding molecular ion for C21H27NO4S 
would have been at 389.16608.  
 
Both the formation of compound 243 and 244 highlight that the N-allyl chain selectively 
isomerises before the aromatic-allyl chain. This is supported by the initial isomerisation 
reactions that were performed under combinatorial conditions in order to synthesise the 2,5-
dihydro-1H-2-benzazepines (Section 2.4.1 above).   
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Scheme 80 (i) 5 mol % catalyst 12, toluene, 105oC, 18 h  
 
Having isolated compound 244 from our reaction mixture, we attempted to synthesize it 
directly in order to determine the exact conditions required. The N-allyl-N-(2-allyl-3-
isopropoxy-4-methoxybenzyl)-4-methylbenzenesulfonamide 139 was dissolved in distilled 
toluene, the solution was degassed with N2 and then heated to 105oC. To the solution was then 
added 5 mol % of the Ru-isomerisation catalyst 12 and it was stirred for 18 h. After this time 
the solution was allowed to cool to rt, the solvent was removed in vacuo and the resulting 
residue was purified by column chromatography. We did not isolate 244, but instead obtained 
N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzenesulfonamide 245, in which the 
aryl allyl group had not isomerised, in 51% yield as a pale yellow oil that solidified on 
standing.  
 
Compound 245 was identified by the loss of the N-allyl peaks (both alkene and CH2) in the 
NMR spectra. The 1H NMR spectrum had a doublet at 3.38ppm for the CH2 group and a 
multiplet at 5.81-5.83ppm for the CH=CH2 proton. The terminal alkene protons were 
observed at 4.74ppm and 4.93ppm for trans and cis positions respectively. The multiplet at 
4.49-4.54ppm also integrated for the NH proton (as well as for OCH(CH3)2). The 
corresponding signals were observed in the 13C NMR spectrum at 30.5ppm (CH2), 115.2ppm 
(CH=CH2) and 137.1ppm (CH=CH2). Both the FTIR and HRMS spectra also supported the 
formation of this product. FTIR showed at peak at 3019cm-1, which may be due to a terminal 
alkene, and HRMS found a molecular ion peak at 389.16714 (C21H27NO4S requires 
389.16608).  
 
As yet we have no concrete evidence to explain the difference in product formed via the 
seemingly similar reaction conditions. We believe that further investigation into this result is 
required, but due to the time limitations it could not be accomplished during the duration of 
this project.  
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3. The 1-Phenyl-1-Propenyl Substituted System 
 
3.1 Synthesis of Phenyl-Substituted Starting Materials 
 
3.1.1 O-Cinnamyl Addition to Isovanillin 
 
Having had a fair amount of success when using our unsubstituted allylated systems we then 
decided to continue our methodology study with a more complex range of phenyl-substituted 
allyl systems. These are based on the addition of the cinnamyl group instead of the allyl chain 
in the initial protection reactions.   
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Scheme 81 (i) 2.5eq K2CO3, 2.5eq cinnamyl bromide, 60oC, 23 h 
 
Initially, a solution was prepared of potassium carbonate in DMF and it was then heated to 
60oC, before the addition of isovanillin. To the reaction mixture was then added the cinnamyl 
bromide, and it was stirred at 60oC for 23 h. The desired product, 4-methoxy-3-{[(2E)-3-
phenyl-2-propenyl]oxy}benzaldehyde 246 was obtained after chromatography as a pale 
yellow semi-solid in 100% yield, which was an improvement on that obtained by Rousseau1 
(85%). The preparation of the product was confirmed by the new phenyl protons, alkene 
protons and the new CH2 group observed in both the proton and carbon NMR spectra. In the 
1H NMR spectrum, the OCH2 peak was observed at 4.83ppm, the one alkene proton was 
found at 6.45ppm and the other one was present at 6.76ppm. The five new phenyl protons 
were found in the multiplet from 7.25 to 7.48ppm. Similarly, the corresponding peaks were 
observed in the 13C NMR spectrum. The peaks observed at 69.6ppm, 123.5ppm, 126.7ppm, 
128.0ppm, 128.5ppm and 134.0ppm were assigned as being OCH2, 10-C, 8-C, OCH2CH=CH, 
9-C and OCH2CH=CH respectively. These correlated well to those observed by Rousseau1 
and no further analyses were performed.  
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3.1.2  Claisen Rearrangement and Protection 
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Scheme 82 (i) DMF, 160-165oC, 44 h,  
(ii) 2.5eq K2CO3, 2.5eq isopropyl bromide, DMF, 60oC, 44 h 
 
We then attempted the Claisen rearrangement on 4-methoxy-3-[(3-phenyl-2-
propenyl)oxy]benzaldehyde 246. As Rousseau had obtained the styrene product in only 51% 
yield using the conventional methodology,1 we decided to try out our microwave based 
method. However, this failed to give us any of the desired product 247 and we instead only 
obtained the Claisen-Cope product. This reaction is discussed in detail in Section 3.4 below. 
We thus returned to the conventional method employed by Rousseau and prepared a solution 
of benzaldehyde 246 in dimethylformamide, which was then heated to 160-165oC for 44 h. 
After this time, the solution was allowed to cool to 60oC, before the addition of the potassium 
carbonate and the isopropyl bromide. The reaction mixture was then stirred at 60oC for a 
further 44 h, before it was subjected to the workup and the residue was purified by 
chromatography. The 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzaldehyde 247 
was obtained as a purple oil in 50% yield. The NMR data correlated well to that reported by 
Rousseau1 and the yields were also similar.  
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3.1.3 Reductive Amination Reactions 
 
5
6
N
O
O
7
8
9
10
9
8
248
5
6
H
O
O
O
7
8
9
10
9
8
247
(i)
 
 
Scheme 83 (i) 1.4eq allyl amine, rt, 24 h 
 
Having the desired aldehyde in our hands, we were then able to continue our synthesis by 
performing the same reductive amination on it. The aldehyde 247 was thus stirred with allyl 
amine at rt for 24 h. After this time the excess allyl amine was removed in vacuo and the 
desired product, N-{(E)-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)phenyl]methyl-
idene}-2-propen-1-amine 248, was obtained as an orange oil in 100% yield. The compound 
was judged clean by spectroscopy and no further purification was required. We were initially 
surprised at the product formation, as Pathak had not managed to synthesize compound 248 
during the course of her research in our laboratories. This result was thus very exciting and 
prompted our further investigation into this area.  
 
The imine 248 was characterized fully as it was a new compound for our laboratories. The 
FTIR spectrum showed the presence of a C=N stretch at 1678cm-1, and the NMR spectra 
showed the disappearance of the aldehyde peak. The new peaks observed in the 1H NMR 
spectrum were a singlet at 8.13ppm for the CH=N proton and those for the allyl chain, at 
4.06-4.08, 5.04-5.15 and 5.88-5.99ppm (NCH2, CH=CH2 and CH=CH2 respectively). These 
peaks were also found in the 13C NMR spectrum at 63.4 (NCH2), 115.7 (CH=CH2), 136.3 
(CH=CH2) and 161.2ppm (CH=N). The preparation of imine 248 was also confirmed by 
HRMS, in which a molecular ion peak was found at 349.20968, which correlates well to that 
for C23H27NO2 at 349.20418. 
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Scheme 84 (i) 1.2eq sodium borohydride, MeOH, 0oC-rt, 2.5 h 
 
The N-{(E)-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)phenyl]methylidene}-2-
propen-1-amine 248 was dissolved in methanol (to which one drop of distilled water was 
added to catalyse the reaction) and the solution was cooled to 0oC. Then sodium borohydride 
was added and the reaction mixture was left to stir for 2.5 h at 0oC-rt. After this time the 
excess sodium borohydride was destroyed and the reaction mixture was extracted. The N-[3-
isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzyl]-2-propen-1-amine 249 was obtained 
after workup as a dark yellow oil that was judged  pure by spectroscopy in quantitative yield.  
 
Product 249 was identified by the characteristic loss of the CH=N peak in both the 1H and 13C 
NMR spectra. A singlet was observed at 1.42ppm in the 1H NMR spectrum that was assigned 
as the NH proton. A doublet was also observed at 3.46ppm in the 1H NMR spectrum that was 
found to be the new CH2 group and this was also observed in the 13C NMR spectrum as peaks 
at 50.3 and 50.7ppm. The reduction was further confirmed by the presence of the NH 
stretches at 1595 and 3494cm-1 in the FTIR spectrum as well as the confirmation of the 
molecular ion peak at 351.21969 (C23H29NO2 requires 351.21983) in the HRMS spectrum.  
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3.1.4 Protection of the Amine 
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Scheme 85 (i) 1.5eq acetic anhydride, 2.5eq pyridine, rt, 3 h, or R = Ac 250 
(ii) 1.2eq Boc2O, 0.1eq DMAP, THF, rt, 2.3 h, or R = Boc 251 
(iii) 2.5eq NEt3, 1.1eq α-toluenesulfonyl chloride, CH2Cl2, rt, 4 h, or R = SO2Bn 252 
(iv) 1.4eq NEt3, 1.2eq tosyl chloride, CH2Cl2, 0oC-rt, 3 h R = Ts 253 
 
The four different protecting groups highlighted for use in this MSc project were again used 
in the protection of the amine. The yields for the protection reactions employed to form 
compounds 250-253 are outlined in Table 10 below.  
 
Table 10 Yields for the Protection Reactions to form 206-209 
Compound R Yield (%) 
250 
251 
251 
253 
Ac  
Boc 
SO2Bn 
Ts 
66 
92 
45 
71 
 
As before a solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-
benzyl]-2-propen-1-amine 249 and pyridine, which was then cooled to 0oC. To this was then 
added dropwise a solution of acetic anhydride and pyridine. The reaction mixture was then 
stirred at 0oC-rt for 3 h. After this time the reaction mixture was purified by extraction and the 
desired product, N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]acet-
amide 250, was obtained as a dark yellow oil. The product was identified by the characteristic 
loss of the NH peak and the formation of a new singlet at 3.93ppm for the methyl group in the 
1H NMR spectrum. This was coupled to the presence of new peaks at 21.2ppm for the methyl 
group and 170.9 and 171.1 for the carbonyl group in the 13C NMR spectrum. FTIR 
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spectroscopy showed the presence of the C-O stretch at 1216cm-1 and the corresponding loss 
of the NH stretches. Also, HRMS analysis of the compound found a peak at 393.23103, 
which corresponds nicely to that for C25H31NO3 at 393.23039. 
 
Amine 249 was dissolved in tetrahydrofuran and to this solution was added Boc2O. It was 
then stirred for 5 min before the addition of DMAP and the reaction mixture was then stirred 
for a further 2.3 h at rt before the solvent was removed in vacuo. The desired product, tert-
butyl allyl[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-carbamate 251, was 
isolated after chromatography as a purple oil. Compound 251 was shown to have formed by 
the presence of the new OC(CH3)3 singlets at 1.39 and 1.44ppm, as well as by the 
characteristic loss of the NH peak in the 1H NMR spectrum. The 13C NMR spectrum showed 
the presence of three new signals, 27.7 and 28.3ppm for OC(CH3)3, 79.6ppm for OC(CH3)3 
and 155.9ppm for the C=O group. A C-O stretch was observed in the FTIR spectrum at 
1216cm-1. Furthermore, HRMS analysis was performed on the compound with the peak 
expected for C28H37NO4 predicted to be at 451.27226 and with the molecular ion peak 
observed at 451.27299. 
 
Compound 249 was dissolved in dichloromethane, with triethylamine being added to the 
mixture and allowed to stir for 15 min, before the dropwise addition of the α-toluenesulfonyl 
chloride-dichloromethane solution. The reaction mixture was then stirred for 4 h at rt, before 
the solvent was removed in vacuo and the resulting residue was purified by column 
chromatography. N-Allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]phen-
ylmethanesulfonamide 252 was obtained as an orange solid with a melting point of 105-
108oC after purification. The formation of 252 was identified by the characteristic loss of the 
amine proton signal in the 1H NMR spectrum and the presence of new signals at 4.11-4.24 
and 7.14-7.28ppm, for the CH2 group and the five benzyl protons respectively. This data was 
supplemented by the observation of new peaks in the 13C NMR spectrum at 59.1ppm (CH2), 
127.5, 128.3, 130.6 and 132.7ppm (benzyl carbons). The FTIR spectrum also showed the 
presence of the protecting group by the peaks at 1151 and 1337cm-1 for SO2-N stretches and 
deformations. HRMS required a peak at 505.22868 for C30H35NO4S and the molecular ion 
was present at 505.22896. 
 
Lastly, compound 249 was dissolved in dichloromethane and the solution was cooled to 0oC. 
To this solution was then added triethylamine and tosyl chloride, subsequently the reaction 
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mixture was stirred at 0oC-rt for 3 h. After this time the reaction mixture was quenched, 
extracted, and the resulting residue was purified by column chromatography. The desired 
product N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-methylbenze-
nesulfonamide 253 was obtained as a pale pink oil that solidified on standing and had a 
melting point of 110-113oC. The product 253 was identified by the loss of the amine proton in 
the 1H  NMR spectrum as well as by the presence of the characteristic tosyl peaks, namely, a 
singlet for the TsCH3 at 2.40ppm, a multiplet at 7.15-7.30 and a doublet at 7.55ppm for the 
two different aromatic regions. This was further confirmed by the presence of the new TsCH3 
peak at 21.5ppm and the characteristic aromatic peaks for a tosyl group at 127.2 and 
129.5ppm in the 13C NMR spectrum. The FTIR supported the other evidence for the product 
formation by the signals at 1163 and 1338cm-1, which are SO2-N stretches. Finally, HRMS 
analysis of the compound gave a peak at 505.22896, with a peak for C30H35NO4S required at 
505.22868. 
 
3.2 Phenyl-Substituted Benzazepines (7-membered rings) 
 
5
6
N
O
O
7
8
9
10
9
8
258
R
5
6
N
O
O
7
8
9
10
9
8
250-253
R
8
9
4
3
N
1
1011
12
13
12
11
O
O
R
(i)
254-257
+
R = Ac, Boc, 
SO2Bn or Ts
 
 
 
Scheme 86 (i) 8 mol % catalyst 11,4 toluene, 80oC, 2.5h 
 
Having our required diene systems 250-253 in hand, we were then able to continue with the 
desired RCM step to form the benzazepine rings. Similar conditions were employed for each 
RCM attempt and the conditions are outlined in Table 11 below.  
 
 
 
                                                 
4 Initially the RCM was attempted using the conditions developed for the simple 8-membered rings, namely 5 
mol % Grubbs II, 60oC for 1 h (increased to overnight), but no consumption of starting material was observed. 
Thus, we reattempted the reaction at elevated temperatures and with more Grubbs II catalyst.  
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Table 11 Conditions for RCM Reactions 
Expected Product R Time Product Formed 
254 
255 
256 
257 
Ac 
Boc 
SO2Bn 
Ts 
2.5 h 
22 h 
22 h 
22 h 
214 (32%) 
Product peaks 
found by HRMS 
but NMR spectra 
uninterperable 
 
A solution was prepared from N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-
propenyl)benzyl]acetamide 250 and distilled toluene, which was degassed using nitrogen for 
10 min. This was then heated to 80oC, 8 mol % Grubbs II catalyst 11 was added and the 
reaction mixture was stirred for 2.5 h. After this time there was total consumption of the 
starting material by thin layer chromatography so the reaction mixture was allowed to cool to 
rt and the solvent was removed in vacuo. The resulting residue was then purified by column 
chromatography and analyzed by NMR spectroscopy. None of the desired product was 
formed, but the isomerised diene 258 was isolated instead in 32% yield (this compound is 
fully characterized in Section 3.3 below). This result was depressing, but not totally 
unexpected, as the system we were attempting the metathesis on is exceptionally hindered, 
with the phenyl group actually locking into certain conformations due to the lack of free 
rotation about the C-C bond because of steric hindrance (observed as doubling of the 
isopropyl and phenyl peaks in NMR spectra of starting materials 250-253). The 
isomerisations too, were not unexpected, as the isomerising ability of the Grubbs II catalyst 
11’s degradation products has been well documented over the past few years.23-26 This is 
explained in detail in Chapter 1, Section 3 above.   
 
For the attempted RCM on compounds 251-253, the protected amines were dissolved in 
distilled toluene and the solution was heated to 80oC, before the addition of 8 mol % Grubbs 
II catalyst 11. The reaction mixtures were then stirred for 22 h, before the solvent was 
removed in vacuo and the resulting residues were purified by column chromatography. The 
NMR spectra for all of the products were complex, with mixtures of isomers, amide rotamers 
and splitting occurring due to the lack of free rotation of the phenyl ring. The presence of the 
desired benzazepines 255-257 were thus not confirmed satisfactorily by NMR spectroscopy 
due to the complexity of the spectra, but the desired molecular ions were however observed in 
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the HRMS spectra. This itself does not confirm the formation of the products, but it may 
suggest that trace amounts of the desired compounds are forming. There exists the possibility 
that by changing the conditions to higher temperatures and more catalyst, one may drive the 
reaction to afford the desired benzazepines, but we felt that the steric hindrances to the Ru-
carbene attachment step may be too great to obtain reasonable yields of the desired products. 
No further attempts were thus made to cyclise these dienes during the course of this project.  
 
3.3 Phenyl Substituted Isoquinolines (6-membered rings) 
 
3.3.1  Isomerisation Reactions 
 
Having isolated the isomerised diene, 258, from our reaction mixture for the attempted 
synthesis of 254, we were excited about the possibility that isomerisation reactions were 
possible for the dienes 250-253. We had initially decided to attempt the isomerisations using 
the Ru-isomerisation catalyst 12 developed by Krompiec et al.29,30 and even after the isolation 
of 258 using Grubbs II catalyst 11, decided to pursue our initial route. It was favoured over 
attempting the isomerisations with Grubbs II catalyst 11 as the Ru-isomerisation catalyst 12 is 
far more selective in that there is no possibility of metathesis occurring.  
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Scheme 87 (i) 2 mol % catalyst 12,  toluene, 90oC, 18-21 h 
 
The general procedure used for the isomerisation reactions was to dissolve the protected 
amines 250-253 in distilled toluene and to heat the resulting solution to 90oC. Then 2 mol % 
of the Ru-isomerisation catalyst 12 was added and the reaction mixture was stirred for 18-21 
h, before the removal of the solvent in vacuo and the purification of the residue by column 
chromatography. The yields for the formation of products 258-261 are outlined in Table 12 
below.  
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Table 12 Yields for Isomerisation Reactions 
Compound R Time Yield (%) 
258 
259 
260 
261 
Ac 
Boc 
SO2Bn 
Ts 
21 h 
17.5 h 
27 h 
26 h 
82 
96 
90 
82 
 
The formation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-N-(1-
propenyl)acetamide 258 was shown by the characteristic loss of the terminal allyl alkene 
protons and the CH2 group in both the proton and the carbon NMR spectra. This was coupled 
to the presence of a new methyl peak at 1.70ppm, as well as the shift of the two alkene 
protons to 4.69 and 7.17-7.29ppm, in the 1H NMR spectrum. The same new peaks were 
observed in the 13C NMR spectrum, with the methyl group at 16.0 and 16.1ppm; and the 
alkenes at 109.0ppm and 125.9 and 126.0ppm. The HRMS spectrum required the peak for 
C25H31NO3 to be at 393.23039, and a molecular ion was found at 393.23162. 
 
The exact same procedure was used to determine whether the isomerised dienes 259-261 had 
formed. The characteristic signals used to determine that these compounds had formed are 
outlined in Table 13 below.  
 
Table 13 Characteristic Peaks used to Identify Compounds 259-261 
 R 1H NMR (ppm) 13C NMR (ppm) HRMS 
259 
 
 
 
260 
 
 
Boc 
 
 
 
SO2Bn 
 
 
1.23-1.60ppm (CH3)  
3.97-4.50 (NCH=CH) 
7.09-7.26 (NCH=CH) 
 
1.44 and 1.51 (CH3) 
4.39 (NCH=CH) 
6.28-6.33 (NCH=CH) 
 
16.0 (CH3) 
104.1 (NCH=CH) 
136.2 (NCH=CH) 
 
15.9 (CH3) 
107.0 (NCH=CH) 
125.4 (NCH=CH) 
 
C28H37NO4  
Calculated: 451.27226 
Found: 451.27373 
 
C30H35NO4S  
Calculated: 505.22868 
Found: 505.22717 
 
Table 13 contd. Characteristic Peaks used to Identify Compounds 259-261 
 R 1H NMR (ppm) 13C NMR (ppm) HRMS 
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261 Ts 1.65 (CH3) 
4.45 (NCH=CH) 
6.52 (NCH=CH) 
16.0 (CH3) 
107.9 (NCH=CH) 
125.6/7 (NCH=CH)
C30H35NO4S 
Calculated: 505.22868 
Found: 505.22739 
 
3.3.2 Ring Closing Metathesis 
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Scheme 88 (i) 8 mol % catalyst 11, toluene, 80oC, 18-24 h 
 
Having our required diene systems 258-261 in hand, we were then able to continue with the 
metathesis step to form the isoquinoline skeletons. Similar conditions were employed in each 
of RCM reactions and differences are outlined in Table 14 below. The general procedure used 
was to dissolve the diene 258-261 in distilled toluene and to heat the solution to 80oC before 
the addition of 8 mol % Grubbs II catalyst 11. The reaction mixtures were then stirred for 18-
24 h, the solvent was removed in vacuo and the resulting residues were purified by column 
chromatography.  
 
Table 14 Conditions for RCM reactions 
Expected Product R Time Compound Isolated  
262 
263 
264 
265 
Ac 
Boc 
SO2Bn 
Ts 
18 h 
19.5 h 
23 h 
24 h 
Starting Material (69%) 
Starting Material (100%) 
Starting Material (79%) 
Starting Material (39%) 
 
In all of the cases, even after long periods of time only starting material was recovered. This 
was a little bit disappointing, as HRMS did indicate the presence of trace amounts of the 
desired products 262-265. However, this was not concrete evidence to prove that the reaction 
had occurred. We think that the bulky phenyl group is preventing the Ru-carbene complex 
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from metathesizing the double bonds, thus preventing the desired reaction from occurring. 
One way of trying to prove this would be to include very small protecting groups on both the 
oxygen and nitrogen atoms, hopefully releasing some of the bulk and allowing the reaction to 
occur. Due to the time restraints on this project, we were unable to test this theory, but 
hopefully it may be attempted in the future.  
 
3.3.3 De-allylated Compound 
 
When increasing the amount of Grubbs II catalyst 11 used to 10 mol % for the metathesis 
reaction outlined in Section 3.3.2 above, we isolated a de-allylated compound, N-[3-
isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-methyl-N-(1-
propenyl)benzenesulfonamide 266, after 17 h at 80oC. Compound 266 was obtained as a 
white semi-solid in 32% yield after column chromatography. This reaction was not surprising, 
considering the literature precedent6,26 and our isolation of the de-allylated materials outlined 
in Section 2.5.  
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Scheme 89 (i) 10 mol % catalyst 11, toluene, 80oC, 17 h 
 
Compound 266 had a melting point of 125-128oC. The compound 266 was identified by the 
loss of the methyl group and the two alkene protons that were present in 1H and 13C NMR 
spectra of the starting material 261. 1H NMR spectroscopy showed the presence of a broad 
singlet at 4.11-4.15ppm that was due to the NH proton. A HRMS analysis of the product 
found a peak at 465.19540 and C27H31NO4S required a molecular ion value of 465.19738. 
 
 
3.4 The Cope Products 
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Scheme 90 General Retrosynthesis for Heterocycles with a  
Substitution Pattern commonly seen in natural products. 
 
The isolation of the product 267 (Scheme 91) that had undergone a Claisen rearrangement 
followed by the Cope rearrangement when performing the reaction under microwave 
conditions (Section 3.1.2) led us to the synthesis of another group of heterocycles. Although 
the proposed metathesis step was not particularly atom economical due to the loss of a phenyl 
group, we continued with this route as we already had the compounds in hand and we simply 
wanted to test the methodology to see if it could be applied to the new substitution pattern. 
This was important as it led us to a number of benzazocines with the same substitution pattern 
as the natural products outlined in Chapter 2. In future a new method will need to be 
developed to access the substitution pattern and to maintain the viability of the route, ie: to be 
atom economical. The general retrosynthesis for the heterocycles with the “natural” 
substitution pattern is outlined in Scheme 90 above.  
 
3.4.1 Claisen-Cope Rearrangement and Protection Reaction 
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Scheme 91 (i) microwave reaction, 200oC, 50W, 150psi max, 5 min run, 5 min hold 
Initially the Claisen-Cope rearrangements were performed by placing the 4-methoxy-3-{(2E)-
3-phenyl-2-propenyl]oxy}benzaldehyde 246 neat in the sealed tube for the microwave 
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reactor. The program was then run with the temperature at 200oC and with a run time of 5 min 
and a hold time of 5 min. This yielded the desired product, 5-hydroxy-4-methoxy-2-[(1E)-3-
phenyl-2-propenyl]benzaldehyde 267, as a dark brown oil with no further purification 
required, in 100% yield (Scheme 91). The product was identified by the characteristic loss of 
the aromatic peak for 2-H in the 1H NMR of the starting material (at 7.25-7.48ppm) and the 
presence of a new OH signal in the 1H NMR spectrum of the product (as a broad singlet at 
1.57ppm). The corresponding results were observed in the 13C NMR spectrum.  
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Scheme 92 (i) 2.5eq K2CO3, 2.5eq isopropyl bromide, DMF, 60oC, 19 h 
 
The substituted benzaldehyde 267 was then dissolved in DMF and the solution was heated to 
60oC. The potassium carbonate was then added and stirred until a suspension formed, before 
the addition of the isopropyl bromide. The reaction mixture was then stirred for 19 h, 
subjected to a workup and the residue was purified by column chromatography. The desired 
product, 5-isopropoxy-4-methoxy-2-[(1E)-3-phenyl-2-propenyl]benzaldehyde 268, was 
obtained as a dark yellow oil in 76% yield (Scheme 92). It was identified by the characteristic 
loss of the phenol proton and by the presence of the new isopropyl peaks, a doublet at 
1.39ppm for OCH(CH3)2 and a septet at 4.62ppm for OCH(CH3)2,  in the 1H NMR spectrum. 
The presence of the isopropyl group was also noted in the 13C NMR spectrum where the 
OCH(CH3)2 peak was found at 21.9ppm and the OCH(CH3)2 peak was found at 71.5ppm. 
HRMS for C20H22O3 required a peak at 310.15689, and analysis of the product found the 
molecular ion peak to be at 310.15830. 
 
 
 
 
3.4.2 Reductive Amination Reactions  
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Scheme 93 (i) 1.4eq allyl amine, rt, 21.5 h 
 
The precursor 268 was subsequently stirred with allyl amine for 21.5 h at rt. After this time 
the excess allyl amine was removed in vacuo. The desired product, N-((E)-{5-isopropoxy-4-
methoxy-2-[(2E)-3-phenyl-2-propenyl]phenyl}methylidene)-2-propen-1-amine 269, was 
obtained as a yellow oil in 100% yield and no further purification was required. The product 
269 was identified by the characteristic loss of the aldehyde peak in both the 1H and 13C NMR 
spectra. The 1H NMR spectrum showed a peak at 8.52ppm for the CH=N proton. It also 
highlighted the presence of the allyl chain by the signals at 4.22, 5.06-5.22 and 5.98-6.10ppm, 
which are assigned as CH2, CH=CH2 and CH=CH2 respectively. The corresponding peaks 
were observed in the 13C NMR spectrum, with the peak for CH=N at 159.5ppm and the peak 
for the allyl CH2 at 63.7ppm. We also observed the terminal alkene peaks at 115.7ppm for the 
CH=CH2 carbon and at 136.3ppm for the CH=CH2 carbon. The FTIR spectrum supported this 
assignment by the presence of the C=N stretch at 1646cm-1. Analysis by HRMS found the 
molecular ion to be at 349.20344 (C23H27NO2 requires 349.20418). 
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Scheme 94 (i) 1.2eq NaBH4, MeOH, 0oC-rt, 4.5 h 
 
Imine 269 was next dissolved in methanol and cooled to 0oC. Then sodium borohydride was 
added and the reaction mixture was left to stir at 0oC-rt for 4.5 h. After this time the excess 
sodium borohydride was destroyed, the mixture was extracted and the solvent was removed in 
vacuo. The reduced N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]benzyl}-2-
propen-1-amine 270 was obtained as a dark yellow oil in 75% yield, with no further 
purification being required. The product was identified by the characteristic loss of the CH=N 
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peaks in the 1H and 13C NMR spectra. The FTIR spectrum highlighted the reduction by the 
presence of the NH stretch at 3618cm-1. The new NH signal was shown as a broad singlet at 
1.58ppm, with the new CH2 group shown as a singlet at 3.73ppm in the 1H NMR spectrum. 
The corresponding CH2 signal was observed in the 13C NMR spectrum at 50.2ppm. In 
addition, the HRMS analysis found a peak at 351.21926, with C23H29NO2 requiring the 
molecular ion be found at 351.21983. 
 
3.4.3  Protection Reactions 
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Scheme 95 (i) 1.2eq Boc2O, 0.1eq DMAP, THF, rt, 3 h, or R = Boc 271 
(ii) 1.4eq NEt3, 1.2eq tosyl chloride, CH2Cl2, 0oC-rt, 2.5 h R = Ts 272 
 
Due to the time constraints in this project only two of the four protecting used previously 
were used for these reactions. The Boc group was chosen as it is relatively simple to remove 
and the tosyl group was chosen as all the products tend to be solids (useful for running single-
crystal X-ray structures). The reactions were performed on compound 270 and the yields for 
the products 271-272 are outlined in Table 15 below. 
 
Table 15 Yields for the Protection Reactions 
Compound R Yield (%) 
271 
272 
Boc 
Ts 
79 
72 
 
The N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]benzyl}-2-propen-1-amine 
270 was dissolved in distilled tetrahydrofuran and to this solution was added Boc2O. After 
stirring the solution for 5 min, DMAP was added. The reaction mixture was then stirred at rt 
for 3 h and after this time the solvent was removed in vacuo. The residue was then purified by 
column chromatography and the desired product, tert-butyl allyl{5-isopropoxy-4-methoxy-2-
[(2E)-3-phenyl-2-propenyl]benzyl}carbamate 271, was obtained as a yellow oil. The product 
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was identified by the characteristic loss of the NH peaks in the 1H NMR and FTIR spectra. 
The 1H NMR spectrum showed the presence of the two new singlets at 1.45 and 1.48ppm for 
the OC(CH3)3 methyl groups (two signals occur due to the amide rotamers). The 
corresponding peaks were observed in the 13C NMR spectrum at 28.4ppm and 79.7ppm, for 
OC(CH3)3 and OC(CH3)3 respectively. The HRMS spectrum showed a peak at 451.27205, 
which correlates well to the peak at 451.27226 for C28H37NO4. 
 
In addition, compound 270 was dissolved in dichloromethane and the solution was cooled to 
0oC. Then triethylamine was added and the solution was stirred for 5 min before the addition 
of the tosyl chloride. The reaction mixture was then stirred at 0oC-rt for 2.5 h, before the 
reaction mixture was quenched, extracted and the solvent removed in vacuo. The resulting 
residue was then purified by chromatography to obtain N-allyl-N-{5-isopropoxy-4-methoxy-
2-[(2E)-3-phenyl-2-propenyl]benzyl}-4-methylbenzenesulfon-amide 272 as a yellow oil that 
solidified on standing (melting point 79-82oC). This product was identified by the 
disappearance of the NH stretch on the FTIR spectrum and by the loss of the NH peak on the 
1H NMR spectrum. Several new peaks were observed in the 1H NMR spectrum for the tosyl 
group, namely, a TsCH3 singlet at 2.43ppm and two different groups of TsH, a multiplet at 
7.20-7.31ppm and doublet at 7.73ppm (J=8.1Hz). The characteristic peaks for the tosyl group 
were also observed in the 13C NMR spectrum. The methyl group was found at 21.5ppm, the 
aromatic groups at 127.3 and 128.5/129.7ppm and the quaternary carbons at 132.6 and 
143.2ppm.  
 
3.4.4 Ring Closing Metathesis to form Compounds 273 and 274 
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Scheme 96 (i) 5 mol % catalyst 11, toluene, 60oC, 20-22.5 h 
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For both of the protected amines 271 and 272 the reaction was set up according to the 
procedure used for the synthesis of the benzazocines described in Section 2.2.1 above. The 
general procedure involved dissolving the amines 271-272 in distilled toluene and heating the 
solutions to 60oC before the addition of 5 mol % Grubbs II catalyst 11. The reaction mixtures 
were then stirred for 20-22.5 h before the solvent was removed in vacuo. The resulting 
residues were then purified by column chromatography and the desired compounds 273-274 
were obtained as outlined in Table 16 below.  
 
Table 16 Yields for Ring Closing Metathesis Reactions 
Compound R Time Yield (%) Compound Detection 
By 
273 
274 
Boc 
Ts 
22.5 h 
20 h 
(73) 
(39) 
HRMS 
1H NMR 
 
As shown in Table 16 above, the formation of tert-butyl 9-isopropoxy-8-methoxy-3,6-
dihydro-2-benzazocine-2(1H)-carboxylate 273 could not be determined by NMR 
spectroscopy due to severe peak broadening (possibly due to amide rotamers). However, the 
compound was detected by HRMS, with the peak found at 347.20925 and with C20H29NO4 
requiring a peak at 347.20966. This is not sufficient evidence on its own to prove the 
formation of the product exclusively and that is why a tentative yield is given in brackets.  
 
A similar problem arose for the preparation of 9-isopropoxy-8-methoxy-2-[(4-
methylphenyl)sulfonyl]-1,2,3,6-tetrahydro-2-benzazocine 274, whereby the product formation 
could only be shown by 1H NMR spectroscopy. The product formation was identified by the 
characteristic loss of the phenyl protons, as well as the loss of the terminal alkene peaks. 
Three signals were observed in the 1H NMR spectrum for the CH2 groups. They were found at 
3.41 (ArCH2C), 3.73-3.77 (NCH2C) and 4.22ppm (ArCH2N), which confirms that no 
isomerisation occurred prior to RCM and thus the presence of the eight membered ring. The 
alkene peaks were observed at 5.41-5.58ppm and 5.84ppm and they were assigned as 
NCH2CH=CH and NCH2CH=CH respectively. 
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This brought to an end our attempted syntheses of the 6,7 and 8 membered nitrogen-
containing benzo-fused heterocycles. The conclusion and future work for this section will be 
discussed in Chapter 6. 
  
 
 
 
 
 
 
 
 
 
Chapter 5:  
 
Results and Discussion for the Synthesis of 
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Chapter 5: Results and Discussion for the Synthesis of Indenols, Indenones 
and Indanones 
 
1. Introduction 
 
As described in the introduction, during the post-doctoral project of Coyanis48 a number of 
different indenones were isolated from the reaction mixtures for the formation of the indenols 
using ring closing metathesis (RCM). This observation led us to the investigation of the 
oxidizing potential of Grubbs II catalyst 11 (or its degradation products). To the best of our 
knowledge this result is the first example of the Grubbs’ catalysts showing catalytic oxidizing 
ability.7  
MeO
O R
OH
R = H,Me, Ph
OH
R
MeO
O
O
R
MeO
O
O
R
MeO
O
 
 
Scheme 97 General retrosynthesis for the synthesis of indenols, indenones and indanones. 
 
The serendipitous isolation of an unsubstituted indanone 205 also required further 
investigation in order to determine if the methodology could be applied to a number of 
different substrates. In addition we also hoped to tell if the conversion was due to the well-
known redox-isomerisation mechanism.  
 
This part of the project thus aims to answer a number of questions posed by the work of 
Coyanis and initially necessitated the preparation of several compounds synthesized 
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previously.48 This chapter first covers the synthesis of a number of common starting materials 
and then the following sections each deal with the synthesis of the indenols, indenones and 
indanones with various substituents on the 5-membered ring. Please refer to the experimental 
section (Chapter 7) for the detailed description of each synthetic step. 
 
2. The 1-Propenyl System 
 
2.1 Synthesis of the Starting Material 
 
Compound 201 was synthesized according to the methodology outlined by Coyanis.48 The 
synthesis is described in detail in the experimental section and has already been discussed in 
Section 2.4.2 in Chapter 4. 
CHO
O
O
201
(i)
OH
O
O
202  
 
Scheme 98 (i) 5eq vinyl magnesium bromide, THF, -60oC, 18 h 
 
A solution was prepared of 3-isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 201 in 
distilled tetrahydrofuran and the solution was cooled to –60oC. To this was then added vinyl 
magnesium bromide and the solution was stirred for 18 h at -60oC. After this time the reaction 
mixture was warmed to rt and then extracted. The residue obtained was then subjected to 
column chromatography. The desired product, 1-[3-isopropoxy-4-methoxy-2-(1-
propenyl)phenyl]-2-propen-1-ol  202, was obtained as a yellow oil in 88% yield.  
 
The product 202 was analyzed by 1H and 13C NMR spectroscopy and the spectra were found 
to correlate well to those of Coyanis.48 A large amount of Grignard reagent was required as 
the solution we had was quite old and may have become contaminated with trace amounts of 
moisture, thus this value is not representative of that for a new bottle of Grignard reagent. A 
more representative value would be the 1.2eq used by Coyanis to obtain the desired product in 
a yield of 99%.48 
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2.2 Synthesis of Indenol 203 
 
Coyanis48 isolated the indenol 203 in 64% yield, by RCM of diene 202 after optimization, and 
we repeated the reaction in the hopes that we would be able to improve the moderate yield.  
 
OH
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202
(i)
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O
OH
203  
 
Scheme 99 (i) 5 mol % catalyst 11, CH2Cl2, rt, 3 h 
 
The diene 202 was thus dissolved in distilled dichloromethane and the solution was degassed 
using nitrogen for 15 min. Then Grubbs II catalyst 11 was added and the reaction mixture was 
stirred at rt for 3 h. After this time the solvent was removed in vacuo and the resulting residue 
was purified by column chromatography. The desired product, 4-isopropoxy-5-methoxy-1H-
inden-1-ol 203, was obtained as a dark yellow oil in a considerably improved 87% yield. A 
spectroscopic analysis of the compound correlated well to that of Coyanis48 and the product 
was thus shown to have formed.  
 
2.3 Synthesis of Indenone 204 
 
Coyanis obtained the desired indenone 204 in 62% yield after 8 mol % catalyst 11 was added 
to a solution of compound 202 in toluene (80oC for 2 h). We hoped that we would be able to 
obtain the desired product 204 using less catalyst at lower temperatures, thus we developed 
the procedure outlined in Scheme 100 below.  
 
OH
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Scheme 100 (i) 5 mol % catalyst 11, toluene, 60oC, 17 h 
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The 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol 202 was dissolved in 
distilled toluene and the solution was heated to 60oC. Then Grubbs II catalyst 11 was added 
and the reaction mixture was stirred for 17 h. After this time the solvent was removed in 
vacuo and the residue obtained was purified by column chromatography. The desired product, 
4-isopropoxy-5-methoxy-1H-inden-1-one 204, was obtained as a bright yellow oil in only 
45% yield. Product formation was proven by a comparison of our NMR spectroscopic data 
with that obtained by Coyanis.48 We were only able to show that the reaction was occurring 
due to the dehydrogenative-oxidation of the indenol after completing our 1H NMR study. This 
is discussed in detail in Section 5 below. 
 
2.4 Synthesis of Indanone 205 
 
Coyanis48 had only isolated the indanone 205 by chance from precursor 202 (in 51% yield 
when the reaction mixture ran dry over night) and had never aimed to synthesize it 
specifically. We wanted to develop a method for the synthesis of this indanone directly, with 
the aim that our method could then be used for the synthesis of a number of other indanones. 
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Scheme 101 (i) 8 mol % catalyst 11, toluene, 80oC, 22 h 
 
We started by dissolving compound 202 in distilled toluene and subsequently heated the 
solution to 80oC. This was then followed by the addition of Grubbs II catalyst 11. The 
reaction mixture was then stirred for 22 h, the solvent was removed in vacuo and the resulting 
black residue was purified by column chromatography. From the column, we were able to 
isolate the desired product, 4-isopropoxy-5-methoxy-1-indanone 205, as a pale orange oil, 
that solidified on standing, in 89% yield, as well as a small amount of the indenone 204 (11% 
yield relative to starting material). The product obtained was positively identified by a 
comparison of our spectroscopic data with that obtained by Coyanis.48 It is postulated that the 
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conversion of the indenol to indanone was occurring via a RCM-redox-isomerisation reaction. 
As mentioned in the introduction the redox isomeriszation is a known reaction mediated by 
ruthenium-based metathesis catalysts.6 In addition we determined the melting point of 
indanone 205 to be 52-55oC. 
 
The formation of the indanone 205 was further confirmed by the single crystal X-ray structure 
that we were able to obtain. It is shown schematically in Figure 32 below as an ORTEP 
diagram. 
 
Figure 32 Ortep diagram of compound 205 
(showing the 50% probability thermal ellipsoids for all non-hydrogen atoms). 
 
3. The 1-Phenyl-1-Propenyl-Substituted System 
 
3.1 Synthesis of the Starting Material 
 
Compound 247 was synthesised according to the procedure described by Rousseau.1 The 
synthesis is described in detail in the experimental section and is further discussed in Section 
3.1.2 in Chapter 4. 
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Scheme 102 (i) 10eq, vinyl magnesium bromide, THF, -60oC, 22 h 
 
The 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzaldehyde 247 was dissolved in 
distilled THF and the solution was cooled to –60oC. Then vinyl magnesium bromide was 
added and the reaction mixture was left to stir for a further 22 h at -60oC. After this time the 
reaction mixture was extracted and the residue obtained was subjected to column 
chromatography. 1-[3-Isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)phenyl]-2-propen-1-ol 
275 was subsequently obtained as a dark red-purple oil in 46% yield. The product was 
characterized by 1H and 13C NMR spectroscopy and the data was found to correlate well to 
that obtained by Coyanis.48 Again as the Grignard was old, a more representative value would 
be the 1.2eq used by Coyanis (0oC) to obtain the desired product in 73% yield.48 
 
3.2 Synthesis of the Indenol 276 
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Scheme 103 (i) 5 mol % catalyst 11, CH2Cl2, rt, 17 h 
 
A solution was prepared of compound 275 in distilled dichloromethane and to this was then 
added Grubbs II catalyst 11. The reaction mixture was then stirred at rt for 17 h, before the 
solvent was removed in vacuo and the resulting residue was purified by column 
chromatography. The desired product, 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-ol 276, 
was obtained as a cream-coloured solid in 49% yield along with the indenone 277 (24% yield 
relative to the starting material). Indenol 276 had a melting point of 56-59oC and the 
spectroscopic data compared well to that of the compound isolated by Coyanis.48  
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3.3 Synthesis of the Indenone 277 
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Scheme 104 (i) 8 mol % catalyst 11, toluene, 80oC, 17 h 
 
Compound 275 was dissolved in toluene and the solution was heated to 80oC before the 
addition of Grubbs II catalyst 11. The reaction mixture was then stirred for 17 h, the solvent 
was removed in vacuo and the resulting residue was purified by column chromatography. 
This time the desired product, 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-one 277 was 
obtained as a bright-orange semi-solid in 69% yield. The melting point for the indenone 277 
was found to be 63-68oC and a spectroscopic analysis of the compound in conjunction with a 
comparison of Coyanis’ data led us to conclude that we had in fact prepared the correct 
compound.  
 
Coyanis48 had obtained the same product in 82% yield when the reaction was set up using 8 
mol % catalyst 11 at 110oC for 12 h. Our milder conditions did not provide a good enough 
yield and we expect that in the future this may be optimized by performing the reaction at a 
lower temperature, eg: 60-80oC with 5 mol % catalyst 11. 
 
We were further able to isolate crystals of good enough quality to be used for a single crystal 
X-ray diffraction on the compound. From this we confirmed the formation of our product 277. 
This is outlined by the ORTEP diagram shown in Figure 33 below. 
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Figure 33 ORTEP diagram of compound 277 
(showing the 50% probability thermal ellipsoids for all non-hydrogen atoms). 
 
3.4 Attempted Synthesis of the Indanone 
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Scheme 105 Synthesis of Indanone 278 
 
Numerous attempts were made for the synthesis of indanone 278 through the use of RCM, 
with all of them failing in one respect or another. A summary of the reagents and conditions 
used for these attempts are outlined in Table 17 below.  
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Table 17 Conditions for Attempted RCM reactions 
Grubbs II catalyst 
11 (mol %) 
Temperature Time Product Formed 
8 
8 
8 
80oC 
110oC 
110oC 
18 h 
17 h 
45 h 
Indenone 277 
Indenone 277 
Indenone 277 
 
The one other procedure that was not attempted due to the time constraints of the project was 
the addition of 10 mol % Grubbs catalyst 11 and the heating of the mixture under solvent-free 
conditions to high temperatures, but we do not feel that the probability of this yielding 
product is good, as with the other reactions not even as trace of the desired indanone was 
seen. 
 
We propose that the reason that no reaction is occurring on this system is not due to the lack 
of metathesis occurring (as it has been proven to work on these types of systems by the 
formation of the indenols and the indenones), but rather to the inability of the subsequent 
redox-isomerisation reaction to occur. This may be due to the fact that the indenol alkene is 
resonance stabilized through both of the phenyl rings (as it is in the α-position to each of the 
systems). There is generally no indenol isolated as it then undergoes the proposed facile 
dehydrogenative-oxidation reaction to form the thermodynamically favoured indenone 277, 
rather than the indanone. 
 
4. The 1-Methyl-2-Propenyl Substituted System  
 
In order for us to obtain the methyl substituted systems that we wanted to prepare, we needed 
to begin our synthesis with the crotyl addition to the phenol in isovanillin 206. This was 
subsequently subjected to the Claisen rearrangement and isomerised before reaction with the 
Grignard reagent, thus setting us up for the metathesis reactions. 
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4.1 Synthesis of Starting Materials 
 
4.1.1 O-Crotylation of Isovanillin 
 
CHO
OH
O
(i)
CHO
O
O
206 279  
 
Scheme 106 (i) 2.5eq crotyl bromide, 2.5eq K2CO3, DMF, 60oC, 22 h 
 
A suspension was made of the potassium carbonate and N,N-dimethylformamide and this was 
then heated to 60oC and stirred for 15 min. After this time the isovanillin 206 was added and 
the solution went bright yellow before the addition of the crotyl bromide. The reaction 
mixture was then stirred for 22 h, subjected to the workup procedure and subsequently 
purified by column chromatography. The desired product, 3-[(2E)-2-butenyloxy]-4-
methoxybenzaldehyde 279 was then obtained as a bright yellow oil in 99% yield. The product 
was analyzed by 1H and 13C NMR spectroscopy and the data was found to correlate well to 
the results obtained by Rousseau,1 with an improved yield noted (Rousseau obtained the 
product in 90% yield). 
 
4.1.2 Claisen Rearrangement and Protection Reaction 
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Scheme 107 (i) DMF, 180oC, 44 h, 
(ii) 2.5eq K2CO3, 2.5eq isopropyl bromide, DMF, 60oC, 18 h 
 
A solution was prepared from 3-[(2E)-2-butenyloxy]-4-methoxybenzaldehyde 279 in DMF 
and it was heated to 180oC for 44 h. After this time the solution was cooled to 60oC and to it 
was added the potassium carbonate and isopropyl bromide. The reaction mixture was then 
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stirred for a further 18 h, subjected to the workup and purified by column chromatography. 3-
Isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)benzaldehyde 280 was subsequently obtained 
as a bright orange oil in 73% yield. The compound was then analyzed by NMR spectroscopy 
and it was found that the data we obtained was in excellent agreement with that reported by 
Rousseau.1 Surprisingly our yield also showed a marked improvement on that obtained by 
Rousseau (62%).  
 
4.1.3 Isomerisation Reactions for Compound 280 
 
We initially attempted the isomerisation of compound 280 through the use of potassium tert-
butoxide as Coyanis had reported numerous difficulties with the isomerisation when using the 
Ru-isomerisation catalyst 12. These attempts by Coyanis48 are summarized in Table 18 
below.  
 
Table 18 Isomerisation Attempts by Coyanis48 
Attempt Catalyst 12 
(mol %) 
Solvent  Temperature Time Product 
Obtained 
1 
2 
3 
4 
1 
1.2 
1.4 
2 
toluene 
toluene 
toluene 
toluene 
90oC 
110oC 
110oC 
110oC 
26 h 
38 h 
15 h 
48 h 
SM 280 
SM 280 
SM 280 
SM 280 
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Scheme 108 (i) 1.1eq KOtBu, DMF, 60oC, 1 h 
 
We attempted the isomerisation of 3-isopropoxy-4-methoxy-2-(1-methyl-2-
propenyl)benzaldehyde 280 by dissolving the compound in DMF and stirring it in the 
presence of potassium tert-butoxide for 1 h at 60oC. After various extractions, the residue was 
purified by column chromatography and two products were obtained from the reaction. The 
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desired product, 3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-propenyl]benzaldehyde 281, 
was obtained as an orange oil in only 8% yield and was found to be the minor product of the 
reaction. The predominant product isolated from the reaction was the naphthol, 5-isopropoxy-
6-methoxy-4-methyl-1-naphthol 282. It was obtained as an orange-brown oil in only 12% 
yield. 
 
Compound 281 was identified by the characteristic loss of the terminal alkene protons and the 
subsequent formation of the methyl group, observed in both the 1H and 13C NMR spectra. The 
data obtained for compound 281 correlated well to that quoted by Coyanis48 and supported 
our assignment of the product. Compound 282 was identified by presence of the new 
hydroxyl and methyl groups as well as by the presence of the extra aromatic protons. 
Rousseau1 had previously reported this result for similar systems and our observations 
corresponded to those reported, thus supporting our assignment of the product.  
 
4.1.4 Grignard Addition to Compound 280 
 
Considering the problem of the exceptionally poor yield obtained for the isomerisation of 
compound 280 to compound 281, we decided to change the order of the reactions, with the 
hope that this would then lead to better yields.  
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Scheme 109 (i) 10eq vinyl magnesium bromide, THF, -60oC, 18 h 
 
Having the 3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)benzaldehyde 280 in hand, we 
decided to try the Grignard addition directly to the unisomerised aldehyde 280. The aldehyde 
280 was dissolved in distilled tetrahydrofuran and the solution was cooled to –60oC before the 
addition of the vinyl magnesium bromide. The reaction mixture was then stirred for 18 h, 
subjected to the workup procedure and purified by column chromatography. The desired 
product, 1-[3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)phenyl]-2-propen-1-ol 283, was 
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obtained as a yellow oil in 72% yield. The formation of the product was shown through the 
use of NMR spectroscopy. Our 1H and 13C NMR spectral data was compared to that of 
Coyanis,48 and there was found to be an excellent correlation. Thus we were able to show that 
the product had formed. 
 
4.1.5 Isomerisation Reaction to form Compound 284 
 
Having obtained the product 283 in good yield, we then attempted the isomerisation on the 
alkene. We did not attempt the isomerisation using the Ru-isomerisation catalyst 12 as we 
envisaged that we would encounter similar problems to those observed by Coyanis48 for the 
transformation 280 to 281. We were also hopeful that this reaction would proceed in better 
yield, as no possibility existed for the formation of the naphthol 282 when compound 283 was 
exposed to potassium tert-butoxide.  
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Scheme 110 (i) 1.3eq KOtBu, DMF, rt, 15 min 
 
The 1-[3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)phenyl]-2-propen-1-ol 283 was 
dissolved in DMF and to this solution was added sublimed potassium tert-butoxide. The 
reaction mixture was stirred at rt for 15 min, the reaction mixture was then extracted and the 
resulting residue was purified by column chromatography. The desired product, 1-[3-
isopropoxy-4-methoxy-2-(1-methyl-1-propenyl)phenyl]-2-propen-1-ol 284, was obtained as a 
yellow oil in 76% yield. The spectroscopic data obtained for the product was compared to that 
of Coyanis48 (the product was prepared by the conversion of compound 281 to compound 
284) and the details were found to be almost identical. It was thus shown that the product had 
in fact formed. Of interest to us was that NMR spectroscopy indicated a complex mixture of 
E/Z isomers. 
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Based on the good yields for the Grignard reaction of compound 280 to compound 283 and 
the isomerisation reaction of compound 283 to compound 284, this synthetic strategy was 
used for all further reactions performed on this system. 
 
4.2 Synthesis of Indenol 285 
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Scheme 111 (i) 5 mol % catalyst 11, CH2Cl2, rt, 1 h 
 
Precursor 284 was dissolved in distilled dichloromethane and the solution was degassed for 
10 min using nitrogen. Then the Grubbs II catalyst 11 was added and the solution was stirred 
for 1 h at rt. After this time the solvent was removed in vacuo and the residue was purified by 
column chromatography. Satisfyingly, the desired product, 4-isopropoxy-5-methoxy-3-
methyl-1H-inden-1-ol 285, was obtained as a bright yellow oil in 57% yield. The yield we 
obtained was comparable to the 64% obtained by Coyanis48 after 2 h. Our NMR spectroscopic 
data for indenol 285 was found to correlate perfectly to that reported by Coyanis and we were 
able to conclude that we had formed the product.  
 
4.3 Synthesis of Indenone 286 
 
O
O
284
OH
O
O
O
(i)
286  
 
Scheme 112 (i) 8 mol % catalyst 11, toluene, 80oC, 16 h 
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For this reaction a solution was prepared of compound 284 in distilled toluene, which was 
subsequently heated to 80oC before the addition of the Grubbs II catalyst 11. The reaction 
mixture was stirred for 16 h, the solvent was removed in vacuo and the residue was purified 
by column chromatography. 4-Isopropoxy-5-methoxy-3-methyl-1H-inden-1-one 286 was 
obtained as a dark yellow semi-solid in 42% yield, with indenol 285 isolated in 23% yield 
(relative to the starting material). Indenone 286 was positively identified by the comparison of 
our 1H and 13C NMR spectra with those reported by Coyanis.48 
 
4.4 Synthesis of Indanone 287 
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Scheme 113 (i) 5 mol % catalyst 11, 110-170oC, 18 h 
 
Compound 284 was transferred to our reaction vessel as a solution in dichloromethane, which 
was subsequently degassed using nitrogen for 10 min. After this time Grubbs II catalyst 11 
was added and the solution was heated to 110oC, with the subsequent loss of the 
dichloromethane to leave a solvent-free reaction mixture. This solventless mixture was then 
stirred at 160-170oC for 18 h and the resulting residue was purified by column 
chromatography. The desired indanone, 4-isopropoxy-5-methoxy-3-methyl-1-indanone 287, 
was obtained as a dark yellow oil in a poor 18% yield. A small amount of indenone 286 was 
also isolated in 7% yield. As the indanone 287 was a novel compound for our laboratories, it 
was fully characterized by HRMS, NMR and FTIR spectroscopy.  
 
The formation of indanone 287 was shown by the C=O signals in the FTIR spectrum at 1217 
and 1699cm-1. 1H NMR spectroscopy highlighted the indanone ring by the presence of the 
methyl group as a doublet at 1.27ppm, the CH2 group by the two of double doublets at 2.25 
and 2.91ppm and by the doublet of quartets for the CHCH3 proton. Similarly, the 13C NMR 
spectrum had the methyl peak at 20.6ppm, the CHCH3 peak at 31.5ppm, the CH2 peak at 
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45.9ppm and lastly, the C=O peak at 205.2ppm. HRMS analysis of the product presented the 
molecular ion peak at 234.12130, with the peak for C14H18O3 expected at 234.12559. 
 
5. NMR Experiments to Probe the Mechanism of Indenone/Indanone Formation  
 
During the post-doctoral work of Coyanis48 the question was posed as to why the indenones 
are found in the reaction mixtures for the formation of the indenols. A large part of the work 
performed in this section was done in order to postulate a mechanism for this process and to 
subsequently support our observation that the reactions were occurring due to the oxidizing 
ability of the Grubbs II metathesis catalyst 11 (or its degradation products) to effect the 
dehydrogenation of the indenols to the indenones.  
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Scheme 114 
 
Before we could even begin to postulate a mechanism for the suspected conversion of the 
indenols to indenones we needed to prove that the ruthenium present in the Grubbs II 
metathesis catalyst 11 or its degradation products was in fact causing the conversion. In order 
to show that ruthenium was playing a pivotal role in the conversion it was necessary for us to 
have a ruthenium depleted “control system”. The preparation of this ruthenium depleted 
system is discussed in detail in Section 5.1 below.  
 
Once we had this control in hand, we were hoping to proceed to our 1H NMR/ICP-MS study 
of the conversion reactions. We were planning on completing a comparative analysis of the 
conversion of indenol to indenone/indanone wherein we were hoping to compare the 
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ruthenium depleted sample with other samples that contained fresh Grubbs II catalyst 11, 
Grubbs II catalyst 11’s degradative products and alternative ruthenium source, eg: ruthenium 
chloride. The 1H NMR/ICP-MS studies of the conversion reaction are outlined in detail in 
Section 5.2 below.  
 
5.1 Ruthenium Removal 
 
Our initial attempts at the ruthenium removal in our systems centered on the removal of 
ruthenium from previously synthesized indenol 203 (Figure 34). We were hoping that by 
removing the ruthenium we could monitor the difference between the ruthenium-free sample 
and the original sample upon heating. A number of different methods have recently been 
reported for the removal of the ruthenium byproducts of the Grubbs metathesis catalysts.  
 
O
O
OH
(160)  
Figure 34 
 
The Grubbs213 method involves conversion of the ruthenium byproducts into water-soluble 
ruthenium phosphine complexes, using the quite expensive tris(hydroxymethyl)phosphine. 
The Paquette group214 utilized the oxidation of the ruthenium species with Pb(OAc)4. 
However this method has a significant drawback in the introduction of a toxic reagent. Georg 
et al.215 have reported the removal of the ruthenium byproducts using the inexpensive 
reagents triphenylphosphine oxide (Ph3P=O) or dimethyl sulfoxide (DMSO). Their procedure 
involves the treatment of the crude reaction mixtures with Ph3P=O or DMSO followed by 
filtration through silica gel or column chromatography with silica gel.215  
 
Also Dixneuf and co-workers216 used carbon black to clean up the ionic liquid after ring 
closing metathesis reactions for the purpose of recycling the ionic liquid. Optimized 
conditions of these methods allowed for the reduction of ruthenium levels down to 
approximately 1-2µg per 5 mg of product.216 Cho and Kim.217 have recently reported a 
method where crude RCM product was adsorbed onto silica gel and filtered through a silica 
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gel pad, the filtrate was treated with activated carbon and the resulting residue further purified 
by silica gel chromatography. Using the optimized conditions, the residual ruthenium levels 
were reduced to 0.06-0.53µg per 5 mg of product, without a detectable loss of product.217 
 
We initially decided to try a mixture of both the Georg215 and Cho217 approaches. We 
dissolved our indenol 203 in a solution of 10% EtOAc-Hexane and the solution was then 
stirred with 50eq of activated carbon (relative to the amount of catalyst 11) at rt for 4 h. After 
this time the solution was filtered through celite and the solvent was removed in vacuo. The 
resulting residue was then dissolved in distilled dichloromethane and 50eq of DMSO (relative 
to the amount of catalyst 11) was added. The reaction mixture was then stirred at rt for 18 h. 
After this time the solvent was removed in vacuo and the resulting residue was purified by 
column chromatography, a yellow oil being obtained.  
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Scheme 115 Overview of Ruthenium Removal Procedure Attempted 
 
This oil was then analyzed and it was found to contain only indenone 204. Thus the procedure 
was repeated and stopped after treatment with activated carbon; the oil obtained here was then 
analyzed and found to contain a mixture of indenol 203 and indenone 204. Based on either 
acid-catalysed conversion in the presence of activated carbon or the fact that the  DMSO was 
apparently oxidizing our indenols, neither of these routes were deemed suitable. Thus, we 
reverted back to the literature.  
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During the course of the project, Breinbauer and co-workers218 published their results on the 
preparation of an efficient and inexpensive scavenger resin for Grubbs catalysts. They 
introduced the resin bound phosphine 288 (Figure 35) as a readily accessible chelate P-ligand 
for the design of immobilized transition metal catalysts in organic synthesis, which can be 
stored at rt under air for more than six months without the formation of P(V)-species. They 
proposed three different ways of using the resin bound phosphine 288, firstly on its own, 
showing 90% ruthenium removal, secondly, compound 288 and silica, giving ruthenium 
removal of 94% or thirdly the use of compound 288 in conjunction with activated carbon, that 
gave a 96% ruthenium removal.218  
 
We then wished to attempt the Breinbauer resin bound phosphine 288 on our system, but 
found that we could not obtain the necessary chemicals in our country in order to synthesize 
it. Thankfully, Professor Breinbauer5 was kind enough to send some of their polymer bound 
resin 288 for use on our system. 
 
N
P
P
288  
 
Figure 35218 
 
We thus proceeded to dissolve indenol 203 in distilled dichloromethane and to degas the 
solution using nitrogen for 30 min. Then 5eq of the Ru-scavenger 288, relative to the amount 
of Grubbs II catalyst 11, was added to the reaction mixture and it was stirred at rt for 17 h. 
After this time the bright white “beads” of the scavenger had turned to a greenish grey-brown. 
The Ru-scavenger 288 was then filtered off through a celite pad, rinsed and the solvent was 
removed in vacuo. The indenol 203 was subsequently recovered in almost quantitative yield 
and was retained for the NMR spectroscopy study.  
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5.2 1H NMR Spectroscopic Studies of the Conversion of the Indenol to Indenone/Indanone 
 
Having a ruthenium-depleated indenol 203 sample in hand,6 we then proceeded to our 1H 
NMR spectroscopic studies. The general procedure for the preparation of the NMR samples 
was to prepare the samples in the NMR tubes and to degas them for 15 min using argon. The 
NMR tubes to be heated were then submerged approximately 3cm deep in a pre-heated oil 
bath, with the samples to be run at rt having been stored in the same room on the counter top. 
The samples were analyzed in 1 h intervals (unless stated otherwise), with the samples being 
removed from the heat and then running the NMR spectra immediately. The general overview 
for the NMR spectroscopy/ICP-MS studies are outlined schematically in Scheme 116 below. 
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Scheme 116 Overview of the NMR/ICP-MS Study 
 
The use of the general procedure outlined above allows us to draw numerous conclusions due 
to the presence of the two controls that are included in the method (A and B). If no conversion 
                                                 
6 The ruthenium free indenol sample was obtained by purification of a previously synthesized indenol 203 
sample using the procedure outlined in Section 5.1 above (employing the Breinbauer scavenger 288). We outline 
how the samples for the 1H NMR analysis were tested for ruthenium removal using ICP-MS in Section 5.3 
below. 
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of indenol 203 to indenone 204 occurs in sample E we can safely say that the lack of 
ruthenium prevents the conversion from occurring. If the conversion of indenol 203 to 
indenone 204 occurs in sample D, we can conclude that the Grubbs II catalyst 11 degradation 
products help catalyze the reaction. Also, if the conversion of indenol 203 to indenone 204 
occurs in C we can assume that the reaction is ruthenium catalyzed and suggest that it is due 
to Grubbs II catalyst 11 or its degradation products. Showing that the conversion of 203 to 
204 is ruthenium catalyzed supports our theory that the indenol to indenone conversion is a 
ruthenium catalyzed dehydrogenative oxidation. Ratios quoted in this section are for 
indenol:indenone:indanone; with 1H NMR spectra run at time zero for all compounds and 
found to be pure indenol 203. The ratios reported are estimated by inspection of the 1H NMR 
spectra. 
 
Case Study 1 
 
The first of the NMR spectroscopy/ICP-MS studies was performed exactly as outlined in 
Scheme 116 above. The three tubes that were heated, namely C-1, D-1 and E-1 were placed 
in an oil bath set to 60oC. The 1H NMR spectra were run in intervals of 45 min and the results 
obtained for the 1H NMR spectra are outlined in Table 19 below. 
 
Table 19 Results for 1H NMR Spectra used in Case Study 1 
Tube  Ru-content Temp Time (min) Producta 
A-1 
 
 
 
B-1 
 
 
 
Residual 
 
 
 
Ru-depleted 
 
 
 
rt 
 
 
 
rt 
 
 
 
 
80 
145 
210 
1180 
80 
145 
210 
1180 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
a ratios = indenol:indenone:indanone 
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Table 19 contd. Results for 1H NMR Spectra used in Case Study 1 
Tube  Ru-content Temp Time (min) Producta 
C-1 
 
 
 
 
D-1 
 
 
 
E-1 
Ru-depleted + 5 
mol % cat. 11 
 
 
 
Residual 
 
 
 
Ru-depleted 
60oC 
 
 
 
 
60oC 
 
 
 
60oC 
80 
145 
 
210 
1180 
80 
145 
210 
1180 
80 
145 
210 
1180 
Indenol (trace Indenone) 
Indenol (trace Indenone 
and Indanone) 
3:2:1 
3:5:1 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
a ratios = indenol:indenone:indanone 
 
As can be seen from Table 19 above, the reaction mixture in NMR tube C-1 shows a 
conversion of the indenol to a mixture of the indenone and indanone. This result is as would 
be expected, as the addition of 5 mol % Grubbs II catalyst 11 greatly increases the amount of 
ruthenium present. This result alludes that the reaction is ruthenium catalyzed but cannot 
confirm it as none of the other reaction tubes showed any significant change. The next step in 
our quest for information was to either increase the concentration or to increase the reaction 
temperature as in our next case study. 
 
Case Study 2 
 
In this case study we decided to increase the temperature to see if we could force the reaction 
to occur in the tubes C-2, D-2 and E-2. The next of the NMR spectroscopy/ICP-MS studies 
was again performed as outlined in Scheme 116 above and the three tubes that were heated, 
namely C-2, D-2 and E-2, were placed in an oil bath set to 100oC. The 1H NMR spectra were 
run in intervals of 45 min and the results obtained for the 1H NMR spectra are outlined in 
Table 20 below. 
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Table 20 Results for 1H NMR Spectra used in Case Study 2 
Tube Ru-content Temp Time (min) Producta 
A-2 
 
B-2 
 
C-2 
 
 
 
 
 
D-2 
 
 
 
 
 
E-2 
Residual 
 
Ru-depleted  
Ru-depleted + 5 
mol % cat. 11 
 
 
 
 
 
Residual 
 
 
 
 
 
Ru-depleted 
rt 
 
rt 
 
100oC 
 
 
 
 
 
100oC 
 
 
 
 
 
100oC 
1328 
6173 
1328 
6173 
101 
180 
259 
355 
1400 
1680 
101 
180 
259 
355 
1400 
1680 
101 
180 
259 
355 
1400 
1680 
Indenol 
Indenol 
Indenol 
Indenol 
5:1:5 
2:2:9 
1:2:9 
1:2:9.5 
1:2:10 
0.5:2.5:10.5 
Indenol 
Indenol 
Indenol 
Indenol 
0.8:13:0 
0.9:12.5:0 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
Indenol 
a ratios = indenol:indenone:indanone 
 
As can be seen from Table 20 above, the tube C-2 clearly showed a conversion of the indenol 
to a mixture of indenone and indanone. As suspected at the outset of the study, the indanone 
formation was favoured at this high temperature. Again, all that the results from tube C-2 
showed, was that the conversion was occurring in the presence of the Ru-catalyst 11, and thus 
that the conversion was ruthenium catalyzed.  
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However, this study differs significantly from case study 1 in that the tube containing the 
residual ruthenium (tube D-2) also showed a small amount of conversion. What is interesting 
to note is that tube D-2 only showed the conversion of indenol to indenone and that none of 
the indanone was detected. This further supports our proposal that the conversion is a 
ruthenium catalyzed dehydrogenative-oxidation, as well as suggesting that this reaction 
occurs preferentially to the redox-isomerisation under residual ruthenium concentrations. 
 
The reason that tube C-2 shows more of the indanone than C-1 (produced by the well know 
redox-isomerisation) could be due to the significantly higher temperature employed for the 
reaction. At this temperature, the indenol to indanone conversion is occurring more rapidly, to 
the detriment of the indenol to indenone transformation. In addition the higher concentration 
of Grubbs II catalyst 11 in C-2 could explain why there is more indanone present than in D-2. 
 
Case Study 3: 
 
The next of the NMR spectroscopy/ICP-MS studies was performed under similar conditions 
to those outlined in Scheme 116 above for tube C-3. Tube C-3 contained the “ruthenium 
depleted” indenol 203 to which 5 mol % Grubbs II catalyst 11 had been added as it showed 
the most significant changes in the previous case studies. Tube C-3 was then heated at 60°C. 
The data obtained is shown graphically in Graph 1 below; note that no indanone 205 was 
detected under the reaction conditions. 
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Scheme 117 
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Graph 1 Graphical Representation of Case Study 3  
(% Amount is given based on the NMR spectrum integration) 
 
As can be seen for Graph 1 above, at time zero the solution contained only indenol and no 
indenone 204, as would be expected. The graph then shows how over time the concentration 
of the indenol 203 decreases and at the same time the indenone 204 concentration increases. 
Both of the curves tend to a point where they may intersect at an equilibrium; however, due to 
the time limits on this study, was not observed. 
 
The graph clearly shows that as the concentration of the indenol 203 is decreasing, the 
concentration of the indenone 204 is increasing by the same factor, thus highlighting the clear 
correlation of the two compounds. This was then the final evidence we required to support our 
theory that the indenol is converting to the indenone by a dehydrogenative oxidation reaction. 
 
5.3 ICP-MS Study to Determine Ruthenium Removal 
 
After performing the ruthenium removal using the Breinbauer218 scavenger, we needed a way 
of testing that we had in fact formed our required “ruthenium depleted” indenol 203. We then 
decided to utilize the procedure used by Georg et al.,215 whereby they used ICP-MS to 
determine the ruthenium concentration in their samples after removal using their procedure. 
We assigned total ruthenium removal to be a value of less than 0.5 µg Ru/5mg of indenol 
sample. 
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Selected samples from the 1H NMR case studies 1 and 2 were analyzed by ICP-MS. The 
standard curve plotted for our investigation is shown in Appendix C. Based on Scheme 116, 
samples A, B and C were initially analyzed in order to determine the ruthenium removal 
capabilities of the scavenger 288. As you may recall, sample A contained the untreated 
indenol 203, sample B contained the indenol after treatment with the scavenger and sample C 
contained the treated indenol + 5 mol % Grubbs II catalyst 11. The reaction order is shown in 
Scheme 118 below.  
 
Add 5 mol % Grubbs 
II catalyst 11, 
heat in d8-toluene
C
OH
O
O
203
A
OH
O
O
203
Treat with Ru-
scavenger 288
B
 
 
Scheme 118 Samples Used for ICP-MS Analysis 
 
Our ICP-MS determination found the following values: 
 Sample A-1 contained 4.000µg Ru/5mg indenol sample 
 Sample B-1 contained 0.108µg Ru/5mg indenol sample 
 Sample C-1 contained 21.736µg Ru/5mg indenol sample 
 
These values show a 97% reduction in the ruthenium levels from sample A-1 to B-1 (ie: after 
treatment with scavenger 288) and a 20 126% increase in the ruthenium levels after the 
addition of the Grubbs II catalyst 11. Having satisfied ourselves that the scavenger 288 was 
working, we then decided to analyze our samples from the second case study.  
 
The samples that were analyzed from case study 2 were A-2, B-2, C-2 and E-2. We included 
sample E-2 in this study as a control to confirm that our ICP-MS analysis was correct. Our 
analysis found: 
• Sample A-2 contained 0.766µg Ru/5mg sample 
• Sample B-2 contained 0.160µg Ru/5mg sample 
• Sample C-2 contained 3.029µg Ru/5mg sample 
• Sample E-2 contained 0.160µg Ru/5mg sample 
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This data highlights a 79% reduction in the ruthenium levels going from sample A-2 to 
sample B-2. After the addition of Grubbs II catalyst 11 to sample B-2, sample C-2 showed a 
1893% increase in the ruthenium levels. The control, sample E-2, showed the exact same 
level of ruthenium as sample B-2. This is as would be expected and confirms that there were 
no errors that occurred under reaction conditions or through the analysis.  
 
This analysis thus allows us to conclude that our samples used after ruthenium removal using 
the Breinbauer scavenger 288 were acceptably termed “ruthenium depleted”. In addition, we 
now have qualitative evidence for the conversion of the indenol 203 to the indenone 204 and 
the indanone 205, supporting our proposal that the reactions occur as dehydrogenative 
oxidation and redox isomerisation respectively. 
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Chapter 6: Conclusion and Future Work 
 
1.  Summaries and Conclusion  
 
The aims of this project were discussed and listed at the end of Chapters 2 and 3. The main 
aims will be discussed in turn, thus giving an idea of the success of the project.  
 
1.1 Synthesis of N-containing benzo-fused heterocycles 
 
¾ To synthesize a range of benzazocines from the common synthetic precursor 138 using 
the ring closing metathesis strategy developed by Pathak.129. 
 
This aim was fulfilled as we were able to synthesize four different protected 8-membered 
benzo-fused benzazocines based on the methodology developed by Pathak.129 The 1-[7-
isopropoxy-8-methoxy-3,6-dihydro-2-benzazocin-2(1H)-yl]-1-ethanone 214 was obtained 
from the corresponding diene in 82% yield as a clear oil. The tert-butyl 7-isopropoxy-8-
methoxy-3,6-dihydro-2-benzazocine-2(1H)-carboxy-late 215 was formed in 99% yield and 
the 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 216 was 
found in 84% yield. Finally, the 7-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-
1,2,3,6-tetrahydro-2-benzazocine 140 was obtained in 98% yield after RCM. 
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Scheme 119 
 
Having isolated the Claisen-Cope product 267 when attempting the Claisen rearrangement of 
the cinnamyl containing aldehyde 246, we then continued our investigation into other 
benzazocines, by including the new substitution pattern on the benzene ring in this study. This 
was very important for us to do, as the substitution pattern obtained by the Cope 
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rearrangement is the same as that found in many of the natural products outlined in Chapter 
2. We then took our protected aldehyde 268, performed the reductive amination on it to obtain 
the amine 270, and accomplished the protection reactions (Boc and Ts groups were used) and 
finally attempted the RCM. From the RCM we were able to isolate tert-butyl 9-isopropoxy-8-
methoxy-3,6-dihydro-2-benzazocine-2(1H)-carboxylate 273 in 73% yield and 9-isopropoxy-
8-me-thoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetrahydro-2-benzazocine 274 in 39% yield. 
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Scheme 120 
 
¾ Test the feasibility of deprotection reactions on the final 6-,7- and 8-membered 
nitrogen containing benzo-fused systems. 
 
Due to the time constraints of the project, we were only able to test the deprotection reactions 
on the benzazocine systems. We were unable to deprotect compound 216 using the 
hydrogenation procedure with palladium on carbon, but we did show that this procedure 
hydrogenated the alkene in the 8-membered ring in excellent yield (98%). Our second 
attempt, at the Boc deprotection of compound 215 gave the desired 7-isopropoxy-8-methoxy-
1,2,3,6-tetrahydro-2-benzazocine 218 in 99% yield from the corresponding precursor.  
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Scheme 121 
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¾ Utilize ring closing metathesis to access a range of benzazepine systems from a 
common synthetic precursor.  
 
Two different approaches were utilized for the formation of the 7-membered benzazepines. 
The first of which allowed us to access the 2,5-dihydro-1H-2-benzazepines via the common 
intermediate 210, of which we protected the amine with our four protecting groups, 
isomerised the diene and performed the ring closing metathesis. We obtained the 2-acetyl-6-
isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzazepine 231 in 9% yield, the tert-butyl 6-
isopropoxy-7-methoxy-1,5-dihydro-2H-2-benzazepine-2-carboxylate 232 in 82% yield, the 2-
(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzazepine 233 in 58% yield 
and the 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-2-
benzazepine 234 in 47% yield after RCM from their respective diene precursors. 
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Scheme 122 
 
The second approach allowed us access to the 2,3-dihydro-1H-2-benzazepines by starting 
from the common intermediate 235, performing the protection reactions and finally 
completing the RCM reaction. The 2-acetyl-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-
benzazepine 240 was obtained in 8% yield, the tert-butyl 6-isopropoxy-7-methoxy-1,3-
dihydro-2H-2-benzazepine-2-carboxylate 241 was obtained in 26% yield, the 2-
(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine 242 in 39% yield 
and 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,3-dihydro-1H-2-benzazepine 
145 in 82% yield after RCM. 
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Scheme 123 
 
Having had limited success with the formation of our allyl based benzazepines. We attempted 
the synthesis of 5-phenyl-2-benzazepines by changing our initial chain in the starting 
materials to the cinnamyl group. Using this, we were then able to synthesize the common 
intermediate, N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-2-propen-1-amine 
249. Amine 249 was then used in the four protection reactions and the products were then 
subjected to the RCM conditions. After RCM, we obtained 32% yield of N-allyl-N-[3-
isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]acetamide 250. For the other three 
protecting groups, we were only able to observe molecular ion peaks in the HRMS, but we 
were not able to isolate and fully characterize the compounds. 
 
¾ Investigate the possibility of selective isomerisations in our diene systems, using the 
ruthenium-based catalyst outlined by Krompiec29 (catalyst 12). 
 
After numerous problems with our synthesis of the isoquinoline based systems, we attempted 
a range of different conditions to isomerise the protected dienes. Our initial investigation 
showed that both of the double bonds in the diene systems could be isomerised by the use of 5 
mol % of the Ru-isomerisation catalyst 12 at a high temperature (100-110oC).  
 
We found that 1 mol % of the Ru-isomerisation catalyst 12 was the optimal amount of 
catalyst to use for the isomerisation of only one of the double bonds in the diene with a 
temperature of 80oC giving the most favourable results. We were able to confirm that the N-
allyl chain had selectively isomerised by 13C NMR spectroscopy (Scheme 124).  
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Scheme 124 
 
While attempting the isomerisations on our diene systems we found that de-allylation of the 
N-allyl chain was occurring when large quantities of the Ru-isomerisation catalyst 12 (5-10 
mol %) and high temperatures (110-140oC) were used. These types of de-allylation reactions 
were shown to occur in the presence of Grubbs first generation catalyst by Alcaide,7 but to the 
best of our knowledge this is the first reported use of catalyst 12 for these reactions. 
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Scheme 125 
 
¾ Examine other diene systems to determine if with double allyl isomerisations it is 
possible to obtain isoquinoline analogues via ring closing metathesis. 
 
We performed double isomerisations on the diene systems 139, 211-213 as outlined above, 
but we only obtained poor yields of the products, if we managed to isolate them at all. We 
prepared the Boc-protected isoquinoline 220 in only 10% yield and the Ts-protected 
isoquinoline 142 in 27% yield, using the one-pot reaction procedure. Having had so many 
problems with the one-pot isomerisation-RCM reaction, we decided to isolate the isomerized 
intermediate and were subsequently able to isolate 2-acetyl-5-isopropoxy-6-methoxy-1,2-
dihydroisoquinoline 223 in 78% yield after RCM. However, none of the SO2Bn-protected 
isoquinoline 224 was obtained.  
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Scheme 126 
 
We then attempted the synthesis of the 4-phenyl substituted isoquinolines by taking the 
protected compounds obtained from the common intermediate 249 and subjecting them to the 
Ru-isomerisation catalyst 12. We were able to isolate the isomerised compounds in excellent 
yield. Having these in hand, we then attempted the RCM on them, but in all instances only the 
starting materials were isolated. Due to the time constraints of the project we were 
unfortunately unable to continue our investigation into the lack of formation of the desired 
isoquinolines.  
 
1.2 Synthesis of Indenols, Indenones and Indanones. 
 
¾ Synthesize a range of indenols, indenones and indanones from common synthetic 
precursors (eg. Compound 202) using the previously developed methodology of 
Coyanis.48  
 
We prepared 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol 202 using 
established methodology and used it for the synthesis of 1-[3-isopropoxy-4-me-thoxy-2-(1-
phenyl-1-propenyl)phenyl]-2-propen-1-ol 275 and 1-[3-isopropoxy-4-methoxy-2-(1-methyl-
1-propenyl)phenyl]-2-propen-1-ol 284. Each of the desired indan compounds was obtained 
using the same RCM methodology, with the procedures differing only in the reaction 
temperature. The indenols 203, 276 and 285 were prepared at rt and were obtained in yields of 
87%, 49% and 57% respectively. The indenones 204, 277 and 286 were synthesized at 60-
80oC and were obtained in yields of 45%, 69% and 42% respectively. The unsubstituted 
indanone 231 was prepared at 80oC using 8 mol % Grubbs II catalyst 11 in 89% yield. 
Unfortunately we were unable to prepare the phenyl-substituted indanone 278 even after 
numerous attempts. Finally the methyl-substituted indanone 287 was obtained in 18% yield 
after 18 h at 110-170oC using 5 mol % Grubbs II catalyst 11. 
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¾ Attempt to explain the role of ruthenium in indenol-indenone-indanone conversions 
via the implementation of a model 1H NMR study which would include control 
standardss where ruthenium has been depleted. 
 
The unsubstituted indenone compounds were isolated from the reaction mixtures for the 
preparation of the unsubstituted indenols by Coyanis.48 We hoped to be able to hypothesize as 
to why they were present and support our ideas through the use of NMR spectroscopy studies. 
We monitored the conversion of the indenol 203 to the indenone 204 and indanone 205 
through the use of 1H NMR spectroscopy studies.  
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Scheme 128 
 
We compared the reactions containing residual ruthenium from the RCM reactions after 
column chromatography, those with 5 mol % Grubbs II catalyst 11 added and in samples 
where the ruthenium had been removed using a scavenger 288. We found that the sample with 
the added Grubbs catalyst in showed the most efficient conversion of indenol 203 to indenone 
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204 at 60-80oC and demonstrated almost exclusive conversion to indanone 205 at 100oC. The 
sample where the ruthenium had been removed with the scavenger showed no conversion at 
all, independent of the temperature, and the sample with the residual ruthenium showed 
conversion of indenol 203 to indenone 204 at 100oC after 1400 min.  
 
The final study on the conversion in the presence of Grubbs II catalyst found that the indenol 
203 converted exclusively to the indenone 204 at lower temperatures. These results support 
our suggestion that the conversion of indenol 203 to indenone 204 is a ruthenium catalysed 
dehydrogenative oxidation, whereas the conversion of indenol to indanone occurs via the well 
known redox isomerisation reaction. To the best of our knowledge, this is the first ever 
reported use of the Grubbs II catalyst 11 or its degradative products for a tandem RCM-
oxidation reaction. 
 
2. Future Work 
 
Having completed the full methodology study for the nitrogen-containing benzo-fused 
heterocycles, we can now extend it to include a substitution pattern that mirrors the one found 
in the natural products. Hopefully, this will then allow us to synthesize a range of different 
compounds, which may then be used in biological testing for various diseases.  
 
The first key aspect of future work should be to fully investigate the possibility of performing 
internal isomerisations of the alkene double bond in both the benzazocines and the 
benzazepines (Scheme 129) using the ruthenium isomerisation catalyst 12 as well as other 
isomerisation methods. An area of particular interest will be to see if it is possible to access 
both isomers from the isomerisation of benzazocines, and whether or not you can access each 
of the isomers selectively. 
 
Chapter 6 Conclusion and Future Work 156
N
Pg
O
O
N
Pg
O
O
N
Pg
O
O
OR
catalyst 12
O
O
N
Pg
catalyst 12
O
O
N
Pg
 
 
Scheme 129  
 
Internal isomerisation of the alkene is of great importance as it allows a far greater scope for 
functionalisation. An isomerised benzazocine can potentially be functionalized at the 3, 4, 5 
and 6 positions and benzazepines at the 3, 4 and 5 positions. 
 
Functionalisation of the ring alkene is the second key aspect of any future work on this 
project. A few of the possible routes of functionalisation include epoxidation, 
aminohydroxylation and oxymercuration. An interesting route would be to utilize the alkene 
in Diels-Alder type reactions, thereby gaining access to tricyclic molecules, and potentially 
polycyclic molecules depending on the diene used [Scheme 130 (a)].  
 
Potentially the most interesting aspect of functionalisation would be to look at performing 
asymmetric Sharpless dihydroxylations thereby giving access to the possibility of 
stereoselective functionalistions [(Scheme 130 (b)]. An alternative approach to asymmetric 
synthesis could be to form arene Cr(CO)3 complexes prior to attempting any functionalisation 
of the alkene, thereby effectively masking the one face of the molecule from attack [(Scheme 
130 (c)]. 
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Scheme 130 
 
A long term goal would no doubt be to synthesize a library of isoquinolines, benzazepines and 
benzazocines for the purpose of investigating their pharmacological activities, through 
biological studies. 
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Chapter 7: Experimental Procedures 
 
1. General Details 
 
1.1 Purification of Solvents and Reagents 
 
All solvents used for reactions and preparative chromatography were distilled prior to use. 
Solvents used in reactions were pre-dried in their reagent bottles and then distilled over the 
appropriate drying mediums under a nitrogen atmosphere.   
 
o Tetrahydrofuran and diethyl ether were distilled from sodium metal wire and 
benzophenone.  
o Benzene and toluene were distilled from sodium metal lumps. 
o Acetonitrile, dichloromethane, N,N-dimethylformamide (stored over 4Å molecular 
sieves after distillation), methanol and triethylamine were distilled from calcium 
hydride. 
o Acetic anhydride was distilled from 4Å molecular sieves. 
o Pyridine was distilled from potassium hydroxide. 
 
Chloroform was dried by passing it through basic alumina (Merck aluminium oxide, basic, 
activity grade I). Potassium tert-butoxide was resublimed under high vacuum immediately 
before use. Tosyl chloride was purified according to Perrin219 before use and stored in a 
dessicator until required. It was purified by dissolving (10g) in the minimum volume CH2Cl2 
(~25cm3), filtered, and diluted with five volumes of hexane (5×25cm3) to precipitate the 
impurities. The solution was then filtered and concentrated to 40cm3 by evaporation. White 
crystals precipitated out on standing (m.p. was in agreement with the literature value of 67-
69oC). 
 
Grubbs II catalyst 11 and the Ru-isomerisation catalyst 12 were stored in Schlenk tubes under 
argon. The procedure for storing the catalysts was to place the Schlenk tubes under vacuum 
and then under argon four to five times to ensure that the systems were free from air and they 
were then stored in the dark. 
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1.2 Experimental Techniques 
 
All reactions were performed under an inert atmosphere (either nitrogen or argon) using a 
standard manifold line and connected to a vacuum pump. The nitrogen and argon were 
dehydrated by bubbling the gas through sulfuric acid, and then neutralizing by passing 
through sodium hydroxide pellets. The vessels were flame-dried while under vacuum and 
were then allowed to cool to room temperature under the inert atmosphere.  
 
1.3 General Procedures 
 
Concentration or evaporation in vacuo refers to the removal of solvent under reduced pressure 
(approximately 20mmHg, 40-50oC) on a rotary evaporator and final drying on an oil pump 
(approximately 1-2mmHg) at room temperature. Items dried under “high vacuum” were also 
dried using an oil pump (approximately 1-2mmHg). 
 
Yields are calculated from the immediate synthetic precursor, unless otherwise specified. 
 
1.4 Chromatographic Separations 
 
Macherey-Nagel Silica gel 60 (particle size 0.063-0.200mm) was used as the adsorbent for 
conventional preparative chromatography, with a silica to compound ratio of 30:1. The silica 
was packed into a suitable column, the product was loaded onto the silica surface and covered 
in acid washed sea sand. The elution process was performed using the indicated solvent 
mixtures and was usually performed under standard air pump pressure conditions.  
 
The Rf values quoted are those obtained from thin layer chromatography on aluminium-
backed Macherey-Nagel ALUGRAM Sil G/UV254 plates pre-coated with 0.25mm silica gel 
60 or Aldrich TLC plates, silica gel on aluminum. Spray reagents were used on thin layer 
chromatography plates for the detection of compounds that were not highly UV active. 
General reagents used include acidic vanillin, basic KMnO4, acidic ceric ammonium sulfate 
and acidic anisaldehyde. Acidic DNPH was used for the detection of ketones and aldehydes 
specifically. 
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1.5 Spectroscopic and Physical Data 
 
Sanyo EM-590 manufactured the commercial microwave oven used in certain reactions. The 
microwave reactor referred to is the CEM Discovery and operating conditions employed for 
the reactions are outlined in the experimental procedures.  
 
The Carousel reactor employed for certain reaction sequences was manufactured by Radleys 
Discovery Technologies and is sold as the Carousel Reaction Station. 
 
All melting points were obtained on a Reichert hot-stage microscope and are uncorrected. 
 
Infrared spectra were obtained either on a Bruker Vector 22 spectrometer, or on a Varian 
800FT-IR spectrometer (Scimitar Series). Liquids were run as thin films between sodium 
chloride plates, while solids were run as solutions in chloroform between sodium chloride 
plates. The absorptions are reported on the wavenumber (cm-1) scale in the 600-3500cm-1 
range. The signals are reported: value (assignment). 
 
Hydrogen nuclear magnetic resonance (1H NMR) spectra were recorded on Bruker AC-200, 
Bruker Advance-300 and Bruker DRX 400 spectrometers at 200.13, 300.13 and 400.13MHz 
respectively using standard pulse sequences. The probe temperature for all experiments was 
300±1K. All spectra were recorded in deuterated chloroform (CDCl3) in 5mm NMR tubes 
unless otherwise specified. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane as the internal standard. The 1H NMR chemical shifts are reported: value 
(number of hydrogens, description of signal, coupling constants in hertz (Hz) where 
applicable, assignment). Abbreviations used: s=singlet, d=doublet, t=triplet, q=quartet, 
p=pentet, sept=septet, m=multiplet and b=broad. 
 
Decoupled carbon nuclear magnetic resonance (13C NMR) spectra were recorded on Bruker 
Advance-300 and Bruker DRX 400 spectrometers at 75 and 100MHz respectively Chemical 
shifts are reported on the δ scale relative to the central signal of deuterated chloroform taken 
as δ 77.00. The 13C NMR chemical shifts are reported: value (assignment). The 1H and 13C 
NMR spectroscopic assignments with the same superscript are interchangeable. DEPT, CH-
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correlated and COSY spectra were routinely used for the complete assignment of NMR 
signals.  
 
High-resolution mass spectra were recorded on a VG7-SEQ Double Focussing Mass 
Spectrometer at 70eV and 200µA. The polarity was positive, ionization employed was EI, 
with a resolution of 3000, a mass range of 3000amu (8kV) and a scan rate of 5secs/decade. 
Data are quoted: m/z value (relative abundance). 
 
Microwave digestion of samples for ICP-MS analysis was performed using the Anton Paar 
Multiwave 3000 (microwave sample preparation platform system). ICP-MS results were 
detected using the Spectro Mass-2000 with the SpecPure Multielement Standards (group 4 
elements) being used for the preparation of our standard curves.  
 
Crystal structure intensity data were collected on a Bruker SMART 1K CCD area 
diffractometer with graphite monochromated Mo Kα radiation (50kV, 30mA). The collection 
method involved ω-scans of width 0.3o. Data reduction was carried out using the program 
SAINT+.220 The crystal structure was solved by direct methods using SHELXTL.221 Non-
hydrogen atoms were first refined isotropically followed by anisotropic refinement by full 
matrix least-squares calculations based on F2 using SHELXTL.221 Hydrogen atoms were first 
located in the difference map then positioned geometrically and allowed to ride on their 
respective parent atoms. Diagrams and publication material were generated using 
SHELXTL,221 PLATON 222 and Mercury.223 
 
1.6 Nomenclature and Numbering of Compounds 
 
The compounds prepared during the course of this project are named in the following 
experimental sections according to systematic nomenclature. However, the numbering system 
used to illustrate the diagrams of these compounds is one adopted for convenience and is not 
meant to reflect the systematic numbering of these compounds. 
 
 
 
 
Chapter 7 Experimental Procedures 163
2. Experimental Procedures: N-containing benzo-fused heterocycles 
 
2.1 Preparation of 3-allyloxy-4-methoxybenzaldehyde 207 
 
Potassium carbonate (2.5eq, 329mmol, 45.6g) was added to DMF 
(250cm3) and the solution was heated to 60oC for 20 min. Isovanillin 
(1eq, 132mmol, 20.1g) was added to the solution along with allyl 
bromide (2.5eq, 329mmol, 28.6cm3) and the mixture changed colour 
from milky white to yellow. The reaction mixture was then stirred at 
60oC under an Ar atmosphere for 20 h. After this time it was cooled to rt and the inorganic 
solids were filtered off through a celite pad. The solvent was then removed in vacuo to yield a 
yellow-orange oil. The crude mixture was purified by column chromatography (10-30% 
EtOAc-Hexane) and the product was obtained as a bright yellow oil (25.1g, 99% yield). 
Spectroscopic data was in agreement with that of Rousseau.1 
 
Rf = 0.50 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 3.96 (1H, s, OCH3), 4.67 (2H, d, 
J=5.4Hz, OCH2), 5.31-5.48 (2H, m, OCH2CH=CH2), 6.05-6.15 (1H, m, OCH2CH=CH2), 6.99 
(1H, d, J=8.2Hz, 5-H), 7.41 (1H, d, J=1.7Hz, 2-H), 7.46 (1H, dd, J=1.7 and 8.2Hz, 6-H), 9.84 
(1H, s, CHO);  δC (50 MHz, CDCl3) 56.1 (OCH3), 69.7 (OCH2), 110.6 (5-C), 110.9 (2-C), 
118.6 (OCH2CH=CH2), 126.8 (6-C), 130.0 (1-C), 132.4 (OCH2CH=CH2), 148.5 (4-Ca), 154.8 
(3-Ca), 190.8 (CHO). 
 
2.2 Preparation of 2-allyl-3-hydroxy-4-methoxybenzaldehyde 208 
 
Method A: 
3-Allyloxy-4-methoxybenzaldehyde 207 (5.26mmol, 1.01g) was 
transferred directly to a round bottom flask and placed inside the Teflon 
container. The commercial microwave was set to high power and the 
Claisen rearrangement was affected by microwaving in short bursts (15, 
15, 20 and 30 sec respectively with 5 min intervals in between each heating). After this time a 
colour change was observed from the yellow oil to a brown oil. This was found to be the 
product and no further purification was required (1.01g, 100% yield). 
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Method B: 
3-Allyloxy-4-methoxybenzaldehyde 207 (31.3mmol, 6.01g) was placed neat in a sealed tube 
for the microwave reactor. The program was set up with the power output at 50W, the 
temperature at 200oC, the maximum allowable pressure at 150psi with no cooling and 
continuous stirring. The run time was set to 5 min with hold times of 5, 5 and 20 min 
respectively or 10 and then 20 min respectively with cool down times of 5-10 min between 
each interval. The progress of the Claisen rearrangement was monitored at each interval by 
200MHz 1H NMR spectroscopy. After the 30 min in total it was found that the reaction had 
gone to completion and the compound was spectroscopically pure. The product was obtained 
as a viscous yellow brown oil and no further purification was required (6.01g, 100% yield). 
 
Rf = 0.41 (30% EtOAc-Hexane); νmax/cm-1 (NaCl plate) 1281 (-OH bending), 1492 (Ar ring), 
1579 (Ar ring), 1603 (Ar ring), 1726 (saturated aldehyde), 2931 (CHO), 3020 (Ar H), 3541 (-
OH stretch);  δH (300 MHz, CDCl3) 3.88 (2H, d, J=5.9Hz, CH2), 3.97 (3H, s, OCH3), 4.96-
5.03 (2H, m, CH=CH2), 5.86 (1H, s, OH), 6.03 (1H, tdd, J=6.0, 10.6 and 16.6Hz, CH=CH2), 
6.88 (1H, d, J=8.5Hz, 5-H), 7.44 (1H, d, J=8.5Hz, 6-H), 10.07 (1H, s, CHO);  δC (50 MHz, 
CDCl3) 28.4 (CH2), 56.1 (OCH3), 108.1 (5-C), 115.3 (CH=CH2), 125.4 (6-C), 127.5 
(CH=CH2a), 128.2 (2-Ca), 136.2 (1-C), 143.8 (3-C), 150.7 (4-C), 191.4 (CHO);  MS m/z 192 
(M+, 90%), 77 (29), 91 (15), 103 (22), 131 (19), 136 (18), 143 (25), 149 (19), 159 (31), 162 
(18), 177 (100), 192 (90), 193 (23), HRMS calculated for C11H12O3: 192.07864, found: 
192.08046. 
 
2.3 Preparation of 2-allyl-3-isopropoxy-4-methoxybenzaldehyde 138 
 
Method A: 
The Claisen rearrangement was affected upon the heating of 3-allyloxy-
4-methoxybenzaldehyde 207 (75.6mmol, 14.6g), which had been 
dissolved in DMF (145cm3) to 150-160oC under an Ar atmosphere for 
64 h. The reaction mixture was then cooled to 60oC before the addition 
of the isopropyl bromide (2.5eq, 189mmol, 17.7cm3) and potassium carbonate (2.5eq, 
189mmol, 26.2g). The reaction mixture was left to stir at 60oC for 18 hours and was then 
cooled to rt before the inorganic solids were filtered off through a celite plug. The solvent was 
removed in vacuo to yield a dark brown oil which was purified by column chromatography 
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(5-10% EtOAc-Hexane). The product was obtained as a bright yellow oil (13.4g, 75% over 2 
steps). 
 
Method B:  
3-Allyloxy-4-methoxybenzaldehyde 207 (1eq, 41.8mmol, 8.02g) was placed neat in a sealed 
tube for the microwave reactor. The program was set up with the power output at 50W, the 
temperature at 200oC, the maximum allowable pressure at 150psi with no cooling and 
continuous stirring. The run time was set to 5 min with hold times of 5, 5 and 20 min 
respectively or 10 and then 20 min respectively with cool down times of 5-10 min between 
each interval. 200MHz 1H NMR spectroscopy monitored the progress of the Claisen 
rearrangement at each interval. After the 30 min in total it was found that the reaction had 
gone to completion and was relatively clean so the phenol 208 was dissolved in DMF (80cm3) 
and heated to 60oC before the addition of the potassium carbonate (2.5eq, 103mmol, 14.2g) 
and isopropyl bromide (2.5eq, 103mmol, 9.70cm3). The reaction mixture was left to stir at 
60oC under an Ar atmosphere for 66 h after which time it was allowed to cool to rt. The 
inorganic solids were filtered off through a celite pad and the solvent was removed in vacuo. 
The dark brown oil was purified by column chromatography (5-10% EtOAc-Hexane) to yield 
the product as a bright yellow oil (8.56g, 89% yield over 2 steps). The spectroscopic results 
correlated well to that obtained by Pathak129 and no further analysis was required. 
 
Rf = 0.65 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.28 [6H, d, J=6.2Hz, OCH(CH3)2], 
3.90 (5H, m, OCH3 and CH2), 4.51 [1H, sept, J=6.2, OCH(CH3)2], 4.97 (2H, two dd, J=1.6, 
13.7 and 18.8Hz, CH=CH2), 6.00 (1H, m, CH=CH2), 6.90 (1H, d, J=8.6Hz, 5-H), 7.64 (1H, d, 
J=8.6Hz, 6-H), 10.08 (1H, s, CHO);  δC (50 MHz, CDCl3) 22.8 [OCH(CH3)2], 29.0 (CH2), 
55.7 (OCH3), 74.9 [OCH(CH3)2], 109.6 (5-C), 115.6 (CH=CH2), 128.0 (1-C), 128.0 (6-C), 
136.4 (2-Ca), 137.1 (CH=CH2a), 144.9 (3-C), 157.6 (4-C), 191.1 (CHO).  
 
2.4 Preparation of N-[(E)-(2-allyl-3-isopropoxy-4-methoxyphenyl)methylidene]-2- 
propen-1-amine 209 
 
2-Allyl-3-isopropoxy-4-methoxybenzaldehyde 138 (7.98 mmol, 
1.87g) was transferred directly to a round-bottomed flask and to this 
was added allyl amine (1.4eq, 11.2mmol, 0.900cm3). The reaction 
5
6
N
O
O
209
Chapter 7 Experimental Procedures 166
mixture was placed under a N2 atmosphere and was allowed to stir at rt for 3 h. After this 
period of time the excess allyl amine was removed in vacuo to yield a yellow oil. The product 
was essentially pure by 1H NMR spectroscopy and no further purification was required 
(2.42g, 99% yield). 
 
Rf = 0.63 (30% EtOAc-Hexane); νmax/cm-1 (NaCl plate) 734 (alkanes), 926 (C=CH2), 1383 
(C-OCH3), 1591 (Ar ring), 1637 (diene), 1682 (C=N-), 2841 (N-CH2), 3020 (C=CH stretch); 
δH (300 MHz, CDCl3) 1.27 [6H, d, J=6.1Hz, OCH(CH3)2], 3.69 (2H, dd, J=1.7 and 3.8Hz, 
Ar-CH2), 3.86 (3H, s, OCH3), 4.21 (2H, dd, J=1.3 and 5.6Hz, N-CH2), 4.49 [1H, sept, 
J=6.2Hz, OCH(CH3)2], 5.00-5.24 (4H, m, NCH2CH=CH2 and ArCH2CH=CH2), 5.90-6.09 
(2H, m, NCH2CH=CH2 and ArCH2CH=CH2), 6.83 (1H, d, J=8.7Hz, 5-H), 7.73 (1H, d, 
J=8.7Hz, 6-H), 8.44 (1H, s, N=CH);  δC (100.6 MHz, CDCl3) 22.6 and 22.7 [OCH(CH3)2], 
30.7 (ArCH2), 55.6 (OCH3), 63.7 (NCH2), 74.4 [OCH(CH3)2], 109.9 (5-C), 114.6 
(NCH2CH=CH2a), 115.8 (ArCH2CH=CH2a), 124.1 (6-C), 131.7 (1-C), 132.5 
(NCH2CH=CH2), 136.9 (2-C), 137.5 (ArCH2CH=CH2), 145.0 (3-C), 151.8 (4-C), 160.4 
(N=CH);  δN (40.6MHz, CDCl3) –62.9;  MS m/z 272 (M+, 67%) 39 (23), 41 (61), 43 (28), 115 
(39), 143 (86), 144 (20), 160 (21), 161 (25), 174 (31), 175 (75), 176 (91), 177 (24), 190 (30), 
216 (42), 218 (100), 230 (98), 231 (68), 232 (23), 258 (32), 272 (67), 273 (26), 274 (25), 
HRMS calculated for C17H23NO2: 273.17288, found: 272.17086.  
 
2.5 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-propen-1-amine 210 
 
Method A: 
2-Allyl-3-isopropoxy-4-methoxybenzaldehyde 138 (29.9 mmol, 
7.01g) was transferred directly to a round-bottomed flask and to 
this was added allyl amine (1.4eq, 41.9mmol, 3.20cm3). The 
reaction mixture was placed under an Ar atmosphere and was 
allowed to stir at rt for 24 h. After this period of time the excess allyl amine and water were 
removed in vacuo to yield an orange oil, which was pure by 1H NMR spectroscopy. The 
imine was then dissolved in MeOH (70cm3) and cooled to 0oC in an ice-water bath. To this 
methanolic solution was added sodium borohydride (1.2eq, 35.9mmol, 1.37g) and the solution 
was allowed to stir for 1 h 40 min. After this time the remaining sodium borohydride was 
destroyed by the addition of water (100cm3) and then 1M HCl solution (until the pH was ~7). 
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The MeOH was removed under reduced pressure, to yield a yellow oil on the aqueous layer. 
This was then extracted with EtOAc (3×100cm3) and the combined organics were dried over 
anhydrous MgSO4. The solvent was removed in vacuo to yield an oil that was purified by 
column chromatography (5-50% EtOAc-Hexane). The product was obtained as an orange oil 
(6.95g, 84% yield over 2 steps). 
 
Method B: 
2-Allyl-3-isopropoxy-4-methoxybenzaldehyde 138 (12.8mmol, 3.00g), allyl amine (3eq, 
38.4mmol, 2.88cm3) and the acid catalyst p-TsOH (0.1eq, 1.28mmol, 0.252g) were dissolved 
in benzene (150cm3). The system was placed under a N2 atmosphere and was heated at reflux 
using a Dean-Stark head for 18 h. After this time the benzene was evaporated under reduced 
pressure, the resulting material was diluted with CH2Cl2 (100cm3) and was then extracted 
with saturated NaHCO3 (100cm3). The organic layer was dried over anhydrous MgSO4 and 
the solvent was removed in vacuo to yield the imine in pure form. The residue was then 
dissolved in MeOH (30cm3) and cooled to 0oC in an ice-water bath. To this methanolic 
solution was added sodium borohydride (1.2eq, 15.4mmol, 0.589g) along with a drop of water 
and the mixture was stirred for 1 h. On completion of the reaction the excess sodium 
borohydride was destroyed using water (20cm3) and 1M HCl. The pH was corrected to ~7 
using saturated NaHCO3. The MeOH was removed under reduced pressure and the remaining 
residue (in the aqueous layer) was extracted with EtOAc (3×20cm3). The combined organics 
were then dried over anhydrous MgSO4 and the solvent was removed in vacuo to yield the 
product as a yellow-orange oil (3.18g, 90% yield over 2 steps). 
 
Method C: 
The N-[(E)-(2-allyl-3-isopropoxy-4-methoxyphenyl)methylidene]-2-propen-1-amine 209 
(3.70mmol, 1.01g) was dissolved in MeOH (10cm3) and cooled to 0oC in an ice-water bath 
before the addition of the sodium borohydride (1.2eq, 4.44mmol, 0.167g). The solution was 
allowed to stir for 1 h 30 min before the addition of water (10cm3) and then 1M HCl solution 
(until the pH was ~7). The MeOH was removed under reduced pressure to yield a yellow oil 
on the aqueous layer. This was then extracted with EtOAc (2×25cm3) and the combined 
organics were dried over anhydrous MgSO4. The solvent was removed in vacuo to yield the 
product as a yellow oil (0.828g, 81%). 
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Rf = 0.41 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.26 [6H, d, J=6.2Hz, OCH(CH3)2], 
1.42 (1H, s, NH), 3.26 (2H, td, J=1.2 and 5.9Hz, ArCH2a), 3.54 (2H, td, J=1.4 and 5.7Hz, 
NHCH2CHa), 3.69 (2H, s, ArCH2NH), 3.81 (3H, s, OCH3), 4.51 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 4.88-4.99 (2H, m, ArCH2CH=CH2), 5.14 (2H, two dd, J=1.5, 13.7 and 11.5Hz, 
NHCH2CH=CH2), 5.88-5.99 (2H, m, ArCH2CH=CH2 and NHCH2CH=CH2), 6.75 (1H, d, 
J=8.4Hz, 5-H), 7.01 (1H, d,  J=8.4Hz, 6-H);  δC (50 MHz, CDCl3) 22.5 [OCH(CH3)2], 29.5 
(ArCH2), 44.6 (ArCH2NH), 55.5 (OCH3), 63.6 (NHCH2CH=CH2), 74.6 [OCH(CH3)2], 110.2 
(5-C), 115.7 and 115.8 (ArCH2CH=CH2 and NHCH2CH=CH2), 123.0 (6-C), 127.9 (1-C), 
133.6 (2-C), 136.2 (NHCH2CH=CH2), 137.1 (ArCH2CH=CH2), 144.4 (3-C), 154.6 (4-C). The 
spectroscopic results correlated well to that obtained by Pathak129 and no further analyses 
were required. 
 
2.6 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)acetamide 211 
 
A solution was prepared of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-
2-propen-1-amine 210 (5.47mmol, 1.51g) in pyridine (5.47mmol, 
0.450cm3) and it was cooled to 0oC in an ice-water bath. To this was 
added dropwise a solution of acetic anhydride (1.5eq, 8.20mmol, 
0.800cm3) in pyridine (1.5eq, 8.20mmol, 0.650cm3). The ice-water bath 
was then removed and the reaction mixture was stirred at rt under an Ar atmosphere for 3 h. 
After this time EtOAc (15cm3) was added and the reaction mixture was then extracted with 
brine (3×10cm3). The combined aqueous layers were then extracted with CH2Cl2 (3×10cm3). 
The organic layers were then combined and washed with a saturated ammonium chloride 
solution that had been basified to pH 10 with 25% ammonia solution (15cm3). The combined 
organic portions were then dried over anhydrous MgSO4 and the solvent was removed in 
vacuo. The residue was purified by column chromatography (10-30% EtOAc-Hexane) to 
yield the desired product as a yellow oil (1.59g, 92%). 
 
Rf = 0.22 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 992 (R2C=CH2), 1520 (Ar ring), 
1637 (tertiary amide), 2838 (OCH3), 2981 (CH2), 3022 (C=CH2 stretch);  δH (300 MHz, 
CDCl3) 1.26 [6H, dd, J=4.8 and 6.1Hz, OCH(CH3)2], 2.05 and 2.14 [3H, two s, CH3],  3.44 
(2H, d, J=5.5Hz, ArCH2CH=CH2), 3.71 (1H, d, J=4.8Hz, NCH2CH=CH2a), 3.82 (3H, d, 
J=4.8Hz, OCH3), 3.98 (1H, d, J=5.9Hz, NCH2CH=CH2a), 4.40 (1H, s, ArCH2Nb), 4.52 [1H, 
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sept, J=6.2Hz, OCH(CH3)2], 4.57 (1H, s, ArCH2Nb), 4.82-5.21 (4H, m, ArCH2CH=CH2 and 
NCH2CH=CH2), 5.74-5.90 (2H, m, ArCH2CH=CH2 and NCH2CH=CH2), 6.75-6.82 (2H, m, 
5-H and 6-H);  δC (50 MHz, CDCl3) 21.4 (CH3), 22.6 [OCH(CH3)2], 30.0 and 30.5 
(ArCH2CH=CH2), 45.1 (ArCH2N), 48.1 and 49.2 (NCH2CH=CH2), 55.5 (OCH3), 74.5 and 
74.6 [OCH(CH3)2], 110.0 and 110.1 (5-C), 114.7 and 115.1 (NCH2CH=CH2), 116.5 and 117.3 
(ArCH2CH=CH2), 119.9 (6-C), 123.4 (1-C), 127.5 and 128.2 (2-C), 132.6 and 133.1 
(NCH2CH=CH2), 135.8 and 136.5 (ArCH2CH=CH2), 145.22 and 145.4 (3-Cc), 152.1 (4-Cc), 
170.8 and 171.2 (C=O);  MS m/z 317 (M+, 30%) 43 (24), 115 (20), 143 (40), 145 (23), 161 
(28), 174 (27), 176 (100), 177 (35), 192 (53), 218 (41), 234 (24), 317 (30), HRMS calculated 
for C22H33NO4: 317.19909, found: 317.19972. 
 
2.7 Preparation of tert-butyl allyl(2-allyl-3-isopropoxy-4-methoxybenzyl)- carbamate 212 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-propen-1-ami-
ne 210 (5.47mmol, 1.51g) was dissolved in THF (150cm3) and to 
this solution was added Boc2O (1.2eq, 6.56mmol, 1.55ml). The 
solution was stirred for 5 min before the addition of the DMAP 
(0.1eq, 0.547mmol, 0.0669g). The reaction mixture was allowed 
to stir at rt under an Ar atmosphere for 3 h after which time the solvent was removed in 
vacuo. The orange oil was purified by column chromatography (5-10% EtOAc-Hexane) to 
yield the desired product as a pale yellow oil (1.99g, 97%). 
 
Rf = 0.80 (30% EtOAc-Hexane); νmax/cm-1 (NaCl plate) 738 (CH2 rock), 909 (R2C=CH2), 
1463 (CH2), 1514 (Ar ring), 1689 (C=O stretch), 2932 and 2978 (CH2 stretching); δH (300 
MHz, CDCl3) 1.26 [6H, d, J=6.2Hz, OCH(CH3)2], 1.46 [9H, d, J=3.7Hz, OC(CH3)3], 3.45 
(2H, d, J=5.6Hz, ArCH2CH=CH2), 3.67 (2H, broad s, NCH2CH=CH2), 3.82 (3H, s, OCH3), 
4.38 (2H, broad s, ArCH2N), 4.51 [1H, sept, J=6.2Hz, OCH(CH3)2], 4.90-5.11 (4H, m, 
ArCH2CH=CH2 and NCH2CH=CH2), 5.72 (1H, s, NCH2CH=CH2), 5.87 (1H, ddt, J=5.7, 10.7 
and 15.9Hz, ArCH2CH=CH2), 6.75 (1H, d, J=8.5Hz, 5-H), 6.83 (1H, d, J=8.5Hz, 6-H);  δC 
(50 MHz, CDCl3) 28.3 [OCH(CH3)2], 30.3 [OC(CH3)3], 46.6 (ArCH2CH=CH2), 48.2 
(NCH2CH=CH2), 55.5 (OCH3), 74.4 [OCH(CH3)2], 80.0 [OC(CH3)3], 109.9 (5-C), 114.8 
(NCH2CH=CH2a), 116.4 (ArCH2CH=CH2a), 122.8 (6-C), 124.6 (1-Cb), 128.9 (2-Cb), 133.7 
(NCH2CH=CH2), 136.2 (ArCH2CH=CH2), 145.1 (3-C), 151.8 (4-C), 155.6 (C=O);  MS m/z 
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375 (M+, 15%) 41 (40), 57 (73), 70 (72), 115 (15), 117 (15), 143 (38), 144 (18), 145 (15), 160 
(20), 162 (28), 175 (32), 176 (100), 177 (36), 236 (25), 278 (32), 319 (21), 375 (15), HRMS 
calculated for C22H33NO4: 375.24096, found: 375.2450. 
 
2.8 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)phenyl-methanesulf-
onamide 213 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-2-propen-1-ami-
ne 210 (2.82mmol, 0.779g) was dissolved in CH2Cl2 (8cm3) and 
stirred for 5 min under an Ar atmosphere. To this was added 
NEt3 (2.5eq, 7.05mmol, 1.00cm3) and the reaction mixture was 
stirred at rt for a further 15 min before the dropwise addition of 
the α-toluenesulfonyl chloride (1.1eq, 3.10mmol, 0.593g) which 
had been dissolved in CH2Cl2 (4cm3). The reaction mixture was stirred for 3 h at rt and then 
the solvent was removed in vacuo. The residue was purified by column chromatography (5% 
EtOAc-Hexane) to yield the product as a yellow oil (0.710g, 62%). 
 
Rf = 0.35 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 671 and 750 (5 adj Ar H), 1152 
(SO2), 1216 (CO-CH3), 1273 and 1337 (SO2-N), 1487 (Ar ring), 1594 (Ar ring), 2838 
(OCH3), 2978 (N-CH2), 3022 (C=CH2 stretch);  δH (300 MHz, CDCl3) 1.23 [6H, d, J=6.2Hz, 
OCH(CH3)2], 3.41 (2H, d, J=5.7Hz, ArCH2a), 3.64 (2H, d, J=6.6Hz, NHCH2CHa), 3.80 (3H, 
s, OCH3), 4.07 (2H, s, ArCH2NH), 4.25 (2H, s, SO2CH2), 4.48 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 4.80 (1H, dd,  J=1.7 and 17.2Hz, ArCH2CH=CH2b), 4.93 (1H, dd, J=1.6 and 
10.2Hz, ArCH2CH=CH2b), 5.02 and 5.08 (2H, two d, J=5.7Hz, NHCH2CH=CH2), 5.62 (1H, 
tdd, J=6.7, 10.1 and 16.8Hz, NHCH2CH=CH2), 5.80 (1H, ddt, J=5.7 and 10.9Hz, 
ArCH2CH=CH2), 6.76 (1H, d, J=8.5Hz, 5-H), 7.04 (1H, d, J=8.5Hz, 6-H), 7.35-7.40 (5H, m, 
SO2BnH);  δC (50 MHz, CDCl3) 22.4 [OCH(CH3)2], 30.0 (ArCH2), 48.1 (ArCH2NH), 50.0 
(NHCH2CH), 55.5 (OCH3), 58.9 (SO2CH2), 74.4 [OCH(CH3)2], 110.0 (5-C), 115.0 
(NHCH2CH=CH2), 119.0 (ArCH2CH=CH2), 123.8 (6-C), 127.1 (11-C), 128.6 (10-C), 129.0 
(1-C), 130.7 (9-C), 132.2 (NHCH2CH=CH2c), 132.8 (SO2CH2PhCc), 136.3 (ArCH2CH=CH2), 
144.9 (3-C), 152.2 (4-C);  MS m/z 429 (M+, 28%) 41 (10), 91 (80), 144 (10), 160 (11), 161 
(12), 176 (100), 232 (32), 274 (11), 429 (28), HRMS calculated for C24H31NO4S: 429.19738, 
found: 429.19707. 
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2.9 Preparation of N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzenesul-
fonamide 139 
 
To a stirred solution of N-(2-allyl-3-isopropoxy-4-
methoxybenzyl)-2-propen-1-amine 210 (1.45 mmol, 0.409g) 
in CH2Cl2 (20cm3) was added NEt3 (1.4eq, 2.03mmol, 0.300 
cm3) and previously recrystallised tosyl chloride (1.2eq, 
1.74mmol, 0.333g) at 0oC under a N2 atmosphere. The 
reaction mixture was allowed to stir at 0oC for 3.5 h and then 
at rt for 40 min. Afterwards the reaction mixture was diluted with water (20cm3) and then 
CH2Cl2 (20cm3) was added. The combined organics were washed with water (2×20cm3) and 
dried over anhydrous MgSO4. The solvent was removed in vacuo and the residue was purified 
by column chromatography (20% EtOAc-Hexane). The product was obtained as a pale yellow 
oil that solidified on standing (0.666g, 94%), with spectroscopic data that correlated well to 
that reported by Pathak129. 
 
Rf = 0.70 (30% EtOAc-Hexane);  m.p. 46-52oC;  δH (300 MHz, CDCl3) 1.25 [6H, d, 
J=6.1Hz, OCH(CH3)2], 2.44 (3H, s, CH3), 3.50 (2H, d, J=5.5Hz, ArCH2), 3.70 (2H, d, 
J=6.3Hz, NHCH2CH), 3.82 (3H, s, OCH3), 4.25 (2H, s, ArCH2N), 4.49 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 4.82-4.98 (4H, m, ArCH2CH=CH2  and NHCH2CH=CH2), 5.43 (1H, tdd, J=6.4, 
10.2 and 12.7Hz, NHCH2CH=CH2), 5.87 (1H, ddt, J=5.6 and 10.7Hz, ArCH2CH=CH2), 6.73  
(1H, d, J=8.5Hz, 5-H), 6.98 (1H, d, J=8.5Hz, 6-H), 7.32 (2H, d, J=8.1Hz, 9-H), 7.73 (2H, d, 
J=8.2Hz, 8-H);  δC (50 MHz, CDCl3) 21.5 (CH3), 22.5 [OCH(CH3)2], 30.1 (ArCH2CH=CH2), 
48.3 (ArCH2N), 49.7 (NHCH2CH=CH2), 55.5 (OCH3), 74.5 [OCH(CH3)2], 109.9 (5-C), 115.0 
(NHCH2CH=CH2), 118.6 (ArCH2CH=CH2), 124.3 (6-C), 126.7 (1-C), 127.4 (8-C), 129.7 (9-
C), 132.6 and 132.8 (NHCH2CH=CH2 and 2-C), 136.5 and 137.0 (7-C and ArCH2CH=CH2), 
143.2 (10-C), 145.1 (3-C), 152.3 (4-C). 
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2.10 Preparation of 1-[7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocin-2(1H)-yl]-1-eth-
anone 214 
 
A solution was prepared from N-allyl-N-(2-allyl-3-isopropoxy-4-
methoxybenzyl)-acetamide 211 (0.288mmol, 0.0914g) and distilled 
toluene (10cm3), which was degassed using N2 for 20 min. Then the 
solution was heated to 60oC before the addition of Grubbs II catalyst 
11 (0.05eq, 0.0144mmol, 0.0133g). The reaction mixture was stirred at 
60oC under an Ar atmosphere for 1 h. After this time the solvent was 
removed in vacuo to yield a dark brown oil that was purified by column chromatography (5-
10% EtOAc-Hexane). The product was obtained as a clear oil (0.0682g, 82%), showing 
evidence of rotamers due to the amide functionality. 
 
Rf = 0.05 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 672 (alkene), 734 (alkane), 1216 
(C-O), 1378 and 1427 (alkane), 1522 (Ar H), 1631 (tertiary amide), 2248 (-N-CO), 2837 and 
2898 (OCH3), 2982 (CH2 stretch), 3022 (Ar H);  δH (300 MHz, CDCl3) 1.27 [6H, d, J=6.2Hz, 
OCH(CH3)2], 2.00 and 2.09 (3H, two s, CH3), 3.49 and 3.53 (2H, two d, J=7.5Hz, 6-H), 3.82 
(3H, d, J=4.5Hz, OCH3), 3.85 (1H, d, J=5.9Hz, 3-Ha), 4.17 (1H, d, J=4.7Hz, 3-Ha), 4.48 [1H, 
sept, J=6.2Hz, OCH(CH3)2], 4.64 (2H, d, J=27.4Hz, 1-H), 5.71-6.01 (2H, m, 4-H and 5-H), 
6.71 and 6.82 (1H, two dd, J=1.6 and 8.3Hz, 9-H), 6.82 and 7.00 (1H, two d, J=8.3Hz, 10-H);  
δC (50 MHz, CDCl3) 22.0 and 22.4 (CH3), 22.5 and 22.6 [OCH(CH3)2], 24.7 and 25.3 (6-C), 
44.1 and 45.4 (3-C), 50.9 and 52.8 (1-C), 55.5 and 55.6 (OCH3), 74.4 and 74.8 [OCH(CH3)2], 
109.5 and 109.7 (9-C), 123.7 and 125.5 (10-C), 126.9 and 127.6 (5-C), 128.6 and 128.2 (10a-
C), 129.3 (4-Ca), 132.2 and 132.6 (6a-C), 133.1 (4-Ca), 144.2 and 145.0 (7-C), 152.6 and 
152.7 (8-C), 170.4 and 170.9 (C=O);  MS m/z 289 (M+, 100%) 43 (64), 73 (46), 115 (41), 143 
(97), 157 (58), 164 (41), 173 (74), 176 (68), 177 (45), 188 (96), 189 (50), 204 (50), 289 (100), 
HRMS calculated for C17H23NO3; 289.16779, found: 289.16371. 
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2.11 Preparation of tert-butyl 7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocine-2(1H)-
carboxylate 215 
 
A solution was prepared of tert-butyl allyl(2-allyl-3-isopropoxy-4-
methoxybenzyl) carbamate 212 (1.07mmol, 0.402g) and toluene 
(40cm3). This was degassed using N2 for 15 min and the solution 
was then heated to 60oC, before the addition of Grubbs II catalyst 
11 (0.05eq, 0.0533mmol, 0.0508g). The reaction mixture was 
allowed to stir at 60oC under an Ar atmosphere for 1 h. After this 
time the solvent was removed in vacuo to yield a black oil that was then purified by column 
chromatography (5% EtOAc-Hexane). The desired product was obtained as a clear oil 
(0.366g, 99%). NMR spectroscopy shows the product as a mixture of amide rotamers. 
 
Rf = 0.63 (20% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 653 (alkene), 1376 (C(CH3)3), 1464 
(alkane), 1514 (Ar H), 1682 (tertiary amide), 2254 (-NCO), 2931 (CH2 stretch), 2976 (-CO-
CH3), 3085 (Ar H);  δH (300 MHz, CDCl3) 1.27 [6H, d, J=6.2Hz, OCH(CH3)2], 1.34 and 1.42 
[9H, two s, OC(CH3)3], 3.51-3.56 (2H, m, 6-H), 3.81-3.84 (4H, m, OCH3 and one of 3-H), 
4.00 (1H, d, J=4.4 Hz, one of 3-H), 4.47-4.54 [3H, m, OCH(CH3)2 and 1-H], 5.81-83 (2H, m, 
4-H and 5-H), 6.69 (1H, t, J=7.3Hz, 9-H), 6.83-6.97 (1H, m, 10-H);  δC (50 MHz, CDCl3) 
22.5 and 22.6 [OCH(CH3)2], 25.2 and 25.3 (6-C), 28.4 [OC(CH3)3], 44.5 and 44.9 (3-C), 51.7 
(1-C), 55.6 (OCH3), 74.5 and 74.6 [OCH(CH3)2], 79.4 and 79.5 [OC(CH3)3], 109.2 and 109.6 
(9-C), 124.5 and 125.2 (10-C), 128.1 and 128.4 (5-C), 129.4 (10a-C), 130.3 and 130.6 (4-C), 
132.9 and 133.2 (6a-C), 144.4 (7-C), 152.2 and 152.4 (8-C), 155.5 (C=O);   MS m/z 347 (M+, 
44%) 41 (27), 57 (100), 137 (30), 143 (50), 175 (37), 187 (27), 188 (67), 204 (22), 249 (20), 
290 (66), 291 (51), 347 (44), HRMS calculated for C20H29NO4; 347.20966, found: 347.20551. 
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2.12 Preparation of 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-ben-
zazocine 216 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxy-benzyl)phen-
ylmethanesulfonamide 213 (0.466 mmol, 0.205g) was 
dissolved in toluene (20cm3) and the solution was degassed 
using N2 for 15 min. The solution was then heated to 60oC 
before the addition of Grubbs II catalyst 11 (0.05eq, 
0.0233mmol, 0.0194g). The reaction mixture was stirred at 
60oC under an Ar atmosphere for 1 h. After this time the 
reaction mixture was allowed to cool to rt and the solvent was removed in vacuo. The crude 
compound was purified by column chromatography (10% EtOAc-Hexane) to yield white 
crystals (0.157g, 84%). 
 
Rf = 0.49 (30% EtOAc-Hexane);  m.p. 119-122oC;  νmax/cm-1 (NaCl plate) 670 and 767 (5 
adj Ar H), 1141 (-N-SO2), 1333 (-N-SO2), 1372 (alkane), 1463 (alkane), 1647 and 1691 (C=C 
isolated), 2977 (-CO-CH3), 3023 (Ar H);  δH (300 MHz, CDCl3) 1.28 [6H, d, J=6.2Hz, 
OCH(CH3)2], 3.63 (2H, d, J=7.3Hz, ArCH2Ca), 3.83-3.86 (7H, m, OCH3, ArCH2Na, 
NCH2Ca), 4.48-4.56 [3H, m, OCH(CH3)2, SO2CH2Ar], 5.60 (1H, td, J=7.1 and 10.5Hz, 4-H), 
6.06 (1H, td, J=7.3 and 10.3Hz, 5-H), 6.75 (1H, d, J=8.3Hz, 9-H), 6.98 (1h, d, J=8.3Hz, 10-
H), 7.23-7.26 (2H, m, 14-H), 7.30-7.32 (3H, m, 13-H, 15-H);  δC (50 MHz, CDCl3) 22.6 
[OCH(CH3)2], 26.8 (6-C), 44.8 (3-C), 52.8 (SO2CH2Ar), 55.6 (OCH3), 59.4 (1-C), 74.6 
[OCH(CH3)2], 109.8 (10-C), 125.6 (4-C), 126.0 (9-C), 127.7 (6a-C), 128.3 (14-C), 128.5 (14-
C), 129.1 (10a-C), 130.7 (13-C, 15-C), 134.4 (12-C), 135.4 (5-C), 144.5 (7-C), 152.8 (8-C);  
MS m/z 401 (M+, 47%) 91 (88), 128 (13), 137 (13), 143 (17), 175 (20), 176 (13), 179 (11), 
188 (16), 204 (100), 205 (13), 246 (15), 252 (16), 253 (15), 265 (19), 284 (70), 285 (14), 401 
(47), 402 (13), HRMS calculated for C22H27NO4S; 401.16608, found: 401.16655. 
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2.13 Preparation of 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,4,5,6-hexahydro-2-
benzazocine 217 
 
The 2-(benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,6-
tetrahydro-2-benzazocine 216 (0.275 mmol, 0.109g) was 
dissolved in absolute ethanol (10cm3) by sonnication. To the 
emulsion was added 10% Pd/C (0.15g/mmol, 0.0430g) and 
this mixture was subjected to hydrogenation in an autoclave at 
5 atm H2 for 18 h. The reaction mixture was then filtered 
through celite and rinsed with CH2Cl2 (3×50cm3). The solvent 
was then removed in vacuo to yield a cream-white solid. This was then recrystallised by 
dissolving the compound in the minimum amount of EtOAc and then adding Hexane 
dropwise to the solution until it became cloudy. The solution was then left to stand overnight 
and the recrystallised material was collected by filtering off the solvent. The pure product was 
obtained as colourless crystals (0.108g, 98%). 
 
Rf = 0.54 (30% EtOAc-Hexane);  m.p. 141-147oC;  νmax/cm-1 (NaCl plate) 669 (5 adj Ar H), 
736 (alkane-CH2 rock), 774 (5 adj Ar H), 850 (2 adj Ar H), 1149 (-N-SO2), 1332 (-N-SO2), 
1425 (alkane), 2977 (-CO-CH3);  δH (300 MHz, CDCl3) 1.25 [6H, d, J=6.2Hz, OCH(CH3)2], 
1.51-1.52 (2H, m, 4-H), 1.66-1.68 (2H, m, 5-H), 2.87-2.91 (2H, m, 6-H), 3.09-3.12 (2H, m, 3-
H), 3.82 (3H, s, OCH3), 4.18 (2H, s, 1-H), 4.22 (2H, s, SO2CH2Ar), 4.53 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 6.73 (1H, d, J=8.4Hz, 9-H), 6.94 (1H, d, J=8.4Hz, 10-H), 7.35-7.37 (5H, m, 13-
H, 14-H and 15-H);  δC (50 MHz, CDCl3) 22.6 [OCH(CH3)2], 24.0 (5-Ca), 27.9 (6-Ca), 29.3 
(4-Ca), 46.9 (3-C), 49.7 (11-C), 55.5 (OCH3), 58.7 (1-C), 74.3 [OCH(CH3)2], 110.0 (9-C), 
125.6 (10-C), 128.1 (6a-C), 128.5 (15-C), 128.7 (13-C), 129.5 (10a-C), 130.7 (14-C), 135.4 
(12-C), 144.3 (7-C), 152.6 (8-C);   MS m/z 403 (M+, 36%) 28 (19), 30 (13), 65 (10), 91 (100), 
92 (10), 120 (17), 160 (12), 176 (21), 177 (22), 178 (17), 190 (13), 205 (20), 206 (71), 253 
(19), 361 (28), HRMS calculated for C22H29NO4S; 403.18173, found: 403.18176. 
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2.14 Preparation of 7-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetrahy-
dro-2-benzazocine 140 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methyl-
benzenesulfonamide 139 (0.364mmol, 0.156g) was dissolved in 
toluene (15cm3) and the solution was degassed using N2 for 20 
min. Then the solution was heated to 60oC and Grubbs II catalyst 
11 (0.05eq, 0.0182mmol, 0.0161g) was added. The reaction 
mixture was left to stir at 60oC under an Ar atmosphere for 1 h 
and then the solvent was removed in vacuo to yield a black-green 
oil. This was then purified by column chromatography (5-10% 
EtOAc-Hexane) and the product was obtained as a pale yellow oil (0.139g, 95%). NMR 
spectroscopic data was found to correspond to that reported by Pathak129. 
 
Rf = 0.59 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.23 [6H, d, J=6.2Hz, OCH(CH3)2], 
2.40 (3H, s, CH3), 3.54 (2H, d, J=6.7Hz, 6-H), 3.75 (2H, d, J=6.7Hz, 3-H), 3.82 (3H, s, 
OCH3), 4.41 [1H, sept,  J=6.2Hz, OCH(CH3)2], 4.47 (2H, s, 1-H), 5.45 (1H, td, J=6.7 and 
11.1Hz, 4-H), 5.79 (1H, td, J=6.7 and 11.2Hz, 5-H), 6.71 (1H, d, J=8.4Hz, 9-H), 6.89 (1H, d, 
J=8.4Hz, 10-H), 7.23 (2H, d, J=8.1Hz, 13-H), 7.62 (2H, d, J=8.3Hz, 12-H);  δC (50 MHz, 
CDCl3) 21.5 (15-C), 22.5 [OCH(CH3)2], 26.5 (6-C), 43.3 (3-C), 50.8 (1-C), 55.6 (OCH3), 
74.8 [OCH(CH3)2], 110.0 (9-C), 124.5 (10-Ca), 125.4 (5-Ca), 127.3 (12-C), 127.7 (10a-C), 
129.4 (13-C), 133.2 (4-Cb), 133.4 (6a-Cb), 136.9 (11-C), 143.0 (14-C), 144.3 (7-C), 152.9 (8-
C). 
 
2.15 Preparation of 7-isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 218 
 
The tert-butyl 7-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocine-
2(1H)-carboxylate 215 (0.300mmol, 0.104g) was dissolved in CH2Cl2 
(2cm3) and to this solution was added triflouroacetic acid (1.5eq, 
0.450mmol, 0.0350cm3). The reaction mixture was allowed to stir at rt 
under an Ar atmosphere for 1 h, after which time the solution had gone dark brown. To the 
reaction mixture was added distilled water (2cm3) and the solution was diluted with EtOAc 
(2cm3). It was then neutralised using a saturated solution of NaHCO3 and 10 % aqueous acetic 
acid. The organic layer was kept aside and the aqueous layer was extracted with EtOAc 
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(3×10cm3). The combined organics were then dried over anhydrous MgSO4 and the solvent 
was removed in vacuo to yield a dark orange semi-solid (0.0731g, 99%) which was 
essentially pure by 1H NMR spectroscopy and no further purification was required. 
 
Rf = 0.05 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 669 (RHC=CHR), 1440 (CH2 
deformations), 1520 (NH), 1603 (Ar ring), 1674 (isolated C=C), 2976 (-CH2 stretch), 3020 
(Ar H), 3618 (NH);  δH (400 MHz, CDCl3) 1.17 [6H, d, J=6.1Hz, OCH(CH3)2], 3.17 (2H, d, 
J=7.8Hz, 6-H), 3.66 (2H, s, 3-H), 3.76 (3H, s, OCH3), 4.21 (2H, s, 1-H), 4.34 [1H, sept, 
J=6.2Hz, OCH(CH3)2], 5.50 (1H, dd, J=8.0 and 18.9Hz, 4-H), 6.13 (1H, td, J=4.1 and 8.7Hz, 
5-H), 6.76 (1H, d, J=8.4Hz, 9-H), 7.00 (1H, d, J=8.4Hz, 10-H), 8.84 (1H, s, NH);  δC (50 
MHz, CDCl3) 22.5 [OCH(CH3)2], 29.1 (6-C), 36.8 (3-C), 45.3 (1-C), 55.6 (OCH3), 75.2 
[OCH(CH3)2], 111.2 (9-C), 117.7 (10-C), 121.6 (5-C), 127.0 (10a-C), 133.4 (4-C), 140.1 (6a-
C), 144.6 (7-C), 154.2 (8-C);  MS m/z 247 (M+, 68%) 51 (23), 77 (19), 91 (15), 115 (31), 137 
(24), 143 (39), 144 (18), 145 (19), 161 (28), 162 (25), 173 (26), 174 (23), 175 (35), 176 (60), 
177 (20), 179 (21), 187 (18), 188 (43), 189 (15), 190 (32), 204 (100), 205 (21), 247 (68), 
HRMS calculated for C15H21NO2; 247.15723, found: 247.15654. 
 
2.16 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-N-(1-propenyl)-
acetamide 221 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)acetamide 211 
(0.956mmol, 0.303g) was dissolved up in toluene (30cm3) and the 
solution was degassed for 15 min using N2. Then Ru-isomerisation 
catalyst 12 (0.05eq, 0.0478mmol, 0.0450g) was added and the 
reaction mixture was heated to 105oC under an Ar atmosphere for 
18.5 h. The progress of the reaction was monitored by 1H NMR spectroscopy and the reaction 
mixture was allowed to cool to rt. The solvent was removed in vacuo to yield a dark brown-
black oil which was purified by column chromatography (5-15% EtOAc-Hexane) to yield the 
desired product as a yellow oil (0.285g, 94%).  
 
Rf = 0.42 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  773 (C-H), 930 (RCH=CHR), 1216 
(C-O), 1481 (Ar ring), 1645 (tertiary amide/ C=C conj with C=O), 2977 (CH3), 3019 (C=CH2 
str);  δH (300 MHz, CDCl3)  1.22-1.24 [6H, m, OCH(CH3)2], 1.59 (1.9H, d, J=6.6Hz, CH3a), 
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1.65 (1.2H, d, J=6.6Hz, CH3a), 1.91-1.95 (2.6H, m, CH3b), 2.04-2.07 (2.2H, m and s, CH3b 
and COCH3c),  2.30 (1.6H, s, COCH3c), 3.80 (3H, d, J=6.3Hz, OCH3), 4.33-4.35 [1H, m, 
OCH(CH3)2], 4.65 and 4.81 (2H, two s, ArCH2N), 4.74-4.76 (1H, m, NCH=CHCH3), 5.94-
5.97 (1H, m, ArCH=CHCH3), 6.41-6.47 (1.5H, m, 5-H and NCH=CHCH3d), 6.64-6.73 (2H, 
m, 6-H and ArCH=CHCH3), 7.31-7.36 (1H, m, NCH=CHCH3d);  δC (50 MHz, CDCl3)  15.3 
and 15.5 (NCH=CHCH3), 19.0 and 19.1 (ArCH=CHCH3), 22.1 and 22.2 (COCH3), 22.4 and 
22.5 [OCH(CH3)2], 44.8 (ArCH2N), 55.6 (OCH3), 75.0 and 75.1 [OCH(CH3)2], 106.9 
(NCH=CHCH3), 109.0 (5-C), 119.9 (6-C), 120.8 (2-C), 124.3 and 124.7 (ArCH=CHCH3), 
126.3 and 126.9 (1-C), 128.0 (ArCH=CHCH3), 132.2 and 132.5 (NCH=CHCH3), 144.7 and 
145.0 (3-C), 151.6 and 152.0 (4-C), 169.1 and 169.4 (C=O);  MS m/z  317 (M+, 29%)  43 
(10), 115 (8), 117 (22), 145 (29), 162 (14), 175 (18), 176 (12), 177 (100), 178 (15), 219 (14), 
261 (19), 317 (29), HRMS calculated for C19H27NO3; 317.19909, found: 317.19862. 
 
2.17 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl](phenyl)-N-(1-pro-
penyl)methanesulfonamide 222 
  
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxy-benzyl)phenyl-
methanesulfonamide 213 (0.707mmol, 0.304g) was dissolved in 
distilled toluene (30cm3) and the solution was degassed using N2 
for 15 min. Then the Ru-isomerisation catalyst 12 (0.05eq, 
0.0354mmol, 0.0326g) was added and the reaction mixture was 
allowed to stir at 90-100oC under an Ar atmosphere for 18.5 h. A 
crude 1H NMR spectrum showed that isomerisation of the double 
bonds had occurred and so the solvent was removed in vacuo to yield a dark brown-black oil. 
This was then purified by column chromatography (5-10% EtOAc-Hexane) to yield the 
product as a pale yellow oil (0.265g, 87%). 
 
Rf = 0.73 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (5 adj Ar H), 772 (C-H), 1047 
(C-O), 1216 (-CO-CH3), 1354 (SO2-N), 1426 and 1521 (Ar ring), 2400 (OCH3), 2977 (N-
CH2), 3020 (C=CH str);  δH (300 MHz, CDCl3)  1.19 [6H, d, J=6.1Hz, OCH(CH3)2], 1.52 
(4H, dd, J=1.3 and 6.6Hz, CH3), 1.85 (3H, dd, J=1.5 and 6.5Hz, CH3), 3.77 (3H, d, J=4.4Hz, 
OCH3), 4.07 (2H, s, ArCH2N), 4.42-4.44 [5H, m, OCH(CH3)2, SO2CH2Ar and 
NCH=CHCH3], 5.45 (1H, dq, J=6.5 and 15.9Hz, NCH=CHCH3a), 6.33 (2H, ddd, J=1.3, 15.1 
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and 17.6Hz, ArCH=CHCH3a and ArCH=CHCH3), 6.74 (1H, dd, J=8.6 and 17.3Hz, 5-H, 
mixture of isomers), 7.01 (1H, dd, J=8.9 and 11.5Hz, 6-H, mixture of isomers), 7.39-7.40 
(5H, m, 9-H, 10-H, 11-H);  δC (50 MHz, CDCl3)  15.2 (NCH=CHCH3), 19.0 
(ArCH=CHCH3), 22.4 [OCH(CH3)2], 48.5 (ArCH2N), 55.5 (OCH3), 58.5 (SO2CH2Ar), 75.0 
[OCH(CH3)2], 106.9 (NCH=CHCH3), 110.6 (5-C), 121.6 (6-C), 124.1 (2-C), 124.6 
(ArCH=CHCH3), 126.0 (11-C), 128.7 (1-C), 128.8 (10-C), 129.6 (ArCH=CHCH3), 131.0 (9-
C), 131.8 (8-C), 131.9 (NCH=CHCH3), 144.3 (3-C), 151.7 (4-C);  MS m/z  429 (M+, 1%)  41 
(5), 91 (49), 115 (7), 117 (18), 131 (5), 145 (20), 161 (8), 175 (10), 176 (8), 177 (100), 178 
(12), 216 (13), 219 (38), 220 (6), 233 (5), 274 (17), 373 (30), 374 (7), HRMS calculated for 
C24H31NO4S; 429.19738, found: 429.19830. 
 
2.18 Preparation of 2-acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 223 
 
The N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-N-(1-prop-
enyl)acetamide 221 (0.321mmol, 0.102g) was dissolved in pre-
distilled toluene (8cm3) and degassed using N2 for 15 min. After this 
time the solution was heated to 110oC before the addition of Grubbs 
II catalyst 11 (0.05eq, 0.0161mmol, 0.0139g). The reaction mixture 
was then left to stir at 110oC under an Ar atmosphere for 3 h. The reaction mixture was 
allowed to cool to rt and the solvent was removed in vacuo to yield a brown-black oil. This 
was then purified by column chromatography (5-30% EtOAc-Hexane) to yield the desired 
product as a clear oil (0.0655g, 78%). NMR spectroscopy highlighted the presence of amide 
rotamers. 
 
Rf = 0.32 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (RHC=CHR cis), 879 (2 adj Ar 
C-H), 1216 (-C-O), 1386 (-COCH3), 1440 and 1462 (CH2 deformations), 1625 (C=C conj 
with C=O or Ar ring), 1661 (tertiary amide), 2839 (N-CH2-), 2938 (CH2 str), 3018 (C=CH);  
δH (300 MHz, CDCl3)  1.29 [6H, d, J=6.2Hz, OCH(CH3)2], 2.21 and 2.25 (3H, two s, CH3, 
major and minor respectively), 3.81 (3H, s, OCH3), 4.23 [1H, sept, J=6.2Hz, OCH(CH3)2], 
4.73 and 4.84 (2H, two s, ArCH2N, minor and major respectively), 6.17 and 6.20 (1H, d, 
J=8.0Hz, 4-H, major and minor respectively), 6.72 and 6.77 (2H,  two d, J=8.2Hz, 7-H and 8-
H), 7.26 and 7.27 (1H, two d, J=10.1Hz, 3-H, minor and major respectively);  δC (50 MHz, 
CDCl3)  21.3 (CH3), 22.1 and 22.5 [OCH(CH3)2], 43.8 (ArCH2N), 55.8 (OCH3), 75.4 and 
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75.5 [OCH(CH3)2], 105.3 and 105.6 (4-C), 110.4 and 110.9 (7-C), 120.3 and 120.8 (8-C), 
122.7 (4a-C), 125.0 (8a-C), 125.4 and 125.8 (3-C), 141.6 and 142.6 (5-C), 152.2 and 152.6 
(6-C), 168.4 (C=O);  MS m/z 261 (M+, 52%)  43 (11), 131 (23), 145 (14), 146 (8), 160 (19), 
161 (15), 175 (42), 176 (100), 177 (29), 217 (8), 218 (18), 219 (28), 226 (8), 261 (52), 262 
(10), 265 (22), 269 (9), HRMS calculated for C15H19NO3; 261.13649, found: 261.13696. 
 
2.19 Preparation of tert-butyl 5-isopropoxy-6-methoxy-2(1H)-isoquinolinecarboxylate 220 
 
A solution was prepared from tert-butyl allyl(2-allyl-3-
isopropoxy-4-methoxybenzyl) carbamate 212 (0.411mmol, 
0.154g) and pre-distilled toluene (13cm3). The solution was 
degassed using N2 for 15 min and then the solution was heated to 
110oC under an Ar atmosphere. Then the Ru-isomerisation 
catalyst 12 (0.01eq, 0.00411mmol, 0.0042g) was added and the reaction mixture was allowed 
to stir for 2 h. After this time Grubbs II catalyst 11 (0.05eq, 0.021mmol, 0.018g) was added 
and the reaction mixture was stirred at 110oC under an Ar atmosphere for 2 h. The reaction 
mixture was cooled to rt and the solvent was removed in vacuo to yield a brown-black oil. 
This was then purified by column chromatography (5% EtOAc-Hexane) to yield the product 
as a clear oil (0.0134g, 10%).  
 
Rf = 0.61 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (RHC=CHR), 850 (2 adj. Ar 
H), 1216 (C-O), 1370 (alkane), 1440 (alkane), 1479 (Ar ring), 1601 (Ar ring), 1666 (C=C aryl 
conj), 1693 (tertiary amide), 2839 (-OCH3), 2937 (C-H), 2978 (CH2), 3019 (Ar H);  δH (300 
MHz, CDCl3)  1.24-1.42 [15H, m, OC(CH3)3 and OCH(CH)32], 3.80-3.83 (3H, m, OCH3), 
4.47-4.77 [3H, m, OCH(CH3)2 and ArCH2N], 5.83-5.91 (1H, m, 4-H), 6.69-6.97 (2H, m, 7-H 
and 8-H), 7.24-7.28 (1H, m, 3-H). Insufficient material remained after FITR for 13C and 
HRMS analysis. 
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2.20 Preparation of 5-isopropoxy-6-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2- 
dihydroisoquinoline 142 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxy-benzyl)-4-
methyl benzenesulfonamide 139 (0.249 mmol, 0.107g) was 
dissolved up in distilled toluene (10cm3) and the solution 
was degassed for 15 min using N2. To this solution was 
added the Ru-isomerisation catalyst 12 (0.005eq, 
0.00125mmol, 0.0031g). The reaction mixture was heated to 110-120oC for 2 h. After this 
time 1H NMR spectroscopy showed no isomerisation of the double bonds. A further 5 mol % 
of the Ru-isomerisation catalyst 12 (0.05eq, 0.0125mmol, 0.0137g) was added and the 
reaction mixture was stirred at 115oC under a N2 atmosphere for 2 h. The 1H NMR spectrum 
showed isomerisation of both of the double bonds. The reaction mixture was then allowed to 
cool to rt and the solvent was removed in vacuo to yield a dark brown-black oil. The crude 
isomerised diene was then dissolved in distilled toluene (10cm3) and the solution was heated 
to 110oC under an Ar atmosphere. Then Grubbs II catalyst 11 (0.05eq, 0.0125mmol, 0.0119g) 
was added and the reaction mixture was left to stir for 2 h. After this time 1H NMR 
spectroscopy showed no ring closing metathesis had occurred so a further 5 mol % Grubbs II 
catalyst 11 (0.05eq, 0.0125mmol, 0.0124g) was added. The reaction mixture was then left to 
stir at 110oC under an Ar atmosphere for 21 h. After this time the reaction mixture was 
allowed to cool to rt and the solvent was removed in vacuo. The compound was then purified 
by column chromatography (5-20% EtOAc-Hexane). The desired product was obtained as a 
cream oil 142 (0.0115g, 21%) along with de-allylated starting material 200 as a yellow solid 
(0.0258g, 27%). NMR spectroscopic data compared well with that observed by Pathak129. 
 
Rf = 0.57 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3)  1.21-1.26 [6H, m, OCH(CH3)2], 
2.38 (3H, s, TsCH3), 3.78 (3H, s, OCH3), 4.35 [1H, sept, J=6.3Hz, OCH(CH3)2], 4.48 (2H, s, 
ArCH2N), 6.21 (1H, d, J=7.9Hz, 7-H), 6.64-6.66 (2H, m, 3-H and 4-H), 6.74 (1H, d, J=7.9Hz, 
8-H), 7.24-7.27 (2H, m, 11-H), 7.68 (2H, d, J=8.3Hz, 10-H);  δC (50 MHz, CDCl3)  21.5 
(TsCH3), 22.5 [OCH(CH3)2], 46.9 (ArCH2N), 55.8 (OCH3), 75.3 [OCH(CH3)2], 106.3 (4-C), 
110.7 (7-C), 120.5 (8-C), 120.8 (4a-C), 125.4 (8a-Ca), 126.2 (3-C), 126.9 (9-Ca), 127.2 (10-
C), 128.8 (12-Ca), 129.7 (11-C), 143.9 (5-C), 152.5 (6-C). 
 
7
4a
8a
8
4
3
N
1
O
O
S
O
O 9
10
11
12
11
10
13
142  
Chapter 7 Experimental Procedures 182
2.21 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl](phenyl)-methane-
sulfonamide 243 
 
The N-Allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl) ph-
enylmethanesulfonamide 213 (0.344 mmol, 0.148g) was 
transferred to the flask using a minimum volume of Et2O 
and the reaction mixture was heated to 80oC under a N2 
atmosphere to remove the solvent. The Ru-isomerisation 
catalyst 12 (0.05eq, 0.0172mmol, 0.0164g) was then added and the reaction mixture was 
further heated to 135-140oC and allowed to stir for 19 h under N2. The dark brown oil was left 
to cool to rt and the crude product was purified by column chromatography (5-15% EtOAc-
Hexane). The solvent was removed in vacuo to yield the product as cream coloured crystals 
(0.0754g, 56%). 
 
Rf = 0.55 (30% EtOAc-Hexane);  m.p.127-130oC;  νmax/cm-1 (NaCl plate)  669 (CH rock), 
775 (CH out of plane deformations), 1153 (-SO2-N-), 1331 (SO2), 1380 (C(CH3)2), 1438 (conj 
Ar ring), 1481 (NH bend), 1573 (conj Ar ring), 2977 (CH2 or CH3 stretch), 3020 (NH stretch 
or C=CH);  δH (300 MHz, CDCl3) 1.22 [6H, d, J=6.2Hz, OCH(CH3)2], 1.49 (0.6H, dd, J=1.6 
and 6.9Hz, C=CHCH3a), 1.60 (1H, s, NH, confirmed by D2O wash), 1.88 (2.3H, dd, J=1.6 and 
6.5Hz, C=CHCH3a), 3.83 (3H, s, OCH3), 4.09-4.20 (4H, m, ArCH2N and SO2CH2Ar), 4.32-
4.35 [1H, m, OCH(CH3)2], 6.02-6.04 (1H, m, ArCH=CHCH3), 6.29-6.34 (1H, m, 
ArCH=CHCH3), 6.76 (1H, d, J=8.4Hz, 5-H), 7.00 (1H, d, J=8.5Hz, 6-H), 7.33-7.35 (5H, m, 
10-H, 11-H, 12-H);  δC (50 MHz, CDCl3)  15.2 and 19.2 (CH3), 22.5 [OCH(CH3)2], 45.5 and 
45.7 (7-C), 55.7 (OCH3), 59.4 (8-C), 75.2 [OCH(CH3)2], 110.3 and 110.6 (5-C), 124.4 
(ArCH=CHCH3), 124.7 (6-C), 127.2 (2-C), 128.7 (11-C), 129.2 (1-C), 130.2 (9-C), 130.6 (10-
C), 132.9 (ArCH=CHCH3), 145.3 (3-C), 153.1 (4-C);  MS m/z 389 (M+, 11%), 40 (12), 41 
(18), 43 (19), 54 (14), 56 (15), 69 (38), 91 (55), 130 (13), 175 (16), 176 (19), 192 (100), 193 
(12), 219 (45), 220 (25), 234 (38), HRMS calculated for C21H27NO4S:  389.16608, found: 
389.16542. 
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2.22 Preparation of N-{3-isopropoxy-4-methoxy-2-[(1E)-1-propenyl]benzyl}-4-methylben-
zenesulfonamide 200 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxy-benzyl)-4-
methyl benzenesulfonamide 139 (0.249 mmol, 0.107g) was 
dissolved up in distilled toluene (10cm3) and the solution 
was degassed for 15 min using N2. To this solution was 
added the Ru-isomerisation catalyst 12 (0.005eq, 
0.00125mmol, 0.0031g) and the reaction mixture was heated 
to 110-120oC for 2 h. After this time 1H NMR spectroscopy showed no isomerisation of the 
double bonds. A further 5 mol % of the Ru-isomerisation catalyst 12 (0.05eq, 0.0125mmol, 
0.0137g) was added and the reaction mixture was stirred at 115oC under a N2 atmosphere for 
2 h. The 1H NMR spectrum showed isomerisation of both of the double bonds. The reaction 
mixture was allowed to cool to rt and the solvent was removed in vacuo to yield a dark 
brown-black oil. The crude isomerised diene was then dissolved in distilled toluene (10cm3) 
and the solution was heated to 110oC under an Ar atmosphere. Then Grubbs II catalyst 11 
(0.05eq, 0.0125mmol, 0.0119g) was added and the reaction mixture was left to stir for 2 h. 
After this time 1H NMR spectroscopy showed no ring closing metathesis had occurred so a 
further 5 mol % Grubbs II 11 (0.05eq, 0.0125mmol, 0.0124g) was added. The reaction 
mixture was then left to stir at 110oC under an Ar atmosphere for 21 h. After this time the 
reaction mixture was allowed to cool to rt and the solvent was removed in vacuo. The 
compound was then purified by column chromatography (5-20% EtOAc-Hexane). The ring-
closed product was obtained as a cream oil 142 (0.0115g, 21%) along with de-allylated 
starting material 200 as a yellow solid (0.0258g, 27%). 
 
Rf = 0.45 (30% EtOAc-Hexane);  m.p. 129-135oC;  νmax/cm-1 (NaCl plate)  814 (2  adj Ar H), 
917 (RHC=CHR trans), 1160 (-SO2-N-), 1330 (-SO2-N-), 1383 (alkane), 1440 (alkane), 1465 
(CH deformations), 1580 (NH), 1636 (C=C aryl conj), 2839 (-OCH3), 2977 (-CH2 or –CH3 
stretching), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.19 [6H, d, J=6.2Hz, OCH(CH3)2], 1.77 
(3H, dd, J=1.5 and 6.5Hz, CH=CHCH3), 2.43 (3H, s, TsCH3), 3.78 (3H, s, OCH3), 4.07 (2H, 
d, J=5.8Hz, ArCH2N), 4.28 [1H, sept, J=6.1Hz, OCH(CH3)2], 4.48 (1H, t, J=5.7Hz, NH, peak 
not present in CH correlated spectrum), 5.96 (1H, qd, J=6.5 and 16.0Hz, CH=CHCH3),  6.21 
(1H, dd, J=1.5 and 16.1Hz, ArCH=CHCH3), 6.65 (1H, d, J=8.4Hz, 5-H), 6.83 (1H, d, 
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J=8.4Hz, 6-H), 7.29 (2H, d, J=8.1Hz, 10-H), 7.73 (2H, d, J=8.2Hz, 9-H);  δC (50 MHz, 
CDCl3)  19.1 (CH=CHCH3), 21.5 (12-C), 22.5 [OCH(CH3)2], 45.5 (ArCH2N), 55.7 (OCH3), 
75.2 [OCH(CH3)2], 110.3 (5-C), 124.2 (ArCH=CHCH3), 124.9 (6-C), 126.2 (2-C), 127.2 (9-
C), 129.6 (10-C), 132.6 (ArCH=CHCH3), 132.9 (1-C), 136.8 (8-C), 143.3 (11-C), 145.1 (3-
C), 153.0 (4-C);  MS m/z 389 (M+, 8%), 43 (15), 65 (5), 69 (28), 91 (15), 131 (14), 160 (5), 
161 (13), 163 (5), 175 (23), 176 (25), 177 (9), 190 (9), 191 (7), 192 (100), 193 (13), 219 (33), 
234 (62), 235 (10), 264 (7), 389 (8), HRMS calculated for C21H27NO4S:  389.16608, found: 
389.16367. 
 
2.23 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methylbenzene-sulfon-
amide 245 
 
The N-allyl-N-(2-allyl-3-isopropoxy-4-methoxy-benzyl)-4-
methylbenzenesulfon-amide 139 (0.705mmol, 0.303g) was 
dissolved in toluene (30cm3) and the solution was degassed 
using N2 for 15 min. After this time the Ru-isomerisation 
catalyst 12 (0.05eq, 0.0353mmol, 0.0356g) was added and 
the reaction mixture was heated to 105oC. The reaction 
mixture was allowed to stir under an Ar atmosphere for 18 h and the solvent was removed in 
vacuo to yield a dark brown-black oil. The crude mixture was purified by column 
chromatography (5% EtOAc-Hexane) to yield the desired product as a pale yellow oil that 
solidified on standing (0.139g, 51%) as well as some of the unreacted diene 139 (0.0625g, 
21% recovery). 
 
Rf = 0.51 (30% EtOAc-Hexane);  m.p. 83-85oC;  νmax/cm-1 (NaCl plate)  706 (alkane), 814 (2 
adj Ar H), 1160 (-SO2-N-), 1328 (-SO2-N-), 1383 (alkane), 1439 (alkane), 1465 (CH 
deformations), 1488 and 1580 (-NH), 1637 (C=C aryl conj), 2839 (-OCH3), 2938 (-CH3), 
2977 (Ar H), 3019 (C=CH2);  δH (300 MHz, CDCl3) 1.21 [6H, two d, J=6.2Hz, OCH(CH3)2], 
2.44 (3H, s, TsCH3), 3.38 (2H, d, J=5.7Hz, ArCH2C), 3.81 (3H, s, OCH3), 4.01 (2H, d, 
J=5.9Hz, ArCH2N), 4.49-4.54 [2H, m, OCH(CH3)2 and NH], 4.74 (1H, dd, J=1.6 and 17.2Hz, 
CH=CH2 trans), 4.93 (1H, dd, J=1.5 and 10.2Hz, CH=CH2 cis), 5.81-5.83 (1H, m, CH=CH2), 
6.68 (1H, d, J=8.5Hz, 5-H), 6.86 (1H, d, J=8.5Hz, 6-H), 7.31 (2H, d, J=8.0Hz, 10-H), 7.74 
(2H, d, J=8.2Hz, 9-H);  δC (50 MHz, CDCl3)  21.5 (12-C), 22.6 [OCH(CH3)2], 30.5 
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(ArCH2C), 55.5 (OCH3), 74.6 [OCH(CH3)2], 110.1 (5-C), 115.2 (CH=CH2), 124.2 (2-C), 
124.7 (6-C), 127.2 (9-C), 129.6 (10-C), 132.6 (1-C), 136.7 (8-C), 137.1 (CH=CH2), 143.4 
(11-C), 145.2 (3-C), 152.7 (4-C);  MS m/z 389 (M+, 37%), 65 (6), 91 (23), 115 (9), 117 (5), 
143 (10), 144 (13), 145 (8), 155 (10), 161 (23), 162 (8), 163 (9), 164 (10), 175 (20), 176 
(100), 177 (19), 184 (10), 190 (13), 191 (18), 192 (75), 193 (10), 234 (27), 389 (37), 390 (10), 
HRMS calculated for C21H27NO4S:  389.16608, found: 389.16714. 
 
2.24 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-N-(1-propenyl) acetamide 
227 
 
The reaction was set up in the Carousel Reactor and the reaction tube 
was evacuated and placed under Ar three times before beginning. The 
N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)acetamide 211 
(0.648mmol, 0.206g) was dissolved in toluene (20cm3) and the 
solution was degassed for 5 min using N2. The solution was then 
heated to 80oC before the addition of the Ru-isomerisation catalyst 12 (0.01eq, 0.00648mmol, 
0.0064g). The reaction mixture was allowed to stir at 80oC under an Ar atmosphere for a 
further 20 h. After this time the reaction mixture was allowed to cool to rt and the solvent was 
removed in vacuo to yield a yellow-brown oil that was purified by column chromatography 
(5-15% EtOAc-Hexane). The desired product was obtained as a pale yellow oil (0.159g, 
77%).  
 
Rf = 0.49 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  774 (alkane), 929 and 1047 
(RCH=CH2), 1216 (C-O), 1486 (alkane), 1522 (Ar ring), 1645 (tertiary amide), ~3000 weak 
(-CO-CH3), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.26 [6H, m, OCH(CH3)2], 1.61-1.66 (3H, 
m, CH=CHCH3), 2.04 and 2.30 (3H, two s, COCH3), 3.50-3.52 (2H, m, ArCH2C), 3.80 (3H, 
d, J=7.6Hz, OCH3), 4.51-5.08 [5H, m, OCH(CH3)2, ArCH2N and CH=CH2 (cis and trans)], 
5.90-5.92 (1H, m, N-CH=CH), 6.53-6.73 (3H, m, CH=CH2, 5-H and 6-H), 7.35 (1H, d, 
J=14.5Hz, NCH=CH);  δC (50 MHz, CDCl3)  15.3 and 15.5 (CH=CHCH3), 22.2 (COCH3), 
22.6 [OCH(CH3)2], 30.2 and 30.4 (ArCH2C), 44.8 and 48.2 (ArCH2N), 55.5 (OCH3), 74.5 and 
75.0 [OCH(CH3)2], 106.9 and 109.0 (CH=CH2 cis), 110.3 and 110.5 (5-C), 115.2 (CH=CH2 
trans), 119.5 and 120.1 (6-C), 126.2 (NCH=CH), 126.9 and 127.6 (), 128.0 (1-C), 128.4 
(CH=CH2), 130.2 and 130.9 (2-C), 135.7 and 136.0 (NCH=CHCH3), 145.2 (3-C), 151.4 and 
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151.8 (4-C), 169.0 and 169.6 (C=O);  MS m/z 317 (M+, 20%) 43 (13), 91 (9), 115 (16), 117 
(31), 144 (8), 145 (33), 161 (15), 175 (13), 176 (46), 177 (100), 178 (4), 214 (10), 218 (8), 
219 (10), 265 (9), 275 (12), 317 (20), HRMS calculated for C19H27NO3:  317.19909, found: 
317.19916. 
 
2.25 Preparation of tert-butyl 2-allyl-3-isopropoxy-4-methoxybenzyl(1-pro-penyl)-carba-
mate 228 
 
The reaction was set up in the Carousel Reactor and the reaction 
tube was evacuated and placed under Ar three times before 
beginning. The tert-butyl allyl(2-allyl-3-isopropoxy-4-
methoxybenzyl)carbamate 212 (0.537mmol, 0.202g) was 
dissolved in toluene (20cm3) and the solution was degassed 
using N2 for 5 min. The solution was then heated to 80oC before the addition of the Ru-
isomerisation catalyst 12 (0.01eq, 0.00537mmol, 0.0054g). Then the reaction mixture was 
allowed to stir at 80oC under an Ar atmosphere for 20 h. After this time the reaction mixture 
was allowed to cool to rt and the solvent was removed in vacuo to yield a yellow-brown oil. 
The crude oil was then purified by column chromatography (5% EtOAc-Hexane) and the 
product was obtained as a pale yellow oil (0.161g, 80%). 
 
Rf = 0.77 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  774 (alkane), 929 (RCH=CH2), 
1216 (C-O), 1376 and 1403 [-C(CH3)3], 1482 (alkane), 1665 (tertiary amide), 1693 (-C=C-N-
), 2978 (-CH3), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.25 [6H, dd, J=6.3 and 8.7Hz, 
OCH(CH3)2], 1.40-1.61 [12H, m, OC(CH3)3 and CH3], 3.50 (2H, d, J=5.6Hz, ArCH2C), 3.80 
(3H, s, OCH3), 4.34-4.59 [3H, m, ArCH2N, OCH(CH3)2 and CH=CHCH3], 4.93 (1H, d, 
J=17.1Hz, CH=CH2), 5.03 (1H, dd, J=1.5 and 10.1Hz, CH=CH2), 5.89 (1H, dq, J=5.7 and 
10.6Hz, CH=CH2), 6.63 (1H, d, J=8.4Hz, NCH=C), 6.73 (1H, d, J=8.4Hz, 6-H), 6.97 (1H, d, 
J=8.4Hz, 5-H);  δC (50 MHz, CDCl3)  15.3 (CH3), 22.5 [OC(CH3)3], 28.2 [OCH(CH3)2], 30.3 
(ArCH2C), 45.4 (ArCH2N), 55.5 (OCH3), 74.5 [OCH(CH3)2], 75.0 [OC(CH3)3], 104.2 
(CH=CHCH3), 110.1 or 110.5 (5-C), 115.2 (CH=CH2), 119.6 (6-C), 124.7 (NCH=C), 128.0 
(2-C), 132.1 (1-C), 135.9 (CH=CH2), 145.0 (3-C), 151.3 (4-Ca), 151.5 (C=Oa);  MS m/z 375 
(M+, 2%) 41 (10), 57 (43), 117 (13), 145 (17), 175 (8), 176 (27), 177 (100), 178 (14), 219 
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(34), 234 (9), 235 (9), 263 (19), 319 (12), 333 (21), HRMS calculated for C22H33NO4: 
375.24096, found: 375.24162. 
 
2.26 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)(phenyl)-N-(1-propenyl)-
methanesulfonamide 229 
 
The reaction was set up in the Carousel Reactor, with the reaction 
tube evacuated and placed under Ar three times before beginning. 
Then the N-allyl-N-(2-allyl-3-isopropoxy-4-methoxybenzyl)phe-
nylmethanesulfonamide 213 (0.488mmol, 0.210g) was dissolved 
in toluene (20cm3) and the solution was degassed using N2 for 5 
min. The solution was then heated to 80oC before the addition of 
the Ru-isomerisation catalyst 12 (0.01eq, 0.00488mmol, 
0.0048g). The reaction mixture was then stirred at 80oC under an Ar atmosphere for 20 h, 
after which time the solvent was removed in vacuo to yield a pale brown oil. The crude 
mixture was then purified by column chromatography (5% EtOAc-Hexane) to yield the 
desired product as a pale yellow oil (0.188g, 90%). 
 
Rf = 0.71 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (5 adj Ar H), 756 (5 adj Ar H), 
929 (RCH=CH2), 1154 (-N-SO2), 1355 (-N-SO2), 1663 (C=C-N-), 2978 (CO-CH3), 3021 (Ar 
H);  δH (300 MHz, CDCl3) 1.21 [6H, dd, J=6.2 and 9.9Hz, OCH(CH3)2], 1.53 (3H, dt, J=1.3 
and 6.7Hz, CH3), 3.28 (2H, d, J=5.8Hz, ArCH2C), 3.76 and 3.77 (3H, two s, OCH3), 4.07 
(2H, br s, ArCH2N), 4.37-4.46 [4H, m, ArCH2SO2, OCH(CH3)2 and NCH=CH], 4.74 (1H, dd, 
J=1.6 and 17.2Hz, CH=CH2 cis)and 4.94 (1H, dd, J=1.5 and 10.2Hz, CH=CH2 trans), 5.45-
5.73 (1H, m, NCH=CH), 6.30-6.44 (1H, m, ArCH2CH=CH), 6.72 (1H, d, J=8.6Hz, 5-H), 6.96 
(1H,  two d, J=8.6Hz, 6-H), 7.38-7.39 (5H, m, Ph-H);  δC (50 MHz, CDCl3)  15.2 (CH3), 22.5 
[OCH(CH3)2], 30.1 (ArCH2C), 48.0 (ArCH2N), 55.5 (OCH3), 58.5 (ArCH2SO2), 74.5 
[OCH(CH3)2], 107.0 (N-CH=CH), 110.2 (5-C), 115.2 (CH=CH2), 121.0 (6-C), 124.6 and 
126.8 (ArCH2CH=C), 128.4 (11-C), 128.8 (2-C), 128.9 (10-C), 130.3 (1-C), 131.9 (9-C), 
135.8 (NCH=CH), 144.7 (3-C), 151.6 (4-C);  MS m/z 429 (M+, 1%) 91 (35), 115 (5), 117 
(14), 145 (16), 161 (5), 175 (6), 176 (12), 177 (100), 178 (13), 216 (4), 219 (29), 220 (4), 232 
(5), 274 (15), 344 (4), 373 (10), 387 (15), 388 (4), HRMS calculated for C24H31NO4S: 
429.19738, found: 429.19812. 
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2.27 Preparation of N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methyl-N-(1-propenyl)-
benzenesulfonamide 230 
 
The reaction was set up in the Carousel Reactor with the 
reaction tube evacuated and placed under Ar three times 
before beginning. The N-allyl-N-(2-allyl-3-isopropoxy-4-
methoxybenzyl)-4-methylbenzenesulfonamide 139 
(0.482mmol, 0.207g) was then dissolved in toluene (20cm3) 
and the solution was degassed using N2 for 5 min. The solution was heated to 80oC before the 
addition of the Ru-isomerisation catalyst 12 (0.01eq, 0.00482mmol, 0.0048g), and it was then 
allowed to stir under an Ar atmosphere for 20 h. The reaction mixture was allowed to cool to 
rt and the solvent was removed in vacuo to yield a yellow oil. The mixture was purified by 
column chromatography (5-10% EtOAc-Hexane) to give recovered starting material (0.120g, 
58% recovery) and the desired product as a pale yellow oil (0.0532g, 26%). 
 
Rf = 0.46 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  815 (2 adj Ar H), 916 and 993 
(RCH=CH2), 1159 and 1342 (-N-SO2), 1580 (Ar ring), 1638 (isolated C=C), 2839 (-OCH3), 
2871 (-CH3), 2977 (-CO-CH3), 3013 (Ar H);  δH (300 MHz, CDCl3) 1.22-1.26 [9H, m, 
OCH(CH3)2 and CH3], 2.44 (3H, d, J=3.1Hz, TsCH3), 3.38 (2H, dd, J=1.6 and 4.2Hz, 
ArCH2C), 3.79 (3H, d, J=3.2Hz, OCH3), 4.01 (2H, d, J=5.9Hz, ArCH2N), 4.47-4.50 [2H, m, 
OCH(CH3)2 and NCH=CHCH3], 4.74 (1H, dd, J=1.7 and 17.2Hz, CH=CH2 trans), 4.93 (1H, 
dd, J=1.6 and 10.2Hz, CH=CH2 cis), 5.82-6.21 (1H, m, NCH=CH), 6.69 (1H, d, J=8.4Hz, 5-
H), 6.86 (1H, d, J=8.4Hz, 6-H), 7.31 (2H, d, J=8.1Hz, 9-H), 7.75 (2H, d, J=8.2Hz, 8-H);  δC 
(50 MHz, CDCl3)  21.5 (CH3), 22.6 [OCH(CH3)2], 30.5 (ArCH2C), 45.0 (ArCH2N), 55.5 
(OCH3), 74.6 [OCH(CH3)2], 110.1 (5-C), 115.2 (CH=CH2), 124.7 (6-C), 127.2 (8-C), 127.3 
(2-C), 129.6 (9-C), 132.6 (1-C), 136.7 (7-C), 137.1 (N-CH=CH), 143.4 (10-C), 145.2 (3-C), 
152.7 (4-C), no peak observed for NCH=CHCH3 in the 13C NMR spectrum;  MS m/z 429 
(M+, 0.6%) 91 (24), 115 (11), 143 (12), 144 (18), 145 (9), 155 (10), 161 (26), 162 (9), 163 (8), 
175 (18), 176 (100), 177 (22), 184 (9), 190 (12), 191 (17), 192 (50), 234 (10), 389 (38), 390 
(9), HRMS calculated for C24H31NO4S: 429.19738, found: 429.19760. 
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2.28 Preparation of 2-acetyl-6-isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzaze-pine 231 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-N-(1-propenyl)aceta-
mide 227 (0.0189mmol, 0.0600g) was dissolved up in toluene (6cm3) 
and the solution was heated to 80oC before the addition of the Grubbs 
II catalyst 11 (0.1eq, 0.0189mmol, 0.0164g). Then the reaction 
mixture was allowed to stir at 80oC under an Ar atmosphere for 25 h, 
after which time thin layer chromatography showed no further change and so the solvent was 
removed in vacuo to yield a dark brown-black oil. This was then purified by column 
chromatography (5-10% EtOAc-Hexane) to yield the desired product as an orange resin 
(0.0061g, 12%). 
 
Rf = 0.24 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (RHC=CHR cis), 849 (2 adj. 
Ar H), 1216 (C-O), 1373 (CH3 symmetrical deformation), 2839 (-OCH3), 2896 (-CH2 or -CH3 
stretch), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.28-1.30 [6H, m, OCH(CH3)2], 1.54 (3H, s, 
ArCH2C), 2.44 (3H, s, CH3), 3.85 (3H, s, OCH3), 4.49 [1H, sept, J=6.1Hz, OCH(CH3)2], 5.30 
(3H, s, ArCH2N), 6.36 (1H, d, J=12.5Hz, 4-H), 6.93 (1H, d, J=8.3Hz, 8-H), 7.16 (1H, d, 
J=8.2Hz, 9-H), 7.57 (1H, d, J=12.5Hz, 3-H);  δC (50 MHz, CDCl3)  22.6 [OCH(CH3)2], 26.9 
(CH3), 29.7 (ArCH2C), 44.9 (ArCH2N), 55.9 (OCH3), 76.4 [OCH(CH3)2], 113.7 (4-C), 123.6 
(8-C), 126.1 (9-C), 135.7 (3-C), 168.2 (C=O), no quarternary carbons were observed on the 
13C NMR spectrum;  MS m/z 275 (M+, 11%), 41 (10), 43 (28), 143 (12), 160 (16), 161 (20), 
162 (15), 163 (26), 174 (11), 175 (44), 176 (45), 177 (38), 190 (18), 204 (100), 205 (70), 206 
(11), 232 (10), 247 (25), 275 (11), 289 (40), HRMS calculated for C16H21NO3: 275.15214, 
found: 275.15020. 
 
2.29 Preparation of tert-butyl 6-isopropoxy-7-methoxy-1,5-dihydro-2H-2-benza-zepine-2-
carboxylate 232 
 
tert-Butyl 2-allyl-3-isopropoxy-4-methoxybenzyl(1-propenyl)-
carbamate 228 (0.553mmol, 0.208g) was dissolved in toluene 
(20cm3) and the solution was heated to 60oC before the addition 
of Grubbs II catalyst 11 (0.05eq, 0.0277mmol, 0.0272g). Then 
the reaction mixture was allowed to stir at 60oC under an Ar 
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atmosphere for 24 h. After this time the reaction mixture was allowed to cool to rt and the 
solvent was removed in vacuo. The dark brown oil was then purified by column 
chromatography (5% EtOAc-Hexane) and the desired product was obtained as a pale yellow 
oil (0.151g, 82%). 
 
Rf = 0.71 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  743 (CH2 rocking), 851 (2 adj Ar 
H), 1216 (C-O), 1370 (CH3 symmetrical deformation), 1455 (alkane), 1482 (Ar ring), 1575 
(Ar ring), 1600 (ar ring), 1694 (C-O tertiary amide), 1665 (C=C isolated), 2733 (N-CH2), 
2839 (-OCH3), 2937 (-CH2 or –CH3 stretches), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.23-
1.25 [6H, m, OCH(CH3)2], 1.40-1.57 [9H, m, OC(CH3)3], 1.92 (2H, d, J=5.9Hz, ArCH2C), 
3.80 (3H, s, OCH3), 4.34-4.85 [5H, m, OCH(CH3)2, ArCH2C and ArCH2N], 5.87-5.93 (1H, 
broad m, 4-H), 6.43 (1H, d, J=16.1Hz, 8-H), 6.72-6.75 (2H, m, 9-H and 3-H), peak 
broadening occurred in the spectrum due to the presence of the amide rotamers;  δC (50 MHz, 
CDCl3)  22.5 [OCH(CH3)2], 28.3 [OC(CH3)3], 45.8 (ArCH2C), 55.7 (OCH3), 60.4 (ArCH2N), 
75.0 [OCH(CH3)2], 80.8 [OC(CH3)3], 104.2 (4-C), 110.5 (8-C), 120.3 (9-C), 124.7 (3-C), 
131.9 (5a-Ca), 132.1 (9a-Ca), 151.5 (C=O), two of the quarternary carbons were not observed 
in the 13C NMR spectrum;  MS m/z 333 (M+, 1%) 57 (93), 69 (14), 117 (13), 145 (20), 156 
(14), 175 (29), 176 (25), 177 (100), 178 (18), 180 (11), 193 (11), 205 (10), 219 (49), 221 (16), 
263 (60), 319 (25), HRMS calculated for C19H27NO4: 333.19401, found: 333.19534. 
 
2.30 Preparation of 2-(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,5-dihydro-1H-2-benzaze-
pine 233 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-(phenyl)-N-
(1-propenyl)methanesulfonamide 229 (0.169mmol, 0.0726g) 
was dissolved in toluene (7cm3) and the solution was heated 
to 60oC before the addition of the Grubbs II catalyst 11 
(0.05eq, 0.00846mmol, 0.0083g). The reaction mixture was 
allowed to stir at 60oC under an Ar atmosphere for 18.5 h, 
after this time thin layer chromatography showed no further change so the solvent was 
removed in vacuo. Then the dark brown oil was purified by column chromatography (5-10% 
EtOAc-Hexane) to yield a white solid (0.0380g, 58%). 
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Rf = 0.43 (30% EtOAc-Hexane);  m.p. 124-127oC;  νmax/cm-1 (NaCl plate)  626 (RHC=CHR 
cis), 850 (2 adj Ar H), 1335 (-SO2-N-), 1477 (Ar ring), 1601 (Ar ring), 2897 (-OCH3), 2929 (-
CH2 or -CH3 stretches), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.24 [6H, dd, J=6.3 and 8.9Hz, 
OCH(CH3)2], 1.87 (1.5H, d, J=6.4Hz, ArCH2Ca), 3.46 (0.9H, d, J=5.5Hz, ArCH2Ca), 3.82 
(3H, s, OCH3), 4.09-4.18 (4.5H, m, ArCH2N), 4.30-4.40 (1.7H, m, ArCH2SO2b), 4.52 [0.5H, 
sept, J=6.3Hz, OCH(CH3)2], 4.82-4.96 (1H, m, ArCH2SO2b), 5.79-6.01 (1H, m, 4-H), 6.32 
(0.5H, d, J=16.1Hz, 3-H), 6.76 (1H, dd, J=2.5 and 8.3Hz, 8-H), 7.00 (1H, dd, J=2.7 and 
8.4Hz, 9-H), 7.23-7.34 (5H, m, 12-H, 13-H and 14-H);  δC (50 MHz, CDCl3)  19.2 
(ArCH2Cc), 22.5 and 22.6 [OCH(CH3)2], 30.6 (ArCH2Cc), 45.1 and 45.6 (ArCH2N), 55.6 and 
55.7 (OCH3), 59.2 and 59.3 (ArCH2SO2), 74.6 and 75.2 [OCH(CH3)2], 110.2 and 110.3 (8-C), 
115.3 (NCH=CH), 124.4 (9-Ca),  124.6 (14-Ca), 128.6 and 128.7 (13-C), 129.3 (5a-C), 130.6 
(12-C), 132.4 (11-C), 132.8 and 132.9 (9a-C), 137.1 (NCH=CH), 145.3 (6-C), 152.7 and 
153.1 (7-C). Insufficient material remained for us to perform HRMS after NMR and FTIR 
spectroscopy. 
 
2.31 Preparation of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,5-dihydro-
1H-2-benzazepine 234 
 
The N-(2-allyl-3-isopropoxy-4-methoxybenzyl)-4-methyl-N-(1-
propenyl)benzenesulfonamide 230 (0.0294mmol, 0.0126g) was 
dissolved in toluene (10cm3) and the solution was heated to 
60oC. Then the Grubbs II catalyst 11 (0.5eq, 0.0149mmol, 
0.0170g) was added and the reaction mixture was allowed to stir 
under an Ar atmosphere for 25 h. After this time no further 
change was observed by thin layer chromatography and the 
solvent was removed in vacuo to yield a dark brown oil. The crude mixture was purified by 
column chromatography (5% EtOAc-Hexane) to give the desired product as a pale yellow 
resin (0.0053g, 47%). 
 
Rf = 0.45 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (RHC=CHR, cis), 784 (2 adj 
Ar H), 1160(-SO2-N-), 1334 (-SO2-N-), 1599 (Ar ring), 2977 (-CH2 or –CH3 stretches), 3020 
(Ar H);  δH (300 MHz, CDCl3) 1.19 [6H, d, J=6.2Hz, OCH(CH3)2], 1.77 (2H, dd, J=1.4 and 
6.5Hz, ArCH2C), 2.43 (3H, s, CH3), 3.79 (3H, s, OCH3), 4.07-4.09 (2H, m, ArCH2N), 4.27 
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[1H, sept, J=6.1Hz, OCH(CH3)2], 5.90-6.02 (1H, m, 4-H), 6.21 (1H, dd, J=1.4 and 16.1Hz, 3-
H), 6.65 (1H, d, J=8.4Hz, 8-H), 6.83 (1H, d, J=8.4Hz, 9-H), 7.30 (2H, d, J=8.1Hz, 12-H), 
7.73 (2H, d, J=8.1Hz, 11-H);  δC (50 MHz, CDCl3)  19.1 (CH3), 22.5 [OCH(CH3)2], 29.7 
(ArCH2C), 45.6 (ArCH2N), 55.7 (OCH3), 75.2 [OCH(CH3)2], 110.3 (8-C), 124.2 (9-C), 124.9 
(4-C), 126.2 (5a-C), 127.2 (11-C), 129.6 (12-C), 132.6 (3-C), 133.0 (9a-C), 136.9 (10-C), 
143.4 (6-C), 145.1 (13-C), 153.0 (7-C). Insufficient material remained for us to perform a 
HRMS analysis after NMR and FTIR spectroscopy were completed. 
 
2.32 Preparation of 3-isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 201 
 
The 2-allyl-3-isopropoxy-4-methoxybenzaldehyde 138 (4.30mmol, 
1.01g) was dissolved in toluene (100cm3) and the solution was heated 
to 80oC. Then the Ru-isomerisation catalyst 12 (0.02eq, 0.0861mmol, 
0.0890g) was added and the reaction mixture was left to stir under an 
Ar atmosphere for 23 h. The reaction mixture was then allowed to cool 
to rt and the solvent was removed in vacuo to yield a brown oil, 1H NMR spectroscopy of the 
crude mixture showed only partial isomerisation, so the oil was redissolved in toluene 
(50cm3) and the solution was again heated to 80oC. Additional Ru-isomerisation catalyst 12 
(0.02eq, 0.0861mmol, 0.0827g) was added and the reaction mixture was left to stir under an 
Ar atmosphere for a further 22.5 h. After this time the reaction mixture was allowed to cool to 
rt and the solvent was removed in vacuo, 1H NMR spectroscopy showed total isomerisation. 
The dark brown oil was then purified by column chromatography (5-10% EtOAc-Hexane) to 
yield a yellow-brown oil that crystallised on standing (0.924g, 92%). A mixture of E/Z 
isomers was observed by NMR spectroscopy, and the spectroscopic data was found to 
correlate well to that reported by Coyanis206. 
 
Rf = 0.66 (30% EtOAc-Hexane);  m.p. 37-40oC;  δH (300 MHz, CDCl3) 1.27 [6H, d, 
J=6.2Hz, OCH(CH3)2], 1.98 (3H, dd, J=1.7 and 6.6 Hz, CH3), 3.91 (3H, s, OCH3), 4.42 [1H, 
sept, J=6.2Hz, OCH(CH3)2], 5.80 and 6.03-6.09 (1H, m, ArCH=CHCH3, mixture of E/Z 
isomers), 6.59-6.60 and 6.73 (1H, m, ArCH=CHCH3, mixture of E/Z isomers), 6.91 (1H, d, 
J=8.7Hz, 5-H), 7.69 (1H, d, J=8.7Hz, 6-H), 10.00 and 10.05 (1H, two s, CHO, mixture of E/Z 
isomers);  δC (50 MHz, CDCl3)  19.0 (CH3), 22.5 [OCH(CH3)2], 55.8 (OCH3), 75.3 
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[OCH(CH3)2], 110.3 (5-C), 122.5 (2-C), 123.0 (6-C), 125.2 (ArCH=CHCH3), 128.3 (1-C), 
136.1 (ArCH=CHCH3), 144.2 (3-C), 157.1 (4-C), 191.6 (CHO).  
 
2.33 Preparation of N-{[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]methyl-idene}-2-
propen-1-amine 236 
 
The 3-isopropoxy-4-methoxy-2-(1-propenyl)benzalde-hyde 201 
(0.436mmol, 0.102g) was placed in a flask that was under an Ar 
atmosphere and to this was added allyl amine (1.4eq, 0.611mmol, 
0.0500cm3). The mixture was then allowed to stir at rt for 22 h. 
After this time the excess allyl amine was removed in vacuo to 
yield a yellow-orange oil. The product was essentially pure by 1H NMR spectroscopy and no 
further purification was required (0.119g, 100%). A mixture of E/Z isomers was observed by 
NMR spectroscopy. 
 
Rf = 0.67 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  929 (RCH=CH2), 2977 (CH3), 
3019 (Ar H), 3617 (imine H);  δH (300 MHz, CDCl3) 1.22-1.28 [6H, m, OCH(CH3)2], 1.94 
(3H, dd, J=1.2 and 5.6Hz, CH3), 3.86 (3H, s, OCH3), 4.20 (2H, dd, J=1.2 and 5.6Hz, 
NCH2C), 4.38 [1H, sept, J=6.1Hz, OCH(CH3)2], 5.12-5.23 (2H, m, CH=CH2), 5.72 (1H, qd, 
J=6.6 and 15.9Hz, CH=CH2), 5.88-6.11 (1H, m, ArCH=CHCH3), 6.60 (1H, dd, J=1.5 and 
16.0 Hz, ArCH=CHCH3), 6.84 (1H, d, J=8.7Hz, 5-H), 7.71 (1H, d, J=8.6Hz, 6-H), 8.41 (1H, 
s, ArCH=N);  δC (50 MHz, CDCl3)  19.0 (CH3), 22.5 and 22.6 [OCH(CH3)2], 55.6 and 55.7 
(OCH3), 63.5 and 63.7 (NCH2C), 74.7 and 75.1 [OCH(CH3)2], 110.7 (5-C), 115.7 (CH=CH2), 
123.0 (2-C), 123.3 (6-C), 124.3 (ArCH=CHCH3), 134.0 (CH=CH2), 134.8 (1-C), 136.3 
(ArCH=CHCH3), 144.2 (3-C), 154.3 (4-C) 161.8 (ArCH=N);  MS m/z 273 (M+, 4%), 39 (7), 
41 (11), 43 (8), 65 (7), 77 (9), 91 (10), 103 (8), 147 (5), 149 (7), 160 (5), 162 (5), 163 (6), 164 
(10), 174 (6), 175 (10), 176 (8), 177 (100), 178 (12), 192 (22), 193 (21), 216 (21), 220 (7), 
234 (37), 235 (7), 258 (26), 259 (6), 274 (5), HRMS calculated for C17H23NO2:  273.17288, 
found: 273.17290. 
 
 
 
236
5
6
N
O
O
Chapter 7 Experimental Procedures 194
2.34 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-2-propen-1-amine 
235 
 
Method A: 
The N-{[3-isopropoxy-4-methoxy-2-(1-propenyl)-phenyl]methylid-
ene}-2-propen-1-amine 236 (0.436 mmol, 0.110g) was dissolved in 
MeOH (1cm3) and the solution was cooled to 0oC in an ice-water 
bath. To this methanolic solution was added sodium borohydride 
(1.2eq, 0.523mmol, 0.0206g), and the reaction mixture was left to stir at 0oC under an Ar 
atmosphere for 2 h. After this time distilled water was added to destroy the excess sodium 
borohydride and the pH was neutralised using 1M HCl and saturated NaHCO3 solutions. The 
MeOH was removed on the rotary evaporator and the remaining aqueous layer was extracted 
with EtOAc (3×5cm3). The combined organics were then dried over anhydrous MgSO4 and 
the solvent was removed in vacuo to yield a yellow oil (0.0985g, 82%), which was 
spectroscopically pure and required no further purification. 
 
Method B: 
The 3-isopropoxy-4-methoxy-2-(1-propenyl)benzaldehyde 201 (1.13mmol, 0.268g) was 
transferred to a flask using the minimum amount of Et2O and this was then removed under 
vacuum. To the aldehyde was then added allyl amine (1.4eq, 1.58mmol, 0.115cm3) and the 
reaction mixture was allowed to stir at rt under an Ar atmosphere for 18 h. After which time a 
small amount was removed and analysed by 1H NMR spectroscopy. It was found that pure 
imine formation had occurred so the imine was dissolved in MeOH (3cm3) and the solution 
was cooled to 0oC in an ice-water bath. This was followed by the addition of sodium 
borohydride (1.2eq, 1.36mmol, 0.528g). The reaction mixture was stirred under an Ar 
atmosphere and was allowed to warm to rt from 0oC over a period of 3.5 h. After this time 
distilled water was added to destroy the excess sodium borohydride and the pH was 
neutralised using 1M HCl and saturated NaHCO3 solutions. The MeOH was removed on the 
rotary evaporator to yield a milky aqueous solution. This was then extracted with EtOAc 
(3×10cm3) and the combined organics were dried over anhydrous MgSO4. The solution was 
filtered through cotton wool and the solvent was removed in vacuo. The desired product was 
obtained as an essentially pure yellow oil and no further purification was required (0.277g, 
89%). 
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Rf = 0.28 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  805 (2 adj Ar H), 994 (RCH=CH2), 
1381 and 1439 (alkane), 2838 (-N-CH2-), 2936 (-OCH3), 2977 (-CH3), 3011 (Ar H), 3080 
(C=CH2), 3666 (-NH);  δH (300 MHz, CDCl3)  1.23 [6H, d, J=6.2Hz, OCH(CH3)2], 1.68 (1H, 
broad s, NH), 1.90 (3H, dd, J=1.5 and 6.5Hz, CH3), 3.24 (2H, d, J=6.0Hz, NCH2C), 3.73 (2H, 
s, ArCH2NH), 3.81 (3H, s, OCH3), 4.32 [1H, sept, J=6.2Hz, OCH(CH3)2], 5.10-5.18 (2H, m, 
CH=CH2), 5.92 (1H, tdd, J=6.0, 10.2 and 16.3Hz, CH=CH2), 6.14 (1H, qd, J=6.5 and 15.9Hz, 
ArCH=CHCH3), 6.43 (1H, dd, J=1.5 and 16.0Hz, ArCH=CHCH3), 6.73 (1H, d, J=8.4Hz, 5-
H), 6.99 (1H, d, J=8.4Hz, 6-H);  δC (50 MHz, CDCl3)  19.2 (CH3), 22.5 [OCH(CH3)2], 51.0 
(ArCH2N), 51.8 (NCH2C), 55.7 (OCH3), 75.0 [OCH(CH3)2], 110.1 (5-C), 115.9 (CH=CH2), 
124.4 (6-Ca), 124.9 (1-Ca), 130.8 (2-Cb), 131.7 (ArCH=CHCH3b), 132.8 (ArCH=CHCH3b), 
136.9 (CH=CH2), 145.0 (3-C), 152.2 (4-C);  MS m/z 275 (M+, 12%), 41 (52), 43 (22), 117 
(22), 145 (24), 161 (51), 163 (21), 175 (55), 176 (58), 177 (55), 178 (28), 190 (37), 192 (41), 
216 (44), 218 (31), 232 (100), 233 (36), 234 (20), HRMS calculated for C17H25NO2:  
275.18853, found: 275.19120. 
 
2.35 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-acetamide 
237 
 
A solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-
propenyl)benzyl]-2-propen-1-amine 235 (0.740mmol, 0.204g) and 
distilled pyridine (1eq, 0.740mmol, 0.060cm3) and it was cooled to 
0oC in an ice-water bath. To this was added dropwise a solution of 
pre-distilled acetic anhydride (1.5eq, 1.11mmol, 0.110cm3) in 
pyridine (1.5eq, 1.11mmol, 0.100cm3). Then the ice-water bath was removed and the reaction 
mixture was stirred at rt under an Ar atmosphere for 3 h. After this time the reaction mixture 
was diluted with EtOAc (5cm3) and stirred for 5 min. Then the organic layer was extracted 
with brine (3×10cm3). The combined aqueous layers were then extracted with CH2Cl2 
(3×10cm3). Then the organic layers were combined and extracted with saturated NH4Cl that 
was basified to pH 11 with a 25 % ammonia solution (40cm3). The combined organics were 
then dried over anhydrous MgSO4, filtered and the solvent was removed in vacuo to yield a 
pale yellow oil. The crude compound was then purified by column chromatography (5-10% 
EtOAc-Hexane) to yield the desired product as a clear oil (0.168g, 72%). Amide rotamers 
were observed in both the 1H and 13C NMR spectra.  
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Rf = 0.24 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  772 (alkane), 929 (RCH=CH2), 
1216 (C-O), 1478 (alkane), 1522 (Ar ring), 1630 (tertiary amide or C=C aryl conj), 3019 (Ar 
H);  δH (300 MHz, CDCl3) 1.21-1.25 [6H, m, OCH(CH3)2], 1.86-1.92 (3H, m, CH3), 2.08 and 
2.13 (3H, two s, COCH3), 3.69 (1H, d, J=4.7Hz, NCH2CHa), 3.81 and 3.83 (3H, two s, 
OCH3), 3.96 (1H, d, J=5.8Hz, NCH2CHa), 4.27-4.36 [1H, m, OCH(CH3)2], 4.23 and 4.62 
(2H, two s, ArCH2N), 5.04-5.18 (2H, m, CH=CH2), 5.60-6.04 (2H, m, CH=CH2 and 
ArCH=CH), 6.29 and 6.34 (1H, two d, J=1.9, ArCH=CH), 6.71-6.87 (2H, m, 5-H and 6-H);  
δC (50 MHz, CDCl3)  19.0 and 19.1 (CH3), 21.4 and 21.5 (COCH3), 22.4 and 22.5 
[OCH(CH3)2], 45.6 and 47.9 (ArCH2N), 49.1 and 49.3 (NCH2C), 55.7 (OCH3), 75.0 and 75.1 
[OCH(CH3)2], 110.2 and 110.4 (5-C), 116.5 and 117.2 (CH=CH2), 120.8 (6-C), 123.6 
(CH=CHCH3), 124.2 and 124.6 (1-Cb), 126.7 and 127.4 (2-Cb), 132.1  and  132.4 
(ArCH=CH), 133.1 and 133.2 (CH=CHCH3), 144.8 and 145.2 (3-C), 152.2 and 152.3 (4-C), 
170.7 and 171.0 (C=O);  MS m/z 317 (M+, 72%), 41 (15), 43 (21), 115 (11), 117 (13), 146 
(13), 161 (30), 175 (100), 176 (80), 177 (31), 193 (86), 193.5 (40), 218 (24), 220 (15), 232 
(30), 234 (22), 235 (11), 274 (19), 176 (21), 302 (10), 317(72), 318 (16), HRMS calculated 
for C19H27NO3: 317.19909, found: 317.19985. 
 
2.36 Preparation of tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]car-
bamate 238 
 
The N-[3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]-2-propen-
1-amine 235 (1.00mmol, 0.277g) was dissolved in pre-distilled 
THF (28cm3) and to this was added Boc2O (1.2eq, 1.21mmol, 
0.290cm3). The solution was then stirred for 5 min before the 
addition of DMAP (0.1eq, 0.100mmol, 0.0160g). Then the reaction 
mixture was allowed to stir at rt under an Ar atmosphere for 3 h. 
After this time the solvent was removed in vacuo and the residue was purified by column 
chromatography (5% EtOAc-Hexane). The desired product was obtained as a pale yellow oil 
(0.324g, 86%). A mixture of E/Z isomers was observed in the spectra. 
 
Rf = 0.76 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  756 (CH2), 843 (2 adj Ar H), 927 
(RCH=CH2), 1119 (C-O), 1371 (-COCH3), 1459 (alkane), 1479 and 1574 (Ar ring), 1678  
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(tertiary amide or isolated C=C), 2839 (-OCH3), 2936 (-CH3), 2980 (-CH2), 3018 (Ar H);  δH 
(300 MHz, CDCl3) 1.22 [6H, d, J=6.2Hz, OCH(CH3)2], 1.53 [9H, s, OC(CH3)3], 1.88 (3H, d, 
J=6.1Hz, CH3), 3.62-3.74 (2H, m, NCH2C), 3.81 (3H, s, OCH3), 4.32 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 4.43 (2H, s, ArCH2N), 5.04 (2H, t, J=14.4Hz, CH=CH2), 5.70-5.96 (2H, m, 
CH=CH2 and ArCH=CH), 6.34 (1H, dd, J=1.4 and 16.0Hz, ArCH=CH), 6.74 (1H, d, 
J=8.5Hz, 5-H), 6.86 (1H, d, J=8.5Hz, 6-H);  δC (50 MHz, CDCl3)  19.1 (CH3), 22.5 
[OCH(CH3)2], 28.4 [OC(CH3)3], 47.0 (ArCH2N), 48.2 (NCH2CH), 55.7 (OCH3), 74.9 
[OCH(CH3)2], 79.5 [OC(CH3)3], 110.1 (5-C), 116.1 (CH=CH2), 123.3 (2-C), 124.6 
(ArCH=CH), 132.0 (ArCH=CH), 133.8 (CH=CH2), 144.9 (3-C), 146.7 (4-C), 155.6 (C=O), 
no peaks were observed in the 13C NMR spectrum for 1-C and 6-C;  MS m/z 375 (M+, 4%), 
41 (28), 57 (100), 70 (26), 161 (16), 175 (67), 176 (33), 177 (24), 232 (34 ), 234 (19), 274 
(82), 275 (17), 276 (15), 318 (15), 319 (71), HRMS calculated for C22H33NO4: 375.24096, 
found: 375.23970. 
 
2.37 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-phenylmet-
hanesulfonamide 239 
 
The N-[3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]-2-prop-
en-1-amine 235 (0.746mmol, 0.205g) was dissolved in pre-
distilled CH2Cl2 (2cm3); to this was added NEt3 (2.5eq, 
1.86mmol, 0.260cm3) and the solution was allowed to stir at rt 
for 15 min. Then the α-toluenesulfonyl chloride (1.1eq, 
0.821mmol, 0.159g) was dissolved in CH2Cl2 (2cm3) and the 
mixture was added dropwise to the amine solution, a cloudy 
white gas evolved during the addition. Then the reaction mixture was stirred at rt under an Ar 
atmosphere for 18 h, before the solvent was removed in vacuo to yield a pink-orange oil that 
solidified on standing. The crude mixture was then purified by column chromatography (5-
20% EtOAc-Hexane) to yield the desired product as a yellow oil (0.0927g, 29%). Mixtures of 
E/Z isomers were observed in the spectra. 
 
Rf = 0.63 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (alkane), 930 (RCH=CH2), 
1150 (-SO2-N-), 1334 (-SO2-N-), 1439 (alkane), 1481 (-CH2), 2977 (CH3), 3020 (Ar H);  δH 
(300 MHz, CDCl3) 1.21 [6H, d, J=6.2Hz, OCH(CH3)2], 1.88 (3H, d, J=6.4Hz, CH3), 3.55 
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(2H, d, J=6.5Hz, NCH2C), 3.81 (3H, s, OCH3), 4.14 (2H, s, ArCH2N), 4.23 (2H, s, 
ArCH2SO2), 4.31 [1H, sept, J=6.2Hz, OCH(CH3)2], 5.01-5.12 (2H, m, CH=CH2), 5.55-5.81 
(2H, m, CH=CH2 and ArCH=CH), 6.34 (1H, d, J=16.1Hz, ArCH=CH), 6.76 (1H, d, J=8.5Hz, 
5-H), 7.08 (1H, d, J=8.5Hz, 6-H), 7.35-7.36 (5H, m, 9-H, 10-H and 11-H);  δC (50 MHz, 
CDCl3)  19.1 (CH3), 22.5 [OCH(CH3)2], 48.2 (ArCH2N), 49.8 (NCH2C), 55.7 (OCH3), 59.4 
(ArCH2SO2), 75.0 [OCH(CH3)2], 110.3 (5-C), 119.0 (CH=CH2), 124.5 (6-Ca), 124.8 (1-Ca), 
126.3 (2-Ca), 128.6 (10-C and CH=CHCH3), 129.2 (11-C), 130.8 (9-C), 132.4 (ArCH=CH), 
132.9 (8-C), 133.2 (CH=CH2), 144.7 (3-C), 152.5 (4-C);  MS m/z 429 (M+, 7%), 41 (6), 91 
(49), 117 (7), 145 (6), 161 (6), 176 (13), 177 (13), 178 (5), 216 (17), 232 (70), 233 (10), 274 
(100), 275 (20), 429 (8), HRMS calculated for C24H31NO4S: 429.19738, found: 429.19619. 
 
2.38 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)benzyl]-4-methyl-
benzenesulfonamide 144 
 
The N-[3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]-2-propen-
1-amine 235 (1.68mmol, 0.463g) was dissolved in pre-distilled 
CH2Cl2 (5cm3) and then cooled to 0oC in an ice-water bath. To this 
solution was added NEt3 (1.4eq, 2.35mmol, 0.350cm3) and it was 
stirred for 5 min before the addition of the tosyl chloride (1.2eq, 
2.02mmol, 0.391g). The reaction mixture was allowed to stir at 
0oC-rt for 3 h, after this time distilled water (5cm3) was added and 
the aqueous layer was extracted with CH2Cl2 (5cm3). The combined organics were then 
extracted with distilled water (2×5cm3) and were dried over anhydrous MgSO4. The solvent 
was then removed in vacuo to yield a dark yellow-orange oil that solidified on standing. The 
crude mixture was then purified by column chromatography (5-10% EtOAc-Hexane) to yield 
the desired product as a cream-white solid (0.553g, 77%), with NMR spectroscopy showing a 
mixture of E/Z isomers. 
 
Rf = 0.70 (30% EtOAc-Hexane);  m.p. 62-64oC;  νmax/cm-1 (NaCl plate)  772 (CH2), 929 
(RCH=CH2), 1159 (-SO2-N-), 1339 (-SO2-N-), 1522 (Ar H), 2977 (-CH3), 3020 (Ar H);  δH 
(300 MHz, CDCl3) 1.23 [6H, two d, J=6.2Hz, OCH(CH3)2], 1.86 (3H, dd, J=1.5 and 6.5Hz, 
CH3), 2.44 (3H, s, TsCH3), 3.66 (2H, d, J=6.4Hz, NCH2C), 3.81 (3H, s, OCH3), 4.09-4.30 
[1H, m, OCH(CH3)2], 4.26 and 4.33 (2H, two s, ArCH2N), 4.85-4.96 (2H, m, CH=CH2), 5.42 
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(1H, tdd, J=6.4, 10.1 and 16.7Hz, CH=CH2), 5.92 (1H, qd, J=6.6 and 16.0Hz, CH=CHCH3), 
6.36 (1H, dd. J=1.5 and 16.0Hz, ArCH=CH), 6.73 (1H, d, J=8.5Hz, 5-H), 7.02 (1H, d, 
J=8.5Hz, 6-H), 7.31 (2H, d, J=8.1Hz, 9-H), 7.73 (2H, d, J=8.2Hz, 8-H);  δC (50 MHz, 
CDCl3) 19.0 (CH3), 21.5 (TsCH3), 22.4 and 22.5 [OCH(CH3)2], 48.2 and 48.3 (ArCH2N), 
49.5 and 49.7 (NCH2C), 55.5 and 55.7 (OCH3), 74.5 and 75.0 [OCH(CH3)2], 109.8 and 110.1 
(5-C), 115.0 (CH=CH2), 118.5 (6-C), 124.5 (1-C), 126.0 (2-C), 126.7 (CH-CH3), 127.3 (8-C), 
129.6 (9-C), 132.4 (ArCH=CH), 133.5 (CH=CH2), 137.3 (7-C), 143.1 (10-C), 144.7 and 
145.0 (3-C), 152.5 (4-C);  MS m/z 429 (M+, 3%), 41 (8), 91 (14), 117 (9), 145 (9), 161 (11), 
176 (22), 177 (13), 215 (20), 220 (6), 224 (6), 232 (56), 233 (9), 274 (100), 275 (18), HRMS 
calculated for C24H31NO4S: 429.19738, found: 429.19780. 
 
2.39 Preparation of 2-acetyl-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benzazepine 240 
 
The N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-propenyl)-benzyl]aceta-
mide 237 (0.266mmol, 0.0845g) was dissolved up in distilled toluene 
(8.5cm3) and the resulting solution was heated to 80oC. To the solution 
was then added Grubbs II catalyst 11 (0.1eq, 0.0266mmol, 0.0229g). 
The reaction mixture was then allowed to stir at 80oC under an Ar 
atmosphere for 21 h. After this time the solvent was removed in vacuo to yield a dark brown 
residue that was then purified by column chromatography (5-15% EtOAc-Hexane). The 
desired compound was obtained as a white solid (0.0054g, 8%). 
 
Rf = 0.51 (30% EtOAc-Hexane);  m.p. >230oC;  νmax/cm-1 (NaCl plate)  669 (RHC=CHR, 
cis), 850 (2 adj Ar H), 1215 (C-O), 1370 (CH3 symmetrical deformation), 1477 (CH2 or CH3 
CH deformations), 1677 (C=C aryl conj or tertiary amide), 2897 (-OCH3), 2938 (-CH2 or –
CH3 stretch), 3019 (Ar H).;  δH (300 MHz, CDCl3) 1.29 [6H, d, J=6.2Hz, OCH(CH3)2], 2.44 
(3H, s, CH3), 3.85 (3H, s, OCH3), 4.49 [1H, sept, J=6.1Hz, OCH(CH3)2], 6.36 (1H, d, 
J=12.5Hz,, ArCH=CH), 6.93 (1H, d, J=8.3Hz, 8-H), 7.16 (1H, d, J=8.3Hz, 9-H), 7.57 (1H, d, 
J=12.5Hz, ArCH=CH);  δC (50 MHz, CDCl3)  22.6 [OCH(CH3)2], 26.9 (CH3), 29.7 
(ArCH2Na), 44.9 (NCH2CHa), 55.9 (OCH3), 76.3 [OCH(CH3)2], 113.7 (8-C), 123.5 (9-C), 
126.1 (4-C), 129.6 (9a-C), 130.1 (5a-C), 135.7 (5-C), 145.9 (6-C), 152.7 (7-C), 168.2 (C=O).  
Insufficient material remained after NMR and FTIR spectroscopy to perform the HRMS 
analysis. 
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2.40 Preparation of tert-butyl 6-isopropoxy-7-methoxy-1,3-dihydro-2H-2-benzazepine-2-
carboxylate 241 
 
The tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-propenyl)-
benzyl]carbamate 241 (0.268mmol, 0.101g) was dissolved in pre-
distilled toluene (10cm3) and the solution was heated to 60oC. 
Then Grubbs II catalyst 11 (0.05eq, 0.0134mmol, 0.0117g) was 
added and the reaction mixture was allowed to stir at 60oC under 
an Ar atmosphere for 18 h. The solvent was then removed in 
vacuo to yield a brown-black oil, that was then purified by column chromatography (5% 
EtOAc-Hexane). The product was obtained as a pale yellow oil (0.0235, 26%). Severe peak 
broadening occurred in the 1H NMR spectrum, which made the assignments extremely 
difficult. 
 
Rf = 0.74 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  668 (RHC=CHR, cis), 852 (2 adj 
Ar H), 1216 (C-O), 1369 (CH3 symmetrical deformation), 1440 (CH2 or CH3 deformations), 
C=C aryl conj. Or tertiary amide), 2855 (-OCH3), 2929 (CH2 or CH3 stretch), 3017 (Ar H);  
δH (300 MHz, CDCl3) 1.22-1.52 [15H, m, OC(CH3)3 and OCH(CH3)2], 3.80-3.86 (5H, m, 
OCH3 and NCH2C), 4.25-4.77 [3H, m, OCH(CH3)2 and Ar CH2N], 5.87-5.89 (1H, m, 4-H), 
6.31-6.39 (1H, m, 8-H), 6.69-7.09 (1H, m, 5-H and 9-H);  δC (50 MHz, CDCl3) 22.6 
[OCH(CH3)2], 29.7 [OC(CH3)3], 47.8 (ArCH2N), 55.8 (OCH3a), 55.9 (NCH2Ca), 75.2 
[OCH(CH3)2], 83.5 [OC(CH3)3], 110.3 (8-C), 113.3 (9-C), 122.5 (4-C), 124.7 (9a-C), 124.9 
(5a-C), 126.7 (5-C), 132.0 (6-C), 134.5 (7-C), 163.2 (C=O). Insufficient material remained 
after NMR and FTIR spectroscopy to perform the HRMS analysis. 
 
2.41 Preparation of 2-(benzylsulfonyl)-6-isopropoxy-7-methoxy-2,3-dihydro-1H-2-benza-
zepine 242 
 
N-Allyl-N-[3-isopropoxy-4-methoxy-2-(1-pro-penyl)ben-
zyl]phenylmethanesulfonamide 239 (0.122mmol, 0.0526g) 
was dissolved in pre-distilled toluene (5cm3) and the 
solution was heated to 80oC. To this solution was added 
Grubbs II catalyst 11 (0.1eq, 0.0122mmol, 0.0107g) and it 
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was allowed to stir at 80oC under an Ar atmosphere for 21 h. After this time the solvent was 
removed in vacuo to yield a dark brown resin that was purified by column chromatography 
(5% EtOAc-Hexane). The desired product was obtained as a yellow oil (0.0184g, 39%). 
 
Rf = 0.49 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (RHC=CHR, cis), 743 (5 adj 
Ar H), 879 (2 adj Ar H), 1150 (-SO2-N-), 1354 (-SO2-N-), 1456 (CH2 or CH3 deformations), 
1490 (Ar ring), 1575 (Ar ring), 1598 (Ar ring), 1666 (C=C aryl conj), 2931 (CH3 or CH2 
stretch), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.28 [6H, d, J=6.2Hz, OCH(CH3)2], 3.79 (2H, 
s, NCH2C), 3.84 (3H, s, OCH3), 4.09-4.11 (2H, m, ArCH2N), 4.33 (2H, s, ArCH2SO2), 4.46 
[1H, sept, J=6.2Hz, OCH(CH3)2], 5.76 (1H, td, J=3.9 and 12.6Hz, ArCH=CH), 6.78 (1H, d, 
J=8.2Hz, 8-H), 6.92-6.99 (2H, m, NCH2CH=CH and 9-H), 7.16-7.29 (5H, m, 12-H, 13-H and 
14-H);  δC (50 MHz, CDCl3)  22.5 [OCH(CH3)2], 50.7 (NCH2C), 51.7 (ArCH2N), 55.8 
(OCH3), 58.6 (ArCH2SO2), 75.5 [OCH(CH3)2], 111.0 (8-C), 122.9 (9a-C), 123.5 (9-C), 124.2 
(5a-C), 125.3 (4-C), 128.3 (14-C), 128.5 (13-C), 128.9 (5-C), 129.7 (11-C), 130.6 (12-C), 
145.3 (6-C), 152.8 (7-C);  MS m/z 387 (M+, 28%), 41 (6), 43 (7), 65 (10), 91 (100), 92 (10), 
103 (7), 131 (6), 146 (5), 147 90, 161 (13), 162 (9), 163 (67), 164 (8), 174 (11), 175 (8), 176 
(5), 189 (42), 190 (49), 191 (7), 204 (8), 205 (20), 232 (8), 280 (6), 359 (11), 387 (28), 388 
(6), 401 (9), HRMS calculated for C21H25NO4S: 387.15043, found: 387.14958. 
 
2.42 Preparation of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-2,3-dihydro-
1H-2-benzazepine 145 
 
The N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-pro-penyl)ben-
zyl]-4-methylbenzenesulfonamide 144 (0.471mmol, 0.203g) 
was dissolved up in pre-distilled toluene (20cm3) and the 
solution was heated to 60oC. Then the Grubbs II catalyst 11 
(0.05eq, 0.0236mmol, 0.0206g) was added and the reaction 
mixture was stirred at 60oC under an Ar atmosphere for 19.5 h. 
After this time the reaction mixture was cooled to rt and the 
solvent was removed in vacuo to yield a dark brown oil. The crude mixture was purified by 
column chromatography (5-10% EtOAc-Hexane) to obtain the desired product as a pale 
yellow oil that solidified on standing (0.149g, 82%). 
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Rf = 0.54 (30% EtOAc-Hexane);  m.p. 147-149oC;  νmax/cm-1 (NaCl plate)  669 (RCH=CHR, 
cis), 747 (CH2 rocking), 813 (2 adj Ar H), 1157 (-SO2-N-), 1342 (-SO2-N-), 1440 (CH2 or 
CH3 defromations), 1490 (Ar ring), 1577 (Ar ring), 1599 (Ar ring), 1670 (C=C aryl conj), 
2840 (-OCH3), 2939 (CH3 or CH2 stretch), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.22 [6H, d, 
J=6.2Hz, OCH(CH3)2], 2.41 (3H, s, TsCH3), 3.14-3.17 (2H, m, NCH2C), 3.85 (3H, s, OCH3), 
4.15 (2H, s, ArCH2N), 4.42 [1H, sept, J=6.2Hz, OCH(CH3)2], 5.86 (1H, td, J=7.8 and 11.2Hz, 
ArCH=CH), 6.68 (1H, d, J=11.2Hz, ArCH=CH), 6.89 (1H, d, J=8.5Hz, 8-H), 7.27 (2H, d, 
J=7.9Hz, 12-H), 7.37 (1H, d, J=8.5Hz, 9-H), 7.66 (2H, d, J=8.3Hz, 11-H);  δC (50 MHz, 
CDCl3)  21.5 (CH3a), 22.5 [OCH(CH3)2], 28.6 (CH3a), 43.5 (NCH2C), 49.7 (ArCH2N), 55.8 
(OCH3), 75.0 [OCH(CH3)2], 111.9 (8-C), 126.6 (9-Cb), 127.1 (11-C), 127.8 (9a-Cb), 128.2 
(5a-Cb), 129.6 (12-C), 130.0 (4-Cb), 132.2 (5-Cb), 136.7 (10-C), 143.0 (13-C), 144.1 (6-C), 
152.1 (7-C);  MS m/z 387 (M+, 3%), 91 (26), 115 (18), 143 (14), 144 (15), 161 (20), 175 (24), 
176 (63), 177 (11), 189 (12), 203 (12), 204 (66), 205 (10), 246 (100), 247 (19), 401 (28), 
HRMS calculated for C21H25NO4S: 387.15043, found: 387.14872. 
 
2.43 Preparation of 4-methoxy-3-{[(2E)-3-phenyl-2-propenyl]oxy}benzaldehyde 246 
 
Distilled and dried DMF (30cm3) and potassium carbonate 
(2.5eq, 49.3mmol, 6.90g) were stirred at rt until a cream 
suspension formed and the solution was then heated to 60oC. 
Then isovanillin 206 (19.7mmol, 3.02g) was added and the 
reaction mixture changed colour to bright yellow. The cinnamyl 
bromide (2.5eq, 49.3mmol, 9.73g) was added and the reaction mixture was stirred at 60oC 
under an Ar atmosphere for 23 h. After this time the reaction mixture was allowed to cool to rt 
and the inorganic solids were filtered off through a celite plug, which was rinsed with CH2Cl2 
(50cm3). The solvent was removed in vacuo to yield a yellow-orange oil that was then 
purified by column chromatography (10-30% EtOAc-Hexane). The desired product was 
obtained as a pale yellow semi-solid (5.29g, 100%). Spectroscopic data was in agreement 
with that reported by Rousseau.1 
 
Rf = 0.45 (30% EtOAc-Hexane);  m.p. 67-69oC after recrystallisation (the product was 
dissolved in the minimum amount of Et2O possible and Hexane was added dropwise until the 
solution became cloudy);  δH (300 MHz, CDCl3) 3.97 (3H, s, OCH3), 4.83 (2H, dd, J=0.7 and 
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6.0Hz, OCH2), 6.45 (1H, td, J=6.0 and 15.9Hz, OCH2CH=CH), 6.76 (1H, d, J=16.0Hz, 
OCH2CH=CH), 7.00 (1H, d, J=8.6Hz, 5-H), 7.25-7.48 (7H, m, 2-H, 5-H and 8-H, 9-H and 
10-H), 9.85 (1H, s, CHO);  δC (50 MHz, CDCl3) 56.2 (OCH3), 69.6 (OCH2), 110.7 (5-C), 
110.9 (2-C), 123.5 (10-C), 126.7 (8-C), 126.8 (6-C), 128.0 (OCH2CH=CH), 128.5 (9-C), 
130.0 (1-C), 134.0 (OCH2CH=CH), 136.2 (7-C), 148.6 (3-C), 154.8 (4-C), 190.8 (CHO). 
 
2.44 Preparation of 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzalde-hyde 247 
 
The Claisen rearrangement was effected by heating the 4-methoxy-3-
{[(2E)-3-phenyl-2-propenyl]oxy}benzaldehyde 246 (9.52mmol, 2.55g) 
in distilled DMF (20cm3) to 160-165oC for 44 h under an Ar 
atmosphere. Then the reaction mixture was cooled to 60oC before the 
addition of the potassium carbonate (2.5eq, 23.8mmol, 3.29g). The 
reaction mixture was then stirred until a cream suspension formed, then 
the isopropyl bromide (2.5eq, 23.8mmol, 2.25cm3) was added. The reaction mixture was 
allowed to stir at 60oC under an Ar atmosphere for a further 44 h. After this time the reaction 
mixture was allowed to cool to rt and the inorganic solids were filtered off through a celite 
plug. The celite was then rinsed with both EtOAc (100cm3) and CH2Cl2 (100cm3) to ensure 
no product was trapped in the solids. Then the solvent was removed on the rotary evaporator 
(70oC) and the remaining DMF was distilled off under high vacuum using a standard oil bath. 
The remaining dark red residue was then purified by column chromatography (5% EtOAc-
Hexane). The desired compound was obtained as a purple oil (1.47g, 50%). Our NMR data 
was found to correlate well with that reported by Rousseau.1 
 
Rf = 0.64 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 0.98 and 1.11 [6H, two d, J=6.2Hz, 
OCH(CH3)2], 1.63 (3H, d, J=7.0Hz, CH3), 3.92 (3H, s, OCH3), 4.36 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 6.51 (1H, q, J=7.0Hz, C=CHCH3), 7.01 (1H, d, J=8.6Hz, 5-H), 7.18-7.28 (5H, 
m, Ph H), 7.83 (1H, d, J=8.6Hz, 6-H), 9.83 (1H, s, CHO);  δC (50 MHz, CDCl3) 16.1 (CH3), 
22.4 [OCH(CH3)2], 55.7 (OCH3), 74.9 [OCH(CH3)2], 111.0 (5-C), 123.8 (10-C), 126.0 (8-C), 
126.9 (6-C), 127.3 (C=CHCH3), 128.3 (9-C), 129.1 (1-C), 134.5 (C=CHCH3), 138.1 (7-C), 
141.6 (2-C), 144.4 (4-C), 158.4 (3-C), 191.8 (CHO). 
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2.45 Preparation of N-{(E)-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-phenyl]-
methylidene}-2-propen-1-amine 248 
 
The 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzaldeh-
yde 247 (0.661mmol, 0.205g) was transferred to the reaction flask 
using the minimum amount of Et2O and this was removed in 
vacuo. Then allyl amine (1.4eq, 0.925mmol, 0.100cm3) was added 
and the mixture was allowed to stir at rt under an Ar atmosphere 
for 24 h. After this time the excess allyl amine was removed in 
vacuo and the desired product was obtained as an orange oil (0.231g, 100%). No further 
purification was required as the compound was spectroscopically pure. 
 
Rf = 0.13 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  771 (5 adj Ar H), 929 (RCH=CH2), 
1381 and 1431 (alkane), 1518 and 1588 (Ar ring), 1639 (C=C isolated), 1678 (C=N), 2840 (-
OCH3), 2902 (-CH2), 2980 (-CH3), 3022 (Ar H);  δH (300 MHz, CDCl3) 0.97 and 1.09 [6H, 
two d, J=6.2Hz, OCH(CH3)2], 1.59 (3H, d, J=7.0Hz, CH3), 3.87 (3H, s, OCH3), 4.06-4.08 
(2H, m, NCH2), 4.32 [1H, sept, J=6.1Hz, OCH(CH3)2], 5.04-5.15 (2H, m, CH=CH2), 5.88-
5.99 (1H, m, CH=CH2a), 6.34-6.44 (1H, m, C=CHCH3a), 6.96 (1H, d, J=8.7Hz, 5-H), 7.17-
7.31 (5H, m, 8-H, 9-H and 10-H), 7.88 (1H, d, J=8.7Hz, 6-H), 8.13 (1H, s, CH=N);  δC (50 
MHz, CDCl3)  16.0 (CH3), 22.1 and 22.4 [OCH(CH3)2], 55.6 (OCH3), 63.4 (NCH2), 74.6 
[OCH(CH3)2], 111.3 (5-C), 115.7 (CH=CH2), 122.1 (6-C), 126.0 (8-C), 126.5 (C=CHCH3), 
126.7 (10-C), 128.2 (9-C), 128.5 (2-C), 131.0 (1-C), 135.4 (C=CHCH3), 136.3 (CH=CH2), 
141.8 (7-C), 144.1 (3-C), 155.2 (4-C), 161.2 (CH=N);  MS m/z 349 (M+, 9%), 28 (8), 69 
(100), 100 (9), 119 (8), 131 (43), 219 (91), 220 (9), 236 (9), 250 (9), 251 (9), 254 (9), 264 
(24), 292 (18), 334 (56), 335 (12), 349 (9), HRMS calculated for C23H27NO2: 349.20418, 
found: 349.20968. 
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2.46 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-2-propen-
1-amine 249 
 
Method A: 
The N-{(E)-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-
propenyl)phe-nyl]methylidene}-2-propen-1-amine 248 
(0.612mmol, 0.214g) was dissolved in MeOH (2cm3) and 1 drop of 
distilled water was added. The methanolic solution was then cooled 
to 0oC in an ice-water bath and to this was added sodium 
borohydride (1.2eq, 0.735mmol, 0.299g). The reaction mixture was allowed to stir at 0oC-rt 
for 2.5 h. After this time the excess sodium borohydride was destroyed by the dropwise 
addition of distilled water and 1M HCl until the reaction mixture was neutral. The MeOH was 
then removed on the rotary evaporator and a yellow oil was found on top of the aqueous layer. 
Then EtOAc (10cm3) was added to dissolve the compound and the aqueous layer was 
extracted with EtOAc (3×10cm3). The combined organics were dried over anhydrous MgSO4, 
filtered and the solvent was removed in vacuo to yield the product as a dark yellow oil 
(0.214g, 100%), with no further purification being required.  
 
Method B:  
The 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzaldehyde 247 (1.77mmol, 0.550g) 
was transferred to a flask using Et2O which was then removed under vacuum. To the aldehyde 
was then added allyl amine (1.4eq, 2.50mmol, 0.200cm3) and the reaction mixture was 
allowed to stir at rt under an Ar atmosphere for 21 h. After which time a small amount was 
removed and analysed by 1H NMR spectroscopy. It was found that pure imine formation had 
occurred so the imine was dissolved in MeOH (5.5cm3) and the solution was cooled to 0oC in 
an ice-water bath. This was followed by the addition of sodium borohydride (1.2eq, 
2.12mmol, 0.0805g). The reaction mixture was then left to stir under an Ar atmosphere at 0oC 
for 2 h. After this time distilled water was added to destroy the excess sodium borohydride 
and the pH was neutralised using 1M HCl and saturated NaHCO3 solutions. The reaction 
mixture was then extracted with CH2Cl2 (10cm3) and EtOAc (3×10cm3) and the combined 
organics were dried over anhydrous MgSO4. The solution was filtered through cotton wool 
and the solvent was removed in vacuo. The desired product was obtained as an essentially 
pure orange oil and no further purification was required (0.620g, 100%). 
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Rf = 0.25 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  752 (5 adj Ar H), 927 (RCH=CH2), 
1377 and 1439 (alkane), 1595 (NH), 1646 (C=C isolated), 2837 (OCH3), 2937 (-CH2), 2978 (-
CH3), 3019 (Ar H), 3494 (N-H);  δH (300 MHz, CDCl3) 1.04 and 1.13 [6H, two d, J=6.1Hz, 
OCH(CH3)2], 1.36 and 1.64 (3H, two d, J=6.1 and 6.9Hz respectively, CH3), 1.42 (1H, s, 
NH), 3.02-3.04 (2H, m, NCH2CH), 3.46 (2H, d, J=2.1Hz, ArCH2N), 3.84 (3H, s, OCH3), 4.27 
[1H, sept, J=6.2Hz, OCH(CH3)2], 4.96-5.06 (2H, m, CH=CH2), 5.69-5.82 (1H, m, CH=CH2), 
6.41 (1H, q, J=6.9Hz, C=CHCH3), 6.88 (1H, d, J=8.4Hz, 5-H), 7.12-7.36 (6H, m, 6-H, 8-H, 
9-H and 10-H);  δC (50 MHz, CDCl3)  16.1 (CH3), 22.4 and 22.7 [OCH(CH3)2], 50.3 and 50.7 
(ArCH2N), 51.7 and 52.0 (NCH2CH), 55.5 and 56.1 (OCH3), 74.7 [OCH(CH3)2], 110.8 (5-C), 
114.0 (2-Ca), 115.6 (CH=CH2), 115.9 (C=CHCH3a), 124.1 (6-Cb), 125.3 (1-Cb), 125.9 and 
126.1 (8-C), 126.6 (10-Cb), 128.2 and 128.5 (9-C), 133.4 (CH=CH2), 136.8 and 136.9 
(C=CHCH3), 141.4 (7-C), 144.8 (3-C), 152.3 (4-C);  MS m/z 351 (M+, 8%), 28 (88), 32 (14), 
69 (100), 131 (18), 161 (5), 219 (30), 220 (5), 252 (17), 253 (7), 264 (6), 294 (4), 310 (9), 351 
(8), HRMS calculated for C23H29NO2: 351.21983, found: 351.21969. 
 
2.47 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzyl]-
acetamide 250 
 
A solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-
phenyl-1-propenyl)benzyl]-2-propen-1-amine 249 (1.43mmol, 
0.504g) and distilled pyridine (1eq, 1.43mmol, 0.120cm3), which 
was then cooled to 0oC in an ice-water bath. To this was added 
dropwise a solution of pre-distilled acetic anhydride (1.5eq, 
2.15mmol, 0.200cm3) and distilled pyridine (1.5eq, 2.15mmol, 
0.190cm3). Then the ice-water bath was removed and the reaction mixture was stirred at rt for 
3 h. Thin layer chromatography indicated that the reaction had gone to completion so the 
reaction mixture was diluted with EtOAc (15cm3) and allowed to stir for 5 min. Then the 
organic mixture was extracted with brine (3×20cm3). The combined aqueous layers were then 
extracted with CH2Cl2 (3×20cm3). The combined organics were then washed with a saturated 
NH4Cl solution that had been basified to pH 11 using a 25% ammonia solution (50cm3). The 
combined organics were then dried over anhydrous MgSO4, filtered and the solvent was 
removed in vacuo to yield an orange oil. This was then purified by column chromatography 
(10-40% EtOAc-Hexane) to yield the desired product as a dark yellow oil (0.373g, 66%). 
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Rf = 0.22 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  698 (alkane), 772 (5 adj Ar H), 985 
(RCH=CH2), 1216 (C-O), 1382 and 1436 (alkane), 1480 and 1575 (Ar ring), 1631 (tertiary 
amide or isolated C=C), 2839 (-OCH3), 2936 (-CH3), 3018 (Ar H);  δH (300 MHz, CDCl3) 
1.01-1.14 [6H, m, OCH(CH3)2], 1.65 (3H, dd, J=4.1 and 6.9Hz, CH3), 1.95 and 1.99 (3H, two 
s, COCH3), 3.85 (3H, d, J=4.5Hz, OCH3), 3.93 (2H, d, J=6.0Hz, NCH2CH), 4.06 and 4.14 
(2H, two s, ArCH2N), 4.20-4.40 [1H, m, OCH(CH3)2], 4.88-5.05 (2H, m, CH=CH2), 5.45-
5.73 (1H, m, CH=CH2), 6.42 (1H, m, C=CHCH3), 6.83-6.97 (2H, m, 5-H and 6-H), 7.14-7.27 
(5H, m, 8-H, 9-H and 10-H);  δC (50 MHz, CDCl3)  15.9 and 16.0 (CH3), 21.2 (COCH3), 22.5 
and 22.6 [OCH(CH3)2], 45.3 (ArCH2Na), 48.1 (NCH2C), 48.5 (ArCH2Na), 55.5 (OCH3), 74.8 
and 74.9 [OCH(CH3)2], 110.9 and 111.0 (5-C), 116.3 and 117.4 (CH=CH2), 119.9 and 123.0 
(6-C), 125.2 (C=CHCH3), 125.5 and 125.7 (8-C), 126.5 (2-Cb), 126.9 (10-Cb), 127.4 (1-Cb), 
128.1 and 128.3 (9-C), 132.5 and 132.8 (CH=CH2c), 135.9 and 136.3 (C=CHCH3c), 140.2 and 
140.7 (7-C), 144.7 and 145.3 (3-C), 152.4 and 152.5 (4-C), 170.9 and 171.1 (C=O);  MS m/z 
393 (M+, 33%), 41 (40), 43 (17), 45 (10), 55 (15), 56 (14), 57 (36), 69 (10), 220 (18), 225 
(13), 237 (17), 251 (47), 252 (100), 253 (38), 268 (18), 294 (17), 322 (10), 365 (23), 393 (33), 
394 (11), HRMS calculated for C25H31NO3: 393.23039, found: 393.23103. 
 
2.48 Preparation of tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-
benzyl]carbamate 251 
 
The N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-pro-penyl)benzyl]-
2-propen-1-amine 249 (1.42mmol, 0.500g) was dissolved in pre-
distilled THF (50cm3). To this was added Boc2O (1.2 eq, 
1.71mmol, 0.400cm3) and the solution was stirred for 5 min before 
the addition of the DMAP (0.1eq, 0.142mmol, 0.0177g). The 
reaction mixture was allowed to stir at rt under an Ar atmosphere 
for 2.25 h. After this time the solvent was removed in vacuo to 
yield a purple oil. The crude mixture was then purified by column chromatography (5-10% 
EtOAc-Hexane) to yield the desired compound as a purple oil (0.592g, 92%). Peak 
broadening was observed in the 1H NMR spectra due to amide rotamers. 
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Rf = 0.76 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (5 adj Ar H), 1216 (C-O), 1404 
(alkane), 1478 (Ar ring), 1693 (tertiary amide), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.00 and 
1.10 [6H, two d, J=5.7Hz, OCH(CH3)2], 1.39 and 1.44 [9H, two s, OC(CH3)3], 1.63 (3H, d, 
J=6.7Hz, CH3), 3.47-3.80 (2H, m, NCH2C), 3.84 (3H, s, OCH3), 4.02-4.20 (2H, ArCH2N), 
4.27 [1H, sept, J=6.2Hz, OCH(CH3)2], 4.81-5.00 (2H, m, CH=CH2), 5.58-5.68 (1H, m, 
CH=CH2), 6.37 (1H, q. J=6.8Hz, C=CHCH3), 6.82-6.95 (2H, m, 5-H and 6-H), 7.15-7.26 
(5H, m, 8-H, 9-H and 10-H);  δC (50 MHz, CDCl3) 15.8 and 15.9 (CH3), 22.5 and 22.6 
[OCH(CH3)2], 27.7 and 28.3 [OC(CH3)3], 46.4 and 46.9 (ArCH2N), 48.9 (NCH2C), 55.5 
(OCH3), 74.7 [OCH(CH3)2], 79.6 [OC(CH3)3], 110.8 (2-Ca), 111.1 (5-Ca), 116.1 and 116.9 
(CH=CH2),  120.5 (6-Cb), 122.0 (1-Cb), 125.0 and 125.2 (C=CHCH3), 125.7 and 126.6 (8-C), 
127.7 (10-C), 128.2 and 129.2 (9-C), 133.5 (CH=CH2), 136.4 (C=CHCH3), 140.9 (7-C), 144.8 
(3-C), 152.1 (4-C), 155.9 (C=O);  MS m/z 451 (M+, 13%), 41 (10), 57 (18), 70 (11), 225 (11), 
237 (12), 239 (10), 251 (46), 252 (100), 253 (29), 254 (10), 292 (5), 293 (8), 294 (55), 296 
(21), 297 (14), 308 (7), 350 (14), 351 (6), 395 (11), 451 (13), 452 (5), HRMS calculated for 
C28H37NO4: 451.27226, found: 451.27299. 
 
2.49 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzyl]-
phenylmethanesulfonamide 252 
 
The N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)ben-
zyl]-2-propen-1-amine 249 (1.34mmol, 0.470g) was dissolved in 
pre-distilled CH2Cl2 (5cm3). Then NEt3 (2.5eq, 3.34mmol, 
0.500cm3) was added and the reaction mixture was allowed to 
stir for 15 min before the dropwise addition of the α-
toluenesulfonyl chloride (1.1eq, 1.47mmol, 0.284g), which had 
been dissolved up in CH2Cl2 (2cm3). During the addition a white 
gas was liberated. The reaction mixture was allowed to stir at rt 
under an Ar atmosphere for 4 h, after which time the colour had changed from yellow to dark 
orange. The solvent was removed in vacuo to yield a yellow oil with crystals in it. The 
mixture was then purified by column chromatography (5-15% EtOAc-Hexane) to give the 
product as an orange solid (0.302g, 45%). 
 
 
5
6
N
O
O
7
8
9
10
9
8
252
S
O O
11
12
13
14
15
14
13
Chapter 7 Experimental Procedures 209
Rf = 0.63 (30% EtOAc-Hexane);  m.p. 105-108oC;  νmax/cm-1 (NaCl plate)  669 (5 adj Ar H), 
702 (alkane), 765 (5 adj Ar H), 999 (RCH=CH2), 1151 (-SO2-N-), 1337 (-SO2-N-), 1377 and 
1442 (alkane), 1482 (Ar ring), 1694 (C=C), 2977 (-CH3), 3020 (Ar H);  δH (300 MHz, 
CDCl3) 1.00 and 1.08 [6H, two d, J=6.1Hz, OCH(CH3)2], 1.49 (3H, d, J=7.0Hz, CH3), 3.59 
(2H, t, J=7.4Hz, NCH2C), 3.73 (2H, two s, ArCH2N), 3.83 (3H, s, OCH3), 4.11-4.24 [3H, m, 
ArCH2SO2 and OCH(CH3)2], 4.92-5.01 (2H, m, CH=CH2), 5.41-5.55 (1H, m, CH=CH2), 6.32 
(1H, q, J=7.0Hz, C=CHCH3), 6.90 (1H, d, J=8.6Hz, 5-H), 7.14-7.28 (11H, m, 6-H, 8-H, 9-H, 
10-H, 13-H, 14-H and 15-H);  δC (50 MHz, CDCl3)  16.0 (CH3), 22.4 and 22.6 [OCH(CH3)2], 
48.3 (ArCH2N), 50.1 (NCH2C), 55.5 (OCH3), 59.1 (ArCH2SO2), 74.7 and 74.8 [OCH(CH3)2], 
111.2 (5-C), 119.2 (CH=CH2), 122.7 (6-C), 125.6 (C=CHCH3), 125.7 (8-Ca), 126.7 (1-C and 
2-C), 127.5 (15-Cb), 128.3 (14-Ca), 128.5 (9-Ca), 129.0 (10-Cb), 130.6 (13-C), 132.3 
(CH=CH2c), 132.7 (12-Cc), 136.0 (C=CHCH3c), 140.8 (7-C), 144.5 (3-C), 152.4 (4-C);  MS 
m/z 505 (M+, 19%), 41 (79), 42 (78), 53 (63), 56 (66), 60 (53), 69 (76), 70 (35), 84 (31), 85 
(30), 91 (55), 129 (32), 254 (62), 255 (39), 256 (76), 308 (49), 350 (100), 351 (28), HRMS 
calculated for C30H35NO4S: 505.22868, found: 505.22896. 
 
2.50 Preparation of N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzyl]-
4-methylbenzenesulfonamide 253 
 
The tosyl chloride was purified according to Perrin219 before use. 
The N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-
2-propen-1-amine 249 (1.38mmol, 0.484g) was dissolved in 
distilled CH2Cl2 (5cm3) and the solution was cooled to 0oC in an 
ice-water bath. To this solution was added NEt3 (1.4eq, 1.93mmol, 
0.270cm3) and it was allowed to stir for 5 min before the addition 
of the tosyl chloride (1.2eq, 1.65mmol, 0.312g). The reaction 
mixture was then allowed to stir at 0oC under an Ar atmosphere for 
2 h and then at rt for a further 1 h. After this time distilled water 
(5cm3) was added and the aqueous layer was extracted with CH2Cl2 (5cm3). The combined 
organics were then extracted with distilled water (2×5cm3) and dried over anhydrous MgSO4. 
The solvent was removed in vacuo to yield a yellow-orange oil that solidified on standing. 
The crude compound was then purified by column chromatography (5-15% EtOAc-Hexane) 
to yield a pale pink oil that solidified on stading (0.493g, 71%). 
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Rf = 0.68 (30% EtOAc-Hexane);  m.p. 110-103oC;  νmax/cm-1 (NaCl plate)  671 and 771 (5 
adj Ar H), 929 (RCH=CH2), 1163 and 1338 (-SO2-N-), 1430 (alkane), 1481 (Ar ring), 1601 
(C=C), 2832 (-OCH3), 2981 (-CH3), 3022 (Ar H);  δH (300 MHz, CDCl3) 1.00 and 1.10 [6H, 
two d, J=6.2Hz, OCH(CH3)2], 1.60 (3H, d, J=6.8Hz, CH3), 2.40 (3H, s, TsCH3), 3.68-3.71 
(2H, m, NCH2C), 3.85 (3H, s, OCH3), 4.02 and 4.08 (2H, two s, ArCH2N), 4.25 [1H, sept, 
J=6.1Hz, OCH(CH3)2], 4.79-4.87 (2H, m, CH=CH2), 5.30-5.44 (1H, m, CH=CH2), 6.33 (1H, 
q, J=6.9Hz, C=CHCH3), 6.92 (1H, d, J=8.6Hz, 5-H), 7.15-7.30 (8H, m, 6-H, 8-H, 9-H, 10-H 
and 13-H), 7.55 (2H, d, J=8.2Hz, 12-H);  δC (50 MHz, CDCl3)  16.0 (CH3), 21.5 (TsCH3), 
22.4 and 22.6 [OCH(CH3)2], 47.9 (ArCH2N), 50.6 (NCH2C), 55.5 (OCH3), 74.7 
[OCH(CH3)2], 111.0 (5-C), 118.8 (CH=CH2), 122.6 (6-C), 125.5 (C=CHCH3), 125.8 (8-C), 
126.6 (2-Ca), 127.2 (12-C), 127.6 (10-C), 128.2 (9-C), 129.2 (1-Ca), 129.5 (13-C), 132.1 
(CH=CH2), 136.1 (C=CHCH3), 137.1 (11-Cb), 140.7 (7-Cb), 143.0 (14-Cb), 144.6 (3-C), 152.4 
(4-C);  MS m/z 505 (M+, 7%), 41 (50), 42 (37), 55 (31), 56 (27), 69 (80), 72 (21), 81 (37), 91 
(22), 251 (20), 252 (69), 253 (32), 294 (23), 308 (34), 350 (100), 351 (26), HRMS calculated 
for C30H35NO4S: 505.22868, found: 505.22896. 
 
2.51 Attempted synthesis of 2-acetyl-6-isopropoxy-7-methoxy-5-phenyl-2,3-dihydro-1H-2-
benzazepine 254 
 
A solution was prepared from N-allyl-N-[3-isopropoxy-4-methoxy-2-
(1-phenyl-1-propenyl)benzyl]acetamide 250 (0.404mmol, 0.159g) 
and pre-distilled toluene (15cm3) and this was degassed using N2 for 
10 min. Then the Grubbs II catalyst 11 (0.08eq, 0.0323mmol, 
0.0282g) was added and the reaction mixture was heated to 80oC 
under an Ar atmosphere for 2.5 h. After this time thin layer 
chromatography confirmed that all the starting material had been consumed, so the solvent 
was removed in vacuo to yield a dark brown oil that was then purified by column 
chromatography (5-15% EtOAc-Hexane). NMR spectroscopy confirmed the formation of the 
isomerised diene N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-N-(1-propen-
yl)acetamide 258 (0.0513g, 32%). 
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2.52 Attempted synthesis of tert-butyl 6-isopropoxy-7-methoxy-5-phenyl-1,3-dihydro-2H-2-
bezazepine-2-carboxylate 255 
 
The tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-phenyl-1-
propenyl)benzyl]carbamate 251 (0.459 mmol, 0.208g) was 
dissolved in pre-distilled toluene (20cm3) and this solution was 
degassed using N2 for 10 min. To this solution was added Grubbs 
II catalyst 11 (0.08eq, 0.0368mmol, 0.0313g) and the reaction 
mixture was heated to 80oC for 22 h. After this time the reaction 
mixture was allowed to cool to rt and the solvent was removed in 
vacuo to yield a dark brown oil. This was then purified by column chromatography (5-10% 
EtOAc-Hexane) to obtain a pale yellow-brown oil (0.062g). We could not use NMR 
spectroscopy to determine if product formation had occurred due to the peak broadening 
because of the amide rotamers. HRMS found a peak at 410.38540, which may have been the 
M+1H peak, but this is inconclusive evidence for product formation. 
 
2.53 Attempted synthesis of 6-isopropoxy-7-methoxy-5-phenyl-2-[(phenylsulfonyl)-methyl]-
2,3-dihydro-1H-2-benzazepine 256 
  
The N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-pro-
penyl)benzyl]phenylmethanesul-fonamide 252 (0.185mmol, 
0.0934g) was dissolved in pre-distilled toluene (10cm3) and 
the solution was degassed using N2 for 10 min. Then the 
Grubbs II catalyst 11 (0.05eq, 0.00924mmol, 0.0083g) was 
added and the reaction mixture was allowed to stir at 60oC 
under an Ar atmosphere for 23 h. After this time the reaction 
mixture was cooled to rt and the solvent was removed in vacuo to yield a dark brown-black 
oil. The crude mixture was then purified by column chromatography (5-20% EtOAc-Hexane) 
to yield pale yellow semi-solid (0.0114g). The NMR spectra were very complex and could not 
be used for identification purposes. HRMS found the molecular ion at 463.18040 as required, 
however, this is not sufficient evidence for product formation. 
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MS m/z 463 (M+, 1%), 41 (10), 43 (12), 91 (100), 100 (21), 137 (12), 163 (12), 175 (26), 176 
(14), 189 (13), 204 (38), 220 (10), 246 (10), 252 (15), 268 (13), 310 (15), 401 (41), 402 (10), 
HRMS calculated for C27H29NO4S: 463.18173, found: 463.18040. 
 
2.54 Attempted synthesis of 6-isopropoxy-7-methoxy-2-[(4-methylphenyl)sulfonyl]-5-phen-
yl-2,3-dihydro-1H-2-benzazepine 257 
 
N-Allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)ben-
zyl]-4-methyl-benzenesulfonamide 253 (0.304mmol, 0.154g) was 
dissolved up in pre-distilled toluene (15cm3) and the solution was 
degassed using N2 for 10 min. Then Grubbs II catalyst 11 (0.08eq, 
0.0243mmol, 0.0219g) was added and the solution was heated to 
80oC for 22 h. After this time the reaction mixture was allowed to 
cool to rt and the solvent was removed in vacuo to yield a brown-
black oil. This was then purified by column chromatography (5-
20% EtOAc-Hexane). HRMS found peaks in the region for the six-membered ring (449.1661) 
and for the seven-membered ring (463.18137), but the NMR spectra were uninterperable.  
 
2.55 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-N-(1-pro-
penyl)acetamide 258 
 
The N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-
benzyl]acetamide 250 (0.265mmol, 0.104g) was dissolved in 
toluene (10cm3). The solution was then heated to 90oC before the 
addition of the Ru-isomerisation catalyst 12 (0.02eq, 
0.00530mmol, 0.0053g). The reaction mixture was then stirred at 
90oC under an Ar atmosphere for 21 h. The isomerisation was 
confirmed by 1H NMR spectroscopy, the reaction mixture was cooled to rt and the solvent 
was removed in vacuo. The crude mixture was then purified by column chromatography (5-
10% EtOAc-Hexane) to yield the desired product as a yellow oil (0.0852g, 82%). 
 
Rf = 0.48 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (alkane), 772 (5 adj Ar H), 
1216 (C-O), 1379 and 1410 (alkanes), 1645 (tertiary amide or isolated C=C), 3019 (Ar H);  
δH (300 MHz, CDCl3) 1.03-1.17 [6H, m, OCH(CH3)2], 1.51 and 1.59 (3H, two d, J=6.6Hz, 
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C=CHCH3), 1.70 (3H, d, J=7.0Hz, CH3), 1.91 and 2.22 (3H, two s, COCH3), 3.82 and 3.85 
(3H, two s, OCH3), 4.13-4.91 [3H, m, ArCH2N and OCH(CH3)2], 4.69 (1H, qd, J=6.6 and 
13.4Hz, CH=CHCH3), 6.40-6.50 (1H, m, C=CHCH3), 6.70 (1H, dd, J=5.7 and 8.4Hz, 5-H), 
6.85 (1H, t, J=8.6Hz, 6-H), 7.17-7.29 (6H, m, NCH=CH, 8-H, 9-H and 10-H);  δC (50 MHz, 
CDCl3)  15.3 and 15.4 (C=CHCH3), 16.0 and 16.1 (CH3), 21.9 and 22.2 (COCH3), 22.5 and 
22.7 [OCH(CH3)2], 44.7 and 47.8 (ArCH2N), 55.5 (OCH3), 74.8 and 75.0 [OCH(CH3)2], 
109.0 (NCH=CHCH3), 111.1 (6-C), 119.7 and 120.6 (5-C), 125.4 (ArC=CHCH3), 125.5 and 
125.6 (8-C), 125.9 and 126.0 (NCH=CH), 126.7 and 126.8 (10-C), 127.9 and 128.3 (9-C), 
132.0 and 132.6 (2-Ca), 135.8 and 136.3 (1-Ca), 140.2 and 140.7 (7-C), 144.9 and 145.3 (3-C), 
152.0 and 152.4 (4-C), 169.1 and 169.5 (C=O);  MS m/z 393 (M+, 60%), 91 (16), 115 (12), 
129 (15), 165 (22), 176 (13), 179 (19), 192 (11), 194 (10), 220 (10), 221 (18), 252 (38), 253 
(100), 337 (20), 393 (60), 394 (17), HRMS calculated for C25H31NO3: 393.23039, found: 
393.23162. 
 
2.56 Preparation of tert-butyl 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzyl(1-
propenyl)carbamate 259 
 
The tert-butyl allyl[3-isopropoxy-4-methoxy-2-(1-phenyl-1-
propenyl)benzyl]carbamate 251 (0.338mmol, 0.152g) was 
dissolved in toluene (15cm3) and the solution was heated to 90oC. 
Then the Ru-isomerisation catalyst 12 (0.02eq, 0.00675mmol, 
0.0065g) was added and the reaction mixture was stirred at 90oC 
under an Ar atmosphere for 17.5 h. After this time a small amount 
was removed for 1H NMR spectroscopy, which showed complete 
isomerisation of the double bond. Thus the reaction mixture was allowed to cool to rt and the 
solvent was removed in vacuo. The crude mixture was purified by column chromatography 
(5% EtOAc-Hexane) to yield the desired compound as a dark pink-purple oil (0.147g, 96%). 
 
Rf = 0.80 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  669 (5adj Ar H), 876 (2 adj Ar H), 
1218 (C-O), 1423 (alkane), 1479 and 1520 (Ar ring), 1682 (tertiary amide), 2978 (-CH3), 
3020 (Ar H);  δH (300 MHz, CDCl3) 1.00-1.13 [6H, m, OCH(CH3)2], 1.23-1.60 [12H, m, 
OC(CH3)3 and CH=CHCH3], 1.69 (3H, d, J=6.0Hz, C=CHCH3), 3.83 (3H, s, OCH3), 3.97-
4.50 [4H, m, ArCH2N, OCH(CH3)2 and NCH=CH], 6.40-6.44 (1H, m, C=CHCH3), 6.67-6.71 
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(1H, m, 5-H), 6.84-6.98 (1H, m, 6-H), 7.09-7.26 (6H, m, NCH=C, 8-H, 9-H and 10-H);  δC 
(50 MHz, CDCl3)  16.0 (CH=CHCH3), 16.1 (C=CHCH3), 22.5 and 22.7 [OCH(CH3)2], 28.2 
and 28.3 [OC(CH3)3], 46.2 (ArCH2N), 55.4 and 55.5 (OCH3), 74.8 [OCH(CH3)2], 80.7 
[OC(CH3)3], 104.1 (NCH=CH), 110.8 and 111.0 (5-C), 119.4 (6-Ca), 120.1 (2-Ca), 124.9 
(C=CHCH3), 125.9 (8-Cb), 126.7 (1-Cb), 127.8 (10-Cc), 128.3 (9-Cc), 129.3 (C=CHCH3), 
136.2 (NCH=CH), 140.7 (7-C), 144.9 (3-C), 151.9 (4-C), 153.6 (C=O);  MS m/z 451 (M+, 
3%), 57 (64), 70 (8), 91 (9), 115 (5), 130 (8), 165 (9), 175 (6), 178 (7), 221 (9), 237 (8), 252 
(47), 253 (100), 254 (19), 280 (7), 292 (9), 295 (37), 297 (38), 308 (5), 322 (7), 339 (70), 340 
(15), 350 (9), 395 (39), 396 (10), HRMS calculated for C28H37NO4: 451.27226, found: 
451.27373. 
 
2.57 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-(phenyl)-
N-(1-propenyl)methanesulfonamide 260 
 
The N-allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propen-
yl)benzyl]phenylmethanesulfonamide 252 (0.277mmol, 0.141g) 
was dissolved up in toluene (14cm3) and the solution was heated 
to 90oC before the addition of the Ru-isomerisation catalyst 12 
(0.02eq, 0.00554mmol, 0.0052g). Then the reaction mixture was 
left to stir at 90oC under an Ar atmosphere for 27 h, after which 
time 1H NMR spectroscopy showed total isomerisation of the 
double bond. The reaction mixture was thus allowed to cool to rt and the solvent was removed 
in vacuo. Then the crude compound was purified by column chromatography (5-10% EtOAc-
Hexane) to yield the desired product as a bright yellow semi-solid (0.127g, 90%). 
 
Rf = 0.76 (30% EtOAc-Hexane);  m.p. 92-95oC;  νmax/cm-1 (NaCl plate) 744 (5 adj Ar H), 
1154 and 1354 (-SO2-N-), 1382 (alkane), 1479 (-CH3 or –CH2 deformations), 2979 (-CH3 or –
CH2);  δH (300 MHz, CDCl3) 1.00 and 1.07 [6H, two d, J=6.1Hz, OCH(CH3)2], 1.25-1.27 
(3H, m, C=CHCH3), 1.44 and 1.51 (3H, two d, J=6.6 and 6.9Hz respectively, CH=CHCH3), 
3.70 (3H, s, OCH3), 3.77-3.83 (2H, m, ArCH2N), 4.08-4.22 [3H, m, OCH(CH3)2 and 
ArCH2SO2], 4.39 (1H, dt, J=6.7 and 13.3Hz, NCH=CH), 6.28-6.33 (2H, m, NCH=CH and 
C=CHCH3), 6.85 (1H, d, J=8.6Hz, 5-H), 7.06 (1H, d, J=8.6Hz, 6-H), 7.14-7.28 (10H, 8-H, 9-
H, 10-H, 13-H, 14-H and 15-H);  δC (50 MHz, CDCl3)  15.0 (C=CHCH3), 15.9 
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(CH=CHCH3), 22.4 and 22.7 [OCH(CH3)2], 48.1 (ArCH2N), 55.5 (OCH3), 58.3 (ArCH2SO2), 
74.8 [OCH(CH3)2], 107.0 (NCH=CH), 111.2 (5-C), 121.3 (6-C), 125.4 (NCH=CHa), 125.8 (8-
C), 126.2 (C=CHCH3a), 126.7 (15-Cb), 128.3 (9-Cc), 128.6 (14-Cc), 128.7 (10-Cb), 130.7 (13-
C), 131.9 (12-C), 135.8 (C=CHCH3), 140.4 (7-C), 144.5 (3-C), 152.2 (4-C);  MS m/z 505 
(M+, 2%), 41 (8), 43 (7), 91 (83), 92 (7), 129 (7), 165 (9), 175 (7), 221 (10), 237 (8), 251 (19), 
252 (38), 253 (100), 254 (19), 268 (23), 292 (12), 294 (16), 295 (27), 296 (8), 308 (15), 310 
(26), 350 (69), 351 (17), 449 (41), 450 (12), HRMS calculated for C30H35NO4S: 505.22868, 
found: 505.22717. 
 
2.58 Preparation of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-methyl-
N-(1-propenyl)benzenesulfonamide 261 
 
N-Allyl-N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-pro-penyl)ben-
zyl]-4-methyl-benzenesulfonamide 253 (0.398mmol, 0.201g) was 
dissolved in toluene (20cm3) and the solution was heated to 90oC 
before the addition of the Ru-isomerisation catalyst 12 (0.02eq, 
0.00796mmol, 0.0085g). The reaction mixture was stirred at 90oC 
under an Ar atmosphere for 26 h. After this time 1H NMR 
spectroscopy showed only starting material was present, additional 
Ru-isomerisation catalyst (0.02eq, 0.00796mmol, 0.0079g) was 
added and the reaction mixture was stirred at 90oC for a further 18 
h. Following this 1H NMR spectroscopy still highlighted the presence of some unreacted 
starting material, thus the reaction mixture was heated to 100oC and Ru-isomerisation catalyst 
(0.02eq, 0.00796mmol, 0.0085g) was added. The reaction mixture was stirred at 100oC for a 
further 21 h. After this time 1H NMR spectroscopy showed complete isomerisation of the 
double bond, so the reaction mixture was allowed to cool to rt and the solvent was removed in 
vacuo to yield a brown oil. The oil was then purified by column chromatography (5% EtOAc-
Hexane) and the desired compound was obtained as a orange-pink solid (0.165g, 82%). 
 
Rf = 0.72 (30% EtOAc-Hexane);  m.p. 124-127oC;  νmax/cm-1 (NaCl plate)  743 (5 adj Ar H), 
1165 and 1382 (-SO2-N-), 1479 (-CH2 or –CH3 deformations), 2980 (-CH2 or –CH3);  δH (300 
MHz, CDCl3) 1.04 and 1.12 [6H, two d, J=6.1Hz, OCH(CH3)2], 1.49 (3H, d, J=6.5Hz, 
C=CHCH3), 1.65 (3H, d, J=6.9Hz, CH=CHCH3), 2.39 (3H, s, TsCH3), 3.84 (3H, s, OCH3), 
4.03 (2H, s, ArCH2N), 4.25 [1H, sept, J=6.0Hz, OCH(CH3)2], 4.45 (1H, dt, J=6.5 and 13.3Hz, 
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CH=CHCH3), 6.38 (1H, q, J=6.9Hz, C=CHCH3), 6.52 (1H, d, J=14.0Hz, NCH=CH), 6.88 
(1H, d, J=8.6Hz, 5-H), 7.13-7.26 (8H, m, 6-H, 8-H, 9-H, 10-H and 13-H), 7.46 (2H, d, 
J=8.1Hz, 12-H);  δC (50 MHz, CDCl3)  15.1 (C=CHCH3), 16.0 (CH=CHCH3), 21.5 (TsCH3), 
22.4 and 22.7 [OCH(CH3)2], 47.3 (ArCH2N), 55.5 (OCH3), 74.9 [OCH(CH3)2], 107.9 
(CH=CHCH3), 111.1 (5-C), 121.5 (6-C), 124.7 (C=CHCH3), 125.6 and 125.7 (NCH=CH), 
125.8 (8-C), 126.7 (2-Ca), 126.8 and 126.9 (12-C), 127.1 (1-Ca), 128.3 and 128.4 (9-C), 129.4 
and 129.6 (13-C), 131.9 (C=CHCH3), 135.9 and 136.6 (11-C), 140.6 and 140.8 (7-C), 143.1 
and 143.3 (14-C), 144.7 and 144.8 (3-C), 152.2 and 153.1 (4-C);  MS m/z 505 (M+, 1%), 58 
(8), 91 (31), 129 (10), 165 (10), 175 (9), 178 (8), 221 (12), 237 (8), 251 (20), 252 (33), 253 
(100), 254 (19), 293 (10), 294 (14), 295 (24), 309 (10), 350 (71), 351 (19), 449 (44), 450 (12), 
HRMS calculated for C30H35NO4S: 505.22868, found: 505.22739. 
 
2.59 Attempted synthesis of 2-acetyl-5-isopropoxy-6-methoxy-4-phenyl-1,2-dihydroisoqui-
noline 262 
 
A solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-
1-propenyl)benzyl]-N-(1-propenyl])acetamide 258 (0.101mmol, 
0.0398g) in distilled toluene (5cm3). The solution was then heated to 
80oC before the addition of Grubbs II catalyst 11 (0.08eq, 
0.00809mmol, 0.0069g). The reaction mixture was then allowed to 
stir at 80oC under an Ar atmosphere for 18 h. After this time the 
solvent was removed in vacuo and the crude reaction mixture was purified by column 
chromatography (5% EtOAc-Hexane). The reaction yielded no product (trace amounts were 
detected by HRMS, peak found at 337.16737) and starting material was recovered (0.0274g, 
69% recovery). 
 
2.60 Attempted synthesis of tert-butyl 5-isopropoxy-6-methoxy-4-phenyl-2(1H)-isoquinoli-
ne carboxylate 263  
 
A solution was prepared of tert-butyl 3-isopropoxy-4-methoxy-
2-(1-phenyl-1-propenyl)benzyl(1-propenyl)-carbamate 259 
(0.258mmol, 0.116g) in distilled toluene (10cm3) and it was 
heated to 80oC. Then Grubbs II catalyst 11 (0.08eq, 
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0.0206mmol, 0.0180g) was added and the reaction mixture was stirred at 80oC under an Ar 
atmosphere for 19.5 h. After this time the solvent was removed in vacuo to yield a dark brown 
oil that was purified by column chromatography (5% EtOAc-Hexane). None of the desired 
product was isolated (trace amounts detected by HRMS, peak found at 395.20854), only 
starting material was recovered (0.116g, 100% recovery). 
 
2.61 Attempted synthesis of 2-(benzylsulfonyl)-5-isopropoxy-6-methoxy-4-phenyl-1,2-dihy-
droisoquinoline 264 
 
The N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-
benzyl](phenyl)-N-(1-propenyl)methanesulfonamide 260 
(0.136mmol, 0.0689g) was dissolved in distilled toluene 
(7cm3) and the solution was heated to 80oC. Then Grubbs II 
catalyst 11 (0.08eq, 0.0109mmol, 0.0105g) was added and 
the reaction mixture was stirred at 80oC under an Ar 
atmosphere for 23 h. After this time thin layer chromatography indicated no change so the 
solvent was removed in vacuo and the crude mixture was purified by column chromatography 
(5% EtOAc-Hexane). No ring-closed product was isolated (trace amounts determined by 
HRMS, peak found at 449.16631), only starting material was recovered (0.0544g, 79% 
recovered). 
 
2.62 Attempted synthesis of 5-isopropoxy-6-methoxy-2-[(4-methylphenyl)sulfonyl]-4-phen-
yl-1,2-dihydroisoquinoline 265 
 
Attempt 1: 
N-[3-Isopropoxy-4-methoxy-2-(1-phenyl-1-pro-penyl)ben-
zyl]-4-methyl-N-(1-propenyl)benzene-sulfonamide 261 
(0.209mmol, 0.106g) was dissolved up in distilled toluene 
(10cm3). The solution was heated to 80oC before the 
addition of the Grubbs II catalyst 11 (0.08eq, 0.0167mmol, 
0.0142g). Then the reaction mixture was allowed to stir at 
80oC under an Ar atmosphere for 24 h. After this time thin layer chromatography showed no 
further change so the solvent was removed in vacuo to yield a dark brown oil that was 
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purified by column chromatography (5% EtOAc-Hexane). None of the desired product was 
isolated but starting material was recovered (0.0813g, 39% recovered). 
 
Attempt 2: 
A solution was prepared of N-[3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]-4-
methyl-N-(1-propenyl)benzenesulfonamide 261 (0.0613mmol, 0.0310g) in distilled toluene 
(2cm3) and it was heated to 80oC. Then Grubbs II catalyst 11 (0.1eq, 0.00490mmol, 0.0054g) 
was added and the reaction mixture was allowed to stir at 80oC under an Ar atmosphere for 17 
h. After this time thin layer chromatography showed no further change so the solvent was 
removed in vacuo. The crude reaction mixture was purified by column chromatography (5-
10% EtOAc-Hexane) to yield the de-allylated product, N-[3-isopropoxy-4-methoxy-2-(1-
phenyl-1-propenyl)benzyl]-4-methylbenzenesulfonamide 266, as a white semi-solid (0.0092g, 
32%). 
Rf = 0.45 (30% EtOAc-Hexane);  m.p. 125-128oC;  νmax/cm-
1 (NaCl plate)  690 (5 adj Ar H), 837 ( 2 adj Ar H), 1158 (-
SO2-N-), 1400 (-SO2-N-), 1462 (CH2 or CH3 deformations), 
1562 (NH), 1605 (Ar ring), 2992 (CH2 or CH3 stretch), 3064 
(Ar H);  δH (300 MHz, CDCl3) 1.00 and 1.09 [6H, two d, 
J=6.1Hz, OCH(CH3)2], 1.55 (3H, d, J=6.9Hz, CH3), 2.41 
(3H, s, TsCH3), 3.70-3.85 (5H, m, OCH3 and ArCH2N), 
4.11-4.15 (1H, broad m, NH), 4.23 [1H, sept, J=6.1Hz, OCH(CH3)2], 6.24 (1H, q, J=6.9Hz, 
C=CHCH3), 6.84 (1H, d, J=8.4Hz, 5-H), 7.05-7.08 (3H, m, 6-H and 9-H), 7.18-7.21 (5H, m, 
8-H, 10-H and 13-H), 7.51 (2H, d, J=8.1Hz, 12-H);  δC (50 MHz, CDCl3)  16.1 (CH3), 21.5 
(TsCH3), 22.4 and 22.7 [OCH(CH3)2], 45.0 (ArCH2N), 55.6 (OCH3), 74.9 [OCH(CH3)2], 
111.1 (5-C), 124.7 (6-C), 125.7 (8-C), 125.9 (2-Ca), 126.9 (1-Ca), 127.1 (12-C), 127.6 (10-C), 
128.4 (9-C), 129.4 (13-C), 133.4 (C=CHCH3), 136.0 (C=CHCH3), 136.7 (11-C), 140.9 (7-C), 
143.1 (14-C), 144.9 (3-C), 153.1 (4-C);  MS m/z 465 (M+, 4%) 43 (6), 91 (16), 115 (5), 152 
(5), 165 (10), 178 (7), 191 (6), 219 (7), 220 (6), 221 (7), 224 (9), 237 (14), 236 (6), 237 (7), 
239 (10), 251 (27), 252 (60), 253 (35), 254 (6), 266 (6), 268 (62), 269 (12), 294 (5), 295 (6), 
310 (100), 311 (22), 337 (5), 393 (15), 394 (5), 465 (4), HRMS calculated for C27H31NO4S: 
465.19738, found: 465.19540. 
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2.63 Preparation of 5-hydroxy-4-methoxy-2-[(1E)-3-phenyl-2-propenyl]-benzaldehyde 267 
 
The Cope rearrangement was effected by placing the 4-
methoxy-3-{[(2E)-3-phenyl-2-propenyl]oxy}benzaldehyde 246 
(0.939mmol, 0.249g) neat in the sealed tube for the microwave 
reactor. The program was set up with the power output at 50W, 
the temperature at 200oC, the maximum allowable pressure at 
150psi with no cooling and continuous stirring. The run time was set to 5 min with a hold 
time of 5 min. This yielded the desired compound as a dark brown oil that was 
spectroscopically pure and no further purification was required (0.249g, 100%).  
 
Rf = 0.61 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 699 (5 adj Ar H), 844 (2 adj Ar H), 
1267 (-OH), 1508 (Ar ring), 1595 (Ar ring), 2565 (CHO), 2983 (CH2 or CH3 stretch), 3064 
(Ar H);  δH (300 MHz, CDCl3) 1.57 (1H, s, OH), 3.91-3.92 (2H, m, CH2), 3.96 (3H, s, 
OCH3), 6.32-6.37 (2H, m, CH=CHPh and CH=CHPh), 6.77 (1H, s, 3-H), 7.19-7.45 (5H, m, 
Ph H), 7.43 (1H, s, 6-H), 10.15 (1H, s, CHO);  δC (50 MHz, CDCl3) 35.0 (CH2), 55.9 
(OCH3), 113.3 (3-C), 115.5 (6-C), 125.7 (8-C0, 125.8 (1-Ca), 125.9 (10-Ca), 128.1 (9-C), 
128.7 (CH=CHPhb), 131.2 (CH=CHPhb), 136.9 (2-C), 137.4 (7-C), 145.9 (5-C), 155.0 (4-C), 
189.9 (C=O). 
 
2.64 Preparation of 5-isopropoxy-4-methoxy-2-[(1E)-3-phenyl-2-propenyl]-benzaldehyde 
268 
 
The 4-methoxy-3-{[(2E)-3-phenyl-2-propenyl]-
oxy}benzaldehyde 246 (9.35mmol, 2.51g) was placed in 
a sealed tube for the microwave reactor in 0.250g batches 
and the Cope rearrangement was performed under solvent 
free conditions. The program was set up with the power 
output at 50W, the temperature at 200oC, the maximum allowable pressure at 150psi with no 
cooling and continuous stirring. The run time was set to 5 min with a hold time of 5 min for 
each of the 0.250g batches of aldehyde. All the Cope products were combined in a round 
bottomed flask and were dissolved in DMF (25cm3). The solution was placed under an Ar 
atmosphere and then heated to 60oC. The K2CO3 (2.5eq, 23.4mmol, 3.24g) was added and the 
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solution was stirred until a suspension formed. Then isopropyl bromide (2.5eq, 23.4mmol, 
2.20cm3) was added and the reaction mixture was allowed to stir at 60oC under an Ar 
atmosphere for 19 h. After this time the reaction mixture was cooled to rt and the inorganic 
solids were filtered off through a celite pad which was rinsed with CH2Cl2 (50cm3). The 
solvent was then removed on the rotary evaporator (75oC) and dried in vacuo. The crude 
mixture was then purified by column chromatography (5-10% EtOAc-Hexane) to obtain the 
desired product as a dark yellow oil (2.20g, 76%).  
 
Rf = 0.63 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 669 (alkane), 772 (5 adj Ar H), 878 
(isolated Ar H), 929 (trans RCH=CHR), 1216 (C-O), 1423 (alkane), 1510 and 1594 (Ar ring), 
1679 (aryl conj C=C), 2978 (-CH2 or –CH3), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.39 [6H, 
d, J=6.1Hz, OCH(CH3)2], 3.90-3.92 (5H, m, CH2 and OCH3), 4.62 [1H, sept, J=6.1Hz, 
OCH(CH3)2], 6.38-6.39 (2H, m, CH=CHPh and CH=CHPh), 6.77 (1H, s, 3-H), 7.16-7.32 
(5H, m, 8-H, 9-H and 10-H), 7.42 (1H, s, 6-H), 10.20 (1H, s, CHO);  δC (50 MHz, CDCl3) 
21.9 [OCH(CH3)2], 35.0 (CH2), 56.1 (OCH3), 71.5 [OCH(CH3)2], 113.5 (3-C), 115.6 (6-C), 
126.1 (8-C), 126.8 (1-Ca), 127.3 (10-Ca), 128.5 (9-C), 128.8 (CH=CHPhb), 131.4 
(CH=CHPhb), 137.1 (2-C), 137.6 (7-C), 146.1 (5-C), 155.2 (4-C), 190.1 (CHO);  MS m/z 310 
(M+, 46%), 91 (23), 136 (33), 151 (12), 152 (16), 163 (82), 164 (12), 177 (100), 178 (15), 219 
(54), 239 (18), 268 (50), 310 (46), 311 (10), HRMS calculated for C20H22O3: 310.15689, 
found: 310.15830. 
 
2.65 Preparation of N-((E)-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]phen-
yl}methylidene)-2-propen-1-amine 269 
 
The 5-isopropoxy-4-methoxy-2-[(1E)-3-phenyl-2-propen-
yl]-benzaldehyde 268 (6.41mmol, 1.99g) was transferred to 
the reaction flask using the minimum amount of Et2O and 
the solvent was removed under high vacuum. To the 
aldehyde was then added allyl amine (1.4eq, 8.97mmol, 0.700cm3) and the reaction mixture 
was stirred at rt under an Ar atmosphere for 21.5 h. After this time the excess allyl amine was 
removed under high vacuum and imine formation was confirmed by 1H NMR spectroscopy. 
The product was obtained as a yellow oil and no further purification was required (2.24g, 
100%). 
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Rf = 0.63 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 669 (alkane), 772 (5 adj Ar H), 927 
(isolated Ar H), 967 (C=C trans), 1216 (C-O), 1508 and 1598 (alkane), 1645 (C=N-), 1677 
(aryl conj C=C), 2980 (-CH2 or –CH3), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.37 [6H, 
J=5.9Hz, OCH(CH3)2], 3.71 (2H, J=2.4Hz, ArCH2C), 3.86 (3H, s, OCH3), 4.22 (2H, d, 
J=5.4Hz, NCH2C), 4.65 [1H, sept, J=5.9Hz, OCH(CH3)2], 5.06-5.22 (2H, m, CH=CH2), 5.98-
6.10 (1H, m, CH=CH2), 6.31-6.32 (2H, m, CH=CHPh and CH=CHPh), 6.70 (1H, s, 3-H), 
7.17-7.33 (5H, m, 8-H, 9-H and 10-H), 7.59 (1H, s, 6-H), 8.52 (1H, s, N=CH);  δC (50 MHz, 
CDCl3) 22.0 [OCH(CH3)2], 35.4 (ArCH2C), 55.9 (OCH3), 63.7 (NCH2C), 71.3 [OCH(CH3)2], 
113.2 (3-C), 113.6 (6-C), 115.7 (CH=CH2), 126.1 (8-C), 126.7 (1-C), 127.1 (10-C), 128.6 (9-
C), 129.3 (CH=CHPh), 130.9 (CH=CHPh), 133.1 (2-C), 136.3 (CH=CH2), 137.3 (7-C), 146.1 
(5-C), 152.3 (4-C), 159.5 (N=CH);  MS m/z 349 (M+, 18%), 41 (28), 43 (22), 91 (46), 115 
(17), 136 (35), 151 (21), 152 (23), 164 (85), 165 (20), 177 (100), 178 (20), 190 (15), 216 (31), 
219 (45), 231 (18), 239 (16), 251 (20), 252 (17), 258 (50), 268 (44), 310 (37), 348 (25), 349 
(18), HRMS calculated for C23H27NO2: 349.20418, found: 349.20344. 
 
2.66 Preparation of N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]-benzyl}-2-
propen-1-amine 270 
 
The N-((E)-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-
propenyl]phenyl}methylidene)-2-propen-1-amine 269 (6.26 
mmol, 2.19g) was dissolved in MeOH (200cm3) and cooled 
to 0oC in an ice-water bath. Then sodium borohydride 
(1.2eq, 7.52mmol, 0.294g) was added and the reaction mixture was allowed to stir at 0oC-rt 
under an Ar atmosphere for 4.5 h. After this time thin layer chromatography showed no 
further change so distilled water (200cm3) was added to the reaction mixture. The pH was 
then neutralised using 1M HCl and saturated NaHCO3 solutions. The solvent was removed in 
vacuo before the aqueous layer was extracted with CH2Cl2 (4×100cm3). The combined 
organics were then extracted with distilled water (200cm3) and dried over anhydrous MgSO4. 
The solvent was then removed in vacuo to give the desired product as a dark yellow oil 
(1.66g, 75%). 
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Rf = 0.43 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 669 (alkane), 772 (5 adj Ar H), 929 
(isolated Ar H), 1216 (C-O), 1513 (Ar ring), 2978 (-CH2 or –CH3), 3019 (Ar H), 3618 (-NH);  
δH (300 MHz, CDCl3) 1.36 [6H, d, J=6.0Hz, OCH(CH3)2], 1.58 (1H, br s, NH), 3.25-3.28 
(2H, m, NCH2C), 3.55 (2H, s, ArCH2C), 3.73 (2H, s, ArCH2N), 3.82 (3H, s, OCH3), 4.53 
[1H, sept, J=6.0Hz, OCH(CH3)2], 5.07-5.20 (2H, m, CH=CH2), 5.85-5.98 (1H, m, CH=CH2), 
6.32-6.35 (2H, m, CH=CHPh and CH=CHPh), 6.74 (1H, s, 3-C), 6.93 (1H, s, 6-C), 7.18-7.34 
(5H, m, 8-H, 9-H and 10-H);  δC (50 MHz, CDCl3)  22.0 [OCH(CH3)2], 35.8 (ArCH2C), 50.2 
(ArCH2N), 51.9 (NCH2C), 56.1 (OCH3), 71.6 [OCH(CH3)2], 114.0 (3-C), 115.9 (CH=CH2), 
117.7 (6-C), 125.9 (2-Ca), 126.0 (8-C), 127.0 (10-C), 127.9 (1-Ca), 128.4 (9-C), 129.6 
(CH=CHPh), 130.5 (CH=CHPh), 136.8 (CH=CH2), 137.4 (7-C), 145.6 (5-C), 149.5 (4-C);  
MS m/z 351 (M+, 18%), 41 (11), 69 (8), 91 (25), 161 (24), 165 (9), 175 (8), 176 (8), 191 (7), 
204 (11), 219 (12), 220 (7), 221 (9), 237 (12), 251 (14), 252 (100), 253 (22), 261 (8), 294 
(33), 295 (8), 310 (9), 351 (18), HRMS calculated for C23H29NO2: 351.21983, found: 
351.21926. 
 
2.67 Preparation of tert-butyl allyl{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]-
benzyl}carbamate 271 
 
The N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-prop-
enyl]benzyl}-2-propen-1-amine 270 (1.47mmol, 0.517g) 
was dissolved in freshly distilled THF (50cm3). To this 
solution was added Boc2O (1.2eq, 1.76mmol, 0.400cm3) 
and it was stirred for 5 min. Then DMAP (0.1eq, 
0.147mmol, 0.0180g) was added and the reaction mixture was left to stir at rt under an Ar 
atmosphere for 3 h. After this time thin layer chromatography showed consumption of the 
starting material so the solvent was removed in vacuo to yield an orange oil. This was then 
purified by column chromatography (5-10% EtOAc-Hexane) to obtain the desired product as 
a yellow oil (0.525g, 79%). 
 
Rf = 0.74 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.35 [6H, d, J=6.1Hz, OCH(CH3)2], 
1.45 and 1.48 [9H, two s, OC(CH3)3], 3.47 (2H, d, J=3.7Hz, ArCH2Ca), 3.53-3.76 (2H, m, 
NCH2Ca), 3.93 (3H, s, OCH3), 4.43-4.49 [3H, m, ArCH2N and OCH(CH3)2], 5.02-5.10 (2H, 
m, CH=CH2), 5.71-5.73 (1H, br m, CH=CH2), 6.25-6.30 (1H, m, CH=CHPhb), 6.75 (1H, d, 
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J=10.9Hz, CH=CHPhb), 7.16-7.33 (7H, m, 3-H, 6-H, 8-H, 9-H and 10-H);  δC (50 MHz, 
CDCl3) 22.1 [OCH(CH3)2], 28.4 [OC(CH3)3], 35.6 (ArCH2C), 46.2 (ArCH2N), 48.0 
(NCH2C), 56.1 (OCH3), 71.6 [OCH(CH3)2], 79.7 [OC(CH3)3], 109.9 (3-C), 114.0 (CH=CH2), 
116.4 (6-C), 126.0 (8-C), 127.0 (10-C), 127.8 (2-Cc), 128.3 (1-Cc), 128.4 (9-C), 128.6 
(CH=CHPhd), 130.6 (CH=CHPhd), 133.7 (CH=CH2), 137.4 (7-C), 145.6 (5-C), 149.6 (4-C), 
155.5 (C=O);  MS m/z 451 (M+, 22%), 57 (37), 70 (25), 91 (37), 161 (26), 162 (9), 170 (9), 
237 (8), 239 (57), 240 (12), 251 (24), 252 (100), 253 (26), 281 (83), 282 (20), 293 (9), 294 
(42), 295 (17),  395 (14), 451 (22), HRMS calculated for C28H37NO4: 451.27226, found: 
451.27205. 
 
2.68 Preparation of N-allyl-N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]ben-
zyl}-4-methylbenzenesulfonamide 272 
 
N-{5-Isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-propenyl]-
benzyl}-2-propen-1-amine 270 (1.43mmol, 0.503g) was 
dissolved in CH2Cl2 (25cm3) and the solution was cooled to 
0oC in an ice-water bath. NEt3 (1.4eq, 2.00mmol, 
0.300cm3) was then added and the reaction mixture was 
allowed to stir for 5 min before the addition of the tosyl 
chloride (1.2eq, 1.72mmol, 0.331g). The reaction mixture 
was then stirred at 0oC-rt for 2.5 h, before being diluted with distilled water (25cm3). The 
aqueous layer was then extracted with CH2Cl2 (25cm3), then the organic layers were 
combined and extracted with distilled water (2×25cm3) before being dried over anhydrous 
MgSO4. The solvent was removed in vacuo to yield a dark orange oil that was then purified 
by column chromatography (5-10%EtOAc-Hexane). The desired compound was obtained as a 
yellow oil that solidified on standing (0.521g, 72%). 
 
Rf = 0.60 (30% EtOAc-Hexane);  m.p. 79-82oC;  νmax/cm-1 (NaCl plate) 742 (5 adj Ar H), 
815 (2 dj Ar H), 934 (RCH=CH2), 968 (RCH=CH2), 1160 (-SO2-N-), 1275 (C=C isolated), 
1343 (-SO2-N-), 1447 (CH2 or CH3 deformations), 1513 (Ar ring), 1599 (Ar ring), 2936 (CH2 
or CH3 stretch), 3013 (ArH);  δH (300 MHz, CDCl3) 1.32 [6H, d, J=6.1Hz, OCH(CH3)2], 2.43 
(3H, s, TsCH3), 3.48 (2H, d, J=5.2Hz, ArCH2C), 3.70-3.74 (2H, m, NCH2C), 3.83 (3H, s, 
OCH3), 4.28-4.42 [3H, m, ArCH2N and OCH(CH3)2], 4.84-5.00 (2H, m, CH=CH2), 5.41-5.52 
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(1H, m, CH=CH2), 6.25-6.35 (2H, m, CH=CHPh and CH=CHPh), 6.70 (1H, s, 3-H), 6.81 
(1H, s, 6-H), 7.20-7.31 (7H, m, 8-H, 9-H, 10-H and 13-H), 7.73 (2H, d, J=8.1Hz, 12-H);  δC 
(50 MHz, CDCl3) 21.5 (TsCH3), 22.1 [OCH(CH3)2], 35.5 (ArCH2C), 47.8 (ArCH2N), 49.5 
(NCH2C), 56.0 (OCH3), 71.5 [OCH(CH3)2], 113.9 (3-C), 117.3 (CH=CH2), 118.7 (6-C), 
125.4 (2-Ca), 126.1 (8-C), 127.1 (10-C), 127.3 (12-C), 128.3 (1-Ca), 128.5 (13-C), 129.7 (13-
C), 130.8 (CH=CHPh), 131.4 (CH=CHPh), 132.6 (11-C), 137.0 (CH=CH2), 137.4 (7-C), 
143.2 (14-C), 145.6 (5-C), 149.9 (4-C). 
 
2.69 Preparation of tert-butyl 9-isopropoxy-8-methoxy-3,6-dihydro-2-benzazocine-2(1H)-
carboxylate 273 
 
The tert-butyl allyl{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-
2-propenyl]benzyl}-carbamate 271 (0.476 mmol, 0.215g) was 
dissolved in distilled toluene (20cm3) and the solution was 
heated to 60oC. Then Grubbs II catalyst 11 (0.05eq, 
0.0238mmol, 0.0237g) was added and the reaction mixture was 
stirred at 60oC under an Ar atmosphere for 22.5 h. After this time the reaction mixture was 
cooled to rt and the solvent was removed in vacuo to yield a dark brown oil. This was then 
purified by column chromatography (5% EtOAc-Hexane) to obtain the desired compound as a 
viscous yellow oil (0.121g, 73%). Peak broadening was observed in the 1H NMR spectrum 
due to the Boc protecting group and further structural determination would require the 
removal of the Boc protecting group, however, due to the time constraints on this project it 
was not possible. 
 
Rf = 0.58 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.26-1.55 [15H, m, OCH(CH3)2 and 
OC(CH3)3], 3.36 (2H, d, J=7.8Hz, ArCH2C), 3.83-3.85 (4H, m, OCH3 and one of NCH2CHa), 
4.05 (1H, d, J=4.9Hz, one of NCH2CHa), 4.44-4.53 [3H, m, ArCH2N and OCH(CH3)2], 5.65-
5.91 (1H, m, 4-H), 6.64-6.83 (1H, m, 5-H), 7.26-7.30 (2H, m, 7-H and 10-H);  δC (50 MHz, 
CDCl3) 22.1 and 22.2 [OCH(CH3)2], 28.4 [OC(CH3)3], 32.6 and 33.0 (ArCH2C), 45.0 and 
45.3 (NCH2CH), 51.6 (ArCH2N), 56.0 (OCH3), 71.4 and 71.9 [OCH(CH3)2], 79.6 
[OC(CH3)3], 113.9 and 114.3 (7-C), 118.3 and 118.5 (10-C), 126.0 and 126.3 (6a-C), 127.5 
and 127.9 (5-C), 128.4 and 128.5 (10a-C), 129.1 and 130.6 (4-C), 131.2 and 131.5 (9-C), 
145.0 (8-C), 149.5 (C=O);  MS m/z 347 (M+, 100%), 57 (91), 77 (10), 115 (13), 137 (41), 143 
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(15), 161 (12), 162 (10), 174 (10), 175 (95), 176 (34), 179 (33), 187 (25), 188 (51), 189 (16), 
204 (28), 205 (10), 246 (18), 248 (21), 249 (28), 290 (71), 291 (52), 347 (100), 348 (23), 
HRMS calculated for C20H29NO4: 347.20966, found: 347.20925. 
 
2.70 Preparation of 9-isopropoxy-8-methoxy-2-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetrahy-
dro-2-benzazocine 274 
 
The N-allyl-N-{5-isopropoxy-4-methoxy-2-[(2E)-3-phenyl-2-
propenyl]benzyl}-4-methylbenzenesulfon-amide 272 (0.411 
mmol, 0.208g) was dissolved in distilled toluene (20cm3) and 
the solution was heated to 60oC before the addition of Grubbs 
II catalyst 11 (0.05eq, 0.0206mmol, 0.0176g). The reaction 
mixture was then stirred at 60oC under an Ar atmosphere for 20 
h. After this time the solvent was removed in vacuo and the crude mixture was purified by 
column chromatography (5-10% EtOAc-Hexane) to give the desired compound as a milky 
yellow oil (0.0649g, 39%) as well as a dimer of the starting material. 
 
Rf = 0.40 (30% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 669 (RHC=CHR, cis), 761 (5 adj Ar 
H), 850 (2 adj Ar H), 1158 (-SO2-N-), 1334 (-SO2-N-), 1517 (Ar ring), 1600 (Ar ring), 2898 
(-OCH3), 2937 (CH2 or CH3 stretch), 3020 (Ar H);  δH (300 MHz, CDCl3) 1.33 and 1.39 [6H, 
two d, J=6.1Hz, OCH(CH3)2], 2.41 (3H, s, TsCH3), 3.41 (2H, d, J=6.3Hz, ArCH2C), 3.73-
3.77 (2H, m, NCH2C), 3.83 (3H, s, OCH3), 4.22 (2H, s, ArCH2N), 4.39-4.47 [1H, m, 
OCH(CH3)2], 5.41-5.58 (1H, m, NCH2CH=CH), 5.76-5.84 (1H, m, ArCH2CH=CH), 6.61 
(1H, s, 7-H), 6.70 (1H, s, 10-H), 7.21-7.27 (2H, m, 13-H), 7.65 (2H, d, J=8.2Hz, 12-H);  δC 
(50 MHz, CDCl3) 21.5 (CH3), 22.1 [OCH(CH3)2], 34.3 (6-C), 43.3 (3-C), 50.5 (1-C), 56.0 
(OCH3), 71.6 [OCH(CH3)2], 113.9 (7-Ca), 118.1 (10-Ca), 124.0 (5-C), 127.2 (12-C), 128.9 
(6a-C), 129.5 (13-C), 131.1 (10a-C), 133.3 (4-C), 136.8 (11-C), 143.0 (14-C), 145.9 (9-C), 
150.1 (8-C). 
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3. Experimental Procedures: Indenols, Indenones and Indanones 
 
3.1 Preparation of 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol 202 
 
A solution was prepared of 3-isopropoxy-4-methoxy-2-(1-
propenyl)benzaldehyde 201 (3.22mmol, 0.755g) in freshly distilled 
THF (100cm3) and this reaction was placed in an acetone bath that was 
cooled to –60oC using the cryostat. To the cooled solution was added 
vinyl magnesium bromide (5eq7, 16.1mmol, 2.20cm3). The reaction 
mixture was then stirred at –60oC under an Ar atmosphere for 18 h. Then the reaction mixture 
was allowed to warm to rt before the addition of distilled water (50cm3). The THF was then 
removed on the rotary evaporator and the remaining aqueous layer was extracted with EtOAc 
(3×10cm3). The combined organics were then dried over anhydrous MgSO4 and the solvent 
was removed in vacuo. The crude mixture was then purified by column chromatography (5-
10% EtOAc-Hexane) to yield the desired compound as a yellow oil (0.742g, 88%). Our NMR 
spectroscopic data was found to correlate well to that reported by Coyanis.206 
 
Rf = 0.54 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.23 [6H, dd, J=1.8 and 6.2Hz, 
OCH(CH3)2], 1.90 (3H, d, J=6.5Hz, CH3), 3.81 (3H, s, OCH3), 4.32 [1H, sept, J=6.2Hz, 
OCH(CH3)2], 5.17-5.32 (2H, m, CH=CH2), 5.44 (1H, s, CH-OH), 5.94-6.12 (2H, m, CH=CH2 
and CH=CHCH3), 6.45 (1H, d, J=16.0Hz, CH=CHCH3), 6.80 (1H, d, J=8.6Hz, 5-H), 7.13 
(1H, d, J=8.6Hz, 6-H), the OH peak was not observed on the 1NMR spectrum;  δC (50 MHz, 
CDCl3) 19.0 (CH3), 22.5 [OCH(CH3)2], 55.7 (OCH3), 71.2 (CH-OH), 75.1 [OCH(CH3)2], 
110.6 (5-C), 114.3 (CH=CH2), 122.0 (6-C), 124.6 (CH=CHCH3), 129.6 (2-C), 132.2 
(CH=CHCH3), 133.1 (1-C), 140.4 (CH=CH2), 144.6 (3-C), 152.4 (4-C). 
 
3.2 Preparation of 4-isopropoxy-5-methoxy-1H-inden-1-ol 203 
The 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol 
202 (1.00mmol, 0.263g) was dissolved in pre-distilled CH2Cl2 (25cm3) 
and the solution was degassed for 15 min using N2. The Grubbs II 
catalyst 11 (0.05eq, 0.0501mmol, 0.0430g) was then added and the 
                                                 
* Our Grignard reagent stock was quite old and may have been contaminated with trace amounts of water, thus 
this value of 5 eq is not a representative amount for a good reagent. 
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reaction mixture was allowed to stir at rt under an Ar atmosphere for 3 h. After this time the 
solvent was removed in vacuo to yield a brown oil that was then purified by column 
chromatography (5-10% EtOAc-Hexane). The desired product was obtained as a dark yellow 
oil (0.191g, 87%), with similar NMR data to that reported by Coyanis.206 
 
Rf = 0.31 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.29 [6H, dd, J=5.1 and 5.8Hz, 
OCH(CH3)2], 3.84 (3H, s, OCH3), 4.37 [1H, sept, J=6.2Hz, OCH(CH3)2], 5.15 (1H, d, 
J=8.6Hz, CH-OH), 6.32 (1H, dd, J=1.8 and 5.7Hz, CHCH=CHAr), 6.71 (1H, d, J=7.9Hz, 6-
H), 6.82 (1H, d, J=5.7Hz, CHCH=CHAr), 7.16 (1H, d, J=7.9Hz, 7-H);  δC (50 MHz, CDCl3) 
22.6 [OCH(CH3)2], 56.1 (OCH3), 75.6 [OCH(CH3)2], 77.4 (CH-OH), 109.7 (6-C), 118.7 (7-
C), 129.6 (2-C), 136.7 (7a-C), 137.5 (3-C), 138.5 (3a-C), 140.6 (4-C), 153.6 (5-C). 
 
3.3 Preparation of 4-isopropoxy-5-methoxy-1H-inden-1-one 204 
 
The 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-pro-pen-1-ol 
202 (0.412mmol, 0.108g) was dissolved in pre-distilled toluene (10cm3) 
and the solution was heated to 60oC before the addition of Grubbs II 
catalyst 11 (0.05eq, 0.0206mmol, 0.0180g). The reaction mixture was 
subsequently stirred at 60oC under an Ar atmosphere for 17 h. After this 
time the solvent was removed in vacuo to yield a dark brown oil. The crude mixture was then 
purified by column chromatography (5% EtOAc-Hexane) to give the desired product as a 
bright yellow oil (0.0400g, 45%). Our NMR spectroscopic data correlated to that obtained by 
Coyanis.206 
 
Rf = 0.58 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.28 [6H, two d, J=6.2Hz, 
OCH(CH3)2], 3.87 (3H, s, OCH3), 4.39-4.48 [1H, m, OCH(CH3)2], 5.85 (1H, d, J=6.1Hz, 6-
H), 6.60 (1H, d, J=7.7Hz, 7-H), 7.08 (1H, d, J=8.3Hz, 2-H), 7.65 (1H, d, J=8.4Hz, 3-H);  δC 
(50 MHz, CDCl3)  22.9 and 23.2 [OCH(CH3)2], 56.3 (OCH3), 76.0 [OCH(CH3)2], 113.4 (6-
C), 119.7 (3a-C), 120.6 (7-C), 128.7 (7a-C), 131.7 (2-C), 143.1 (3-C), 149.1 (4-C), 158.9 (5-
C), 196.1 (C=O).. 
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3.4 Preparation of 4-isopropoxy-5-methoxy-1-indanone 205 
 
The 1-[3-isopropoxy-4-methoxy-2-(1-propenyl)phenyl]-2-propen-1-ol 202 
(0.755mmol, 0.198g) was dissolved in pre-distilled toluene (20cm3) and 
the solution was heated to 80oC. Then Grubbs II catalyst 11 (0.08eq, 
0.0604mmol, 0.0518g) was added and the reaction mixture was allowed to 
stir at 80oC under an Ar atmosphere for 22 h. After this time the solvent 
was removed in vacuo to give a brown-black oil that was then purified by column 
chromatography (5-10% EtOAc-Hexane). The desired product was obtained as a pale orange 
oil that solidified on standing (0.147g, 89%) as well as a small amount of 4-isopropoxy-5-
methoxy-1H-inden-1-one 204 (0.0276g, 17% relative to starting material). The NMR 
spectroscopic data was compared to that of Coyanis206 and found to be in excellent agreement. 
 
Rf = 0.45 (30% EtOAc-Hexane);  m.p. 52-55oC;  δH (300 MHz, CDCl3) 1.32 [6H, d, 
J=6.2Hz, OCH(CH3)2], 2.66 (2H, dd, J=5.2 and 6.7Hz, ArCH2), 3.05-3.09 (2H, m, COCH2), 
3.93 (3H, s, OCH3), 4.54 [1H, sept, J=6.1Hz, OCH(CH3)2], 6.96 (1H, d, J=8.4Hz, 6-H), 7.51 
(1H, d, J=8.3Hz, 7-H);  δC (50 MHz, CDCl3) 22.7 [OCH(CH3)2], 22.9 (ArCH2), 36.4 
(COCH2), 56.1 (OCH3), 74.7 [OCH(CH3)2], 112.2 (6-C), 119.8 (7-C), 131.1 (3a-C), 143.5 
(7a-C), 149.1 (4-C), 157.9 (5-C), 205.7 (C=O). 
 
3.5 Ruthenium Removal, NMR experiments and ICP-MS testing 
 
3.5.1 Ruthenium Removal 
 
Attempt 1:  
The indenol 203 (0.112g, with 0.0322g of Grubbs II catalyst 11 present from the RCM 
reaction) was dissolved in 10% EtOAc-Hexane (15cm3) and the solution was placed in the 
reaction vessel under a N2 atmosphere. To the solution was then added Activated Carbon, 
Darco G-60, 100 mesh (50eq relative to Grubbs II catalyst 11, 1.62g) and it was left to stir at 
rt for 4 h. After this time the solution was filtered through a celite pad and rinsed with 5% 
EtOAc-Hexane (200cm3) and then 10% EtOAc-Hexane (150cm3). The solvent was removed 
in vacuo to yield a yellow oil (0.0823g). The oil was then dissolved in distilled CH2Cl2 
(200cm3) and to the solution was added DMSO (50eq relative to Grubbs II catalyst 11, 
1.91mmol, 0.140cm3). The reaction mixture was then left to stir at rt under a N2 atmosphere 
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overnight. The solvent was then removed in vacuo to yield a yellow oil that was purified by 
column chromatography (10% EtOAc-Hexane). A bright yellow oil was then obtained off of 
the column (0.0047g). The oil obtained was analysed by 1H NMR spectroscopy and it was 
found to contain a only the pure indenone 204.  
 
As the mass obtained after columning was so low, it appeared as though a large amount of the 
indenol may have been trapped in the activated carbon, thus it was rewashed with 10-40% 
EtOAc-Hexane (4×100cm3) and CH2Cl2 (100cm3). After the solvent was removed in vacuo 
more of the yellow oil was isolated (0.0605g). Thus this oil had not been subjected to 
treatment with DMSO. The oil obtained was then analysed by 1H NMR spectroscopy and it 
was found to contain a mixture of indenol 203 and indenone 204.  
 
Attempt 2: 
The indenol 203 (0.485mmol, 0.107g) was dissolved in distilled CH2Cl2 (10cm3) and the 
solution was then degassed for 30 min using N2. Then the Ru-scavenger (0.77mmol/g, 5eq 
relative to Grubbs II catalyst 11 present in the indenol sample, 0.0162g) was added and the 
reaction mixture was left to stir for 17 h at rt under an Ar atmosphere. After this time the 
white “beads” of the Ru-scavenger had changed colour from bright white to grey-brown. The 
Ru-scavenger was then filtered off through a celite pad, which was subsequently rinsed with 
CH2Cl2 (50cm3). The solvent was then removed in vacuo to yield a bright yellow semi-solid. 
The percentage recovery of the indenol 203 was found to be 99.7%.  
 
 3.5.2 1H NMR Spectroscopy Experiments 
 
General Procedure: 
Indenol 203 was used as prepared in Section 3.2 above for the samples containing residual 
ruthenium (NMR tubes A and D). Indenol 203 was subjected to the ruthenium removal 
process outlined in Section 3.5.1 above for use in the ruthenium-depleted samples, (NMR 
tubes B, C and E). To the ruthenium depleted indenol 203 (in NMR tube C) was added a 
further 5 mol % Grubbs II catalyst 11.  
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A
B
D
E
(Ru-conc =  A  )
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A Untreated indenol - control
B Ru depleted indenol - control
C Ru depleted indenol + 5 mol  
   % Grubbs II at 60oC
D Untreated indenol at 60oC
E Ru depleted indenol at 60oC
C
Heat in d8-
toluene with 5 
mol % Grubbs II 
catalyst 11 added
 
 
Each of the samples A-E above, were dissolved in d8-toluene and the resulting solutions were 
then degassed using Ar for 2 min. The NMR tubes C, D and E were then each submerged 
approximately 3cm deep in an oil bath that had previously been heated to 60oC in Case Study 
1 (or 100oC in Case Study 2). NMR tubes A and B were kept at rt for the duration of the 
study. The NMR tubes were removed from the heat and the samples were run on the 300MHz 
NMR spectrometer in 45 min to 1 h intervals. Ratios of indenol 203 : indenone 204 : indanone 
205 reported are calculated based on their relative intensities in the 1H NMR spectra. For final 
data analysis please refer to the Results and Discussion, Chapter 5, Section 5.2, Tables 19-20 
and Graph 1. 
 
 3.5.3 ICP-MS Testing 
 
The general procedure used for our ICP analysis of the indenol 203 follows that of Georg and 
co-workers.215 Samples were accurately weighed (0.0200-0.0300mg) and then digested with 
6N nitric acid (6cm3). We employed microwave digestion, with the program set at a power 
output of 1200W, a ramp time of 15 min and a hold time of 30 min, with no cooling. The 
system was then set to hold, with cooling, for 20 min. After this time the resulting residue was 
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diluted to a total volume of 25cm3 using deionised water, and the samples were stored in the 
refrigerator until required.  
 
Our standard curve was prepared through the use of the SpecPure Multielement Standards for 
the Group 4 Elements. The stock solution was prepared as a 10ppm solution. The standard 
curve and the supporting information on the instruments may be found in Appendix C. We 
then analysed our previously prepared samples by a comparison of our data to that obtained 
for the standard curve. The results we obtained are discussed fully in the Results and 
Discussion, Chapter 5, Section 5.3. 
 
3.6 Preparation of 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-phenyl-1-propenyl]- 
phenyl}-2-propen-1-ol 275 
 
The 3-isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)-benzaldehyde 247 (1.96mmol, 0.607g) 
was dissolved in pre-distilled THF (80cm3) and the solution was cooled to –60oC in an 
acetone bath using the cryostat. Then vinyl magnesium bromide (10eq8, 19.6mmol, 2.60cm3) 
was added and the reaction mixture was allowed to stir at –60oC under an Ar atmosphere for 
22 h. After this time the reaction mixture was allowed to warm to rt and distilled water 
(50cm3) was added. The reaction mixture was neutralised using aqueous 1M HCl and the 
solvent was then removed on the rotary evaporator. The remaining 
aqueous layer was extracted with CH2Cl2 (4×50cm3). The combined 
organics were then dried over anhydrous MgSO4 and the solvent was 
removed in vacuo to yield a purple oil. This was then purified by 
column chromatography (5% EtOAc-Hexane) and the product was 
obtained as a dark red-purple oil (0.307g, 46%). NMR spectroscopic 
data correlated well to that obtained by Coyanis.206 
 
Rf = 0.56 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.00 and 1.13 [6H, two d, J=6.1Hz, 
OCH(CH3)2], 1.56-1.59 (3H, m, CH3), 3.85 (3H, s, OCH3), 4.26 [1H, sept, J=6.1Hz, 
OCH(CH3)2], 5.07-5.30 (3H, m, CH-OH and CH=CH2), 5.93 (1H, ddd, J=5.6, 10.2 and 
17.0Hz, CH=CH2), 6.45 (1H, q, J=6.9Hz, C=CHCH3), 6.96 (1H, d, J=8.6Hz, 5-H), 7.18-7.33 
(6H, m, 6-H, 8-H, 9-H and 10-H);  δC (50 MHz, CDCl3) 16.3 (CH3), 22.4 and 22.7 
                                                 
8 Our Grignard reagent stock was quite old and may have been contaminated with trace amounts of water, thus 
this value of 10 eq is not a representative amount for a good reagent. 
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[OCH(CH3)2], 55.6 (OCH3), 71.2 (CH-OH), 74.7 [OCH(CH3)2], 111.6 (5-C), 113.9 
(CH=CH2), 122.0 (6-C), 125.9 (8-C), 126.1 (C=CHCH3a), 126.8 (2-Ca), 128.1 (10-Ca), 128.4 
(9-C), 134.3 (1-Cb), 136.0 (C=CHCH3b), 140.2 (CH=CH2), 141.4 (7-C), 144.3 (3-C), 152.8 
(4-C). 
 
3.7 Preparation of 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-ol 276 
 
A solution was prepared of 1-[3-isopropoxy-4-methoxy-2-(1-
phenyl-1-propenyl)phenyl]-2-propen-1-ol 275 (0.227 mmol, 
0.0769g) in distilled CH2Cl2 (8cm3) and to this was added Grubbs II 
catalyst 11 (0.05eq, 0.0114mol, 0.0107g). Then the reaction 
mixture was stirred at rt under an Ar atmosphere for 17 h. After this 
time the solvent was removed in vacuo to yield a dark brown oil 
that was then purified by column chromatography (5% EtOAc-Hexane). The desired 
compound was obtained as a cream solid (0.0328g, 49%) as well as 4-isopropoxy-5-methoxy-
3-phenyl-1H-inden-1-one (277) (0.0150g, 24% relative to starting material). The NMR 
spectroscopic data correlated well to that obtained by Coyanis.206 
 
Rf = 0.39 (30% EtOAc-Hexane);  m.p. 56-59oC;  δH (300 MHz, CDCl3) 0.68 and 0.74 [6H, 
two d, J=6.2Hz, OCH(CH3)2], 1.62 (1H, br s, OH), 3.84 (3H, s, OCH3), 3.92-3.98 [1H, m, 
OCH(CH3)2], 5.19 (1H, d, J=1.2Hz, CH-OH), 6.25 (1H, d, J=2.1Hz, CH=CPh), 6.78 (1H, d, 
J=8.0Hz, 6-H), 7.23-7.53 (5H, m, 7-H, 8-H, 9-H and 10-H);  δC (50 MHz, CDCl3) 21.3 and 
21.4 [OCH(CH3)2], 56.0 (OCH3), 75.7 (CH-OHa), 75.8 [OCH(CH3)2a], 109.6 (6-C), 111.9 (2-
C), 118.9 (7-C), 127.4 (9-C), 127.5 (11-Cb), 128.5 (3a-Cb), 128.9 (10-C), 136.2 (7a-C), 139.9 
(8-Cc), 141.5 (3-Cc), 146.2 (4-C), 154.6 (5-C). 
 
3.8 Preparation of 4-isopropoxy-5-methoxy-3-phenyl-1H-inden-1-one 277 
 
A solution was prepared of 1-[3-isopropoxy-4-methoxy-2-(1-phenyl-
1-propenyl)phenyl]-2-propen-1-ol 275 (0.302 mmol, 0.102g) in 
distilled toluene (10cm3). The solution was heated to 80oC before the 
addition of Grubbs II catalyst 11 (0.08eq, 0.0241mmol, 0.0218g). The 
reaction mixture was allowed to stir at 80oC under an Ar atmosphere 
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for 17 h. After this time the reaction mixture was cooled to rt and the solvent was removed in 
vacuo. The dark brown oil obtained was then purified by column chromatography (5% 
EtOAc-Hexane) and the desired compound was found as a bright-orange semi-solid (0.0615g, 
69%). The NMR spectroscopic data was compared to that of Coyanis206 and found to be in 
excellent agreement. 
 
Rf = 0.31 (30% EtOAc-Hexane);  m.p. 63-68oC;  δH (300 MHz, CDCl3) 0.87 [6H, d, 
J=6.1Hz, OCH(CH3)2], 3.98 (3H, s, OCH3), 4.12-4.16 [1H, s, CH=CPh), 6.78 (1H, d, 
J=7.9Hz, 6-H), 6.95-7.59 (6H, m, 7-H and Ph-H);  δC (50 MHz, CDCl3) 21.5 [OCH(CH3)2], 
56.1 (OCH3), 76.3 [OCH(CH3)2], 110.0 (6-C), 119.4 (7-Ca), 126.6 (CH=CPha), 127.6 (9-C), 
128.3 (10-C), 129.5 (11-C), 130.0 (3a-C), 134.4 (7a-C), 140.4 (8-C), 142.2 (4-C), 159.7 (3-
C), 163.1 (5-C), 195.4 (C=O). 
 
3.9 Preparation of 3-[(2E)-2-butenyloxy]-4-methoxybenzaldehyde 279 
 
Potassium carbonate (2.5eq, 83.6mmol, 11.6g) and DMF (65cm3) were 
heated to 60oC and left to stir for 15 min under an Ar atmosphere. After 
this time the isovanillin 206 (33.4mmol, 5.09g) was added and the 
solution turned bright yellow. To this solution was then added crotyl 
bromide (2.5eq, 83.6mmol, 8.60cm3) and the mixture changed to a 
biscuit colour with the evolution of a cloudy white gas. The reaction mixture was then stirred 
at 60oC under an Ar atmosphere for 22 h. After this time the inorganic solids were filtered off 
through a celite pad and the solvent was removed on the rotary evaporator (75oC) and then 
under high vacuum. The crude mixture was then purified by column chromatography (5-20% 
EtOAc-Hexane) to yield the product as a bright yellow oil (6.83g, 99%), with similar NMR 
data to that reported by Rousseau.1 
 
Rf = 0.54 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.76 (3H, dd, J=0.9 and 6.1Hz, 
CH3), 3.96 (3H, s, OCH3), 4.58 and 4.73 (2H, two d, J=5.9 and 5.3Hz respectively, OCH2), 
5.73-5.96 (2H, m, CH=CHCH3 and CH=CHCH3), 6.98 (1H, d, J=8.2Hz, 5-H), 7.42-7.47 (1H, 
m, 6-H), 9.84 (1H, s, CHO);  δC (50 MHz, CDCl3) 17.8 (CH3), 56.1 (OCH3), 69.5 (OCH2), 
110.5 (2-C and 5-C), 125.3 (6-C), 126.6 (CH=CHCH3), 129.9 (1-C), 131.5 (CH=CHCH3), 
148.6 (3-C), 154.7 (4-C), 190.8 (CHO). 
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3.10 Preparation of 3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)benzaldehyde 280 
 
The 3-[(2E)-2-butenyloxy]-4-methoxybenzaldehyde 279 (24.3mmol, 
5.01g) was dissolved in DMF (50cm3) and the solution was heated to 
180oC under an Ar atmosphere for 44 h. After this time the reaction 
mixture was cooled to 60oC before the addition of the potassium 
carbonate (2.5eq, 60.7mmol, 8.37g) and the isopropyl bromide (2.5eq, 
60.7mmol, 5.70cm3). The reaction mixture was then allowed to stir at 60oC under an Ar 
atmosphere for a further 18 h. Then the reaction mixture was allowed to cool to rt and the 
inorganic salts were filtered off through a celite plug that was rinsed with CH2Cl2 (100cm3). A 
brown oil was then obtained by removing the solvents in vacuo (the rotary evaporator was set 
to 75oC), and this was then purified by column chromatography (5% EtOAc-Hexane). The 
desired product was obtained as a bright orange oil (4.39g, 73%), with similar NMR 
spectroscopic data to that reported by Coyanis.206 
 
Rf = 0.70 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.29 [6H, dd, J=6.2 and 17.2Hz, 
OCH(CH3)2], 1.50 (3H, d, J=7.4Hz, CH3), 3.91 (3H, s, OCH3), 4.46-4.59 [2H, m, OCH(CH3)2 
and ArCH(CH3)C], 4.99-5.03 (2H, m, CH=CH2), 6.23 (1H, ddd, J=3.8, 10.6 and 17.4Hz, 
CH=CH2), 6.88 (1H, d, J=8.6Hz, 5-H), 7.75 (1H, d, J=8.7Hz, 6-H), 10.33 (1H, s, CHO);  δC 
(50 MHz, CDCl3) 21.2 (CH3), 22.4 and 22.6 [OCH(CH3)2], 33.2 (ArCH(CH3)C), 55.7 
(OCH3), 74.9 [OCH(CH3)2], 109.8 (5-C), 113.7 (CH=CH2), 125.9 (6-C), 128.5 (1-C), 142.2 
(2-C), 143.4 (CH=CH2), 144.1 (3-C), 157.4 (4-C), 191.3 (CHO). 
 
3.11 Preparation of 3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-propenyl]-benzaldehyde 
281 
 
The 3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)ben-zaldehyde 
280 (2.02mmol, 0.502g) was dissolved up in DMF (25cm3) and then 
potassium tert-butoxide (1.1eq, 2.22mmol, 0.251g) was added. The 
solution was then heated to 60oC and allowed to stir under an Ar 
atmosphere for 1 h.  Distilled water (20cm3) was then added and the 
reaction mixture was stirred for 5 min. The pH was then neutralised using 1M aqueous HCl 
and saturated NaHCO3 solutions. The solvent was removed on the rotary evaporator and the 
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remaining aqueous layer was extracted with EtOAc (3×50cm3). The combined organics were 
then dried over anhydrous MgSO4, filtered and the solvent was removed in vacuo. The crude 
mixture was purified by column chromatography (5-10% EtOAc-Hexane) to yield the desired 
product as a orange oil (0.0377g, 8%). However, a second predominant product (orange-
brown oil) was recovered and this was found to be 5-isopropoxy-6-methoxy-4-methyl-1-
naphthol 282 (0.0601g, 12% relative to starting material). Our spectroscopic data correlated 
well to that reported by Coyanis.206 
 
Rf = 0.81 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.24 [6H, two dd, J=6.1Hz, 
OCH(CH3)2, 1.42 and 1.82 (3H, two d, J6.8Hz, CH3), 2.04 (3H, two s, CH3), 3.91 (3H, two s, 
OCH3), 4.36-4.45 [1H, m, OCH(CH3)3], 5.41 and 5.79 (1H, two q, C=CHCH3), 6.92 (1H, dd, 
J=6.5Hz and J8.4Hz, 6H), 7.72 (1H, dd, J=8.7Hz and 11.3 Hz, 5-H), 9.91 (1H, two s, CHO);  
δC (50 MHz, CDCl3) 13.7 and 18.0 (C=CHCH3), 15.3 [C(CH3)CH], 22.6 and 22.7 
[OCH(CH3)2], 55.8 (OCH3), 75.3 and 75.4 [OCH(CH3)2], 110.4 and 110.5 (5-C), 124.0 and 
124.1 (6-C), 125.5 (C=CHCH3a), 127.0 and 128.0 (1-C), 128.5 (C=CHCH3a), 130.5 and 130.8 
(C=CHCH3), 140.9 (2-Cb), 143.9 and 144.9 (3-Cb), 157.6 and 158.2 (4-C), 191.8 and 192.0 
(C=O). 
 
5-isopropoxy-6-methoxy-4-methyl-1-naphthol 282:  Rf = 0.61 (30% 
EtOAc-Hexane);  νmax/cm-1 (NaCl plate)  809 (2 adj Ar H), 1485 (Ar 
ring), 1590 (Ar ring), 1636 (Ar ring), 2843 (-OCH3), 2938 (CH2 or CH3 
stretch), 3017 (Ar H), 3255 (-OH);  δH (300 MHz, CDCl3) 1.22-1.27 
[6H, m, OCH(CH3)2], 1.60-1.77 (3H, m, CH3), 3.82-3.95 (3H, m, 
OCH3), 4.73-4.80 (1H, m, OCH(CH3)2], 5.32 (1H, broad m, OH), 6.24-6.27 (1H, m, 2-H), 
6.93-7.03 (2H, m, 3-H and 7-H), 7.87-7.99 (1H, m, 8-H);  δC (50 MHz, CDCl3) 22.4 and 22.6 
[OCH(CH3)2], 30.7 (CH3), 55.8 (OCH3), 74.3 [OCH(CH3)2], 111.6 (2-C), 123.0 (8-C), 125.8 
(7-C), 127.1 (4-C), 139.0 (8a-Ca), 142.4 (4a-Ca), 149.9 (6-Cb), 151.8 (5-Cb), 152.9 (3-C), 
155.4 (1-C);  MS m/z 246 (M+, 34%) 41 (12), 43 (13), 77 (15), 83 (11), 103 (11), 115 (18), 
131 926), 159 (15), 160 (13), 161 (12), 165 (11), 175 (21), 184 (23), 187 (15), 189 (62), 202 
(100), 203 (46), 204 (84), 205 (28), 246 (34), 262 (18), HRMS calculated for C15H18O3: 
246.12559, found: 246.12414. 
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3.12 Preparation of 1-[3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)phenyl]-2-propen-
1-ol 283 
 
The 3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)-benzaldehyde 
280 (8.06mmol, 2.00g) was dissolved in distilled THF (200cm3) and the 
solution was cooled to –60oC  in an acetone bath using a cryostat. To 
this solution was added vinyl magnesium bromide (10eq9, 80.6mmol, 
10.8cm3) and the reaction mixture was allowed to stir at –60oC under an 
Ar atmosphere for 18 h. Then the reaction mixture was allowed to warm to rt before the 
addition of distilled water (200cm3). The pH was then neutralised using 1M aqueous HCl and 
the solvent was remove in vacuo. The remaining aqueous layer was then extracted with 
EtOAc (3×150cm3). The combined organics were then dried over anhydrous MgSO4, filtered 
and the solvent was removed in vacuo. The crude mixture was then purified by column 
chromatography (5-10% EtOAc-Hexane) to give the desired product as a yellow oil (1.61g, 
72%). NMR spectroscopic data correlated well with that reported by Coyanis.206 
 
Rf = 0.64 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.27 [6H, dd, J=6.2Hz and 14.8Hz, 
OCH(CH3)2], 1.43 (3H, two d, J=7.3Hz, CH3), 3.82 (3H, s, OCH3), 4.41-4.54 [1H, m, 
OCH(CH3)2], 4.95-5.38 (4H, m, CH=CH2 and CH=CH2), 5.56 (1H, s, CHOH), 5.96-6.30 (2H, 
m, CH=CH2 and CH=CH2), 6.81 (1H, dd, J=3.5 and 8.6Hz, 6-H), 7.10 (1H, dd, J=6.1Hz and 
8.5Hz, 5-H);  δC (50 MHz, CDCl3) 19.3 and 20.0 (CH3), 22.6 and 22.7 [OCH(CH3)2], 33.5 
and 33.7 (CCH3-CH=), 55.6 (OCH3), 69.8 and 69.9 (CH-OH), 74.4 and 74.5 [OCH(CH3)2], 
110.6 and 110.7 (5-C), 112.9, 113.5 and 114.0 (CH=CCH2 and CH=CH2), 123.5 and 123.9 (6-
C), 134.4 and 134.5 (2-C), 137.4 and 137.6 (1-C), 140.3 and 140.4 (CHOH-CH=), 143.7 and 
143.9 (CH=CH2), 144.0 and 144.2 (3-C), 152.0 and 152.2 (4-C). 
 
 
 
 
 
 
                                                 
9 Our Grignard reagent stock was quite old and may have been contaminated with trace amounts of water, thus 
this value of 10 eq is not a representative amount for a good reagent. 
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3.13 Preparation of 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-propenyl]-phenyl}-2-
propen-1-ol 284 
 
The 1-[3-isopropoxy-4-methoxy-2-(1-methyl-2-propenyl)-phenyl]-2-
propen-1-ol 283 (1.47mmol, 0.406g) was dissolved up in DMF 
(15cm3). To this was added sublimed potassium tert-butoxide (1.3eq, 
1.91mmol, 0.217g) and the reaction mixture was stirred at rt under an 
Ar atmosphere for 15 min. After this time distilled water (15cm3) was 
added and the pH was neutralised using 1M aqueous HCl. The solvent was removed in vacuo 
and then the remaining aqueous layer was extracted with EtOAc (3x15cm3). The combined 
organics were then extracted with distilled water (3×100cm3) and a small amount of brine. 
They were then dried over anhydrous MgSO4 and the solvent was removed in vacuo to yield a 
bright yellow oil. This was purified by column chromatography (5% EtOAc-Hexane) with the 
desired product being obtained as a yellow oil (0.306g, 76%).The NMR data we obtained was 
similar to that reported by Coyanis.206 
 
Rf = 0.36 (30% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.15-1.49 [6H, m, OCH(CH3)2], 
1.77-1.90 (3H, m, CH3), 3.82 (3H, s, OCH3), 4.32-4.54 [1H, m, OCH(CH3)2], 4.95-5.64 (4H, 
m, CH-OH, CH=CH2 and C=CHCH3), 5.93-6.10 (1H, m, CH=CH2), 6.79-6.88 (1H, m, 5-H), 
7.08-7.20 (1H, m, 6-H);  δC (50 MHz, CDCl3) 13.4 and 13.5 (CH3), 15.5 and 15.7 
[OCH(CH3)2], 17.9 (CH3), 19.3 and 19.9 [OCH(CH3)2], 22.6 and 22.7 [OCH(CH3)2], 24.5 
(CH3), 55.5 and 55.6 (OCH3), 69.8, 69.9, 70.8, 71.0, 71.3, 71.5 and 71.6 (CH-OH), 74.5, 75.0 
and 75.4 [OCH(CH3)2], 110.7, 110.8, 110.9 and 111.0 (5-C), 112.8, 113.5, 113.7, 113.9 and 
114.0 (CH=CH2), 121.4, 121.8, 121.9, 122.0 and 123.5 (6-C), 123.8 (2-C), 124.5 and 125.4 
(C=CHCH3), 132.5, 132.9, 133.0, 133.1 and 133.5 (1-C), 134.4, 136.1 and 137.6 
(C=CHCH3), 140.3, 140.4, 140.7 and 141.1 (CH=CH2), 143.6 and 143.9 (3-C), 152.2 and 
152.3 (4-C).   
 
3.14 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1H-inden-1-ol 285 
 
The 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-pro-penyl]phenyl}-
2-propen-1-ol 284 (0.374mmol, 0.103g) was dissolved in distilled 
CH2Cl2 (10cm3) and the solution was degassed using N2 for 10 min. Then 
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Grubbs II catalyst 11 (0.05eq, 0.0187mmol, 0.0160g) was added and the solution was stirred 
at rt under an Ar atmosphere for 1 h, after which time the solvent was removed in vacuo to 
give a dark brown oil. This was purified by column chromatography (5-10% EtOAc-Hexane) 
to give the desired product as a bright yellow oil (0.0496g, 57%), confirmed by an NMR 
comparison to the data of Coyanis.206 
 
Rf = 0.23 (20% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.26 [6H, dd, J=6.2 and 16.3Hz, 
OCH(CH3)2], 1.77 (1H, br s, OH), 2.23 (3H, t, J=1.5Hz, CH3), 3.82 (3H, s, OCH3), 4.63 [1H, 
sept, J=6.2Hz, OCH(CH3)2], 4.99 (1H, s, CH-OH), 5.93 (1H, s, CH=CCH3), 6.68 (1H, d, 
J=7.9Hz, 6-H), 7.10 (1H, d, J=7.9Hz, 7-H);  δC (50 MHz, CDCl3) 16.5 (CH3), 22.3 and 22.5 
[OCH(CH3)2], 56.0 (OCH3), 74.2 [OCH(CH3)2a], 75.4 (CH-OHa), 109.8 (6-C), 118.1 
(CH=CCH3b), 133.4 (7-Cb), 136.5 (3a-Cc), 140.1 (7a-Cc), 141.3 (3-Cc), 141.6 (4-C), 153.6 (5-
C). 
 
3.15 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1H-inden-1-one 286 
 
The 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-pro-penyl]phenyl}-2-
propen-1-ol 284 (0.326mmol, 0.0900g) was dissolved in distilled toluene 
(9cm3) and the solution was heated to 80oC before the addition of Grubbs 
II catalyst 11 (0.08eq, 0.0260mmol, 0.0226g). The reaction mixture was 
allowed to stir at 80oC under an Ar atmosphere for 16 h. After this time the 
solvent was removed in vacuo to give a dark brown oil that was then purified by column 
chromatography (5-10% EtOAc-Hexane). The desired product was obtained as a dark yellow 
semi-solid (0.0316g, 42%) and a small amount of 4-isopropoxy-5-methoxy-3-methyl-1H-
inden-1-ol 285 (0.0316g, 23% relative to the starting material) was isolated. NMR 
spectroscopic data correlated well to that reported by Coyanis.206 
 
Rf = 0.48 (20% EtOAc-Hexane);  δH (300 MHz, CDCl3) 1.30 [6H, d, J=6.2Hz, OCH(CH3)2], 
2.39 (3H, s, CH3), 3.86 (3H, s, OCH3), 4.72 [1H, sept, J=6.2Hz, OCH(CH3)2], 5.61 (1H, s, 
CH=CCH3), 6.61 (1H, d, J=7.8Hz, 6-H), 7.12 (1H, d, J=7.8Hz, 7-H);  δC (50 MHz, CDCl3) 
17.9 (CH3), 22.5 [OCH(CH3)2], 56.0 (OCH3), 74.7 [OCH(CH3)2], 110.1 (6-C), 118.1 (7-C), 
125.5 (CH=CCH3), 125.9 (7a-C), 136.7 (3a-C), 141.9 (4-C), 158.5 (5-C), 162.1 (3-C), 196.4 
(C=O). 
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3.16 Preparation of 4-isopropoxy-5-methoxy-3-methyl-1-indanone 287 
 
The 1-{3-isopropoxy-4-methoxy-2-[(1E)-1-methyl-1-pro-penyl]phenyl}-2-
propen-1-ol 284 (0.288mmol, 0.0795g) was transferred to the round 
bottomed flask using CH2Cl2 (8cm3) and then the solution was degassed 
using N2 for 11 min. After this time Grubbs II catalyst 11 (0.05eq, 
0.0144mmol, 0.0130g) was added and the solution was heated to 110oC 
(all the CH2Cl2 evaporated off over time). Then the solventless reaction mixture was allowed 
to stir at 110-170oC under an Ar atmosphere for 18 h. After this time the residue was purified 
by column chromatography (5-10% EtOAc-Hexane) to yield the desired compound as a dark 
yellow oil (0.0124g, 18%) and a trace amount of 4-isopropoxy-5-methoxy-3-methyl-1H-
inden-1-one 286 (0.0049g, 7% relative to starting material). 
 
Rf = 0.34 (20% EtOAc-Hexane);  νmax/cm-1 (NaCl plate) 753 (alkane), 1217 (-C-O), 1335 (-
COCH3), 1379 and 1437 (alkane), 1490 and 1594 (Ar ring), 1699 (aryl C=O), 2882 (-OCH3), 
2981 (-CH2 or –CH3), 3019 (Ar H);  δH (300 MHz, CDCl3) 1.27 (3H, d, J=6.1Hz, CH3), 1.39 
[6H, dd, J=6.6 and 17.5Hz, OCH(CH3)2], 2.25 (1H, dd, J=2.6 and 19.0Hz, 2-Ha), 2.91 (1H, 
dd, J=7.7 and 19.0Hz, 2-Ha), 3.51(1H, dp, J=2.5 and 7.2Hz, 3-H), 3.83-3.94 (3H, m, OCH3), 
4.58 [1H, sept, J=6.1Hz, OCH(CH3)2], 6.96 (1H, d, J=8.4Hz, 6-H), 7.49 (1H, d, J=8.3Hz, 7-
H);  δC (50 MHz, CDCl3)  20.6 (CH3), 22.6 and 22.7 [OCH(CH3)2], 31.5 (3-C), 45.9 (2-C), 
56.1 (OCH3), 75.6 [OCH(CH3)2], 112.3 (6-C), 119.6 (7-C), 130.6 (7a-C), 143.7 (3a-C), 153.1 
(4-C), 158.3 (5-C), 205.2 (C=O);  MS m/z 234 (M+, 21%), 41 (11), 43 (14), 69 (100), 77 (8), 
91 (8), 131 (18), 132 (15), 177 (57), 178 (8), 190 (9), 191 (7), 192 (64), 219 (80), 220 (28), 
234 (21), 263 (9), 264 (7), HRMS calculated for C14H18O3: 234.12559, found: 234.12130.
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Appendix A:  
 
Selected NMR Spectra 
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 2-(Benzylsulfonyl)-7-isopropoxy-8-methoxy-1,2,3,45,6-hexahydro- 
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 7-Isopropoxy-8-methoxy-1,2,3,6-tetrahydro-2-benzazocine 218 
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N-(1-propenyl)methansulfonamide 222 
 
 
 
ppm (f1)
1.02.03.04.05.06.07.0
6.26
1.09
1.00
2.14
0.91
4.97
1.95
3.73
2.81
3.89
3.18
6.76
 
 
 
ppm (f1)
50100150
5
6
N
O
O
S
O
O
7
8
9
10
11
10
9
222
 2-Acetyl-5-isopropoxy-6-methoxy-1,2-dihydroisoquinoline 223 
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 N-[3-Isopropoxy-4-methoxy-2-(1-phenyl-1-propenyl)benzyl]- 
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Appendix B: 
 
Single-Crystal X-Ray Diffraction Data 
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1.4 Crystal Structure Data for Compound XX 
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Appendix C:  
 
ICP-MS Data 
 1. The Standard Curve 
 
Graph 2:
Standard Curve for Intensity vs. Concentration
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2. MS Operating Conditions: 
 
• Generator Parameters: 
 
o Plasma Power: 1350W 
o Pump Step:  2 
o Coolant Step:  3 
o Auxiliary Step: 1 
o Nebulizer Step:  1 
o Nebulizer Flow  925ml/min 
 
• Detector Parameters: 
 
o Sensitivity Range:  E01-E05 
o SEM:   -2600V 
o Resolution:  Normal 
o Pause Calibration: Factor 3.0 
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